ID-datalake,nct_id,brief_title,official_title,phase,recruitment_status,start_date,completion_date,primary_completion_date,enrollment,enrollment_type,lead_sponsor,sponsor_organization,indications,interventions_drugs,drugs_datalake,main_technologies,specific_technologies,target_names,target_abbreviations
61690,NCT06669572,Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment,"A Phase II, Multi-center, Single Arm Trial of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Locally Advanced and/or Metastatic Anorectal Squamous Cell Carcinoma (ASCC) After Progression on First Line Chemotherapy.",PHASE2,NOT_YET_RECRUITING,13/1/2026,26/3/2029,26/3/2029,35,ESTIMATED,,,"['Anorectal Cancer', 'Epithelial Neoplasm']","['Pembrolizumab', 'Lenvatinib']","['B936', 'B261']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['PD-1'], ['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
63117,NCT06883552,"An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer","An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer",PHASE2,NOT_YET_RECRUITING,1/10/2025,1/10/2026,1/10/2026,21,ESTIMATED,,,['Thoracic Neoplasm'],['Tislelizumab'],['B1344'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
56177,NCT06366490,Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer,Phase 1 Study to Assess the Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer,PHASE1,NOT_YET_RECRUITING,30/6/2025,30/6/2026,30/12/2025,8,ESTIMATED,,,['Ovarian Cancer'],['Innocell'],['B11796'],[['Cancer Vaccine']],[['Whole Tumor Cell Vaccine']],[[]],[[]]
62820,NCT06835387,Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors,Phase II Study of NALIRIFOX (Nanoliposomal Irinotecan + Oxaliplatin With Fluorouracil and Folinic Acid) in Advanced Unresectable Small Bowel Tumors,PHASE2,RECRUITING,31/5/2025,31/8/2028,31/8/2027,36,ESTIMATED,,,['Small Intestinal Adenocarcinoma'],"['Irinotecan Sucrosofate', 'Dexamethasone', '5-HT3 Receptor Antagonist', 'Oxaliplatin', 'Fluorouracil', 'Folinic acid']","['B1128', 'B1229', 'B493', 'B226']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Glucocorticoid receptor'], ['DNA'], ['Thymidylate synthase'], []]","[['GR'], ['DNA'], ['TYMS'], []]"
63206,NCT06896188,"9-ING-41 Combined with Retifanlimab, Plus Modified FOLFIRINOX for Patients with Advanced Pancreatic Adenocarcinoma (RiLEY)","A Phase Ib Study of 9-ING-41 (elraglusib), a Glycogen Synthase Kinase 3-beta (GSK-3Î²) Inhibitor, Combined with Retifanlimab, a PD-1 Inhibitor, Plus Modified FOLFIRINOX As Frontline Therapy for Patients with Advanced Pancreatic Adenocarcinoma (RiLEY)",PHASE1,NOT_YET_RECRUITING,31/5/2025,31/12/2028,31/5/2027,12,ESTIMATED,,,['Pancreatic Cancer'],"['Retifanlimab', 'Oxaliplatin', 'Folinic acid', 'Irinotecan', 'Fluorouracil', 'Elraglusib']","['B1394', 'B1229', 'B226', 'B1679', 'B493', 'B1684']","[['Antibody'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['DNA'], [], ['DNA topoisomerase I'], ['Thymidylate synthase'], ['Glycogen synthase kinase-3 beta']]","[['PD-1'], ['DNA'], [], ['TOP1'], ['TYMS'], ['GSK-3Î²']]"
62724,NCT06822972,HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM,A Phase II Safety and Efficacy Study of Selinexor in Combination With Bispecific Antibody in Patients With Relapsed/Refractory Multiple Myeloma,PHASE2,NOT_YET_RECRUITING,1/5/2025,31/12/2027,30/4/2026,27,ESTIMATED,,,"['Multiple Myeloma', 'Multiple Myeloma']",['Selinexor'],['B1030'],[['Small Molecule']],[['Small Molecule']],[['Exportin-1 protein']],[['XPO1']]
63277,NCT06906562,A Phase II Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreas Cancer With FGFR Genetic Alterations,A Phase II Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreas Cancer With FGFR2 Gene Fusions or Other FGFR Genetic Alterations,PHASE2,NOT_YET_RECRUITING,1/5/2025,31/12/2026,31/12/2026,40,ESTIMATED,,,"['Pancreatic Cancer', 'FGFR Mutation', 'Renal Cell Carcinoma', 'FGFR2 Gene Translocation', 'Pancreatic Cancer', 'Epithelial Neoplasm']","['Pemigatinib', 'Computed Tomography Colonography', 'Magnetic Resonance Imaging']",['B1274'],[['Small Molecule']],[['Small Molecule']],"[['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3']]","[['FGFR1', 'FGFR2', 'FGFR3']]"
55910,NCT06328036,Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma,Phase 2 and Biomarker Trial of Anti-TIGIT and Anti-PDL1 in Patients With Recurrent Glioblastoma,PHASE2,WITHDRAWN,30/4/2025,1/7/2025,1/7/2025,0,ACTUAL,,,['Glioblastoma'],"['Atezolizumab', 'Biospecimen Collection', 'Magnetic Resonance Imaging', 'Surgical Procedure', 'Tiragolumab']","['B1084', 'B1397']","[['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Programmed death-ligand 1'], ['T cell immunoglobulin and ITIM domains']]","[['PDL1'], ['TIGIT']]"
54225,NCT06066138,A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing,A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing,PHASE1,RECRUITING,10/4/2025,31/1/2027,31/1/2026,40,ESTIMATED,,,"['Soft Tissue Sarcoma', 'Soft Tissue Sarcoma', 'Non-Small Cell Lung Cancer', 'Epithelial Neoplasm', 'Neuroendocrine Carcinoma', 'Epithelial Neoplasm', 'Hepatocellular Carcinoma', 'Hepatocellular Carcinoma', 'Skin Melanoma', 'Metastatic Melanoma']",['Atezolizumab'],['B1084'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed death-ligand 1']],[['PDL1']]
63290,NCT06908031,SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer,"Short-Course Radiotherapy Combined With mFOLFOX6, PD-1 Antibody and Cetuximab (for RAS/BRAF Wild-Type)/Bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma: a Prospective, Multicenter Phase II Study",PHASE3,RECRUITING,2/4/2025,1/4/2027,1/4/2027,49,ESTIMATED,,,"['Osteosarcoma', 'MSS', 'Rectal Carcinoma']","['Radiation Therapy', 'Iparomlimab', 'mFOLFOX6', 'Cetuximab', 'Bevacizumab', 'Resection']","['B4868', 'B164', 'B167']","[['Antibody'], ['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Programmed cell death protein 1'], ['Epidermal growth factor receptor erbB1'], ['Vascular endothelial growth factor A']]","[['PD-1'], ['EGFR'], ['VEGF-A']]"
63319,NCT06912152,MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors,"Phase I Dose-Escalation Study of MT027: Evaluating Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors",PHASE1,RECRUITING,2/4/2025,31/12/2028,31/10/2028,12,ESTIMATED,,,['Peritoneal Malignant Mesothelioma'],"['Fludarabine', 'Cyclophosphamide', 'MT-027']","['B346', 'B2818', 'B9987']","[['Small Molecule'], ['Small Molecule'], ['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']]","[['Small Molecule'], ['Small Molecule'], ['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']]","[['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA'], ['CD276 antigen']]","[['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA'], ['B7H3']]"
53135,NCT05903833,"Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy","Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy (A Multicenter, Single-arm Phase II, Open-label Study of the AGO Study Group)",PHASE2,NOT_YET_RECRUITING,1/4/2025,30/10/2029,30/10/2027,42,ESTIMATED,,,"['Vulvar Carcinoma', 'Vulvar Carcinoma', 'Vulvar Carcinoma', 'Vulvar Carcinoma']","['Pembrolizumab', 'Lenvatinib']","['B936', 'B261']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['PD-1'], ['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
56156,NCT06364267,Low Dose Exemestane Vs Low Dose Tamoxifen in Post-menopausal Women At High Risk for Breast Cancer.,Randomized Double Blind Phase II Trial of Baby Exemestane Vs Baby Tamoxifen in Post-menopausal Women At High Risk for Breast Cancer.,PHASE2,NOT_YET_RECRUITING,1/4/2025,31/1/2027,31/1/2027,140,ESTIMATED,,,['Breast Cancer'],"['Tamoxifen', 'Exemestane']","['B2062', 'B86']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Estrogen receptors'], ['Aromatase']]","[['ER'], ['aromatase']]"
57195,NCT06508931,Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With Relapsed or Refractory B-Cell Neoplasms,"A Single-arm, Multi-center, Open-label Phase II Study to Determine the Safety and Efficacy of MB-CART2019.1 in Pediatric Subjects With Relapsed/Refractory (r/r) Mature B-cell Neoplasms Who Have Relapsed After One or More Prior Therapies, Including Subjects With Primary Refractory Disease",PHASE2,NOT_YET_RECRUITING,1/4/2025,1/10/2029,29/9/2029,31,ESTIMATED,,,['Hematology'],['Zamtocabtagene autoleucel'],['B3067'],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],"[['B-lymphocyte antigen CD19', 'B-lymphocyte antigen CD20']]","[['CD19', 'CD20']]"
57250,NCT06517017,"Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma","Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma: A Phase 2 Multicenter Study",PHASE2,NOT_YET_RECRUITING,31/3/2025,30/11/2027,30/11/2026,40,ESTIMATED,,,"['Multiple Myeloma', 'Plasma Cell Leukemia']","['Isatuximab', 'Dexamethasone', 'Lenalidomide']","['B1027', 'B1128', 'B2071']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Molecular glue']]","[['Lymphocyte differentiation antigen CD38'], ['Glucocorticoid receptor'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos']]","[['CD38'], ['GR'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3']]"
63142,NCT06887803,A Study of Roginolisib in Combination with Ruxolitinib in Patients with Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors,"A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination with Ruxolitinib in Patients with Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors (HEMA-MED)",PHASE1/PHASE2,NOT_YET_RECRUITING,31/3/2025,31/7/2028,31/3/2028,26,ESTIMATED,,,['Primary Myelofibrosis'],"['Roginolisib', 'Ruxolitinib']","['B1079', 'B481']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Phosphatidylinositol 3 kinase delta'], ['Tyrosine-protein kinase JAK1', 'Tyrosine-protein kinase JAK2']]","[['PI3KÎ´'], ['JAK1', 'JAK2']]"
63111,NCT06882746,"A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas","A Phase I, Open-label, Non-randomised, Multi-center Dose Escalation Trial of BI 765049 Administered by Parenteral Route in Patients With Advanced, Unresectable, and/or Metastatic Colorectal Carcinoma (CRC), Gastric Carcinoma (GC), or Pancreatic Ductal Adenocarcinoma (PDAC) to Determine the MTD and the RP2D and to Determine the Dosing Regimen for Further Development of BI 765049",PHASE1,RECRUITING,28/3/2025,12/5/2027,11/12/2026,100,ESTIMATED,,,"['Colorectal Cancer', 'Gastric Cancer', 'Pancreatic Cancer']",['BI 765049'],['B6032'],[['Antibody']],[['Bispecific Antibody']],"[['natural killer cell cytotoxicity receptor 3 ligand 1', 'T cell surface glycoprotein CD3']]","[['NCR3LG1', 'CD3']]"
61771,NCT06682637,Melflufen for Elderly Patients With Relapsed Myeloma,Melflufen for Elderly Myeloma Patients in Second or Subsequent Relapse,PHASE2,WITHDRAWN,26/3/2025,26/3/2025,26/3/2025,0,ACTUAL,,,['Multiple Myeloma'],"['Melphalan flufenamide', 'Dexamethasone']","['B1434', 'B1128']","[['Engineered Protein Therapy'], ['Small Molecule']]","[['Synthetic Peptide Drug Conjugate'], ['Small Molecule']]","[['DNA'], ['Glucocorticoid receptor']]","[['DNA'], ['GR']]"
63329,NCT06914128,A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors,"A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.",PHASE1,RECRUITING,21/3/2025,17/6/2029,17/6/2029,70,ESTIMATED,,,['Solid Tumors'],['PH020'],['B11897'],[['Small Molecule']],[['Small Molecule']],[['Protein arginine methyltransferase 5']],[['PRMT5']]
62073,NCT06728072,Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer,"Pilot Study Evaluating Microbiome Modulation Therapy (MBMT) With Ciprofloxacin, Metronidazole, and Aspirin in Addition to Standard of Care Chemotherapy in Patients Undergoing First-Line Therapy for Metastatic Colorectal Cancer",PHASE2,RECRUITING,7/3/2025,1/7/2035,1/7/2035,97,ESTIMATED,,,"['Colorectal Cancer', 'Colorectal Cancer']","['Metronidazole', 'Ciprofloxacin', 'Aspirin']","['B282', 'B2048', 'B856']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], [], ['Cyclooxygenases']]","[[], ['Bacterial DNA gyrase'], ['COX']]"
56535,NCT06417190,Bladder Preservation for Patients with Muscle Invasive Bladder Cancer (MIBC) with Variant Histology,IIT2023-13-BALLAS-VHTMT: Bladder Preservation for Patients with Muscle Invasive Bladder Cancer (MIBC) with Variant Histology,PHASE2,RECRUITING,1/3/2025,30/9/2030,30/9/2030,20,ESTIMATED,,,"['Glioma', 'Muscle Invasive Bladder Cancer']",[],[],[],[],[],[]
62816,NCT06834672,"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","A Multicenter, Randomized, Open-label Phase III Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",PHASE3,NOT_YET_RECRUITING,28/2/2025,28/11/2029,28/12/2027,450,ESTIMATED,,,"['Fallopian Tube Cancer', 'Ovarian Cancer', 'Primary Peritoneal Cancer']","['IBI 354', 'Paclitaxel', 'Gemcitabine', 'Pegylated liposomal doxorubicin']","['B4829', 'B1250', 'B2079', 'B2819']","[['Antibody Drug Conjugate (ADC)'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Antibody Drug Conjugate (ADC)'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA topoisomerase I', 'Receptor protein-tyrosine kinase erbB-2'], ['Tubulin beta-1 chain'], ['DNA', 'Ribonucleotide reductase'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)']]","[['TOP1', 'HER2'], ['TUBB1'], ['DNA', 'RNR'], ['DNA', 'TOP2']]"
62949,NCT06856200,A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer,"An Investigator-initiated Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Sirolimusï¼ˆAlbumin-boundï¼‰in Combination With Palbociclib and Fulvestrant in Patients With Advanced HR- Positive, HER2- Negative Breast Cancer",,RECRUITING,28/2/2025,30/6/2026,31/10/2025,36,ESTIMATED,,,"['HER2-Negative Breast Cancer', 'Endocrine Neoplasm']","['Sirolimus', 'Palbociclib', 'Fulvestrant']","['B1227', 'B504', 'B276']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Serine/threonine-protein kinase mTOR'], ['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6'], ['Estrogen receptors']]","[['mTOR'], ['CDK4', 'CDK6'], ['ER']]"
60900,NCT06560879,Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children with Leukemia,Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity and Changes in Gut Microbiota in Children with Acute Lymphoblastic Leukemia,PHASE2,ENROLLING_BY_INVITATION,1/2/2025,31/8/2026,31/12/2025,120,ESTIMATED,,,"['Thoracic Neoplasm', 'Probiotics', 'Gastrointestinal Diseases']","['Lactobacillus rhamnosus', 'Bifidobacterium bifidum', 'Placebo Control']",[],[],[],[],[]
62610,NCT06801730,Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma,Exploratory Study of Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Progressive or Recurrent Glioma,PHASE2,RECRUITING,8/1/2025,15/12/2026,15/12/2026,38,ESTIMATED,,,['Glioma'],"['irinotecan liposomal', 'Bevacizumab']","['B9057', 'B167']","[[], ['Antibody']]","[[], ['Monoclonal Antibody']]","[[], ['Vascular endothelial growth factor A']]","[[], ['VEGF-A']]"
62916,NCT06851247,GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.,"Toripalimab Plus Anlotinib Combined with GP Induction Chemotherapy and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for High-risk, Locally Advanced Nasopharyngeal Carcinomaï¼šA Single-arm, Phase II Clinical Trial",PHASE2,RECRUITING,3/1/2025,30/6/2027,30/6/2027,47,ESTIMATED,,,['Nasopharyngeal Cancer'],"['Toripalimab', 'Catequentinib', 'Gemcitabine', 'Cisplatin', 'Intensity-Modulated Radiation Therapy']","['B1346', 'B1436', 'B2079', 'B49']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['DNA', 'Ribonucleotide reductase'], ['DNA']]","[['PD-1'], ['c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['DNA', 'RNR'], ['DNA']]"
56076,NCT06352866,Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM,Phase II Trial of Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to Treatment With Teclistamab in Relapsed or Refractory Multiple Myeloma (RRMM),PHASE2,WITHDRAWN,1/1/2025,1/12/2025,1/4/2025,0,ACTUAL,,,"['Multiple Myeloma', 'Cytokine Release Syndrome', 'Multiple Myeloma', 'Immune Effector Cell Associated Neurotoxicity Syndrome']","['Siltuximab', 'Teclistamab']","['B454', 'B1522']","[['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Bispecific T-Cell Engager']]","[['Interleukin-6'], ['B-cell maturation protein', 'T cell surface glycoprotein CD3']]","[['IL-6'], ['BCMA', 'CD3']]"
62186,NCT06744894,SIL as Maintenance Therapy in Multiple Myeloma,Selinexor Combined With Ixazomib and Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma,PHASE2,NOT_YET_RECRUITING,1/1/2025,1/1/2030,1/1/2028,50,ESTIMATED,,,['Multiple Myeloma'],"['Selinexor', 'Ixazomib', 'Lenalidomide']","['B1030', 'B783', 'B2071']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Molecular glue']]","[['Exportin-1 protein'], ['Proteasome'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos']]","[['XPO1'], ['Proteasome'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3']]"
62408,NCT06772428,Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.,"A Prospective, Randomized, Parallel-controlled Clinical Study of Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment Alone for Adjuvant Therapy in Patients With High-risk Factor Squamous Cell Carcinoma of the Head and Neck After Surgery.",PHASE3,NOT_YET_RECRUITING,1/1/2025,31/12/2027,30/6/2027,96,ESTIMATED,,,"['Head and Neck Squamous Cell Carcinoma', 'Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors']","['Megestrol acetate', 'Radiation Therapy', 'Chemotherapy']",['B9385'],[[]],[[]],[[]],[[]]
62032,NCT06720324,CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors,An Open-label Clinical Study on the Efficacy and Safety of CD7-specific CAR-T Cell Injection in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors,PHASE1/PHASE2,RECRUITING,31/12/2024,31/12/2027,31/12/2027,80,ESTIMATED,,,['Hematology'],"['Fludarabine', 'Cyclophosphamide', 'Anti-CD7 CAR T-cells']","['B346', 'B2818']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA']]","[['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA']]"
62128,NCT06735131,The Optimal Radioimmunotherapy Combinations for Advanced TNBC,"A Prospective, Multicenter Clinical Trial Exploring the Optimal Combination Strategies of Radiotherapy and Immunotherapy for Advanced Triple-Negative Breast Cancer",PHASE2,NOT_YET_RECRUITING,31/12/2024,31/1/2027,31/7/2026,60,ESTIMATED,,,['Triple-Negative Breast Cancer'],"['Toripalimab', 'Radiation Therapy', 'Chemotherapy', 'Nab-paclitaxel', 'Gemcitabine', 'Carboplatin']","['B1346', 'B7744', 'B2079', 'B274']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Tubulin beta-1 chain'], ['DNA', 'Ribonucleotide reductase'], ['DNA']]","[['PD-1'], ['TUBB1'], ['DNA', 'RNR'], ['DNA']]"
62094,NCT06730932,"A Prospectiveï¼ŒSingle Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy","A Prospectiveï¼ŒSingle Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy",PHASE2,NOT_YET_RECRUITING,30/12/2024,30/12/2026,30/3/2026,31,ESTIMATED,,,['Clear Cell Renal Cell Carcinoma'],"['Tifcemalimab', 'Toripalimab']","['B1784', 'B1346']","[['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['B- and T-lymphocyte attenuator'], ['Programmed cell death protein 1']]","[['BTLA'], ['PD-1']]"
61674,NCT06667908,A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC),"A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC",PHASE2,RECRUITING,6/12/2024,31/12/2028,31/12/2028,130,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['Hafnium oxide', 'Durvalumab', 'Intensity-Modulated Radiation Therapy', 'Carboplatin', 'Paclitaxel']","['B1398', 'B977', 'B274', 'B1250']","[['Small Molecule Radiopharmaceutical'], ['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule Radiopharmaceutical'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[[], ['Programmed death-ligand 1'], ['DNA'], ['Tubulin beta-1 chain']]","[[], ['PDL1'], ['DNA'], ['TUBB1']]"
61889,NCT06700395,A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma,Phase I Clinical Study Evaluating the Tolerability and Pharmacokinetics of TQB2029 for Injection in Subjects With Multiple Myeloma,PHASE1,RECRUITING,28/11/2024,31/3/2028,31/3/2026,136,ESTIMATED,,,['Multiple Myeloma'],['TQB2029'],['B11968'],[['Antibody']],[['Bispecific Antibody']],"[['G-protein coupled receptor family C group 5member D', 'T cell surface glycoprotein CD3']]","[['GPRC5D', 'CD3']]"
62216,NCT06749886,An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting,An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting,PHASE2,RECRUITING,19/11/2024,30/6/2027,30/11/2026,22,ESTIMATED,,,['Thoracic Neoplasm'],"['Denosumab', 'Tislelizumab', 'Docetaxel']","['B235', 'B1344', 'B2814']","[['Antibody'], ['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Tumor necrosis factor ligand superfamily member 11'], ['Programmed cell death protein 1'], ['Tubulin beta-1 chain']]","[['RANKL'], ['PD-1'], ['TUBB1']]"
54915,NCT06171685,MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM,A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma,PHASE2,RECRUITING,17/11/2024,31/7/2030,31/7/2029,300,ESTIMATED,,,"['Multiple Myeloma', 'Multiple Myeloma']","['Teclistamab', 'Investigational New Drug']",['B1522'],[['Antibody']],[['Bispecific T-Cell Engager']],"[['B-cell maturation protein', 'T cell surface glycoprotein CD3']]","[['BCMA', 'CD3']]"
61770,NCT06682611,Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.,"An, Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.",PHASE1/PHASE2,NOT_YET_RECRUITING,13/11/2024,13/11/2027,13/11/2026,380,ESTIMATED,,,['Solid Tumors'],"['SYHA-1813', 'SG 001', 'HB 1801', 'Carboplatin', 'Cisplatin', 'Paclitaxel', 'Etoposide', 'Everolimus', 'Regorafenib']","['B11091', 'B2752', 'B11566', 'B274', 'B49', 'B1250', 'B1463', 'B511', 'B526']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Colony stimulating factor 1 receptor', 'Vascular endothelial growth factor receptor'], ['Programmed cell death protein 1'], ['Tubulin'], ['DNA'], ['DNA'], ['Tubulin beta-1 chain'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Mammalian target of Rapamycin', 'mTOR Complex 2'], ['Colony stimulating factor 1 receptor', 'Ephrin type-A receptor 2', 'Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Nerve growth factor receptor Trk-A', 'Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'RAF serine/threonine protein kinase', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'TEK receptor tyrosine kinase', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['CSF-1R', 'VEGFR'], ['PD-1'], ['Tubulin'], ['DNA'], ['DNA'], ['TUBB1'], ['TOP2'], ['mTORC1', 'mTORC2'], ['Abl', 'BRAF V600E', 'CSF-1R', 'EphA2', 'FGFR1', 'FGFR2', 'TRKA', 'PDGFRÎ±', 'PDGFRÎ²', 'Raf kinase', 'BRAF', 'c-Kit', 'Tie-2', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3', 'DDR2', 'FRK', 'MAPK11']]"
61534,NCT06647563,Neoadjuvant Toripalimab + Chemotherapy Â± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT),A Randomized Controlled Study of Toripalimab Combined With Chemotherapy or With Chemotherapy/Cetuximab as Neoadjuvant Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Neo-ICT),PHASE3,NOT_YET_RECRUITING,1/11/2024,30/9/2030,30/9/2029,355,ESTIMATED,,,['Head and Neck Squamous Cell Carcinoma'],"['Toripalimab', 'Cetuximab', 'Nab-paclitaxel', 'Carboplatin', 'Cisplatin', 'Radiation Therapy']","['B1346', 'B164', 'B7744', 'B274', 'B49']","[['Antibody'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Epidermal growth factor receptor erbB1'], ['Tubulin beta-1 chain'], ['DNA'], ['DNA']]","[['PD-1'], ['EGFR'], ['TUBB1'], ['DNA'], ['DNA']]"
61716,NCT06673693,Tislelizumab Combined with SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma,Neoadjuvant SBRT Sequential Tislelizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma: a Single-Arm Phase II Clinical Study,PHASE2,NOT_YET_RECRUITING,1/11/2024,31/12/2028,31/12/2027,24,ESTIMATED,,,"['Head and Neck Squamous Cell Carcinoma', 'Head and Neck Squamous Cell Carcinoma']","['Tislelizumab', 'Stereotactic Body Radiation Therapy']",['B1344'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
55212,NCT06217536,Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas,"Phase 1b/2 Trial Using Neoadjuvant Lurbinectedin With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas of Extremity, Trunk, and Retroperitoneum",PHASE1/PHASE2,WITHDRAWN,31/10/2024,31/10/2027,31/5/2026,0,ACTUAL,,,['Soft Tissue Sarcoma'],"['Lurbinectedin', 'Radiation Therapy', 'Surgery']",['B1273'],[['Small Molecule']],[['Small Molecule']],[['DNA']],[['DNA']]
61283,NCT06613152,HS-IT201 Injection in the Treatment of Advanced Solid Tumors,Clinical Study on the Safety and Efficacy of HS-IT201 Injection in the Treatment of Advanced Solid Tumors,EARLY_PHASE1,NOT_YET_RECRUITING,31/10/2024,31/10/2028,31/10/2026,9,ESTIMATED,,,['Solid Tumors'],['HS-IT201'],['B11232'],[['Tumor Inflitrating Lymphocyte Therapy (TIL)']],[['Tumor Inflitrating Lymphocyte Therapy (TIL)']],[[]],[[]]
57054,NCT06490536,The Sagittarius Trial,A Precision Medicine Trial Leveraging Blood-Based Tumor Genomics to Optimize Treatment in Operable Stage III and High-Risk Stage II Colon Cancer Patients,PHASE3,RECRUITING,22/10/2024,1/9/2028,1/3/2026,700,ESTIMATED,,,"['Colon Carcinoma', 'Colon Carcinoma']","['Oxaliplatin', 'Capecitabine', 'Folinic acid', 'Fluorouracil', 'Temozolomide', 'Irinotecan', 'Nivolumab', 'Ipilimumab', 'Trastuzumab', 'Pertuzumab', 'Panitumumab']","['B1229', 'B474', 'B226', 'B493', 'B2056', 'B1679', 'B714', 'B480', 'B168', 'B538', 'B194']","[['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Antibody'], ['Antibody'], ['Antibody'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['DNA'], ['Thymidylate synthase'], [], ['Thymidylate synthase'], ['DNA'], ['DNA topoisomerase I'], ['Programmed cell death protein 1'], ['Cytotoxic T-Lymphocyte-Associated Antigen 4'], ['Receptor protein-tyrosine kinase erbB-2'], ['Receptor protein-tyrosine kinase erbB-2'], ['Epidermal growth factor receptor erbB1']]","[['DNA'], ['TYMS'], [], ['TYMS'], ['DNA'], ['TOP1'], ['PD-1'], ['CTLA4'], ['HER2'], ['HER2'], ['EGFR']]"
55495,NCT06253637,Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program,Daratumumab in Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR),PHASE2,RECRUITING,17/10/2024,31/10/2029,31/10/2029,31,ESTIMATED,,,['T-cell acute lymphoblastic leukemia'],['Daratumumab'],['B415'],[['Antibody']],[['Monoclonal Antibody']],[['Lymphocyte differentiation antigen CD38']],[['CD38']]
61054,NCT06578286,ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd,Evaluate the Efficacy and Safety of ARX788 in Patients With HER2-positive Advanced Breast Cancer Whose Disease Has Progressed Following T-DXd Therapy,PHASE2,NOT_YET_RECRUITING,30/9/2024,30/9/2030,30/9/2026,44,ESTIMATED,,,['Breast Cancer'],['JNJ-0683'],['B2500'],[['Antibody Drug Conjugate (ADC)']],[['Antibody Drug Conjugate (ADC)']],[['Receptor protein-tyrosine kinase erbB-2']],"[['Beta-tubulin ', 'HER2']]"
57266,NCT06519370,"FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","A Phase 3, Open-label, Randomised Study of FDA018-ADC Versus Investigator's Choice of Chemotherapy in Patients Who Recurred During or After Taxane Therapy in Locally Advanced or Metastatic Triple-negative Breast Cancer",PHASE3,RECRUITING,9/8/2024,20/6/2027,18/8/2026,350,ESTIMATED,,,['Triple-Negative Breast Cancer'],"['FDA018-ADC', 'Eribulin', 'Capecitabine', 'Gemcitabine', 'Vinorelbine']","['B5157', 'B387', 'B474', 'B2079', 'B1929']","[['Antibody Drug Conjugate (ADC)'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Antibody Drug Conjugate (ADC)'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA topoisomerase I', 'Tumor-associated calcium signal transducer 2'], ['Tubulin beta-1 chain'], ['Thymidylate synthase'], ['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain']]","[['TOP1', 'TROP2'], ['TUBB1'], ['TYMS'], ['DNA', 'RNR'], ['TUBB1']]"
55552,NCT06261814,Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors,2D and 3D Contrast Enhanced Ultrasound of Chemoembolization,PHASE2,RECRUITING,7/8/2024,1/1/2028,1/7/2027,266,ESTIMATED,,,['Liver Cancer'],"['Sulfur Hexafluoride Lipid Microspheres', 'Contrast-Enhanced Ultrasound', 'Transarterial Chemoembolization']",[],[],[],[],[]
56528,NCT06416410,JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation,"An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation",PHASE3,RECRUITING,7/8/2024,28/2/2027,30/9/2026,392,ESTIMATED,,,"['Lung Non-Squamous Non-Small Cell Carcinoma', 'Lung Non-Squamous Non-Small Cell Carcinoma']","['Glecirasib', 'Tislelizumab', 'JAB 3312', 'Pemetrexed', 'Carboplatin']","['B1847', 'B1344', 'B2830', 'B814', 'B274']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['GTPase KRas G12C'], ['Programmed cell death protein 1'], ['Src homology phosphotyrosyl phosphatase 2'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase'], ['DNA']]","[['KRAS G12C'], ['PD-1'], ['SHP2'], ['DHFR', 'GART', 'TYMS'], ['DNA']]"
60818,NCT06549595,A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients,"A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)",PHASE3,RECRUITING,7/8/2024,28/2/2035,15/4/2031,1015,ESTIMATED,,,['Follicular Lymphoma'],"['AZD0486', 'Rituximab', 'Cyclophosphamide', 'Doxorubicin', 'Vincristine', 'Prednisone', 'Bendamustine']","['B2625', 'B163', 'B2818', 'B1914', 'B2083', 'B1979', 'B1689']","[['Antibody'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Bispecific T-Cell Engager'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['B-lymphocyte antigen CD19', 'T cell surface glycoprotein CD3'], ['B-lymphocyte antigen CD20'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Tubulin beta-1 chain'], ['Glucocorticoid receptor'], ['DNA']]","[['CD19', 'CD3'], ['CD20'], ['DNA'], ['TOP2'], ['TUBB1'], ['GR'], ['DNA']]"
57199,NCT06509568,Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinomaï¼ˆCRIS-2 Trialï¼‰,"Comparison of Neoadjuvant Chemoradiotherapy Followed by Immunotherapy With Neoadjuvant Chemoimmunotherapy in the Treatment for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-center, Phase II Randomized Clinical Study",PHASE2,RECRUITING,1/8/2024,1/8/2026,1/8/2025,92,ESTIMATED,,,['Esophageal Cancer'],"['Nab-paclitaxel', 'Carboplatin', 'Toripalimab', 'Esophagectomy', 'Intensity-Modulated Radiation Therapy', 'Volume Modulated Arc Therapy', 'Immunotherapy']","['B274', 'B1346']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['DNA'], ['Programmed cell death protein 1']]","[['DNA'], ['PD-1']]"
54300,NCT06080165,Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations,A Randomized Controlled Double-Blind Trial of Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations,PHASE1/PHASE2,WITHDRAWN,31/7/2024,30/6/2028,30/6/2028,0,ACTUAL,,,"['PTEN Gene Mutation', 'PTEN Hamartoma Tumor Syndrome', 'PTEN Hamartoma Syndrome']","['Sirolimus', 'Placebo Control']",['B1227'],[['Small Molecule']],[['Small Molecule']],[['Serine/threonine-protein kinase mTOR']],[['mTOR']]
60676,NCT06525948,Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA,Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of Transfusion-dependent Non-severe Aplastic Anaemia (TD-NSAA),PHASE4,NOT_YET_RECRUITING,30/7/2024,30/12/2025,30/6/2025,54,ESTIMATED,,,"['Aplastic Anemia', 'Transfusion-dependent Anemia']","['Recombinant Human Thrombopoietin', 'Cyclosporin']",['B2845'],[['Small Molecule']],[['Small Molecule']],[[]],[['CaN']]
56722,NCT06444412,An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients with Glioma,GA-68 PSMA-11 PET to Evaluate Malignant Glioma Recurrence - a Pilot Study,PHASE2,RECRUITING,26/7/2024,30/4/2026,30/4/2026,25,ESTIMATED,,,"['WHO Grade 3 Glioma', 'WHO Grade 4 Glioma']","['Computed Tomography', 'Gallium Ga-68 gozetotide', 'Positron Emission Tomography']",['B3880'],[['Radiopharmaceutical Imaging']],[['Radiopharmaceutical Imaging']],[['Prostate-specific membrane antigen']],[['PSMA']]
60922,NCT06562920,Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer,"A Single-arm, Prospective, Exploratory Study of Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer and Analysis of Biological Markersï¼ˆASSESSï¼‰",PHASE2,RECRUITING,24/7/2024,31/7/2028,31/7/2027,20,ESTIMATED,,,['Small Cell Lung Cancer'],"['Adebrelimab', 'Chemotherapy', 'Stereotactic Body Radiation Therapy', 'Surgical Procedure']",['B2489'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed death-ligand 1']],[['PDL1']]
55546,NCT06260033,Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer,A Phase II Trial of Stereotactic Body Radiation Therapy and Fluoroestradiol Positron Emission Tomography in Patients With Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer,PHASE2,RECRUITING,23/7/2024,29/10/2026,29/10/2026,18,ESTIMATED,,,"['Breast Cancer', 'Hormone Receptor-Positive Breast Cancer', 'Breast Cancer']","['Biospecimen Collection', 'Bone Scan', 'Computed Tomography', '18F-fluoroestradiol', 'Positron Emission Tomography', 'Questionnaire Administration', 'Stereotactic Body Radiation Therapy']",['B3726'],[['Radiopharmaceutical Imaging']],[['Radiopharmaceutical Imaging']],[[]],[[]]
53115,NCT05901194,Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma,Study of the Benefit of Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma (HCC),PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,10/7/2024,30/4/2027,30/4/2027,25,ESTIMATED,,,['Hepatocellular Carcinoma'],['Lenvatinib'],['B261'],[['Small Molecule']],[['Small Molecule']],"[['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
62121,NCT06734182,Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer,"A Prospective, Single-arm, Multicenter, Phase II Clinical Study on Envafolimab Combined With Disitamab Vedotin And Carboplatin for Resectable, Stage II-III, HER2-Mutant Non-Small Cell Lung Cancer",PHASE2,RECRUITING,22/6/2024,22/6/2028,22/6/2027,25,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['Envafolimab', 'Disitamab vedotin', 'Carboplatin']","['B1384', 'B1763', 'B274']","[['Antibody'], ['Antibody Drug Conjugate (ADC)'], ['Small Molecule']]","[['Antibody Fragment'], ['Antibody Drug Conjugate (ADC)'], ['Small Molecule']]","[['Programmed death-ligand 1'], ['Receptor protein-tyrosine kinase erbB-2'], ['DNA']]","[['PDL1'], ['Beta-tubulin ', 'HER2'], ['DNA']]"
56572,NCT06422156,SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer,"A Prospective, Multicenter, Single Arm Study of SBRT Combined With Nimotuzumab and Mono-chemotherapy in the Treatment of Locally Advanced Pancreatic Cancer",PHASE2,NOT_YET_RECRUITING,1/6/2024,1/6/2026,1/6/2026,73,ESTIMATED,,,['Pancreatic Cancer'],"['Stereotactic Body Radiation Therapy', 'Nimotuzumab', 'Gemcitabine', 'Gimeracil/oteracil/tegafur', 'Capecitabine']","['B662', 'B2079', 'B2855', 'B474']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['DNA', 'Ribonucleotide reductase'], ['Thymidylate synthase'], ['Thymidylate synthase']]","[['EGFR'], ['DNA', 'RNR'], ['TYMS'], ['TYMS']]"
63100,NCT06881537,CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer,CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer,PHASE2,RECRUITING,1/6/2024,30/6/2028,30/6/2025,15,ESTIMATED,,,['Epithelial Neoplasm'],"['Capecitabine', 'Oxaliplatin', 'Bevacizumab', 'Tislelizumab']","['B474', 'B1229', 'B167', 'B1344']","[['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Thymidylate synthase'], ['DNA'], ['Vascular endothelial growth factor A'], ['Programmed cell death protein 1']]","[['TYMS'], ['DNA'], ['VEGF-A'], ['PD-1']]"
55942,NCT06332430,Intratumoral CAN2109 in Subjects With Solid Tumors,"A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors.",PHASE1,RECRUITING,28/5/2024,30/5/2026,30/5/2025,27,ESTIMATED,,,"['Solid Tumors', 'Hematology']",['Immunogenic Cell Death Inducer CAN2109'],[],[],[],[],[]
56443,NCT06402383,Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living with HIV,Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living with HIV: NECST-HIV,,ACTIVE_NOT_RECRUITING,25/5/2024,30/4/2026,31/1/2026,2000,ESTIMATED,,,['Cervical Cancer'],['Human papillomavirus vaccine'],['B3475'],[[]],[[]],[[]],[[]]
56475,NCT06408194,Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies,Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells Following Commercial CD19 CAR T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies,PHASE1,RECRUITING,13/5/2024,30/6/2025,30/6/2025,20,ESTIMATED,,,"['Leukemia', 'Acute Lymphoblastic Leukemia']","['Anti-CD22 CAR T Cells Preparation', 'Tisagenlecleucel', 'Lymphodepletion Therapy']",['B971'],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['B-lymphocyte antigen CD19']],[['CD19']]
56621,NCT06428682,Role of TXA in Patients Undergoing Breast Free Flap Reconstruction,Role of Intravenous Tranexamic Acid Use in Patients Undergoing Breast Free Flap Reconstruction: Randomized Controlled Trial,PHASE4,RECRUITING,13/5/2024,13/5/2026,13/5/2025,100,ESTIMATED,,,"['Breast Cancer', 'Blood Loss, Surgical']","['Tranexamic Acid', 'Placebo Control']",[],[],[],[],[]
60592,NCT06300320,A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease,"A Randomized, Open-label, Multicenter Phase II Clinical Trial of Rovadicitinib in the Treatment of Third-line and Subsequent Moderate to Severe Chronic Graft-versus-host Disease (cGVHD).",PHASE2,RECRUITING,7/5/2024,30/4/2026,31/10/2025,52,ESTIMATED,,,['Chronic Graft Versus Host Disease'],['Rovadicitinib'],['B1844'],[['Small Molecule']],[['Small Molecule']],"[['Rho-associated protein kinase 1', 'Rho-associated protein kinase 2', 'Tyrosine-protein kinase JAK1', 'Tyrosine-protein kinase JAK2']]","[['ROCK1', 'ROCK2', 'JAK1', 'JAK2']]"
55513,NCT06255379,Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer,"An Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC",PHASE2,NOT_YET_RECRUITING,6/5/2024,21/3/2027,21/3/2027,52,ESTIMATED,,,"['Colorectal Cancer', 'Colon Carcinoma', 'Rectal Carcinoma']","['Fruquintinib', 'Gimeracil/oteracil/tegafur']","['B1437', 'B2855']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Thymidylate synthase']]","[['VEGFR1', 'VEGFR2', 'VEGFR3'], ['TYMS']]"
60609,NCT06358638,Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY,Sickle Cell Disease Transplant Using a Nonmyeloablative Approach: Adding Daratumumab for Patients With Anti-donor Red Cell AntibodY,PHASE2,RECRUITING,3/4/2024,30/9/2054,30/9/2044,12,ESTIMATED,,,['Sickle Cell Disease'],"['Daratumumab', 'Alemtuzumab', 'Sirolimus', 'Total-Body Irradiation']","['B415', 'B169', 'B1227']","[['Antibody'], ['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Lymphocyte differentiation antigen CD38'], ['CAMPATH-1 antigen'], ['Serine/threonine-protein kinase mTOR']]","[['CD38'], ['CD52'], ['mTOR']]"
57086,NCT06494514,NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer,"A Single-center, Randomized, Interventional Controlled Study of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy for First-line Treatment of Locally Advanced Pancreatic Cancer",,RECRUITING,1/4/2024,1/4/2027,1/4/2027,40,ESTIMATED,,,['Pancreatic Cancer'],"['Eculizumab', 'Oxaliplatin', 'Fluorouracil', 'FU-LV Regimen', 'PDCD1 wt Allele', 'Stereotactic Body Radiation Therapy', 'Gemcitabine', 'Nab-paclitaxel']","['B195', 'B1229', 'B493', 'B2079']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['DNA'], ['Thymidylate synthase'], ['DNA', 'Ribonucleotide reductase']]","[['C5'], ['DNA'], ['TYMS'], ['DNA', 'RNR']]"
55598,NCT06271551,Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy,Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy: A Randomized Controlled Trial,PHASE2,NOT_YET_RECRUITING,31/3/2024,31/12/2029,31/12/2028,310,ESTIMATED,,,['Prostate Cancer'],"['Transdermal Estrogen', 'Resistance Training']",[],[],[],[],[]
55726,NCT06297226,Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,"A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)",PHASE2,RECRUITING,21/3/2024,30/6/2032,30/6/2027,175,ESTIMATED,,,['Multiple Myeloma'],['Arlocabtagene autoleucel'],['B4660'],[['Cell Therapy']],[['T-Cell Chimeric Antigen Receptor (CAR) Therapy']],[['G-protein coupled receptor family C group 5member D']],[['GPRC5D']]
60632,NCT06432296,Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody,"A Randomized, Controlled, Multi-Center Phase III Clinical Study to Evaluate the Efficacy and Safety of M701 for Intraperitoneal Injection in Patients With Malignant Ascites Caused by Advanced Epithelial Solid Tumors",PHASE3,RECRUITING,20/3/2024,11/11/2025,3/8/2025,270,ESTIMATED,,,['Malignant Ascites'],"['M 701', 'Paracentesis']",['B3160'],[['Antibody']],[['Bispecific Antibody']],"[['Epithelial cell adhesion molecule', 'T cell surface glycoprotein CD3']]","[['EpCAM', 'CD3']]"
54453,NCT06099366,Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children,Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in,PHASE2,RECRUITING,5/3/2024,31/12/2033,31/12/2033,116,ESTIMATED,,,['Acute Lymphoblastic Leukemia'],"['Vincristine', 'Asparaginase', 'Dexamethasone', 'Cytarabine Intrathecal Regimen', 'Intrathecal Methotrexate/Methotrexate/Pegaspargase/Vincristine Regimen', 'Mercaptopurine', 'Methotrexate Intrathecal Regimen', 'Cyclophosphamide', 'Cytarabine', 'Methotrexate', 'Doxorubicin']","['B2083', 'B725', 'B1128', 'B2978', 'B2818', 'B2050', 'B997', 'B1914']","[['Small Molecule'], ['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Enzyme'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['Asparagine'], ['Glucocorticoid receptor'], [], ['DNA'], ['DNA-directed DNA polymerase'], ['Dihydrofolate reductase'], ['Top II inhibitors (Topoisomerase II inhibitors)']]","[['TUBB1'], ['ASN'], ['GR'], ['HPRT1'], ['DNA'], ['DNA-directed DNA polymerase'], ['DHFR'], ['TOP2']]"
51669,NCT05679921,Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma,"Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma: Open-label, Multicenter, Randomized, Phase 2 Trials",PHASE2,RECRUITING,1/3/2024,31/12/2026,31/12/2026,116,ESTIMATED,,,['Soft Tissue Sarcoma'],"['Pembrolizumab', 'Pazopanib']","['B936', 'B1649']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['PD-1'], ['PDGFRÎ±', 'PDGFRÎ²', 'c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
52009,NCT05735028,The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer,A Preliminary Study on the Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer,PHASE1,RECRUITING,7/2/2024,7/12/2025,7/8/2025,8,ESTIMATED,,,['Thoracic Neoplasm'],"['Centipeda minima Decoction', 'PD-1/PD-L1 inhibitor']",[],[],[],[],[]
55925,NCT06329999,"A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML","A Prospective, Multicenter, and Exploratory Study of Mitoxantrone Liposomes, Cytarabine and G-CSF Combined With Vineclavone in the Treatment ofRecurrent Adult AML and MDS-EB-2/Elder AML",,RECRUITING,3/2/2024,31/12/2027,31/12/2025,78,ESTIMATED,,,"['Acute Myeloid Leukemia', 'Myelodysplastic Syndrome', 'Acute Myeloid Leukemia']","['Mitoxantrone liposomal', 'Cytarabine', 'Filgrastim', 'Vincristine', 'Hematopoietic Cell Transplantation']","['B2930', 'B2050', 'B157', 'B2083']","[['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Colony-Stimulating Factor'], ['Small Molecule']]","[['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA-directed DNA polymerase'], ['Colony stimulating factor 3 receptor'], ['Tubulin beta-1 chain']]","[['TOP2'], ['DNA-directed DNA polymerase'], ['CSF-3R'], ['TUBB1']]"
55152,NCT06208462,Neoadjuvant Therapy of HAICï¼ˆGEMOXï¼‰ Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors,Neoadjuvant Therapy of HAICï¼ˆGEMOXï¼‰ Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factorsï¼šNEO-ERA-01 Study,PHASE2,RECRUITING,19/1/2024,31/1/2027,31/1/2026,33,ESTIMATED,,,['Intrahepatic Cholangiocarcinoma'],"['Adebrelimab', 'Lenvatinib', 'Gemcitabine', 'Oxaliplatin']","['B2489', 'B261', 'B2079', 'B1229']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Programmed death-ligand 1'], ['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['DNA', 'Ribonucleotide reductase'], ['DNA']]","[['PDL1'], ['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['DNA', 'RNR'], ['DNA']]"
53541,NCT05967182,A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma,A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma,PHASE2,RECRUITING,16/1/2024,31/7/2029,31/7/2027,24,ESTIMATED,,,['Bile Duct Cancer'],"['Pembrolizumab', 'Gemcitabine', 'Cisplatin']","['B936', 'B2079', 'B49']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['DNA', 'Ribonucleotide reductase'], ['DNA']]","[['PD-1'], ['DNA', 'RNR'], ['DNA']]"
56699,NCT06440811,Preoperative Adjuvant SOX Plus PL-1 Antibody and FLOT Plus PD-1 Antibody for Locally Advanced dMMR Gastric Cancer,Safety and Efficacy of Preoperative Adjuvant SOX Regimen Combined With PD-1 Antibody Versus FLOT Regimen With PD-1 Antibody for the Treatment of Localized Deficient Mismatch Repair Gastric Cancer: a Chinese Trial,PHASE1,RECRUITING,1/1/2024,1/3/2025,1/1/2025,200,ESTIMATED,,,"['Gastric Cancer', 'Immune-related Adverse Event', 'Chemotherapeutic Toxicity']","['SOX', 'PD-1 Inhibitor', 'FLOT']",[],[],[],[],[]
50893,NCT05567770,ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer,ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer,PHASE1,WITHDRAWN,31/12/2023,31/1/2030,31/1/2025,0,ACTUAL,,,['Prostate Cancer'],"['Actinium Ac 225 Rosopatamab Tetraxetan', 'Stereotactic Body Radiation Therapy']",[],[],[],[],[]
54283,NCT06077760,A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002),"A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)",PHASE3,RECRUITING,6/12/2023,21/12/2035,25/6/2030,868,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['V 940', 'Pembrolizumab', 'Placebo Control']","['B5475', 'B936']","[['Cancer Vaccine'], ['Antibody']]","[['mRNA Vaccine'], ['Monoclonal Antibody']]","[[], ['Programmed cell death protein 1']]","[[], ['PD-1']]"
54679,NCT06132438,Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma,Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma (INTERROGATE-GBM),PHASE1,NOT_YET_RECRUITING,30/11/2023,30/9/2026,30/9/2024,26,ESTIMATED,,,['Glioblastoma'],['PEP-CMV Vaccine'],[],[],[],[],[]
53735,NCT05995041,Universal CAR-T Cells Targeting AML,Universal CAR T Cells for the Treatment of Acute Myeloid Leukemia,PHASE1,RECRUITING,31/10/2023,31/12/2026,30/9/2026,30,ESTIMATED,,,['Acute Myeloid Leukemia'],['CLL-1/CD33/CD38/CD123-specific universal CAR- T cells (Shenzhen Geno-Immune Medical Institute)'],['B11726'],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[[]],[[]]
53903,NCT06017323,Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma,Phase I Study of Proglumide With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic DuctalAdenocarcinoma,PHASE1,WITHDRAWN,31/10/2023,31/7/2026,31/7/2026,0,ACTUAL,,,['Pancreatic Cancer'],"['Gemcitabine', 'Nab-paclitaxel', 'Proglumide']","['B2079', 'B7744', 'B945']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain'], ['Cholecystokinin receptors']]","[['DNA', 'RNR'], ['TUBB1'], ['CCK receptor']]"
54523,NCT06109207,Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas,The Safety and Feasibility of Neoadjuvant Camrelizumab With Dalpiciclib for the Treatment of Resectable Head and Neck Squamous Cell Carcinomaï¼šA Phase 1 Trial,PHASE1,RECRUITING,31/10/2023,31/10/2025,31/10/2024,6,ESTIMATED,,,['Head and Neck Squamous Cell Carcinoma'],"['Camrelizumab', 'Dalpiciclib']","['B1309', 'B1659']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6']]","[['PD-1'], ['CDK4', 'CDK6']]"
54311,NCT06081595,Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment,"Fluzoparib Combined With Apatinib for Maintenance Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Phase II Single-arm, Open Label, Multicenter Trial",PHASE2,NOT_YET_RECRUITING,30/10/2023,30/12/2026,30/12/2024,54,ESTIMATED,,,['Ovarian Cancer'],"['Fuzuloparib', 'Rivoceranib']","['B2371', 'B948']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Poly'], ['SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 2']]","[['PARP'], ['SRC', 'c-Kit', 'VEGFR2']]"
54522,NCT06109064,Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS,A Clinical Study to Evaluate the Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk Myelodysplastic Syndromes,PHASE2,RECRUITING,27/10/2023,1/2/2026,1/2/2024,14,ESTIMATED,,,['Myelodysplastic Syndrome'],"['Venetoclax', 'Decitabine', 'Azacitidine']","['B927', 'B113', 'B322']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Apoptosis regulator Bcl-2'], ['DNA', 'DNA (cytosine-5)-methyltransferase 3A', 'DNA (cytosine-5)-methyltransferase 3B'], ['DNA']]","[['Bcl-2'], ['DNMT1', 'DNMT3A', 'DNMT3B'], ['DNMT1']]"
53826,NCT06008119,Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer,"A Multicenter, Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer",PHASE3,RECRUITING,25/10/2023,24/12/2026,24/12/2026,165,ESTIMATED,,,['Colorectal Cancer'],"['Tunlametinib', 'Vemurafenib', 'Bevacizumab', 'Cetuximab']","['B1757', 'B216', 'B167', 'B164']","[['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2'], [], ['Vascular endothelial growth factor A'], ['Epidermal growth factor receptor erbB1']]","[['MEK1', 'MEK2'], ['BRAF V600E'], ['VEGF-A'], ['EGFR']]"
60603,NCT06321887,EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD,A Pilot Study to Assess the Efficacy and Tolerability of Reduced Dose Oral Iron in the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease Patients.,PHASE3,RECRUITING,20/10/2023,1/10/2025,1/10/2024,30,ESTIMATED,,,"['Inflammatory Bowel Disease', 'Iron-Deficiency Anemia']",['Ferrous fumarate'],['B97'],[['Small Molecule']],[['Small Molecule']],[[]],[['Fe']]
52874,NCT05863195,Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial,A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial,PHASE3,RECRUITING,19/10/2023,30/6/2034,30/6/2029,408,ESTIMATED,,,"['Colorectal Cancer', 'Liver Cancer', 'Colorectal Cancer', 'Colorectal Cancer']","['Bevacizumab', 'Cetuximab', 'Computed Tomography', 'Floxuridine', 'Fluorouracil', 'Ganciclovir', 'Intrahepatic Infusion Procedure', 'Irinotecan', 'Folinic acid', 'Oxaliplatin', 'Panitumumab', 'Single Photon Emission Computed Tomography']","['B167', 'B164', 'B2088', 'B493', 'B488', 'B1679', 'B226', 'B1229', 'B194']","[['Antibody'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Monoclonal Antibody']]","[['Vascular endothelial growth factor A'], ['Epidermal growth factor receptor erbB1'], ['Thymidylate synthase'], ['Thymidylate synthase'], ['Human herpesvirus 1 DNA polymerase'], ['DNA topoisomerase I'], [], ['DNA'], ['Epidermal growth factor receptor erbB1']]","[['VEGF-A'], ['EGFR'], ['TYMS'], ['TYMS'], ['UL30'], ['TOP1'], [], ['DNA'], ['EGFR']]"
49193,NCT05318469,Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer,A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with Expansion Cohort in PD-L1 Negative TNBC,PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,13/10/2023,31/10/2026,31/10/2026,9,ACTUAL,,,"['Breast Cancer', 'Triple-Negative Breast Cancer']","['Ivermectin', 'Balstilimab']","['B96', 'B1355']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[[], ['Programmed cell death protein 1']]","[['GluCls'], ['PD-1']]"
62807,NCT06080893,The Effect of Preoperative Ferric Carboxymaltose Administration on Mortality in Geriatric Hip Fractures,The Effect of Preoperative Ferric Carboxymaltose Administration on Mortality in Geriatric Hip Fractures,PHASE4,COMPLETED,10/10/2023,24/3/2025,10/6/2024,209,ACTUAL,,,"['Anemia', 'Complication,Postoperative', 'Hip Fractures']",['Ferric carboxymaltose'],['B685'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
53042,NCT05888844,A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma,A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma,PHASE2,ACTIVE_NOT_RECRUITING,9/10/2023,31/12/2026,31/12/2025,63,ACTUAL,,,['Skin Squamous Cell Carcinoma'],['INCB 099280'],['B5063'],[['Small Molecule']],[['Small Molecule']],[['Programmed death-ligand 1']],[['PDL1']]
54410,NCT06092957,Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy,"Reduced-dose Radiotherapy With/Without Concurrent Chemotherapy Versus Standard Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma Who Achieved Complete Response After Induction Chemotherapy Plus Immunotherapy: a Randomized, Open-label, Multicenter, Phase III Trial",PHASE3,RECRUITING,9/10/2023,30/10/2031,30/10/2029,504,ESTIMATED,,,"['Nasopharyngeal Cancer', 'De-escalation Therapy']","['Cisplatin', 'Camrelizumab', 'Toripalimab', 'Adebrelimab', 'Intensity-Modulated Radiation Therapy']","['B49', 'B1309', 'B1346', 'B2489']","[['Small Molecule'], ['Antibody'], ['Antibody'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['DNA'], ['Programmed cell death protein 1'], ['Programmed cell death protein 1'], ['Programmed death-ligand 1']]","[['DNA'], ['PD-1'], ['PD-1'], ['PDL1']]"
54074,NCT06045689,A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants,"A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)",PHASE3,RECRUITING,5/10/2023,30/12/2027,1/1/2026,100,ESTIMATED,,,['Myelodysplastic Syndrome'],['Luspatercept'],['B911'],[['Engineered Protein Therapy']],[['Fusion Protein']],[['Transforming growth factor beta']],[['TGF-Î²']]
60404,NCT05786573,A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety and Dose Confirmation Run-In Period, To Evaluate the Efficacy and Safety of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)",PHASE3,ACTIVE_NOT_RECRUITING,25/9/2023,31/8/2026,30/6/2026,134,ESTIMATED,,,['Warm Autoimmune Hemolytic Anemia'],['Obexelimab'],[],[],[],[],[]
54165,NCT06057168,Performance of EluciremÂ® in DSC-MRI Perfusion of Brain Gliomas,Performance of EluciremÂ® (Gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) Perfusion of Brain Gliomas Phase IIIb Clinical Trial,PHASE3,RECRUITING,7/9/2023,30/4/2024,29/4/2024,138,ESTIMATED,,,"['Central Nervous System Neoplasm', 'Central Nervous System Neoplasm']","['Gadopiclenol', 'Gadoterate-meglumine']","['B1298', 'B3447']","[['Radiopharmaceutical'], ['Small Molecule']]","[['Radiopharmaceutical'], ['Small Molecule']]","[[], []]","[[], []]"
53885,NCT06015568,Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation,"Phase I Study of Anti-EGFR/c-Met Bispecific Antibody MCLA-129 Combined With Befotertinib in Patients of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation To Evaluate The Safety, Pharmacokinetic Characteristics and Antitumor Activity",PHASE1,NOT_YET_RECRUITING,1/9/2023,4/7/2029,4/11/2028,172,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['MCLA-129', 'Befotertinib']","['B5742', 'B1736']","[['Antibody'], ['Small Molecule']]","[['Bispecific Antibody'], ['Small Molecule']]","[['c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)', 'Epidermal growth factor receptor erbB1'], ['Epidermal growth factor receptor erbB1']]","[['c-Met', 'EGFR'], ['EGFR']]"
53919,NCT06020833,A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS,A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS,PHASE1/PHASE2,NOT_YET_RECRUITING,31/8/2023,31/12/2026,31/10/2025,25,ESTIMATED,,,['Myelodysplastic Syndrome'],"['Roxadustat', 'Tretinoin']","['B825', 'B1110']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Hypoxia-inducible factor prolyl hydroxylase'], ['Retinoic acid receptors']]","[['HIF-PHs'], ['RARs']]"
62646,NCT06809426,"Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer","Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer",,COMPLETED,21/8/2023,24/10/2024,14/10/2024,13,ACTUAL,,,['Castration-Resistant Prostate Carcinoma'],['[177Lu]-LNC1011'],['B10548'],[['Radiopharmaceuticals']],[['Radiopharmaceutical Therapy']],[['Prostate-specific membrane antigen']],[['PSMA']]
36532,NCT03529448,TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma,"Phase Ib, Open-label, Multicenter, Intrapatient Dose-escalation Clinical Trial to Assess the Safety Profile of the TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma",PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,18/8/2023,31/12/2025,31/3/2025,33,ACTUAL,,,['Glioblastoma'],"['Dronabinol', 'Temozolomide', 'Radiation Therapy']","['B1565', 'B2056']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Cannabinoid receptor'], ['DNA']]","[['CB'], ['DNA']]"
53159,NCT05907304,A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations,An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations,PHASE1,RECRUITING,17/8/2023,30/11/2025,31/7/2025,115,ESTIMATED,,,['Solid Tumors'],"['Naporafenib', 'Trametinib']","['B2556', 'B575']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['C-Raf kinase', 'Serine/threonine-protein kinase B-raf'], ['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2']]","[['CRAF', 'BRAF'], ['MEK1', 'MEK2']]"
53241,NCT05918250,mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM),"A Phase 1, Open-Label, Multicenter, Study of mRNA-2736 in Patients With Relapsed or Refractory Multiple Myeloma",PHASE1,WITHDRAWN,15/8/2023,27/5/2026,27/5/2026,0,ACTUAL,,,['Multiple Myeloma'],['MRNA 2736'],['B6406'],[['mRNA']],[['mRNA']],[[]],[[]]
50115,NCT05453396,Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies,A Pilot Study of Loncastuximab Tesirine in Specific Populations of Relapsed/Refractory B-Cell Malignancies,PHASE2,RECRUITING,7/8/2023,6/7/2026,15/12/2025,40,ESTIMATED,,,"['Post-Transplant Lymphoproliferative Disorder', 'B-Cell Non-Hodgkin Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Follicular Lymphoma', 'Mantle Cell Lymphoma', 'Post-Transplant Lymphoproliferative Disorder', 'Mantle Cell Lymphoma', 'Post-Transplant Lymphoproliferative Disorder', 'B-Cell Non-Hodgkin Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Follicular Lymphoma']",['Loncastuximab tesirine'],['B1323'],[['Antibody Drug Conjugate (ADC)']],[['Antibody Drug Conjugate (ADC)']],"[['B-lymphocyte antigen CD19', 'DNA']]","[['CD19', 'DNA']]"
50774,NCT05553041,18F-Fluciclovine PET-MRI in High-grade Glioma,Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG),EARLY_PHASE1,RECRUITING,7/8/2023,31/12/2026,31/12/2025,30,ESTIMATED,,,"['Glioma', 'High-Grade Glioma', 'High-Grade Glioma', 'Glioma', 'Glioma']","['18F-Fluciclovine', 'Positron Emission Tomography and Magnetic Resonance Imaging', 'Magnetic Resonance Imaging']",['B2849'],[['Radiopharmaceutical Imaging']],[['Radiopharmaceutical Imaging']],[['Prostate-specific antigen']],[['KLK3']]
54044,NCT06041425,The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE,The Effects of Single Dose Oxycodone Versus Sufentanil on Pain and Inflammatory Response After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: a Randomized Controlled Study,PHASE4,COMPLETED,7/8/2023,25/12/2023,17/12/2023,40,ACTUAL,,,"['Hepatocellular Carcinoma', 'Leiomyosarcoma', 'Connective and Soft Tissue Neoplasm', 'Inflammation']","['Oxycodone', 'Transarterial Chemoembolization', 'Sufentanil']","['B1993', 'B1995']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Opioid receptors'], ['Opioid receptors']]","[['Opioid receptors'], ['Opioid receptors']]"
52251,NCT05770531,Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy,A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast Cancer,PHASE2,RECRUITING,4/8/2023,1/10/2028,1/8/2028,160,ESTIMATED,,,"['HER2-Negative Breast Cancer', 'Triple-Negative Breast Cancer']","['Biospecimen Collection', 'Computed Tomography', 'Magnetic Resonance Imaging', 'Sacituzumab govitecan']",['B1036'],[['Antibody Drug Conjugate (ADC)']],[['Antibody Drug Conjugate (ADC)']],"[['DNA topoisomerase I', 'Tumor-associated calcium signal transducer 2']]","[['TOP1', 'TROP2']]"
53820,NCT06007846,A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer,A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score â‰¥ B7 Cirrhosis and Hepatocellular Carcinoma,PHASE2/PHASE3,RECRUITING,31/7/2023,31/8/2025,31/7/2025,12,ESTIMATED,,,"['Hepatocellular Carcinoma', 'Cirrhosis']",['memantine hydrochloride'],['B9273'],[[]],[[]],[[]],[[]]
53467,NCT05954312,A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors,"A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors",PHASE1,RECRUITING,28/7/2023,31/12/2027,31/12/2027,280,ESTIMATED,,,['Solid Tumors'],['VVD-130037'],['B5009'],[['Small Molecule']],[['Small Molecule']],[['Kelch like ECH associated protein 1']],[['KEAP1']]
52299,NCT05777278,Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression,A Prospective Study of Savolitinib Plus Docetaxel in Pretreated EGFR/ALK/ROS1/MET ex14m-wildtype Advanced NSCLC Patients With MET Overexpression (FirstMET),PHASE1/PHASE2,RECRUITING,26/7/2023,31/8/2027,31/8/2027,29,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['Savolitinib', 'Docetaxel']","['B988', 'B2814']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)'], ['Tubulin beta-1 chain']]","[['c-Met'], ['TUBB1']]"
52793,NCT05850234,"A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma","A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma",PHASE1/PHASE2,RECRUITING,20/7/2023,29/9/2028,13/4/2027,80,ESTIMATED,,,['Multiple Myeloma'],['GC 012F'],['B4400'],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],"[['B-cell maturation protein', 'B-lymphocyte antigen CD19']]","[['BCMA', 'CD19']]"
51704,NCT05687110,Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes,A Phase 1 Study of the Polymerase Theta Inhibitor Novobiocin in BRCA-Mutant and Other DNA Damage Repair-Deficient Solid Tumors,PHASE1,RECRUITING,6/7/2023,1/9/2026,1/8/2026,31,ESTIMATED,,,"['Solid Tumors', 'Solid Tumors']","['Biopsy', 'Biospecimen Collection', 'Diagnostic Imaging', 'novobiocin sodium']",['B8884'],[[]],[[]],[[]],[[]]
53508,NCT05961696,A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia,A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia,PHASE1,WITHDRAWN,5/7/2023,3/10/2023,3/10/2023,0,ACTUAL,,,['Acute Lymphoblastic Leukemia'],['Mosunetuzumab'],['B1328'],[['Antibody']],[['Bispecific T-Cell Engager']],"[['B-lymphocyte antigen CD20', 'T cell surface glycoprotein CD3']]","[['CD20', 'CD3']]"
52123,NCT05751265,Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer,"Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer, Single-arm, Exploratory Clinical Study",PHASE2,NOT_YET_RECRUITING,1/7/2023,1/6/2025,1/6/2024,39,ESTIMATED,,,['Gastric Cancer'],"['Tislelizumab', 'Fluorouracil', 'Paclitaxel']","['B1344', 'B493', 'B1250']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Thymidylate synthase'], ['Tubulin beta-1 chain']]","[['PD-1'], ['TYMS'], ['TUBB1']]"
50050,NCT05443425,Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies,Pilot Trial of Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies,PHASE1,RECRUITING,16/6/2023,5/7/2025,5/7/2025,18,ESTIMATED,,,"['Hematology', 'Acute Graft Versus Host Disease']","['Colestyramine', 'Leflunomide', 'Steroid Therapy']","['B3231', 'B2103']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[[], ['Dihydroorotate dehydrogenase']]","[['FABP6'], ['DHODH']]"
52541,NCT05812807,Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab,OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy,PHASE3,RECRUITING,14/6/2023,31/5/2033,31/5/2033,1295,ESTIMATED,,,"['Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Triple-Negative Breast Cancer']","['Pembrolizumab', 'Patient Observation', 'Biopsy', 'Biospecimen Collection', 'Questionnaire Administration']",['B936'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
53298,NCT05926960,"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI-PD-1 THERAPY",PHASE2,ACTIVE_NOT_RECRUITING,13/6/2023,23/5/2027,23/5/2025,38,ACTUAL,,,['Male Reproductive System Neoplasm'],"['Encorafenib', 'Binimetinib', 'Pembrolizumab', 'Ipilimumab', 'Nivolumab']","['B981', 'B949', 'B936', 'B480', 'B714']","[['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Antibody'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Serine/threonine-protein kinase B-raf'], ['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2'], ['Programmed cell death protein 1'], ['Cytotoxic T-Lymphocyte-Associated Antigen 4'], ['Programmed cell death protein 1']]","[['BRAF'], ['MEK1', 'MEK2'], ['PD-1'], ['CTLA4'], ['PD-1']]"
60267,NCT05443464,Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD),A Phase I Safety Study of Single Dose Allogeneic Bone Marrow Derived MSCs for Steroid Refractory Acute Graft vs. Host Disease,PHASE1,WITHDRAWN,5/6/2023,14/10/2024,10/6/2024,0,ACTUAL,,,['Acute Graft Versus Host Disease'],['OSSM 001'],['B11522'],[['Mesenchymal Stem Cell Therapy (MSCs)']],[['Mesenchymal Stem Cell Therapy (MSCs)']],[[]],[[]]
53074,NCT05894837,Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases,"Serplulimab in Combination With Regorafenib and Hepatic Artery Bicarbonate Infusion for Third-line Treatment in Patients With Colorectal Cancer and Liver Metastases: a Single-center, Single-arm, Phase 2 Trial",PHASE2,NOT_YET_RECRUITING,1/6/2023,1/6/2025,1/6/2024,30,ESTIMATED,,,"['Colorectal Cancer', 'Liver Cancer']","['Serplulimab', 'Regorafenib', 'Intrahepatic Infusion Procedure']","['B1535', 'B526']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Colony stimulating factor 1 receptor', 'Ephrin type-A receptor 2', 'Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Nerve growth factor receptor Trk-A', 'Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'RAF serine/threonine protein kinase', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'TEK receptor tyrosine kinase', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['PD-1'], ['Abl', 'BRAF V600E', 'CSF-1R', 'EphA2', 'FGFR1', 'FGFR2', 'TRKA', 'PDGFRÎ±', 'PDGFRÎ²', 'Raf kinase', 'BRAF', 'c-Kit', 'Tie-2', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3', 'DDR2', 'FRK', 'MAPK11']]"
49770,NCT05400902,HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma,"Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Bevacizumab in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: A Prospective, Single-Center, Phase II Study",PHASE2,UNKNOWN,31/5/2023,31/12/2023,31/12/2023,17,ESTIMATED,,,['Intrahepatic Cholangiocarcinoma'],"['Oxaliplatin', 'Folinic acid', 'Fluorouracil', 'Sintilimab', 'Bevacizumab']","['B1229', 'B226', 'B493', 'B1337', 'B167']","[['Small Molecule'], [], ['Small Molecule'], ['Antibody'], ['Antibody']]","[['Small Molecule'], [], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['DNA'], [], ['Thymidylate synthase'], ['Programmed cell death protein 1'], ['Vascular endothelial growth factor A']]","[['DNA'], [], ['TYMS'], ['PD-1'], ['VEGF-A']]"
53017,NCT05885464,A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL),"A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)",PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,25/5/2023,31/12/2026,31/12/2026,5,ACTUAL,,,"['T Lymphoblastic Lymphoma', 'Hematology', 'Acute Lymphoblastic Leukemia']",['BEAM 201'],['B5601'],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['T-cell antigen CD7']],[['CD7']]
53597,NCT05976997,"Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)","Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)",PHASE2,RECRUITING,8/5/2023,31/12/2024,31/12/2023,36,ESTIMATED,,,"['Peripheral T-Cell Lymphoma, Not Otherwise Specified']","['Duvelisib', 'Chidamide']","['B901', 'B9734']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Phosphatidylinositol 3 kinase delta', 'Phosphatidylinositol 3 kinase gamma'], ['Histone deacetylase']]","[['PI3KÎ´', 'PI3KÎ³'], ['HDAC']]"
51876,NCT05716516,STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER),Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer,PHASE2,RECRUITING,4/5/2023,31/5/2027,31/5/2026,36,ESTIMATED,,,['Brain Metastasis'],['Estradiol'],['B273'],[[]],[[]],[['Estrogen receptors']],[['ER']]
47909,NCT05139056,Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas,A Phase I Study of Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAd-S-pk7) Administered Intracerebrally to Patients With Recurrent High-Grade Gliomas,PHASE1,RECRUITING,2/5/2023,7/8/2025,7/8/2025,36,ESTIMATED,,,"['Anaplastic Astrocytoma', 'WHO Grade 3 Glioma', 'Anaplastic Oligodendroglioma', 'Glioblastoma', 'Gliosarcoma', 'High-Grade Glioma', 'WHO Grade 2 Glioma', 'WHO Grade 3 Glioma']","['Neural Stem Cells-expressing CRAd-S-pk7', 'Resection']",[],[],[],[],[]
52784,NCT05848999,UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors,"Exploratory Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors",PHASE1,RECRUITING,27/4/2023,31/7/2025,31/5/2025,87,ESTIMATED,,,['Solid Tumors'],['UCLM-802'],['B3311'],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['MSLN inhibitors(Mesothelin inhibitors)']],[['MSLN']]
52753,NCT05843448,"IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer","Pilot Study of an IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer",PHASE1,RECRUITING,19/4/2023,31/12/2026,30/6/2026,30,ESTIMATED,,,"['Muscle Invasive Bladder Cancer', 'Urothelial Carcinoma', 'Urothelial Carcinoma', 'Bladder Cancer']","['IO102 IO103', 'Pembrolizumab']","['B3545', 'B936']","[['Subunit Vaccine'], ['Antibody']]","[['Subunit Vaccine'], ['Monoclonal Antibody']]","[['Indoleamine 2,3-dioxygenase', 'Programmed death-ligand 1'], ['Programmed cell death protein 1']]","[['IDO1', 'PDL1'], ['PD-1']]"
51789,NCT05701709,Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors,"An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of SHR-A2102 in Patients With Advanced Solid Tumors",PHASE1,ACTIVE_NOT_RECRUITING,6/4/2023,31/8/2025,31/8/2025,395,ACTUAL,,,['Solid Tumors'],['SHR A2102'],['B5193'],[['Antibody Drug Conjugate (ADC)']],[['Antibody Drug Conjugate (ADC)']],"[['DNA topoisomerase I', 'nectin-4 inhibitors(Nectin-4 inhibitors)']]","[['TOP1', 'NECTIN4']]"
49551,NCT05371054,"Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies","Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies",PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,5/4/2023,1/7/2029,22/7/2024,130,ESTIMATED,,,"['Hematology', 'Non-Hodgkin Lymphoma', 'Non-Hodgkin Lymphoma', 'Hematology', 'Leukemia']","['Venetoclax', 'Enitociclib', 'Prednisone']","['B927', 'B1646', 'B1979']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Apoptosis regulator Bcl-2'], ['Cyclin-dependent kinase 9'], ['Glucocorticoid receptor']]","[['Bcl-2'], ['CDK9'], ['GR']]"
52155,NCT05754801,Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer,"Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer: A Randomized, Double-blinded, Placebo-controlled Trial",PHASE2,NOT_YET_RECRUITING,1/4/2023,30/9/2026,31/3/2026,172,ESTIMATED,,,"['Cancer', 'Palliative Care']","['Coriolus Versicolor Extract', 'Placebo Control']",[],[],[],[],[]
60391,NCT05744921,A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works.,"An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria",PHASE3,RECRUITING,7/3/2023,5/2/2029,5/2/2029,202,ESTIMATED,,,['Paroxysmal Nocturnal Hemoglobinuria'],"['Pozelimab', 'Cemdisiran']",[],[],[],[],[]
51535,NCT05661591,Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects,"Pharmacokinetic Effect of Fluconazole on SHR2554 in Healthy Subjects in Single-center, Open-label, Single-dose, Auto-controlled Pharmacokinetics",PHASE1,COMPLETED,28/2/2023,31/3/2023,31/3/2023,18,ACTUAL,,,['Malignant Tumor'],"['SHR-2554', 'Fluconazole']","['B2938', 'B15']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Histone-lysine N-methyltransferase EZH2'], ['Cytochrome P450 51']]","[['EZH2'], ['CYP51A1']]"
51867,NCT05715398,BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer,"A Multicenter, Open Phase â… /â…¡a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BR790 in Combination With Anlotinib in Subjects With Advanced Non-small Cell Lung Cancer",PHASE1/PHASE2,NOT_YET_RECRUITING,28/2/2023,31/12/2025,31/12/2024,90,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['BR 790', 'Catequentinib']","['B2985', 'B1436']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Src homology phosphotyrosyl phosphatase 2'], ['Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['SHP2'], ['c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
51641,NCT05675813,Genotype-guided Treatment in Newly Diagnosed PTCL,Guidance-04ï¼šT-cell Lymphoma Seriesï¼šA Genotype-guided Therapy in Newly Diagnosed Patients With Peripheral T-cell Lymphoma ï¼ˆTHEORY Studyï¼‰,PHASE1/PHASE2,RECRUITING,13/2/2023,15/7/2028,15/7/2026,264,ESTIMATED,,,['T-Cell Non-Hodgkin Lymphoma'],"['Cyclophosphamide', 'Doxorubicin', 'Vincristine', 'Prednisone', 'Azacitidine', 'Selinexor', 'Duvelisib', 'Tislelizumab', 'Chidamide']","['B2818', 'B1914', 'B2083', 'B1979', 'B322', 'B1030', 'B901', 'B1344', 'B9734']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule']]","[['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Tubulin beta-1 chain'], ['Glucocorticoid receptor'], ['DNA'], ['Exportin-1 protein'], ['Phosphatidylinositol 3 kinase delta', 'Phosphatidylinositol 3 kinase gamma'], ['Programmed cell death protein 1'], ['Histone deacetylase']]","[['DNA'], ['TOP2'], ['TUBB1'], ['GR'], ['DNMT1'], ['XPO1'], ['PI3KÎ´', 'PI3KÎ³'], ['PD-1'], ['HDAC']]"
51874,NCT05716113,CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL,"A Study for Safety, Efficacy and Cellular Pharmacokinetics of CD7 CAR-T Cell for Patients With Relapsed or Refractory CD7 Positive T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma",EARLY_PHASE1,COMPLETED,9/2/2023,31/8/2024,31/8/2024,20,ACTUAL,,,"['Neoplasms', 'Hematology', 'Hematology', 'Hematology']",['RD 13'],['B3149'],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['T-cell antigen CD7']],[['CD7']]
52345,NCT05784870,A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors,A Multicenter Randomized Controlled Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors,PHASE3,RECRUITING,7/2/2023,31/12/2024,31/12/2024,168,ESTIMATED,,,"['Hematology', 'Cancer-Related Anemia']","['Traditional Chinese Medicine Formulation', 'Ferrous succinate']",['B11815'],[[]],[[]],[[]],[[]]
51923,NCT05722795,Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC),Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer,,UNKNOWN,6/2/2023,31/12/2024,30/6/2024,40,ESTIMATED,,,"['Breast Cancer', 'Triple-Negative Breast Cancer']",['Imatinib'],['B2099'],[['Small Molecule']],[['Small Molecule']],"[['Bcr-Abl tyrosine kinase', 'Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor']]","[['BCR-ABL1', 'PDGFRÎ²', 'c-Kit']]"
52930,NCT05870995,Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia,"A Phase II Single Arm Study of Cladribine, Cytarabine, Etoposide and Venetoclax Sequential With Reduced Dose Conditioning of Fludarabine, Busulfan and Melphalan or Total Marrow Radiation for Refractory Acute Myeloid Leukemia",PHASE2,RECRUITING,1/2/2023,1/9/2026,1/2/2026,100,ESTIMATED,,,['Leukemia'],"['Cladribine', 'Cytarabine', 'Etoposide', 'Venetoclax', 'Fludarabine', 'Busulfan', 'Melphalan', 'Total Marrow Irradiation']","['B365', 'B2050', 'B1463', 'B927', 'B346', 'B2060', 'B2073']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Ribonucleotide reductase'], ['DNA-directed DNA polymerase'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Apoptosis regulator Bcl-2'], ['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA'], ['DNA']]","[['RNR'], ['DNA-directed DNA polymerase'], ['TOP2'], ['Bcl-2'], ['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA'], ['DNA']]"
51665,NCT05679258,"A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects","A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 With Daratumumab Injection in Healthy Chinese Male Subjects",PHASE1,COMPLETED,31/1/2023,28/6/2024,16/3/2024,172,ACTUAL,,,['Multiple Myeloma'],['Daratumumab'],['B415'],[['Antibody']],[['Monoclonal Antibody']],[['Lymphocyte differentiation antigen CD38']],[['CD38']]
51119,NCT05603559,177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer,Safety and Dosimetry of 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer,EARLY_PHASE1,COMPLETED,1/1/2023,4/10/2023,5/9/2023,9,ACTUAL,,,['Castration-Resistant Prostate Carcinoma'],"['Lutetium Lu 177 Vipivotide Tetraxetan', 'Lutetium Lu-177 PNT2002']",[],[],[],[],[]
51158,NCT05608785,"Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes","Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes",PHASE1/PHASE2,UNKNOWN,1/1/2023,1/10/2024,31/12/2023,45,ESTIMATED,,,"['Gastric Cancer', 'Gastroesophageal Junction Cancer']","['Fidasimtamab', 'Oxaliplatin', 'Capecitabine', 'Osemitamab', 'Benmelstobart', 'Catequentinib']","['B4347', 'B1229', 'B474', 'B1792', 'B1911', 'B1436']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Antibody'], ['Small Molecule']]","[['Bispecific Antibody'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1', 'Receptor protein-tyrosine kinase erbB-2'], ['DNA'], ['Thymidylate synthase'], ['Claudin 18.2'], ['Programmed death-ligand 1'], ['Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['PD-1', 'HER2'], ['DNA'], ['TYMS'], ['CLDN18.2'], ['PDL1'], ['c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
51575,NCT05668767,Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC,"Multi-centered, Single-arm, Phase II Study on Surufatinib in Combination of Durvalumab and Etoposide and Carboplatin/Cisplatin in the Firstly-line Treatment of Extensive-stage Small-cell Lung Cancer",PHASE2,NOT_YET_RECRUITING,31/12/2022,31/12/2025,31/12/2023,20,ESTIMATED,,,['Extensive Stage Lung Small Cell Carcinoma'],"['Surufatinib', 'Durvalumab', 'Etoposide', 'Cisplatin', 'Carboplatin']","['B1259', 'B977', 'B1463', 'B49', 'B274']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Colony stimulating factor 1 receptor', 'Fibroblast growth factor receptor 1', 'Vascular endothelial growth factor receptor'], ['Programmed death-ligand 1'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], ['DNA']]","[['CSF-1R', 'FGFR1', 'VEGFR'], ['PDL1'], ['TOP2'], ['DNA'], ['DNA']]"
51587,NCT05669807,Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer,"A Randomized, Controlled, Multicenter Phase II Study of Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer",PHASE2,NOT_YET_RECRUITING,31/12/2022,30/11/2025,30/11/2023,184,ESTIMATED,,,['Second Line Treatment of Gastric Cancer'],"['Camrelizumab', 'Nab-paclitaxel', 'Irinotecan']","['B1309', 'B7744', 'B1679']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Tubulin beta-1 chain'], ['DNA topoisomerase I']]","[['PD-1'], ['TUBB1'], ['TOP1']]"
53714,NCT05990998,"A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study",First Affiliated Hospital of Fujian Medical University,PHASE1/PHASE2,COMPLETED,20/11/2022,1/9/2023,31/8/2023,38,ACTUAL,,,['Tumor Positron-Emission Tomography'],"['Gallium 68-DOTATATE', '68Ga-FAPI-46', 'Positron Emission Tomography and Computed Tomography Scan']","['B3690', 'B2955']","[['Radiopharmaceutical Imaging'], ['Radiopharmaceutical Imaging']]","[['Radiopharmaceutical Imaging'], ['Radiopharmaceutical Imaging']]","[['Somatostatin receptor'], ['Fibroblast activation protein alpha']]","[['SSTR'], ['FAP']]"
56066,NCT06350838,Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC),A Phase I Clinical Study to Investigate the Safety and Tolerance of Therapeutic Bacillus Calmette-Guerin( BCG) in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC),PHASE1,COMPLETED,11/11/2022,13/2/2023,13/2/2023,10,ACTUAL,,,['Muscle Invasive Bladder Cancer'],['BCG Regimen'],[],[],[],[],[]
48338,NCT05198843,Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body,Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast Cancer,PHASE1/PHASE2,TERMINATED,8/11/2022,20/12/2023,19/12/2023,1,ACTUAL,,,"['Breast Cancer', 'Triple-Negative Breast Cancer']","['Dasatinib', 'Icosapent Ethyl']",['B293'],[['Small Molecule']],[['Small Molecule']],"[['Bcr-Abl tyrosine kinase', 'Ephrin type-A receptor 2']]","[['BCR-ABL1', 'EphA2', 'FYN']]"
48418,NCT05208762,A Study of SGN-PDL1V in Advanced Solid Tumors,A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors,PHASE1,RECRUITING,25/10/2022,17/11/2028,18/11/2027,315,ESTIMATED,,,"['Non-Small Cell Lung Cancer', 'Head and Neck Squamous Cell Carcinoma', 'Esophageal Cancer', 'Female Reproductive System Neoplasm', 'Male Reproductive System Neoplasm', 'Triple-Negative Breast Cancer', 'Gastric Cancer']","['PF-08046054', 'Pembrolizumab']","['B6023', 'B936']","[['Antibody Drug Conjugate (ADC)'], ['Antibody']]","[['Antibody Drug Conjugate (ADC)'], ['Monoclonal Antibody']]","[['Programmed death-ligand 1'], ['Programmed cell death protein 1']]","[['Beta-tubulin ', 'PDL1'], ['PD-1']]"
49922,NCT05425862,Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer,Phase 1 Trial of Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer,PHASE1,SUSPENDED,21/10/2022,30/12/2025,12/7/2024,48,ESTIMATED,,,['Castration-Resistant Prostate Carcinoma'],"['Pidnarulex', 'Talazoparib']","['B2544', 'B928']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['G-Quadruplex'], ['PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors)', 'PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)']]","[['G4'], ['PARP1', 'PARP2']]"
46090,NCT04892277,CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies,Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies,PHASE1,RECRUITING,3/10/2022,27/3/2026,27/3/2025,25,ESTIMATED,,,"['B-Cell Non-Hodgkin Lymphoma', 'Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma', 'Chronic Lymphocytic Leukemia', 'B-Cell Non-Hodgkin Lymphoma', 'Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma', 'Chronic Lymphocytic Leukemia']","['Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563', 'Bendamustine', 'Biospecimen Collection', 'Bone Marrow Aspiration', 'Bone Marrow Biopsy', 'Computed Tomography', 'Cyclophosphamide', 'Fludarabine', 'Magnetic Resonance Imaging', 'Positron Emission Tomography']","['B1689', 'B2818', 'B346']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['DNA'], ['Ribonucleotide reductase', 'RNA polymerase II']]","[['DNA'], ['DNA'], ['DNA polymerase III', 'RNR', 'RNA polymerase II']]"
50582,NCT05521412,EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T,EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T: Phase I/II Study,PHASE1/PHASE2,RECRUITING,29/9/2022,31/12/2026,3/8/2025,42,ESTIMATED,,,"['Prostate Cancer', 'Castration-Resistant Prostate Carcinoma']",['[161 Tb]Tb PSMA I&T'],['B12065'],[['Radiopharmaceutical Imaging']],[['Radiopharmaceutical Imaging']],[['Prostate-specific membrane antigen']],[['PSMA']]
50351,NCT05489731,VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer,Phase I Clinical Study of VIC-1911 Combined With Osimertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGRF- Mutation,PHASE1,RECRUITING,21/9/2022,24/4/2024,24/2/2024,72,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['TAS 119', 'osimertinib mesylate']","['B2354', 'B8852']","[['Small Molecule'], []]","[['Small Molecule'], []]","[['Neurotrophic tyrosine kinase receptor', 'Serine/threonine-protein kinase Aurora-A'], []]","[['NTRK', 'Aurora A'], []]"
50293,NCT05480449,Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy),Phase 1/2b Trial of Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells Manufactured Using the CliniMACS Prodigy Platform for the Treatment of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL),PHASE1/PHASE2,RECRUITING,20/9/2022,20/9/2029,20/9/2027,89,ESTIMATED,,,"['Acute Lymphoblastic Leukemia', 'B-Cell Non-Hodgkin Lymphoma']",[],[],[],[],[],[]
48970,NCT05285358,Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases,Safety of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Biliary Tract Cancer Patients With Peritoneal Metastases,PHASE1,RECRUITING,19/9/2022,11/10/2028,11/10/2028,12,ESTIMATED,,,"['Extrahepatic Cholangiocarcinoma', 'Gallbladder Carcinoma', 'Intrahepatic Cholangiocarcinoma', 'Peritoneal and Retroperitoneal Neoplasm', 'Extrahepatic Bile Duct Carcinoma', 'Liver Cancer', 'Intrahepatic Cholangiocarcinoma', 'Gallbladder Carcinoma']","['Cisplatin', 'Gemcitabine', 'Nab-paclitaxel', 'Questionnaire Administration']","['B49', 'B2079', 'B7744']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain']]","[['DNA'], ['DNA', 'RNR'], ['TUBB1']]"
49222,NCT05322135,A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma,A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma,EARLY_PHASE1,TERMINATED,14/9/2022,7/3/2025,7/3/2025,3,ACTUAL,,,"['Head and Neck Squamous Cell Carcinoma', 'Head and Neck Neoplasm']","['BAY 949392', 'Carbon C 11 Glutamine']",['B3276'],[['Radiopharmaceutical Imaging']],[['Radiopharmaceutical Imaging']],[[]],[[]]
50399,NCT05496231,A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age,"A Phase 1/2 Randomized, Observer-blinded, Multi-country Study to Evaluate Safety and Immunogenicity of Investigational Adjuvanted Human Papillomavirus Vaccine in Females (16 to 26 Years of Age)",PHASE1/PHASE2,COMPLETED,22/8/2022,25/2/2024,23/2/2024,1080,ACTUAL,,,['Intraepithelial Neoplasia'],"['Human papillomavirus vaccine', 'Human Papillomavirus 9-valent Vaccine, Recombinant']","['B3475', 'B2983']","[[], []]","[[], []]","[[], []]","[[], []]"
52307,NCT05779514,Effect of Mirabegron on Promoting Brown Adipose Tissue Activation,Effect of Mirabegron on Promoting Brown Adipose Tissue Activation,,UNKNOWN,18/8/2022,31/12/2023,31/12/2023,20,ESTIMATED,,,['Solid Tumors'],['Mirabegron'],['B556'],[['Small Molecule']],[['Small Molecule']],[[]],[['GP IIb/IIIa']]
47738,NCT05111574,Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery,A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma,PHASE2,RECRUITING,11/8/2022,19/12/2025,19/12/2025,99,ESTIMATED,,,"['Acral Melanoma', 'Urinary System Neoplasm', 'Female Reproductive System Neoplasm', 'Digestive System Neoplasm', 'Digestive System Neoplasm', 'Head and Neck Neoplasm', 'Head and Neck Neoplasm', 'Urinary System Neoplasm', 'Head and Neck Neoplasm', 'Head and Neck Neoplasm', 'Male Reproductive System Neoplasm', 'Digestive System Neoplasm', 'Recurrent Mucosal Melanoma', 'Head and Neck Neoplasm', 'Vulvar Carcinoma', 'Vulvar Carcinoma', 'Vulvar Carcinoma', 'Urinary System Neoplasm', 'Female Reproductive System Neoplasm', 'Vulvar Melanoma']","['Biospecimen Collection', 'cabozantinib s-malate', 'Computed Tomography', 'Echocardiography', 'Magnetic Resonance Imaging', 'Nivolumab', 'Placebo Administration', 'Positron Emission Tomography']","['B8690', 'B714']","[[], ['Antibody']]","[[], ['Monoclonal Antibody']]","[[], ['Programmed cell death protein 1']]","[[], ['PD-1']]"
50370,NCT05491512,A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People with HPV-Positive Throat Cancer,Major Radiation Dose De-Escalation Concurrent with Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma,PHASE2,RECRUITING,4/8/2022,4/8/2025,4/8/2025,121,ESTIMATED,,,"['Female Reproductive System Neoplasm', 'Head and Neck Neoplasm', 'Oropharyngeal Cancer', 'Oropharyngeal Cancer', 'Human Papilloma Virus']","['18F-Fluoromisonidazole', 'Radiation Therapy', 'Cisplatin', 'Carboplatin', 'Fluorouracil', 'Paclitaxel']","['B49', 'B274', 'B493', 'B1250']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['DNA'], ['Thymidylate synthase'], ['Tubulin beta-1 chain']]","[['DNA'], ['DNA'], ['TYMS'], ['TUBB1']]"
56900,NCT06469138,A Study to Investigate 14C-bemcentinib in Healthy Male Subjects,"A Phase 1, Open-label, Nonrandomized Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects",PHASE1,COMPLETED,2/8/2022,23/9/2022,23/9/2022,6,ACTUAL,,,"['Non-Small Cell Lung Cancer', 'Metastatic Melanoma', 'Acute Myeloid Leukemia', 'Myelodysplastic Syndrome', 'Pancreatic Cancer', 'Glioblastoma', 'Pleural Malignant Mesothelioma', 'COVID-19']",['Bemcentinib'],['B1111'],[['Small Molecule']],[['Small Molecule']],[['AXL receptor tyrosine kinase']],[['AXL']]
50179,NCT05463601,Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer,"Efficacy and Safety of Mecapegfilgrastim for Prophylaxis of Dalpiciclib -Induced Neutropenia in Patients With Advanced HR+/HER2- Breast Cancer: a Open-label, Multicenter, Investigator-initiated, Randomized Controlled Phase II Trial",PHASE2,UNKNOWN,1/8/2022,1/12/2024,1/12/2023,132,ESTIMATED,,,['Brain Metastasis'],"['Mecapegfilgrastim', 'Dalpiciclib', 'Exemestane', 'Fulvestrant', 'Letrozole', 'Tamoxifen']","['B1765', 'B1659', 'B86', 'B276', 'B302', 'B2062']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Colony-Stimulating Factor'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Colony stimulating factor 3 receptor'], ['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6'], ['Aromatase'], ['Estrogen receptors'], ['Aromatase', 'Estrogen receptors'], ['Estrogen receptors']]","[['CSF-3R'], ['CDK4', 'CDK6'], ['aromatase'], ['ER'], ['aromatase', 'ER'], ['ER']]"
49797,NCT05406466,Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis,A Phase II Study of Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis (CASTLE-05),PHASE2,UNKNOWN,15/7/2022,16/8/2024,10/7/2024,25,ESTIMATED,,,['Male Reproductive System Neoplasm'],"['Tislelizumab', 'Lenvatinib', 'Cryosurgery']","['B1344', 'B261']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['PD-1'], ['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
50191,NCT05465343,"Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trialï¼ˆiFORCEï¼‰","Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trialï¼ˆiFORCEï¼‰",PHASE2,UNKNOWN,11/7/2022,30/6/2023,30/6/2023,36,ESTIMATED,,,"['Furmonertinib', 'Lung Adenocarcinoma', 'Non-Small Cell Lung Cancer', 'Brain Metastasis']",['Furmonertinib'],['B2403'],[['Small Molecule']],[['Small Molecule']],[['EGFR T790M']],[['EGFR T790M']]
50295,NCT05480865,SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation,A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation,PHASE1,TERMINATED,6/7/2022,22/8/2024,22/8/2024,28,ACTUAL,,,"['Epithelial Neoplasm', 'Solid Tumors', 'Metastatic NSCLC', 'Non-Small Cell Lung Cancer']","['BBP 398', 'Sotorasib']","['B4021', 'B1474']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Src homology phosphotyrosyl phosphatase 2'], ['GTPase KRas G12C']]","[['SHP2'], ['KRAS G12C']]"
46715,NCT04978727,"A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma","A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients With Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma",PHASE1,RECRUITING,1/7/2022,28/2/2030,30/4/2027,35,ESTIMATED,,,"['Medulloblastoma', 'Glioblastoma', 'Anaplastic Astrocytoma', 'Anaplastic Astrocytoma', 'Anaplastic Oligodendroglioma', 'WHO Grade 3 Glioma', 'Ependymoma', 'Diffuse Intrinsic Pontine Glioma']","['SVN53-67-M57-KLH peptide vaccine', 'Sargramostim', ""Incomplete Freund's adjuvant"", 'Radiation Therapy']","['B2623', 'B181', 'B1603']","[['Subunit Vaccine'], ['Other Protein Therapy'], ['Vaccine Adjuvant']]","[['Subunit Vaccine'], ['Colony-Stimulating Factor'], ['Vaccine Adjuvant']]","[['Baculoviral IAP repeat-containing protein 5'], ['Granulocyte-macrophage colony-stimulating factor receptor'], []]","[['survivin'], ['CSF-2R'], []]"
48252,NCT05186545,An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer,An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer Refractory to Endocrine Therapy,PHASE2,RECRUITING,1/7/2022,31/7/2025,31/1/2024,63,ESTIMATED,,,"['Breast Cancer', 'Breast Cancer']","['Surufatinib', 'Fulvestrant', 'Chidamide']","['B1259', 'B276', 'B9734']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Colony stimulating factor 1 receptor', 'Fibroblast growth factor receptor 1', 'Vascular endothelial growth factor receptor'], ['Estrogen receptors'], ['Histone deacetylase']]","[['CSF-1R', 'FGFR1', 'VEGFR'], ['ER'], ['HDAC']]"
49623,NCT05381038,Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI,Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours Using the Quadratic Phenotypic Optimization Platform (QPOP) and an Artificial Intelligence-based Platform (CURATE.AI),PHASE1/PHASE2,NOT_YET_RECRUITING,30/6/2022,4/4/2027,4/10/2026,10,ESTIMATED,,,"['Solid Tumors', 'Digestive System Neoplasm', 'Breast Cancer']","['Azacitidine', 'Docetaxel', 'Paclitaxel', 'Irinotecan']","['B322', 'B2814', 'B1250', 'B1679']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Tubulin beta-1 chain'], ['Tubulin beta-1 chain'], ['DNA topoisomerase I']]","[['DNMT1'], ['TUBB1'], ['TUBB1'], ['TOP1']]"
49941,NCT05429398,A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor,"A Single-arm, Open-label, Multicenter,Phase I Study of Linperlisib Combination With Camrelizumab in Patients With Advanced Solid Tumor",PHASE1,UNKNOWN,30/6/2022,30/5/2024,31/8/2023,118,ESTIMATED,,,['Solid Tumors'],"['Linperlisib', 'Camrelizumab']","['B1481', 'B1309']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Phosphatidylinositol 3 kinase delta'], ['Programmed cell death protein 1']]","[['PI3KÎ´'], ['PD-1']]"
49496,NCT05362409,Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma,A Phase 1 Multi-center Clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy(SDT) in Patients With Recurrent High Grade Glioma (HGG),PHASE1,ACTIVE_NOT_RECRUITING,29/6/2022,30/4/2025,3/12/2024,22,ACTUAL,,,['High-Grade Glioma'],"['Aminolevulinic acid', 'CV01-delivered ultrasound']",['B1965'],[[]],[[]],[[]],[[]]
44441,NCT04655391,Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation,A Pilot/Phase 1b Study of Glasdegib-Based Treatment Combinations in Adult Patients With Relapsed AML Post Allogeneic Hematopoietic Cell Transplantation,PHASE1,WITHDRAWN,25/6/2022,15/12/2023,15/12/2023,0,ACTUAL,,,['Acute Myeloid Leukemia'],"['bosutinib monohydrate', 'Decitabine', 'enasidenib mesylate', 'gilteritinib fumarate', 'glasdegib maleate', 'Ivosidenib', 'Venetoclax']","['B8815', 'B113', 'B8943', 'B8848', 'B8673', 'B1174', 'B927']","[[], ['Small Molecule'], [], [], [], ['Small Molecule'], ['Small Molecule']]","[[], ['Small Molecule'], [], [], [], ['Small Molecule'], ['Small Molecule']]","[[], ['DNA', 'DNA (cytosine-5)-methyltransferase 3A', 'DNA (cytosine-5)-methyltransferase 3B'], [], [], [], ['Isocitrate dehydrogenase [NADP] cytoplasmic'], ['Apoptosis regulator Bcl-2']]","[[], ['DNMT1', 'DNMT3A', 'DNMT3B'], [], [], [], ['IDH1'], ['Bcl-2']]"
51095,NCT05600309,A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study,A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (KEYFORM-007),PHASE3,COMPLETED,14/6/2022,21/2/2025,15/8/2024,94,ACTUAL,,,['Colorectal Cancer'],"['Favezelimab', 'Pembrolizumab', 'Regorafenib', 'Tipiracil/trifluridine']","['B1325', 'B936', 'B526', 'B2936']","[['Antibody'], ['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Lymphocyte activation gene 3 protein'], ['Programmed cell death protein 1'], ['Colony stimulating factor 1 receptor', 'Ephrin type-A receptor 2', 'Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Nerve growth factor receptor Trk-A', 'Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'RAF serine/threonine protein kinase', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'TEK receptor tyrosine kinase', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Thymidine phosphorylase', 'Thymidylate synthase']]","[['LAG3'], ['PD-1'], ['Abl', 'BRAF V600E', 'CSF-1R', 'EphA2', 'FGFR1', 'FGFR2', 'TRKA', 'PDGFRÎ±', 'PDGFRÎ²', 'Raf kinase', 'BRAF', 'c-Kit', 'Tie-2', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3', 'DDR2', 'FRK', 'MAPK11'], ['TYMP', 'TYMS']]"
47541,NCT05085054,Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT),"Induction Therapy With Targeted Therapy Followed by Surgery for Stage IIIB and IV Non-small Cell Lung Cancer: a Multi-center, Single-arm, Prospective Clinical Study",PHASE2,UNKNOWN,1/6/2022,1/8/2024,1/5/2024,30,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['osimertinib mesylate', 'Salvage Surgery']",['B8852'],[[]],[[]],[[]],[[]]
49687,NCT05389293,A Study of Mosunetuzumab in People With Follicular Lymphoma,"An Open-Label, Multicenter, Single-Arm, Sequential Phase-2 Study of Mosunetuzumab Alone or With Zanubrutinib for the Treatment of Patients With Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy",PHASE2,RECRUITING,27/5/2022,31/12/2025,31/12/2025,76,ESTIMATED,,,"['Follicular Lymphoma', 'Hematology']","['Mosunetuzumab', 'Zanubrutinib']","['B1328', 'B1139']","[['Antibody'], ['Small Molecule']]","[['Bispecific T-Cell Engager'], ['Small Molecule']]","[['B-lymphocyte antigen CD20', 'T cell surface glycoprotein CD3'], ['Tyrosine-protein kinase BTK']]","[['CD20', 'CD3'], ['BTK']]"
49716,NCT05393804,A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant,Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy Using Ide-Cel for Multiple Myeloma Patients Status Post Hematopoietic Cell Transplantation,PHASE2,RECRUITING,20/5/2022,31/5/2025,31/5/2025,32,ESTIMATED,,,['Multiple Myeloma'],"['Idecabtagene vicleucel', 'Ciltacabtagene autoleucel', 'Leukapheresis', 'Lymphodepletion Therapy', 'Chimeric Antigen Receptor T-Cell Therapy']","['B1423', 'B1674']","[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)'], ['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']]","[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)'], ['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']]","[['B-cell maturation protein'], ['B-cell maturation protein']]","[['BCMA'], ['BCMA']]"
50288,NCT05479812,Dose Escalation and Expansion Study of WTX-124 As Monotherapy and in Combination with Pembrolizumab (pembro) in Patients with Selected Advanced or Metastatic Solid Tumors,A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 As Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors,PHASE1,RECRUITING,20/5/2022,31/7/2025,1/7/2025,150,ESTIMATED,,,"['Solid Tumors', 'Solid Tumors']","['WTX-124', 'Pembrolizumab']","['B4837', 'B936']","[['Other Protein Therapy'], ['Antibody']]","[['Interleukin'], ['Monoclonal Antibody']]","[['Interleukin-2'], ['Programmed cell death protein 1']]","[['IL-2'], ['PD-1']]"
47331,NCT05055063,"A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma","A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma (BELLA)",PHASE1,RECRUITING,18/5/2022,2/2/2027,2/2/2027,30,ESTIMATED,,,['Multiple Myeloma'],['Belantamab mafodotin'],['B1428'],[['Antibody Drug Conjugate (ADC)']],[['Antibody Drug Conjugate (ADC)']],[['B-cell maturation protein']],"[['Beta-tubulin ', 'BCMA']]"
60201,NCT05263999,A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease",PHASE3,ACTIVE_NOT_RECRUITING,29/4/2022,31/12/2025,31/10/2025,200,ESTIMATED,,,"['Graft Versus Host Disease', 'Graft Versus Host Disease', 'Acute Graft Versus Host Disease', 'Acute Graft Versus Host Disease', 'aGVHD']","['Itolizumab', 'Placebo']",[],[],[],[],[]
47884,NCT05135715,"A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)","A Single-arm, Multicentre, Open Phase â…¡a Clinical Study of RC48-ADC in the Treatment of HER2 Variant (Mutation, Amplification, Overexpression) Advanced Melanoma",PHASE2,RECRUITING,19/4/2022,30/12/2025,30/12/2024,50,ESTIMATED,,,"['Skin Melanoma', 'HER2-Positive Breast Cancer', 'Skin Melanoma']",['Disitamab vedotin'],['B1763'],[['Antibody Drug Conjugate (ADC)']],[['Antibody Drug Conjugate (ADC)']],[['Receptor protein-tyrosine kinase erbB-2']],"[['Beta-tubulin ', 'HER2']]"
48340,NCT05198934,Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation,"A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation",PHASE3,ACTIVE_NOT_RECRUITING,19/4/2022,30/6/2025,14/3/2025,160,ACTUAL,,,['Colorectal Cancer'],"['Sotorasib', 'Panitumumab', 'Trifluridine', 'Tipiracil/trifluridine', 'Regorafenib']","['B1474', 'B194', 'B43', 'B2936', 'B526']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['GTPase KRas G12C'], ['Epidermal growth factor receptor erbB1'], ['DNA-directed DNA polymerase'], ['Thymidine phosphorylase', 'Thymidylate synthase'], ['Colony stimulating factor 1 receptor', 'Ephrin type-A receptor 2', 'Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Nerve growth factor receptor Trk-A', 'Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'RAF serine/threonine protein kinase', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'TEK receptor tyrosine kinase', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['KRAS G12C'], ['EGFR'], ['DNA-directed DNA polymerase'], ['TYMP', 'TYMS'], ['Abl', 'BRAF V600E', 'CSF-1R', 'EphA2', 'FGFR1', 'FGFR2', 'TRKA', 'PDGFRÎ±', 'PDGFRÎ²', 'Raf kinase', 'BRAF', 'c-Kit', 'Tie-2', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3', 'DDR2', 'FRK', 'MAPK11']]"
60252,NCT05397184,Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7),Phase 1 Study of Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7),PHASE1,RECRUITING,19/4/2022,28/2/2025,1/4/2024,10,ESTIMATED,,,['T-cell acute lymphoblastic leukemia'],['Chimeric Antigen Receptor T-Cell Therapy'],[],[],[],[],[]
49259,NCT05327582,"An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC","A Phase I/II, Open-label, One-arm, Single-center Study to Evaluate the Safety and Efficacy of the PLENA Regimen in Subjects With Unresectable Pancreatic Cancer or Biliary Tract Cancer",PHASE1/PHASE2,UNKNOWN,12/4/2022,30/4/2024,30/4/2023,65,ESTIMATED,,,"['Pancreatic Cancer', 'Biliary Tract Cancer']","['Durvalumab', 'Lenvatinib', 'Nab-paclitaxel']","['B977', 'B261', 'B7744']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Programmed death-ligand 1'], ['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Tubulin beta-1 chain']]","[['PDL1'], ['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['TUBB1']]"
49185,NCT05317325,A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC,A Translational Study of Tumor Antigen-pulsed Dendritic Cell Vaccine for Esophageal Squamous Cell Carcinoma,PHASE1,UNKNOWN,1/4/2022,1/4/2024,30/12/2023,20,ESTIMATED,,,['Esophageal Cancer'],"['Vaccine Therapy', 'Tumor antigen-pulsed DC vaccine - Sichuan University']",['B11777'],[['Cancer Vaccine']],[['Dendritic Cell Vaccine']],[[]],[[]]
45606,NCT04826016,POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer,A Phase Ib/II Study to Optimize POL6326 (Balixafortide) in Combination With Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer,PHASE1/PHASE2,WITHDRAWN,16/3/2022,16/3/2022,16/3/2022,0,ACTUAL,,,['Breast Cancer'],"['Balixafortide', 'Eribulin', 'Nab-paclitaxel']","['B1653', 'B387', 'B7744']","[['Engineered Protein Therapy'], ['Small Molecule'], ['Small Molecule']]","[['Synthetic Peptide'], ['Small Molecule'], ['Small Molecule']]","[['C-X-C motif chemokine receptor 4'], ['Tubulin beta-1 chain'], ['Tubulin beta-1 chain']]","[['CXCR4'], ['TUBB1'], ['TUBB1']]"
49168,NCT05315700,Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration,"An Open-Label, Phase 1/2 Study of ORIC-114 As a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration",PHASE1/PHASE2,RECRUITING,10/3/2022,31/3/2026,31/3/2025,350,ESTIMATED,,,['Solid Tumors'],['ORIC 114'],['B4328'],[['Small Molecule']],[['Small Molecule']],"[['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2']]","[['EGFR', 'HER2']]"
47093,NCT05024305,"Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.","A Multi-center, Phase I, Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.",PHASE1,UNKNOWN,8/3/2022,30/6/2023,31/12/2022,81,ESTIMATED,,,['Solid Tumors'],['TWP-102'],['B5417'],[['Antibody']],[['Antibody']],[[]],[[]]
47516,NCT05081193,Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer,A Phase II Study Assessing the Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer,PHASE2,RECRUITING,7/3/2022,30/12/2027,30/12/2025,30,ESTIMATED,,,"['Prostate Cancer', 'Castration-Resistant Prostate Carcinoma', 'Castration-Resistant Prostate Carcinoma']","['Testosterone undecanoate', 'Enzalutamide']","['B602', 'B25']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Androgen Receptor'], ['Androgen Receptor']]","[['AR'], ['AR']]"
48574,NCT05231850,A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage â…¡ and Stage â…¢ Colon Cancer and dMMR/MSI.,A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With High-risk Stage â…¡ and Stage â…¢ Colon Cancer and Deficient Mismatch Repair or Microsatellite Instability.,PHASE2,NOT_YET_RECRUITING,1/3/2022,1/9/2027,1/9/2023,70,ESTIMATED,,,['Colon Carcinoma'],['Tislelizumab'],['B1344'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
49049,NCT05296772,Phase 1 First-in-human Study of JS014,"A Phase 1 Study of JS014, a Recombinant Fusion Protein of Interleukin-21 and Humanized Anti-human Serum Albumin VHH Antibody as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Cancer",PHASE1,RECRUITING,28/2/2022,31/1/2025,30/6/2024,60,ESTIMATED,,,"['Digestive System Neoplasm', 'Neoplasm, Experimental', 'Epithelial Neoplasm', 'Hematology']","['Denenicokin', 'Exenokine-21', 'Pembrolizumab']","['B620', 'B4335', 'B936']","[['Other Protein Therapy'], ['Engineered Protein Therapy'], ['Antibody']]","[['Interleukin'], ['Fusion Protein'], ['Monoclonal Antibody']]","[['Interleukin-21'], ['Interleukin 21 Receptor'], ['Programmed cell death protein 1']]","[['IL-21'], ['IL-21R'], ['PD-1']]"
49087,NCT05302921,Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors,"Phase II Study Investigating the Efficacy of Neoadjuvant Dual Checkpoint Inhibition and Cryoablation Therapy in Children, Adolescents, and Young Adults With Relapsed/Refractory Solid Tumors",PHASE2,COMPLETED,18/2/2022,12/3/2024,12/3/2024,5,ACTUAL,,,"['Osteosarcoma', 'Ewing Sarcoma', 'Rhabdomyosarcoma', 'Relapsed Pediatric Solid Tumor', 'Solid Tumors', 'Male Reproductive System Neoplasm', 'Liver Cancer', 'Hepatocellular Carcinoma', 'Kidney Wilms Tumor', 'Kidney Wilms Tumor']","['Cryoablation', 'Nivolumab', 'Ipilimumab']","['B714', 'B480']","[['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Programmed cell death protein 1'], ['Cytotoxic T-Lymphocyte-Associated Antigen 4']]","[['PD-1'], ['CTLA4']]"
51358,NCT05636566,Comparing TIVA Using Propofol or Dexmedetomidine Versus Sevoflurane During Anaesthesia of Children Undergoing Bone-Marrow Aspiration,Comparison Between TIVA Using Propofol or Dexmedetomidine Versus Sevoflurane During Anaesthesia of Children Undergoing Bone-Marrow Aspiration,PHASE2/PHASE3,COMPLETED,15/2/2022,25/10/2022,15/9/2022,60,ACTUAL,,,"['Epithelial Neoplasm', 'Follicular Lymphoma']","['Sevoflurane', 'Propofol', 'Dexmedetomidine']","['B100', 'B1822', 'B2039']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Gamma-aminobutyric acid A receptor'], ['Adrenergic receptors alpha-2']]","[[], ['GABAA receptor'], ['ADRA2']]"
48391,NCT05204628,A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib,Randomized Multicenter Phase III Open-Label Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib in Chinese Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer,PHASE3,NOT_YET_RECRUITING,7/2/2022,1/7/2025,7/5/2025,238,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['XZP-3621', 'Crizotinib']","['B4712', 'B1966']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Anaplastic lymphoma kinase', 'Proto-oncogene tyrosine-protein kinase ROS'], ['Anaplastic lymphoma kinase', 'c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)', 'Macrophage-stimulating protein receptor', 'Proto-oncogene tyrosine-protein kinase ROS']]","[['ALK', 'ROS1'], ['ALK', 'c-Met', 'MST1R', 'ROS1']]"
40778,NCT04119830,Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer,A Phase IIa Study of Rintatolimod Plus Pembrolizumab in Refractory Metastatic Colorectal Cancer,PHASE2,WITHDRAWN,1/2/2022,1/2/2024,1/2/2024,0,ACTUAL,,,"['Colorectal Cancer', 'Colon Carcinoma', 'Mismatch Repair Proficient', 'Colorectal Cancer', 'Colorectal Cancer', 'Colorectal Cancer', 'Colorectal Cancer', 'Colorectal Cancer', 'Colorectal Cancer', 'Colorectal Cancer', 'Colorectal Cancer', 'Colorectal Cancer', 'Colorectal Cancer']","['Pembrolizumab', 'Questionnaire Administration', 'Rintatolimod']","['B936', 'B623']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Toll like receptor 3']]","[['PD-1'], ['TLR3']]"
43996,NCT04591028,A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients,Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer,PHASE4,WITHDRAWN,31/1/2022,10/8/2022,31/1/2022,0,ACTUAL,,,['Gastric Cancer'],['Indocyanine green'],['B361'],[['Imaging']],[['Imaging Agent']],[[]],[[]]
48626,NCT05239182,9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma,"A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3-beta (GSK-3Î²) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Gemcitabine/Nab-Paclitaxel as Frontline Therapy for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)",PHASE2,ACTIVE_NOT_RECRUITING,26/1/2022,30/6/2025,30/12/2024,32,ESTIMATED,,,['Pancreatic Cancer'],"['Elraglusib', 'Retifanlimab', 'Gemcitabine', 'Nab-paclitaxel']","['B1684', 'B1394', 'B2079', 'B7744']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Glycogen synthase kinase-3 beta'], ['Programmed cell death protein 1'], ['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain']]","[['GSK-3Î²'], ['PD-1'], ['DNA', 'RNR'], ['TUBB1']]"
46610,NCT04965077,Treatment of Advanced and Metastatic Solid Tumors With MIL97,"A Phase I Multicenter, Open Label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MIL97 in Subjects With Advanced or Metastatic Solid Tumors",PHASE1,RECRUITING,18/1/2022,31/12/2026,31/12/2025,62,ESTIMATED,,,['Solid Tumors'],['MIL 97'],['B3112'],[['Antibody']],[['Monoclonal Antibody']],[['Tumor necrosis factor receptor superfamily member 5']],[['CD40']]
49109,NCT05305859,Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML,"A Multi-center, Prospective, Single-arm Study of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia (R/R AML)",PHASE2,RECRUITING,12/1/2022,30/6/2027,31/1/2026,30,ESTIMATED,,,"['Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Leukemia']","['Venetoclax', 'Chidamide', 'Azacitidine']","['B927', 'B9734', 'B322']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Apoptosis regulator Bcl-2'], ['Histone deacetylase'], ['DNA']]","[['Bcl-2'], ['HDAC'], ['DNMT1']]"
47734,NCT05111366,TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection,"An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection",PHASE2,UNKNOWN,6/1/2022,20/5/2024,20/1/2024,37,ESTIMATED,,,"['Hepatocellular Carcinoma', 'Adjuvant Therapy']","['Benmelstobart', 'catequentinib hydrochloride']","['B1911', 'B9013']","[['Antibody'], []]","[['Monoclonal Antibody'], []]","[['Programmed death-ligand 1'], []]","[['PDL1'], []]"
60078,NCT04956276,Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia,"A Phase 2, Multiple Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study of ALXN1830 Administered Subcutaneously in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA)",PHASE2,WITHDRAWN,1/1/2022,31/7/2024,31/7/2022,0,ACTUAL,,,['Warm Autoimmune Hemolytic Anemia'],"['Bis-choline Tetrathiomolybdate', 'Placebo Control']",['B1491'],[['Small Molecule']],[['Small Molecule']],[['Superoxide dismutase']],[['SOD1']]
52402,NCT05796089,Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy,"A Phase II Study of Platinum and Etoposide Chemotherapy, Durvalumab With Thoracic Radiotherapy in the First Line Treatment of Patients With Extensive-stage Small-cell Lung Cancer",PHASE2,RECRUITING,1/1/2022,28/2/2028,30/9/2027,35,ESTIMATED,,,['Extensive Stage Lung Small Cell Carcinoma'],"['Thoracic Radiation Therapy', 'Etoposide', 'Carboplatin', 'Cisplatin', 'Durvalumab']","['B1463', 'B274', 'B49', 'B977']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], ['DNA'], ['Programmed death-ligand 1']]","[['TOP2'], ['DNA'], ['DNA'], ['PDL1']]"
48241,NCT05183958,"A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer","A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer",PHASE2,NOT_YET_RECRUITING,31/12/2021,1/12/2025,1/12/2023,118,ESTIMATED,,,['Esophageal Cancer'],"['Stereotactic Body Radiation Therapy', 'Normofractionated Radiotherapy', 'Camrelizumab', 'Chemotherapy']",['B1309'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
47417,NCT05067283,A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001),"A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors",PHASE1,RECRUITING,17/12/2021,25/2/2030,25/2/2030,830,ESTIMATED,,,['Solid Tumors'],"['MK-1084', 'Pembrolizumab', 'Carboplatin', 'Pemetrexed', 'Cetuximab', 'Oxaliplatin', 'Folinic acid', 'Fluorouracil']","['B5279', 'B936', 'B274', 'B814', 'B164', 'B1229', 'B226', 'B493']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Small Molecule'], [], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], [], ['Small Molecule']]","[['GTPase KRas G12C'], ['Programmed cell death protein 1'], ['DNA'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase'], ['Epidermal growth factor receptor erbB1'], ['DNA'], [], ['Thymidylate synthase']]","[['KRAS G12C'], ['PD-1'], ['DNA'], ['DHFR', 'GART', 'TYMS'], ['EGFR'], ['DNA'], [], ['TYMS']]"
47501,NCT05078671,"Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness","Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness",PHASE4,RECRUITING,15/12/2021,31/12/2025,31/12/2025,160,ESTIMATED,,,['Cancer'],"['Olaparib', 'Cobicistat']","['B1818', 'B555']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors)', 'PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)', 'Poly'], []]","[['PARP1', 'PARP2', 'PARP3'], ['CYP3A4', 'CYP3A5', 'CYP3A7']]"
48126,NCT05170334,Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma,A Phase II Study of Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma,PHASE2,RECRUITING,15/12/2021,31/1/2028,31/1/2027,32,ESTIMATED,,,['Uveal Melanoma'],"['Binimetinib', 'Belinostat']","['B949', 'B1217']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2'], ['Histone deacetylase']]","[['MEK1', 'MEK2'], ['HDAC']]"
42530,NCT04372927,ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy,Adaptive-Dose to Mediastinum With Immunotherapy (Durvalumab MEDI4736) and Radiation in Locally-Advanced Non-Small Cell Lung Cancer,PHASE2,TERMINATED,10/12/2021,23/4/2022,23/4/2022,1,ACTUAL,,,"['Non-Small Cell Lung Cancer', 'Thoracic Neoplasm', 'Thoracic Neoplasm', 'Thoracic Neoplasm', 'Thoracic Neoplasm']","['Cisplatin', 'Durvalumab', 'Etoposide', 'Hypofractionated Radiation Therapy', 'Pemetrexed']","['B49', 'B977', 'B1463', 'B814']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Programmed death-ligand 1'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase']]","[['DNA'], ['PDL1'], ['TOP2'], ['DHFR', 'GART', 'TYMS']]"
48017,NCT05155189,A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma,A Clinical Study to Evaluate Safety and Efficacy of C-CAR031 Armored CAR-T Cell Injection in Treatment of Advanced Hepatocellular Carcinoma,PHASE1,RECRUITING,9/12/2021,31/5/2041,31/5/2026,44,ESTIMATED,,,['Hepatocellular Carcinoma'],"['C CAR 031', 'Lenvatinib', 'Anti-PD-L1 Monoclonal Antibody']","['B3953', 'B261']","[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)'], ['Small Molecule']]","[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)'], ['Small Molecule']]","[[], ['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[[], ['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
45681,NCT04837196,Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen,"A Phase 1/2, Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express WT1 Antigen",PHASE1/PHASE2,COMPLETED,6/12/2021,21/6/2024,21/6/2024,24,ACTUAL,,,"['Solid Tumors', 'Digestive System Neoplasm']","['ASP 7517', 'Pembrolizumab']","['B4076', 'B936']","[['Cell Therapy'], ['Antibody']]","[['Cell Therapy'], ['Monoclonal Antibody']]","[[""Wilms' Tumour 1""], ['Programmed cell death protein 1']]","[['WT1'], ['PD-1']]"
47761,NCT05114720,Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer,"A Multicenter, Placebo-Controlled, Phase III Trial of Standard Adjuvant Chemotherapy Plus Moxifloxacin in Operable Breast Cancer",PHASE3,RECRUITING,11/11/2021,31/12/2028,31/12/2025,520,ESTIMATED,,,['Breast Cancer'],"['Moxifloxacin', 'Docetaxel', 'Nab-paclitaxel', 'Cyclophosphamide', 'Doxorubicin', 'Placebo Control']","['B952', 'B2814', 'B7744', 'B2818', 'B1914']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Tubulin beta-1 chain'], ['Tubulin beta-1 chain'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)']]","[['Bacterial DNA gyrase', 'Topoisomerase IV'], ['TUBB1'], ['TUBB1'], ['DNA'], ['TOP2']]"
46889,NCT05001347,A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQÂ®) in Patients With Ovarian Cancer and Selected Solid Tumors,A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQÂ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors,PHASE2,COMPLETED,2/11/2021,8/2/2023,8/2/2023,25,ACTUAL,,,"['Ovarian Cancer', 'Ovarian Cancer', 'Head and Neck Neoplasm', 'Non-Small Cell Lung Cancer', 'Digestive System Neoplasm', 'Triple-Negative Breast Cancer']",['Uliledlimab'],['B1632'],[['Antibody']],[['Monoclonal Antibody']],"[[""5'-nucleotidase""]]",[['CD73']]
46872,NCT04999540,Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer,Trial of Tucidinostat in Combination With Fulvestrant in Patients With Hormone-receptor Positive Advanced Breast Cancer,PHASE2,UNKNOWN,1/11/2021,30/12/2024,1/12/2023,73,ESTIMATED,,,['Breast Cancer'],"['Tucidinostat', 'Fulvestrant']","['B1065', 'B276']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Histone deacetylase'], ['Estrogen receptors']]","[['HDAC'], ['ER']]"
51286,NCT05627778,68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis,A Head-to-head Comparison of 68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis,PHASE1/PHASE2,UNKNOWN,1/11/2021,1/12/2022,1/12/2022,30,ESTIMATED,,,['Prostate Cancer'],"['Gallium Ga-68 gozetotide', '68Ga-P15-041']","['B3880', 'B5858']","[['Radiopharmaceutical Imaging'], ['Radiopharmaceutical Imaging']]","[['Radiopharmaceutical Imaging'], ['Radiopharmaceutical Imaging']]","[['Prostate-specific membrane antigen'], []]","[['PSMA'], []]"
42349,NCT04337177,"Flavored, Oral Irinotecan VAL-413 (OrotecanÂ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors",Pilot Pharmacokinetic Study of VAL-413 (OrotecanÂ®) in Patients With Recurrent Pediatric Solid Tumors,PHASE1,RECRUITING,25/10/2021,30/6/2025,30/6/2025,20,ESTIMATED,,,"['Solid Tumors', 'Kidney Wilms Tumor', 'Rhabdomyosarcoma', 'Ewing Sarcoma', 'Liver Cancer', 'Medulloblastoma']","['Irinotecan', 'Temozolomide']","['B1679', 'B2056']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA topoisomerase I'], ['DNA']]","[['TOP1'], ['DNA']]"
46084,NCT04891809,Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged â‰¥70 Years) With NDMM,Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged â‰¥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650),PHASE2,RECRUITING,20/10/2021,31/12/2028,31/12/2027,198,ESTIMATED,,,['Multiple Myeloma'],"['Isatuximab', 'Lenalidomide', 'Dexamethasone']","['B1027', 'B2071', 'B1128']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Molecular glue'], ['Small Molecule']]","[['Lymphocyte differentiation antigen CD38'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos'], ['Glucocorticoid receptor']]","[['CD38'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3'], ['GR']]"
47378,NCT05061537,Study of PF-07263689 in Participants With Selected Advanced Solid Tumors,"A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND PHARMACODYNAMICS OF PF-07263689, EITHER ALONE OR IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY, IN PREVIOUSLY TREATED PARTICIPANTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC SOLID TUMORS",PHASE1,TERMINATED,20/10/2021,14/10/2022,14/10/2022,13,ACTUAL,,,"['Renal Cell Carcinoma', 'Male Reproductive System Neoplasm', 'Non-Small Cell Lung Cancer', 'Hepatocellular Carcinoma', 'Bladder Cancer', 'Sarcoma', 'Head and Neck Neoplasm', 'Colorectal Cancer', 'Ovarian Cancer', 'Epithelial Neoplasm']","['PF-07263689', 'Sasanlimab']","['B6343', 'B1422']","[['Oncolytic Virus'], ['Antibody']]","[['Oncolytic Virus'], ['Monoclonal Antibody']]","[[], ['Programmed cell death protein 1']]","[[], ['PD-1']]"
47531,NCT05083481,A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors,A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants With Locally Advanced or Metastatic Solid Tumors,PHASE1/PHASE2,RECRUITING,19/10/2021,31/5/2028,31/5/2028,310,ESTIMATED,,,['Solid Tumors'],"['ASP1570', 'Pembrolizumab']","['B3801', 'B936']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['diacylglycerol kinase zeta'], ['Programmed cell death protein 1']]","[['DGKÎ¶'], ['PD-1']]"
46949,NCT05008224,Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11),Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11),PHASE2,COMPLETED,7/10/2021,26/5/2024,11/10/2023,146,ACTUAL,,,['Classic Hodgkin Lymphoma'],"['Pembrolizumab', 'Doxorubicin', 'Vinblastine', 'Dacarbazine', 'Bleomycin', 'Etoposide', 'Cyclophosphamide', 'Vincristine', 'Procarbazine', 'Prednisone']","['B936', 'B1914', 'B355', 'B1647', 'B1205', 'B1463', 'B2818', 'B2083', 'B267', 'B1979']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Tubulin beta-1 chain'], ['DNA'], [], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], ['Tubulin beta-1 chain'], ['DNA'], ['Glucocorticoid receptor']]","[['PD-1'], ['TOP2'], ['TUBB1'], ['DNA'], [], ['TOP2'], ['DNA'], ['TUBB1'], ['DNA'], ['GR']]"
46402,NCT04933903,"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab for Patients With Resectable Stage IB - III Non-Small Cell Lung Cancer",PHASE2,RECRUITING,5/10/2021,1/12/2025,1/8/2025,25,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['Ipilimumab', 'Nivolumab', 'Stereotactic Body Radiation Therapy']","['B480', 'B714']","[['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Cytotoxic T-Lymphocyte-Associated Antigen 4'], ['Programmed cell death protein 1']]","[['CTLA4'], ['PD-1']]"
46735,NCT04982900,Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities,"A Prospective, Multi-center, Double-blind Randomized Controlled Clinical Trial on the Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities",PHASE2,UNKNOWN,1/10/2021,1/8/2022,1/8/2022,138,ESTIMATED,,,['Multiple Primary Lung Cancers'],"['Furmonertinib', 'Placebo Control']",['B2403'],[['Small Molecule']],[['Small Molecule']],[['EGFR T790M']],[['EGFR T790M']]
59830,NCT04278651,Early Antenatal Support for Iron Deficiency Anemia,Early Antenatal Support for Iron Deficiency Anemia: A Randomized Controlled Trial of Early Initiation of Intravenous Versus Oral Iron Therapy for Treatment of Iron Deficiency Anemia in Pregnancy,PHASE4,RECRUITING,29/9/2021,30/12/2025,30/8/2025,80,ESTIMATED,,,"['Pregnancy Related', 'Anemia, Iron Deficiency', 'Anemia of Pregnancy']","['Ferumoxytol', 'Ferrous sulfate']","['B202', 'B105']","[['Small Molecule'], []]","[['Small Molecule'], []]","[[], []]","[[], []]"
46763,NCT04985851,To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.,Durvalumab (MEDI4736) Combined With Anlotinib Versus Durvalumab (MEDI4736) Alone as Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC),,ACTIVE_NOT_RECRUITING,28/9/2021,1/12/2024,1/6/2024,90,ESTIMATED,,,['Extensive Stage Lung Small Cell Carcinoma'],"['Durvalumab', 'Catequentinib']","['B977', 'B1436']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed death-ligand 1'], ['Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['PDL1'], ['c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
39993,NCT04003896,A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma,A Pilot Study to Evaluate the Response and Tolerability of Verzenio (Abemaciclib) in Patients With Advanced Biliary Tract Carcinoma,PHASE2,TERMINATED,24/9/2021,15/8/2023,15/8/2023,4,ACTUAL,,,['Biliary Tract Cancer'],['Abemaciclib'],['B980'],[['Small Molecule']],[['Small Molecule']],"[['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6']]","[['CDK4', 'CDK6']]"
47030,NCT05017012,A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18),"A Phase 1 Clinical Study to Evaluate the Bioavailability of Pembrolizumab Via Subcutaneous Injection of MK-3475A, a Formulation of Pembrolizumab With MK-5180, in Participants With Advanced Solid Tumors",PHASE1,ACTIVE_NOT_RECRUITING,21/9/2021,26/9/2026,26/9/2026,72,ESTIMATED,,,['Solid Tumors'],"['Subcutaneous Pembrolizumab', 'Pembrolizumab', 'Pemetrexed', 'Carboplatin', 'Paclitaxel', 'Nab-paclitaxel', 'Axitinib', 'Cisplatin']","['B5520', 'B936', 'B814', 'B274', 'B1250', 'B7744', 'B262', 'B49']","[[], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Programmed cell death protein 1'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase'], ['DNA'], ['Tubulin beta-1 chain'], ['Tubulin beta-1 chain'], ['Protein-tyrosine kinases', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['DNA']]","[[], ['PD-1'], ['DHFR', 'GART', 'TYMS'], ['DNA'], ['TUBB1'], ['TUBB1'], ['Protein-tyrosine kinases', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['DNA']]"
47209,NCT05039931,"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors","An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerabilityï¼ŒPharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Locally Advanced or Metastatic Solid Tumors",PHASE1,WITHDRAWN,15/9/2021,30/6/2023,30/6/2023,0,ACTUAL,,,"['Breast Cancer', 'Solid Tumors']",['GNC 035'],['B4281'],[['Antibody']],[['Tetraspecific Antibody']],"[['CD3e molecule', 'Inactive tyrosine-protein kinase transmembrane receptor ROR1', 'Programmed death-ligand 1', 'Tumor necrosis factor receptor superfamily member 9']]","[['CD3Îµ', 'ROR1', 'PDL1', '4-1BB']]"
46901,NCT05002270,JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation,"A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation",PHASE1/PHASE2,RECRUITING,3/9/2021,31/7/2025,31/1/2024,100,ESTIMATED,,,"['Solid Tumors', 'Non-Small Cell Lung Cancer', 'Colorectal Cancer']","['Glecirasib', 'Cetuximab']","['B1847', 'B164']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['GTPase KRas G12C'], ['Epidermal growth factor receptor erbB1']]","[['KRAS G12C'], ['EGFR']]"
47677,NCT05103891,Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations,"A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Study to Investigate the Relative Bioavailability of Binimetinib 3 x15 mg and 45 mg Tablets in Healthy Participants",PHASE1,UNKNOWN,3/9/2021,29/11/2021,29/11/2021,14,ACTUAL,,,"['Male Reproductive System Neoplasm', 'BRAF V600 Mutation', 'Uveal Melanoma', 'Metastatic Melanoma']",['Binimetinib'],['B949'],[['Small Molecule']],[['Small Molecule']],"[['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2']]","[['MEK1', 'MEK2']]"
60131,NCT05078138,Impact of Erythropoietin on Hematological Adaptations and Physical Performance,Impact of Erythropoietin on Hematological Adaptations and Physical Performance,PHASE4,COMPLETED,1/9/2021,1/4/2023,1/4/2023,8,ACTUAL,,,"['Exercise-Induced Anemia', 'Physical Performance']",['Epoetin alfa'],['B155'],[['Other Protein Therapy']],[['Colony-Stimulating Factor']],[['Erythropoietin receptor']],[['EPO receptor']]
45607,NCT04826107,Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer,"An Open-label, Multicentre, Phase II Study of DP303c Injection in Patients With Unresectable Locally Advanced, Recurrent or Metastatic Gastric Cancer With HER2 Expression",PHASE2,UNKNOWN,31/8/2021,31/12/2024,31/8/2024,196,ESTIMATED,,,['Gastric Cancer'],"['DP 303c', 'PD-1/PD-L1 inhibitor']",['B3943'],[['Antibody Drug Conjugate (ADC)']],[['Antibody Drug Conjugate (ADC)']],[['Receptor protein-tyrosine kinase erbB-2']],"[['Beta-tubulin ', 'HER2']]"
46556,NCT04955886,Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma,"Efficacy and Safety of Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma : a Prospective, Single Arm and Multicenter Trial",PHASE2,UNKNOWN,31/8/2021,31/8/2023,31/8/2022,14,ESTIMATED,,,['Nasopharyngeal Cancer'],"['Surufatinib', 'Toripalimab']","['B1259', 'B1346']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Colony stimulating factor 1 receptor', 'Fibroblast growth factor receptor 1', 'Vascular endothelial growth factor receptor'], ['Programmed cell death protein 1']]","[['CSF-1R', 'FGFR1', 'VEGFR'], ['PD-1']]"
45485,NCT04807166,Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer,"A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer",PHASE2,ACTIVE_NOT_RECRUITING,24/8/2021,31/12/2027,30/9/2025,56,ACTUAL,,,"['Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm', 'Hematology', 'Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm', 'Neoplasms by Histologic Type', 'Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm', 'Endocrine Neoplasm', 'Epithelial Neoplasm', 'Anlotinib', 'Angiogenesis', 'Antineoplastic Agents', 'Tyrosine Kinase Inhibitor']","['Catequentinib', 'Paclitaxel', 'Carboplatin']","['B1436', 'B1250', 'B274']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Tubulin beta-1 chain'], ['DNA']]","[['c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['TUBB1'], ['DNA']]"
45971,NCT04877613,GFRÎ±4 CAR T Cells in MTC Patients,Phase I Trial of GFRÎ±4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer,PHASE1,RECRUITING,19/8/2021,1/6/2039,1/6/2039,18,ESTIMATED,,,['Thyroid Cancer'],"['Fludarabine', 'Cyclophosphamide', 'Autologous Anti-GFRa4 CAR-TCR-zeta-4-1BB-expressing T-cells']","['B346', 'B2818']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA']]","[['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA']]"
47467,NCT05075122,Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab,Phase 2 Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic PD-L1 Positive (CPSâ‰¥1) Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab,PHASE2,UNKNOWN,2/8/2021,28/2/2025,31/8/2024,75,ESTIMATED,,,['Head and Neck Squamous Cell Carcinoma'],"['Pembrolizumab', 'UV1 Telomerase Peptide Vaccine', 'Sargramostim']","['B936', 'B181']","[['Antibody'], ['Other Protein Therapy']]","[['Monoclonal Antibody'], ['Colony-Stimulating Factor']]","[['Programmed cell death protein 1'], ['Granulocyte-macrophage colony-stimulating factor receptor']]","[['PD-1'], ['CSF-2R']]"
43493,NCT04517227,The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD),A Single-Arm Open-Label Pilot Study of Combination Therapy of TACE and Ablation With Durvalumab in A Selected Hepatocellular Carcinoma Population at Intermediate Stage,,NOT_YET_RECRUITING,31/7/2021,31/10/2025,30/6/2025,30,ESTIMATED,,,['Hepatocellular Carcinoma'],"['Durvalumab', 'Transarterial Chemoembolization', 'Ablation Therapy']",['B977'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed death-ligand 1']],[['PDL1']]
46326,NCT04924101,Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99),A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99),PHASE2,ACTIVE_NOT_RECRUITING,15/7/2021,14/7/2026,14/7/2026,120,ESTIMATED,,,['Small Cell Lung Cancer'],"['Pembrolizumab', 'MK-4830', 'Boserolimab', 'Lenvatinib', 'Etoposide', 'Cisplatin', 'Carboplatin']","['B936', 'B4637', 'B1787', 'B261', 'B1463', 'B49', 'B274']","[['Antibody'], ['Antibody'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Leukocyte immunoglobulin-like receptor subfamily B member 2'], ['CD27 antigen'], ['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], ['DNA']]","[['PD-1'], ['LILRB2'], ['CD27'], ['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['TOP2'], ['DNA'], ['DNA']]"
46144,NCT04898634,"A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer","A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer",PHASE1,RECRUITING,13/7/2021,16/2/2026,13/2/2026,260,ESTIMATED,,,['Male Reproductive System Neoplasm'],['Pasritamig'],['B5933'],[['Antibody']],[['Bispecific T-Cell Engager']],"[['Kallikrein 2', 'T cell surface glycoprotein CD3']]","[['KLK2', 'CD3']]"
46198,NCT04906395,Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer,"Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",PHASE3,RECRUITING,1/7/2021,30/4/2026,30/4/2026,250,ESTIMATED,,,['Breast Cancer'],"['leuprolide acetate', 'Tamoxifen', 'Letrozole', 'Anastrozole', 'Exemestane']","['B9379', 'B2062', 'B302', 'B289', 'B86']","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Estrogen receptors'], ['Aromatase', 'Estrogen receptors'], ['Aromatase'], ['Aromatase']]","[[], ['ER'], ['aromatase', 'ER'], ['aromatase'], ['aromatase']]"
46429,NCT04937972,SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma,SHR-1701 Combined With Fluzoparib as Maintenance Therapy for Advanced Lung Squamous Cell Carcinoma After Platium Based Chemo-immunotherapy,PHASE2,RECRUITING,1/7/2021,1/6/2025,1/12/2024,71,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['Retlirafusp alfa', 'Fuzuloparib']","['B1790', 'B2371']","[['Engineered Protein Therapy'], ['Small Molecule']]","[['Fusion Protein'], ['Small Molecule']]","[['Programmed death-ligand 1', 'Transforming growth factor beta receptor 2'], ['Poly']]","[['PDL1', 'TGFBR2'], ['PARP']]"
46493,NCT04946890,A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia,"Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effectiveness of MRX2843 Tablets in Patients With Relapsed/Refractory Acute Myeloid Leukemia",PHASE1/PHASE2,UNKNOWN,1/7/2021,31/12/2024,31/12/2024,104,ESTIMATED,,,['Acute Myeloid Leukemia'],['MRX-2843'],['B1604'],[['Small Molecule']],[['Small Molecule']],"[['Tyrosine-protein kinase Mer', 'Tyrosine-protein kinase receptor FLT3']]","[['MerTK', 'FLT3']]"
46589,NCT04961788,Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma,A Phase 2 Study of Anti-PD1 Antibody Toripalimab Combined With Gemox (Gemcitabine and Oxaliplatin) as First-line Therapy in Patients With Advanced or Unresectable Intrahepatic Cholangiocarcinoma,PHASE2,UNKNOWN,1/7/2021,31/12/2022,31/12/2021,30,ESTIMATED,,,['Intrahepatic Cholangiocarcinoma'],"['Toripalimab', 'Oxaliplatin', 'Gemcitabine']","['B1346', 'B1229', 'B2079']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['DNA'], ['DNA', 'Ribonucleotide reductase']]","[['PD-1'], ['DNA'], ['DNA', 'RNR']]"
45762,NCT04846920,A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018),"A Phase 1, Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)",PHASE1,ACTIVE_NOT_RECRUITING,14/6/2021,21/7/2026,21/7/2026,52,ESTIMATED,,,['Non-Clear Cell Renal Cell Carcinoma'],['Belzutifan'],['B1486'],[['Small Molecule']],[['Small Molecule']],[['Endothelial PAS domain-containing protein 1']],[['HIF-2Î±']]
45500,NCT04808570,A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,"A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)",PHASE1/PHASE2,TERMINATED,5/6/2021,22/11/2023,22/11/2023,23,ACTUAL,,,['Hematology'],['TQ-B3525'],['B3089'],[['Small Molecule']],[['Small Molecule']],"[['Phosphatidylinositol 3 kinase alpha', 'Phosphatidylinositol 3 kinase delta']]","[['PI3KÎ±', 'PI3KÎ´']]"
44890,NCT04717531,Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer,"Pyrotinib as Neoadjuvant Agent for Non-objective Response Patients of HER2-positive Early Breast Cancer Treated by Trastuzumab, Pertuzumab, and Chemotherapy (PYHOPE-BC-104): a Randomized, Controlled, Phase â…¡ Trial",PHASE2,UNKNOWN,3/6/2021,31/5/2024,1/6/2023,60,ESTIMATED,,,['Breast Cancer'],"['Pyrotinib', 'Trastuzumab', 'Pertuzumab', 'Docetaxel', 'Epirubicin', 'Cyclophosphamide']","['B1071', 'B168', 'B538', 'B2814', 'B1236', 'B2818']","[['Small Molecule'], ['Antibody'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2', 'Receptor protein-tyrosine kinase erbB-4'], ['Receptor protein-tyrosine kinase erbB-2'], ['Receptor protein-tyrosine kinase erbB-2'], ['Tubulin beta-1 chain'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA']]","[['EGFR', 'HER2', 'HER4'], ['HER2'], ['HER2'], ['TUBB1'], ['DNA', 'TOP2'], ['DNA']]"
45981,NCT04878692,Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies,Evaluation of a Cosmetic Product (Onco-Rash) to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies Which Are Known to Fragilize Epidermis,,UNKNOWN,1/6/2021,1/7/2022,1/7/2022,96,ESTIMATED,,,"['Non-Small Cell Lung Cancer', 'Digestive System Neoplasm', 'Head and Neck Neoplasm']",['Cream Dosage Form'],[],[],[],[],[]
46433,NCT04938297,"Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma","Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma",PHASE2,RECRUITING,26/5/2021,31/12/2025,31/10/2022,100,ESTIMATED,,,['Central Nervous System Lymphoma'],"['Rituximab', 'Lenalidomide', 'Zanubrutinib']","['B163', 'B2071', 'B1139']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Molecular glue'], ['Small Molecule']]","[['B-lymphocyte antigen CD20'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos'], ['Tyrosine-protein kinase BTK']]","[['CD20'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3'], ['BTK']]"
46174,NCT04902885,"Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients","A Randomized, Double-blind, Placebo-controlled, Multi-center Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients",PHASE3,COMPLETED,25/5/2021,31/12/2022,29/12/2021,95,ACTUAL,,,['Extensive Stage Lung Small Cell Carcinoma'],"['Trilaciclib', 'Carboplatin', 'Etoposide', 'Topotecan', 'Placebo Control']","['B1132', 'B274', 'B1463', 'B2067']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA topoisomerase I']]","[['CDK4', 'CDK6'], ['DNA'], ['TOP2'], ['TOP1']]"
61684,NCT06669013,Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas,"A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With Investigator's Choice of Chemotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas With High Levels of GD2 Expression and Disease Progression During 1st Line Chemotherapy",PHASE3,RECRUITING,20/5/2021,30/9/2025,30/9/2025,40,ESTIMATED,,,"['Rhabdomyosarcoma', 'Bone Sarcoma', 'Rhabdomyosarcoma']",['Dinutuximab beta'],['B1912'],[['Antibody']],[['Monoclonal Antibody']],[['Disialoganglioside GD2']],[['GD2']]
44717,NCT04690595,BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL,A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,PHASE1,RECRUITING,18/5/2021,18/11/2027,18/11/2026,24,ESTIMATED,,,['Acute Lymphoblastic Leukemia'],['Autologous BAFFR-targeting CAR T Cells'],[],[],[],[],[]
53064,NCT05893654,Melphalan Chemoreduction for Ocular Melanoma,Melphalan Intra-arterial Chemotherapy for Choroidal Melanoma Chemoreduction - a Phase I Clinical Trial,PHASE1/PHASE2,UNKNOWN,1/5/2021,30/6/2024,31/5/2024,10,ESTIMATED,,,['Uveal Melanoma'],"['Melphalan', 'Brachytherapy']",['B2073'],[['Small Molecule']],[['Small Molecule']],[['DNA']],[['DNA']]
46241,NCT04912765,Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC,"An Open Label, Single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) Vaccine and Anti-PD1 (Nivolumab) as Adjuvant Treatment in Resected Hepatocellular Carcinoma (HCC) (Group A) and Liver Metastases From Colorectal Cancer (CRLM) (Group B)",PHASE2,RECRUITING,15/4/2021,31/5/2025,31/5/2025,60,ESTIMATED,,,"['Hepatocellular Carcinoma', 'Hepatocellular Carcinoma', 'Colorectal Cancer', 'Colorectal Cancer', 'Liver Cancer']","['Nivolumab', 'Neoantigen-loaded Autologous Dendritic Cell Vaccine']",['B714'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
43444,NCT04511078,Phase II Panitumumab-IRDye800 in Head & Neck Cancer,Phase II Open-Label Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures,PHASE2,RECRUITING,2/4/2021,31/12/2027,31/12/2026,25,ESTIMATED,,,['Head and Neck Neoplasm'],['Panitumumab-IRDye800'],[],[],[],[],[]
45909,NCT04868747,The Effect of Perioperative Lidocaine Infusion on Neutrophil Extracellular Trapping,The Effect of Perioperative Lidocaine Intravenous Infusion on Neutrophil Extracellular Trapping After Surgery for Stomach Cancer,,WITHDRAWN,1/4/2021,2/4/2021,2/4/2021,0,ACTUAL,,,['Gastric Cancer'],"['Lidocaine', 'Gastrectomy', 'Sodium chloride']","['B2044', 'B93']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Sodium channel alpha subunit'], []]","[['SCN1A'], []]"
60077,NCT04954001,"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","A Multi-center, Open-label, Single-arm Phase I Dose-escalation and Phase II Dose-expansion Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1",PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,26/3/2021,30/3/2025,28/2/2025,160,ESTIMATED,,,"['Neurofibromatosis', 'Neurofibroma', 'Malignant Peripheral Nerve Sheath Tumor']",['FCN 159'],['B6549'],[['Small Molecule']],[['Small Molecule']],"[['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2']]","[['MEK1', 'MEK2']]"
44409,NCT04649476,Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma,A Randomized Phase II Study of Neoadjuvant PD-1 Blockade Alone or Plus TPF Induction Chemotherapy for Resectable Local Advanced Oral Squamous Cell Carcinoma,PHASE2,COMPLETED,22/3/2021,10/8/2024,10/8/2022,68,ACTUAL,,,['Lip and Oral Cavity Cancer'],"['Camrelizumab', 'Docetaxel', 'Cisplatin', 'Fluorouracil']","['B1309', 'B2814', 'B49', 'B493']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Tubulin beta-1 chain'], ['DNA'], ['Thymidylate synthase']]","[['PD-1'], ['TUBB1'], ['DNA'], ['TYMS']]"
46613,NCT04965155,A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone),Isatuximab and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Patients (Isabel Study),PHASE2,ACTIVE_NOT_RECRUITING,21/3/2021,31/3/2027,28/11/2023,50,ESTIMATED,,,['Multiple Myeloma'],"['Isatuximab', 'Dexamethasone']","['B1027', 'B1128']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Lymphocyte differentiation antigen CD38'], ['Glucocorticoid receptor']]","[['CD38'], ['GR']]"
44998,NCT04731467,A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors,"A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors",PHASE1/PHASE2,COMPLETED,19/3/2021,30/9/2024,30/9/2024,79,ACTUAL,,,"['Solid Tumors', 'Non-Small Cell Lung Cancer', 'Pancreatic Cancer', 'Ovarian Cancer', 'Thyroid Gland Papillary Carcinoma', 'Male Reproductive System Neoplasm', 'Colorectal Cancer']","['CM 24', 'Nivolumab', 'Nab-paclitaxel', 'Gemcitabine', 'Eculizumab', 'Fluorouracil', 'Liposome Vesicle']","['B3630', 'B714', 'B7744', 'B2079', 'B195', 'B493']","[['Antibody'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule']]","[[], ['Programmed cell death protein 1'], ['Tubulin beta-1 chain'], ['DNA', 'Ribonucleotide reductase'], [], ['Thymidylate synthase']]","[['CEACAM1'], ['PD-1'], ['TUBB1'], ['DNA', 'RNR'], ['C5'], ['TYMS']]"
45124,NCT04749394,A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy,"A Phase II, Open-Label, Multi-Centre Study of Camrelizumab Plus Apatinib As Consolidation Therapy in Patients With Locally Advanced, Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy",PHASE2,RECRUITING,17/3/2021,30/6/2025,31/1/2025,42,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['Camrelizumab', 'Rivoceranib']","['B1309', 'B948']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 2']]","[['PD-1'], ['SRC', 'c-Kit', 'VEGFR2']]"
43413,NCT04508309,Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (CecolinÂ®) in Young Girls,"Phase 3 Randomized, Active-Comparator Controlled, Open-Label Trial to Evaluate the Immunogenicity & Safety of Alternate 2-Dose Regimens of CecolinÂ® Compared to GardasilÂ® in 9-14 Year-Old Girls in Low and Low-Middle Income Countries",PHASE3,COMPLETED,15/3/2021,14/12/2023,14/12/2023,1025,ACTUAL,,,['Cervical Cancer'],"['Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax', 'Human Papillomavirus 9-valent Vaccine, Recombinant']","['B4948', 'B2983']","[[], []]","[[], []]","[[], []]","[[], []]"
46316,NCT04923529,"TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma","Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma",PHASE2,ACTIVE_NOT_RECRUITING,1/3/2021,31/12/2024,25/3/2024,28,ACTUAL,,,['Pancreatic Cancer'],['Tipiracil/trifluridine'],['B2936'],[['Small Molecule']],[['Small Molecule']],"[['Thymidine phosphorylase', 'Thymidylate synthase']]","[['TYMP', 'TYMS']]"
44918,NCT04721015,Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors,A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors,PHASE1,ACTIVE_NOT_RECRUITING,23/2/2021,31/8/2025,31/8/2025,81,ACTUAL,,,"['Solid Tumors', 'Non-Small Cell Lung Cancer']","['ABBV-637', 'Docetaxel', 'Osimertinib']","['B3082', 'B2814', 'B991']","[['Antibody Drug Conjugate (ADC)'], ['Small Molecule'], ['Small Molecule']]","[['Antibody Drug Conjugate (ADC)'], ['Small Molecule'], ['Small Molecule']]","[['Apoptosis regulator Bcl-X', 'Epidermal growth factor receptor erbB1'], ['Tubulin beta-1 chain'], ['EGFR T790M']]","[['Bcl-XL', 'EGFR'], ['TUBB1'], ['EGFR L858R', 'EGFR-Ex19del', 'EGFR T790M']]"
47932,NCT05143112,Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma,Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma,PHASE1/PHASE2,UNKNOWN,5/2/2021,29/2/2024,29/2/2024,20,ESTIMATED,,,['B-Cell Non-Hodgkin Lymphoma'],['Allogeneic Anti-CD19 T-cells ThisCART19A'],[],[],[],[],[]
44835,NCT04709731,Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia,Cardiovascular Assessment of Ponatinib as Third Line Treatment Option in Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib and Bosutinib (CarPAs),PHASE2,UNKNOWN,1/2/2021,1/4/2025,31/10/2024,50,ESTIMATED,,,['Chronic Leukemia'],['Ponatinib'],['B64'],[['Small Molecule']],[['Small Molecule']],"[['Bcr-Abl tyrosine kinase', 'Protein-tyrosine kinases']]","[['BCR-ABL1', 'Protein-tyrosine kinases']]"
44706,NCT04688983,Study in Adult Ph-positive ALL,"An Open Label, 3-arm, Randomised Phase II Study to Compare the Safety and Efficacy of Ponatinib in Combination With Either Chemotherapy or Blinatumomab With Imatinib Plus Chemotherapy as Front-line Therapy for Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)",PHASE2,NOT_YET_RECRUITING,31/1/2021,31/1/2026,31/1/2024,180,ESTIMATED,,,['Acute Lymphoblastic Leukemia'],"['Ponatinib', 'Blinatumomab', 'Imatinib']","['B64', 'B406', 'B2099']","[['Small Molecule'], ['Antibody'], ['Small Molecule']]","[['Small Molecule'], ['Bispecific T-Cell Engager'], ['Small Molecule']]","[['Bcr-Abl tyrosine kinase', 'Protein-tyrosine kinases'], ['B-lymphocyte antigen CD19', 'T cell surface glycoprotein CD3'], ['Bcr-Abl tyrosine kinase', 'Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor']]","[['BCR-ABL1', 'Protein-tyrosine kinases'], ['CD19', 'CD3'], ['BCR-ABL1', 'PDGFRÎ²', 'c-Kit']]"
43167,NCT04471974,"ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer",A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer,PHASE2,RECRUITING,26/1/2021,30/4/2027,30/4/2027,54,ESTIMATED,,,"['Castration-Resistant Prostate Carcinoma', 'Prostate Cancer', 'Prostate Neuroendocrine Carcinoma', 'Prostate Cancer', 'Prostate Cancer', 'Prostate Cancer']","['ZEN 3694', 'Enzalutamide', 'Pembrolizumab']","['B2841', 'B25', 'B936']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['Bromodomain and extra terminal domain protein'], ['Androgen Receptor'], ['Programmed cell death protein 1']]","[['BET'], ['AR'], ['PD-1']]"
44346,NCT04640246,Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies,"A Phase 1/2 Multi-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies",PHASE1/PHASE2,UNKNOWN,25/1/2021,30/4/2023,31/1/2023,60,ESTIMATED,,,"['Cancer', 'Solid Tumors', 'Testicular Germ Cell Cancer']","['TBX-3400', 'Blood Transfusion']",['B3374'],[['Cell Therapy']],[['T-Cell Therapy']],[[]],[[]]
46469,NCT04942730,"Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)","Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)",PHASE2,COMPLETED,21/1/2021,30/4/2024,30/4/2024,50,ACTUAL,,,"['Acute Lymphoblastic Leukemia', 'Acute Myeloid Leukemia', 'Acute Leukemia', 'T Lymphoblastic Lymphoma', 'Myelodysplastic Syndrome', 'Myeloproliferative Neoplasm']","['Fludarabine', 'bendamustine hydrochloride', 'Busulfan', 'Cyclophosphamide', 'Mycophenolate mofetil', 'Tacrolimus']","['B346', 'B9064', 'B2060', 'B2818', 'B310', 'B2846']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Ribonucleotide reductase', 'RNA polymerase II'], [], ['DNA'], ['DNA'], [""Inosine-5'-monophosphate dehydrogenase""], []]","[['DNA polymerase III', 'RNR', 'RNA polymerase II'], [], ['DNA'], ['DNA'], ['IMPDH'], ['CaN']]"
46478,NCT04943757,Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies,Graft-versus-host Disease Prophylaxis With Combination of Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy),PHASE2,COMPLETED,21/1/2021,30/5/2024,30/5/2024,50,ACTUAL,,,"['Acute Myeloid Leukemia', 'Chronic Myeloid Leukemia', 'Myelodysplastic Syndrome', 'Myeloproliferative Neoplasm']","['bendamustine hydrochloride', 'Cyclophosphamides']","['B9064', 'B3286']","[['Small Molecule'], []]","[['Small Molecule'], []]","[[], ['DNA']]","[[], ['DNA']]"
46070,NCT04890392,Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC,A Single-arm Exploratory Study of Safety and Efficacy of Tislelizumab in Combination With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Cancer,PHASE2,UNKNOWN,15/1/2021,28/2/2022,28/1/2022,20,ESTIMATED,,,"['Gastric Cancer', 'Gastroesophageal Junction Cancer']","['Tislelizumab', 'Gimeracil/oteracil/tegafur', 'Oxaliplatin', 'Surgical Procedure']","['B1344', 'B2855', 'B1229']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Thymidylate synthase'], ['DNA']]","[['PD-1'], ['TYMS'], ['DNA']]"
53154,NCT05906615,Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis,Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis (LIDOPAN),PHASE2,COMPLETED,14/1/2021,1/7/2023,1/7/2023,30,ACTUAL,,,"['Pancreatic Cancer', 'Chronic Pancreatitis']",['Lidocaine'],['B2044'],[['Small Molecule']],[['Small Molecule']],[['Sodium channel alpha subunit']],[['SCN1A']]
44300,NCT04634071,Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment,Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment,PHASE2,RECRUITING,12/1/2021,31/1/2026,31/1/2026,126,ESTIMATED,,,"['Smoking Cessation', 'Leukemia']","['Varenicline', 'Bupropion', 'Long-acting Nicotine Replacement Therapy', 'Counseling']","['B2773', 'B2081']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[[], ['Dopamine transporter']]","[['nAChRÎ±4&Î²2'], ['5-HT3A receptor', 'SLC6A2', 'CHRNA3', 'DAT']]"
44081,NCT04605185,Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma,Dose Escalation Study Of Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma,PHASE1,ACTIVE_NOT_RECRUITING,8/1/2021,31/12/2024,31/12/2024,18,ESTIMATED,,,['Hepatocellular Carcinoma'],"['Donafenib', 'Toripalimab']","['B2802', 'B1346']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['C-Raf kinase', 'Platelet-derived growth factor receptor beta', 'Vascular endothelial growth factor receptor'], ['Programmed cell death protein 1']]","[['CRAF', 'PDGFRÎ²', 'VEGFR'], ['PD-1']]"
50752,NCT05549778,Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC,Safety and Efficacy of the Stomach Ulcer Drug Polaprezinc (POL) on Enzalutamide- or Abiraterone-resistant CRPC,PHASE1/PHASE2,COMPLETED,6/1/2021,31/1/2023,20/1/2023,12,ACTUAL,,,['Castration-Resistant Prostate Carcinoma'],"['Polaprezinc', 'Abiraterone']","['B853', 'B860']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[[], ['Steroid 17-alpha-hydroxylase']]","[[], ['CYP17A1']]"
44208,NCT04622566,Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma,A Phase II Study of Neoadjuvant Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma,PHASE2,UNKNOWN,30/12/2020,30/12/2023,30/12/2021,26,ESTIMATED,,,"['Head and Neck Neoplasm', 'Neoadjuvant Treatment']","['Lenvatinib', 'Pembrolizumab', 'Surgical Procedure']","['B261', 'B936']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Programmed cell death protein 1']]","[['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['PD-1']]"
44688,NCT04686383,"Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors","A Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Solid Tumors Resistant or Refractory to Standard Treatments",PHASE1,COMPLETED,29/12/2020,30/6/2022,7/6/2022,17,ACTUAL,,,['Solid Tumors'],['CAL056 mesylate'],['B3316'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
43307,NCT04493060,Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer,Phase II Study of Niraparib and TSR-042 in Patients with Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer,PHASE2,ACTIVE_NOT_RECRUITING,28/12/2020,1/6/2025,7/12/2023,22,ACTUAL,,,"['Pancreatic Cancer', 'Pancreatic Cancer']","['Dostarlimab', 'Niraparib']","['B1415', 'B33']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors)', 'PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)']]","[['PD-1'], ['PARP1', 'PARP2']]"
44666,NCT04683354,Study of HL-085 in Patients With Advanced Solid Tumor Tumors,"A Phase I, Open-Label, Multi-Center Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 in Patients With Advanced Solid Tumors",PHASE1,COMPLETED,23/12/2020,8/12/2022,15/9/2022,28,ACTUAL,,,['Epithelial Neoplasm'],['Tunlametinib'],['B1757'],[['Small Molecule']],[['Small Molecule']],"[['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2']]","[['MEK1', 'MEK2']]"
44412,NCT04650451,Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors,"A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors",PHASE1,SUSPENDED,7/12/2020,2/1/2027,31/12/2025,220,ESTIMATED,,,"['HER-2 Gene Amplification', 'HER2-positive Gastric Cancer', 'HER2-Positive Breast Cancer', 'HER-2 Protein Overexpression', 'Epithelial Neoplasm']",['Chimeric Antigen Receptor T-Cell Therapy'],[],[],[],[],[]
49104,NCT05304754,"""Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients""",Phase I / II Study on Infusion of Alloreactive or Stimulated Natural Killer Cells With IL-15 ex Vivo After Haploidentical Transplantation of Hematopoietic Progenitors in Pediatric Patients With Hematological Neoplasms,PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,30/11/2020,31/7/2026,30/6/2026,18,ESTIMATED,,,['High-risk Leukemias'],"['Interleukin-15', 'NK cells stimulated ex vivo with IL-15', 'Alloreactive NK cells - Instituto de InvestigaciÃ³n Hospital Universitario La Paz']","['B3878', 'B12054', 'B11992']","[['Other Protein Therapy'], [], ['Cell Therapy']]","[['Interleukin'], [], ['NK-Cell Therapy']]","[[], [], []]","[[], [], []]"
43600,NCT04532281,A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies,Clinical Trial for the Safety and Efficacy of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma,EARLY_PHASE1,RECRUITING,1/11/2020,1/11/2026,1/11/2023,120,ESTIMATED,,,"['Acute Lymphoblastic Leukemia', 'Non-Hodgkin Lymphoma']",['Anti-CD19 CAR T Cells Preparation'],[],[],[],[],[]
44064,NCT04602689,Fibrin Glue After ESD for High Risk Patients of Bleeding,Effectiveness of Fibrin Glue to Prevent Bleeding in High-risk Patients After Endoscopic Submucosal Dissection in Gastric Neoplasm : A Prospective Randomized Controlled Study,,COMPLETED,30/10/2020,14/7/2022,14/7/2022,134,ACTUAL,,,"['Gastric Cancer', 'Digestive System Neoplasm']","['Fibrinogen Human', 'Aprotinin', 'Thrombin', 'Calcium Chloride']",['B177'],[['Small Molecule']],[['Small Molecule']],[['Protease']],"[['Trypsin', 'Protease']]"
43362,NCT04501094,A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma,A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma,PHASE2,TERMINATED,26/10/2020,13/10/2021,19/1/2021,2,ACTUAL,,,['Urothelial Carcinoma'],['Bintrafusp alfa'],['B1389'],[['Engineered Protein Therapy']],[['Fusion Protein']],"[['Programmed death-ligand 1', 'Transforming growth factor beta']]","[['PDL1', 'TGF-Î²']]"
41605,NCT04225676,Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL),"A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia",PHASE2,TERMINATED,19/10/2020,19/10/2021,19/10/2021,5,ACTUAL,,,['Acute Lymphoblastic Leukemia'],['Tisagenlecleucel'],['B971'],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['B-lymphocyte antigen CD19']],[['CD19']]
44151,NCT04614636,FT538 in Subjects With Advanced Hematologic Malignancies,"A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma",PHASE1,TERMINATED,17/10/2020,8/8/2023,13/7/2023,42,ACTUAL,,,"['Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Multiple Myeloma', 'Multiple Myeloma']","['FT538', 'Cyclophosphamide', 'Fludarabine', 'Daratumumab', 'Elotuzumab']","['B5013', 'B2818', 'B346', 'B415', 'B418']","[['Cell Therapy'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Antibody']]","[['Chimeric Antigen Receptor NK-Cell Therapy (CAR-NK)'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Low affinity immunoglobulin gamma Fc region receptor III-A'], ['DNA'], ['Ribonucleotide reductase', 'RNA polymerase II'], ['Lymphocyte differentiation antigen CD38'], ['SLAM family member 7']]","[['CD16a'], ['DNA'], ['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['CD38'], ['SLAMF7']]"
44079,NCT04604132,"Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma","A Phase 1b/2 Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-negative Gastric Adenocarcinoma Expressing FGFR2 Genetic Aberrations",PHASE1/PHASE2,TERMINATED,6/10/2020,21/11/2022,21/11/2022,47,ACTUAL,,,['Gastric Cancer'],"['Derazantinib', 'Paclitaxel', 'Ramucirumab']","['B1257', 'B1250', 'B449']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3'], ['Tubulin beta-1 chain'], ['Vascular endothelial growth factor receptor 2']]","[['FGFR1', 'FGFR2', 'FGFR3'], ['TUBB1'], ['VEGFR2']]"
44004,NCT04592653,Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3),Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3,PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,30/9/2020,31/12/2024,31/7/2024,78,ESTIMATED,,,['Solid Tumors'],"['Nemvaleukin-alfa', 'Pembrolizumab']","['B2688', 'B936']","[['Other Protein Therapy'], ['Antibody']]","[['Interleukin'], ['Monoclonal Antibody']]","[['Interleukin-2 receptor'], ['Programmed cell death protein 1']]","[['IL-2R'], ['PD-1']]"
43944,NCT04584008,Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics,A Real-world Study to Explore and Evaluate Individualized Targeted Agents for Patients of Digestive Cancers Based on Molecular Characteristics After Standard Therapy Failure in China,,ACTIVE_NOT_RECRUITING,23/9/2020,31/3/2025,30/11/2024,600,ACTUAL,,,"['Biliary Tract Cancer', 'Gastric Cancer', 'Esophageal Cancer', 'Colorectal Cancer', 'Gastrointestinal Stromal Tumor', 'Pancreatic Cancer', 'Neuroendocrine Tumors', 'Carcinoma of Unknown Primary', 'Digestive System Neoplasm']",[],[],[],[],[],[]
43744,NCT04552769,Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,PHASE2,ACTIVE_NOT_RECRUITING,10/9/2020,31/12/2024,12/4/2023,9,ACTUAL,,,"['Thyroid Cancer', 'Thyroid Gland Anaplastic Carcinoma', 'Thyroid Gland Anaplastic Carcinoma']",['Abemaciclib'],['B980'],[['Small Molecule']],[['Small Molecule']],"[['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6']]","[['CDK4', 'CDK6']]"
43844,NCT04566380,ONO-4538 Phase II Rollover Study (ONO-4538-98),"A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination With Other Therapies and Are Continuing ONO-4538 Treatment (ONO-4538-98)",PHASE2,RECRUITING,10/9/2020,31/12/2026,31/12/2026,59,ESTIMATED,,,['Pan-tumor'],"['Nivolumab', 'Oxaliplatin', 'Gimeracil/oteracil/tegafur', 'Capecitabine', 'Bevacizumab', 'Temozolomide']","['B714', 'B1229', 'B2855', 'B474', 'B167', 'B2056']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['DNA'], ['Thymidylate synthase'], ['Thymidylate synthase'], ['Vascular endothelial growth factor A'], ['DNA']]","[['PD-1'], ['DNA'], ['TYMS'], ['TYMS'], ['VEGF-A'], ['DNA']]"
43094,NCT04459663,JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.,"A Single-arm, Single-center, Phase II Clinical Study to Investigate the Efficacy and Safety of JS001 Combined With Axitinib in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) With Negative Driving Gene After First-line Chemotherapy",PHASE2,UNKNOWN,31/8/2020,31/12/2023,30/9/2023,50,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['Toripalimab', 'Axitinib']","['B1346', 'B262']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Protein-tyrosine kinases', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['PD-1'], ['Protein-tyrosine kinases', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
43454,NCT04512417,A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer,"A Multi-Center, Randomized Controlled, Phase II Clinical Study Of Camrelizumab With Or Without Radiotherapy For The Treatment Of Recurrent Or Metastatic Esophageal Cancer That Has Progressed After Chemotherapy",PHASE2,UNKNOWN,31/8/2020,31/8/2022,31/8/2021,63,ESTIMATED,,,['Esophageal Cancer'],"['Camrelizumab', 'Radiation Therapy']",['B1309'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
42680,NCT04398108,A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC,"An Open-Label, Single-arm, Phase I Study to Evaluate the Pharmacokinetics, Tolerability and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies",PHASE1,COMPLETED,25/8/2020,27/4/2021,27/4/2021,16,ACTUAL,,,['HER2-Positive Breast Cancer'],"['Margetuximab', 'Capecitabine', 'Vinorelbine', 'Gemcitabine']","['B836', 'B474', 'B1929', 'B2079']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Receptor protein-tyrosine kinase erbB-2'], ['Thymidylate synthase'], ['Tubulin beta-1 chain'], ['DNA', 'Ribonucleotide reductase']]","[['HER2'], ['TYMS'], ['TUBB1'], ['DNA', 'RNR']]"
41313,NCT04189107,"Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS","An Investigation of Postoperative Pain, Why Still in Hospital and Days Alive and Out of Hospital Following Transoral Robotic Surgery for Squamous Cell Carcinoma of Unknown Primary and Obstructive Sleep Apnea",PHASE3,COMPLETED,18/8/2020,9/11/2022,9/11/2022,18,ACTUAL,,,"['Analgesia', 'Surgery', 'Head and Neck Neoplasm', 'Oropharyngeal Cancer', 'Carcinoma of Unknown Primary', 'Pain, Postoperative', 'Postoperative Pain']","['Dexamethasone', 'Placebo Control']",['B1128'],[['Small Molecule']],[['Small Molecule']],[['Glucocorticoid receptor']],[['GR']]
42401,NCT04344158,A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC),"A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)",PHASE3,ACTIVE_NOT_RECRUITING,11/8/2020,31/12/2026,31/12/2026,648,ESTIMATED,,,['Hepatocellular Carcinoma'],"['Penpulimab', 'catequentinib hydrochloride', 'sorafenib tosylate']","['B1279', 'B9013', 'B8463']","[['Antibody'], [], []]","[['Monoclonal Antibody'], [], []]","[['Programmed cell death protein 1'], [], []]","[['PD-1'], [], []]"
42926,NCT04435197,Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma,Multicenter Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophageus,PHASE2,COMPLETED,11/8/2020,30/6/2024,30/6/2024,143,ACTUAL,,,['Esophageal Cancer'],['Pembrolizumab'],['B936'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
50520,NCT05513612,Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies,Safety and Efficacy Study of Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies,PHASE1,WITHDRAWN,1/8/2020,31/12/2026,31/12/2025,0,ACTUAL,,,"['Acute Myeloid Leukemia', 'B-Cell Non-Hodgkin Lymphoma', 'Multiple Myeloma', 'Adult T-Cell Leukemia/Lymphoma', 'Acute Lymphoblastic Leukemia']","['Autologous CAR-T Cells', 'Fludarabine', 'Cyclophosphamide']","['B346', 'B2818']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA']]","[['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA']]"
43309,NCT04493125,Effect of Mosapride Citrate on Gastrointestinal Motility After Laparoscopic Gastrectomy,"The Effect of Mosapride Citrate on Gastrointestinal Motility After Laparoscopic Gastrectomy: Prospective, Double Blind Placebo-controlled Study",,COMPLETED,27/7/2020,30/3/2021,30/3/2021,104,ACTUAL,,,['Gastric Cancer'],"['Mosapride', 'Placebo Control']",[],[],[],[],[]
42560,NCT04379739,Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer,Neoadjuvant Camrelizumab Plus Apatinib or Platinum-based Chemotherapy for Potentially Resectable (Resectable and Initially Unresectable) II-III Non-small Cell Lung Cancer,PHASE2,ACTIVE_NOT_RECRUITING,26/7/2020,30/12/2026,29/6/2022,89,ACTUAL,,,['Non-Small Cell Lung Cancer'],['Camrelizumab'],['B1309'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
43148,NCT04469075,Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields,"The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields",PHASE2,RECRUITING,9/7/2020,31/7/2025,31/7/2025,58,ESTIMATED,,,"['Glioblastoma', 'Glioblastoma', 'Skin Toxicity']","['clindamycin phosphate', 'triamcinolone acetonide']","['B8613', 'B8506']","[[], []]","[[], []]","[[], []]","[[], []]"
42916,NCT04433221,Combination Immunotherapy Targeting Sarcomas,Safety and Efficacy Evaluation of a Combination Immunotherapy Targeting Sarcomas,PHASE1/PHASE2,UNKNOWN,1/7/2020,31/12/2023,31/5/2023,20,ESTIMATED,,,"['Sarcoma', 'Osteoid Sarcoma', 'Ewing Sarcoma']","['Multiple sarcoma-specific CAR-T cells - Shenzhen Geno-Immune Medical Institute', 'sarcoma vaccines - Shenzhen Geno-Immune Medical Institute']","['B12022', 'B12023']","[[], []]","[[], []]","[[], []]","[[], []]"
60752,NCT06540937,Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor,Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor,PHASE2,RECRUITING,1/7/2020,30/12/2024,30/12/2024,50,ESTIMATED,,,['Neuroendocrine Tumors'],['Leflunomide'],['B2103'],[['Small Molecule']],[['Small Molecule']],[['Dihydroorotate dehydrogenase']],[['DHODH']]
42305,NCT04329949,Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma,A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT),PHASE3,TERMINATED,30/6/2020,25/3/2022,23/8/2021,43,ACTUAL,,,['Pancreatic Cancer'],"['Relacorilant', 'Nab-paclitaxel']","['B1209', 'B7744']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Glucocorticoid receptor'], ['Tubulin beta-1 chain']]","[['GR'], ['TUBB1']]"
42868,NCT04427774,A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor,"A Phase Ib Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor",PHASE1,TERMINATED,29/6/2020,27/4/2021,8/2/2021,8,ACTUAL,,,['Solid Tumors'],"['Surufatinib', 'Sintilimab']","['B1259', 'B1337']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Colony stimulating factor 1 receptor', 'Fibroblast growth factor receptor 1', 'Vascular endothelial growth factor receptor'], ['Programmed cell death protein 1']]","[['CSF-1R', 'FGFR1', 'VEGFR'], ['PD-1']]"
46819,NCT04992988,"Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial","Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial",PHASE2,UNKNOWN,28/6/2020,30/6/2022,30/6/2022,40,ESTIMATED,,,"['Nasopharyngeal Cancer', 'Toripalimab', 'Nasopharyngeal Cancer']",['Toripalimab'],['B1346'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
42202,NCT04314089,"Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)","Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)",PHASE1,ACTIVE_NOT_RECRUITING,9/6/2020,31/3/2025,11/4/2024,31,ACTUAL,,,['Non-Small Cell Lung Cancer'],['GT-103'],['B6085'],[['Antibody']],[['Monoclonal Antibody']],[[]],[['CFH']]
42693,NCT04400383,Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors,"An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors",PHASE1,COMPLETED,4/6/2020,28/9/2023,8/7/2023,62,ACTUAL,,,"['Solid Tumors', 'Gastric Cancer', 'Pancreatic Cancer']","['AB 011', 'Moxifloxacin', 'Nab-paclitaxel']","['B6399', 'B952']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Claudin 18.2'], []]","[['CLDN18.2'], ['Bacterial DNA gyrase', 'Topoisomerase IV']]"
42882,NCT04429438,Multi-CAR-T Cells Targeting B Cell Lymphomas,"Primary, Booster and Consolidation Multi-CAR-T Cell Therapy for the Treatment of Refractory B Cell Lymphomas",PHASE1/PHASE2,UNKNOWN,1/6/2020,31/12/2023,31/7/2023,11,ESTIMATED,,,['B-Cell Non-Hodgkin Lymphoma'],[],[],[],[],[],[]
42587,NCT04383977,Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer,"A Phase 2 Randomized, Open-label, Multicenter Trial of Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant or Refractory Ovarian Cancer",PHASE2,UNKNOWN,31/5/2020,30/6/2021,31/12/2020,54,ESTIMATED,,,['Ovarian Cancer'],"['Rivoceranib', 'Etoposide']","['B948', 'B1463']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 2'], ['Top II inhibitors (Topoisomerase II inhibitors)']]","[['SRC', 'c-Kit', 'VEGFR2'], ['TOP2']]"
42328,NCT04334174,Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas,"A Phase II Single Arm Proof of Concept, Safety, Efficacy, Multicenter Study of Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplant in CD30 Expressing Peripheral T Cell Lymphomas",PHASE2,WITHDRAWN,29/5/2020,1/2/2023,14/12/2022,0,ACTUAL,,,['T-Cell Non-Hodgkin Lymphoma'],['Brentuximab vedotin'],['B407'],[['Antibody Drug Conjugate (ADC)']],[['Antibody Drug Conjugate (ADC)']],[['CD30 modulators(Tumor necrosis factor receptor superfamily member 8 modulators)']],"[['Beta-tubulin ', 'CD30']]"
41944,NCT04275713,"Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC","Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in Locally Advanced Cervical Cancer.",PHASE2,COMPLETED,22/5/2020,8/11/2024,11/6/2024,41,ACTUAL,,,['Cervical Cancer'],"['Metformin', 'Cisplatin']","['B298', 'B49']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Protein kinase AMP-activated non-catalytic subunit beta 1'], ['DNA']]","[['PRKAB1'], ['DNA']]"
42861,NCT04426669,A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering,A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System,PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,15/5/2020,31/1/2026,31/1/2026,20,ESTIMATED,,,"['Epithelial Neoplasm', 'Digestive System Neoplasm', 'Digestive System Neoplasm', 'Digestive System Neoplasm', 'Digestive System Neoplasm', 'Colorectal Cancer', 'Pancreatic Cancer', 'Gallbladder Carcinoma', 'Colon Carcinoma', 'Esophageal Cancer', 'Gastric Cancer']","['Cyclophosphamide', 'Mesna', 'Fludarabine', 'Tumor Infiltrating Lymphocyte', 'Aldesleukin']","['B2818', 'B2825', 'B346', 'B136']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Interleukin']]","[['DNA'], [], ['Ribonucleotide reductase', 'RNA polymerase II'], ['Interleukin-2 receptor']]","[['DNA'], [], ['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['IL-2R']]"
41928,NCT04272957,A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms,"A Phase I, Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics and Efficacy of HMPL-306 in Patients of Relapsed/Refractory Myeloid Leukemia/Neoplasms With IDH1 and/or IDH2 Mutation",PHASE1,UNKNOWN,14/5/2020,30/12/2022,30/6/2021,75,ESTIMATED,,,['Acute Myeloid Leukemia'],['HMPL-306'],['B4358'],[['Small Molecule']],[['Small Molecule']],"[['Isocitrate dehydrogenase [NADP] cytoplasmic', 'Isocitrate dehydrogenase [NADP], mitochondrial']]","[['IDH1', 'IDH2']]"
41290,NCT04186845,Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence,"A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy (SPOTLIGHT)",PHASE3,COMPLETED,4/5/2020,28/4/2021,28/4/2021,391,ACTUAL,,,['Prostate Cancer'],['18F-rhPSMA 7.3 PET/CT Scan'],[],[],[],[],[]
42437,NCT04353102,"A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies","A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies",PHASE1,COMPLETED,22/4/2020,24/11/2021,14/9/2021,15,ACTUAL,,,['Solid Tumors'],['YH 002'],['B4291'],[['Antibody']],[['Monoclonal Antibody']],[['Tumor necrosis factor receptor superfamily member 4']],[['OX40']]
41971,NCT04279561,Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer,Effects of Novel Androgen Receptor Signaling Inhibitors on PSMA PET Signal Intensity in Patients With Castrate-Resistant Prostate Cancer: A Prospective Exploratory Study,PHASE1,TERMINATED,16/4/2020,15/9/2022,15/9/2022,9,ACTUAL,,,"['Castration-Resistant Prostate Carcinoma', 'Prostate Cancer', 'Prostate Cancer', 'Prostate Cancer', 'Prostate Cancer']","['Computed Tomography', 'Gallium Ga-68 gozetotide', 'Positron Emission Tomography']",['B3880'],[['Radiopharmaceutical Imaging']],[['Radiopharmaceutical Imaging']],[['Prostate-specific membrane antigen']],[['PSMA']]
40881,NCT04134884,Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer,A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,PHASE1,COMPLETED,1/4/2020,14/3/2024,30/1/2024,34,ACTUAL,,,"['Brain Metastasis', 'Triple-Negative Breast Cancer', 'Hormone Receptor-Positive Breast Cancer']","['Talazoparib', 'Cedazuridine/decitabine']","['B928', 'B3021']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors)', 'PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)'], ['Cytidine deaminase', 'DNA']]","[['PARP1', 'PARP2'], ['CDA', 'DNMT1']]"
40665,NCT04102020,A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy,"Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy",PHASE3,ACTIVE_NOT_RECRUITING,26/3/2020,30/4/2025,29/9/2022,112,ACTUAL,,,['Acute Myeloid Leukemia'],"['Venetoclax', 'Azacitidine']","['B927', 'B322']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Apoptosis regulator Bcl-2'], ['DNA']]","[['Bcl-2'], ['DNMT1']]"
39943,NCT03996473,Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases,"An Open-label, Multicenter, Phase 1/2 Study of Radium-223 Dichloride in Combination With Pembrolizumab in Participants With Stage IV Non-small Cell Lung Cancer",PHASE1,TERMINATED,6/3/2020,30/1/2023,14/4/2021,8,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Radium 223 chloride', 'Pembrolizumab']","['B2869', 'B936']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[[], ['Programmed cell death protein 1']]","[[], ['PD-1']]"
42237,NCT04319263,Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-GuÃ©rin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer,Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-GuÃ©rin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer,,COMPLETED,1/3/2020,18/3/2020,18/3/2020,1600,ACTUAL,,,['Bladder Cancer'],['BCG vaccine'],['B722'],[['Live biotherapeutics']],[['Live biotherapeutics']],[[]],[[]]
53762,NCT05999994,A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer,CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research,PHASE2,RECRUITING,22/1/2020,31/5/2027,31/5/2027,105,ESTIMATED,,,"['Neoplasms', 'Child', 'Rhabdomyosarcoma']","['Ramucirumab', 'Cyclophosphamide', 'Vinorelbine', 'Gemcitabine', 'Docetaxel', 'Abemaciclib', 'Irinotecan', 'Temozolomide']","['B449', 'B2818', 'B1929', 'B2079', 'B2814', 'B980', 'B1679', 'B2056']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Vascular endothelial growth factor receptor 2'], ['DNA'], ['Tubulin beta-1 chain'], ['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain'], ['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6'], ['DNA topoisomerase I'], ['DNA']]","[['VEGFR2'], ['DNA'], ['TUBB1'], ['DNA', 'RNR'], ['TUBB1'], ['CDK4', 'CDK6'], ['TOP1'], ['DNA']]"
41339,NCT04192253,Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize),Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize),PHASE2,RECRUITING,14/1/2020,1/1/2029,1/1/2024,51,ESTIMATED,,,"['Locally Advanced, Squamous Cell Carcinoma of the Vulva']","['Paclitaxel', 'Carboplatin']","['B1250', 'B274']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['DNA']]","[['TUBB1'], ['DNA']]"
41295,NCT04187456,A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body,"An Open Label, 2 Period, Fixed-sequence Study to Assess the Effect of Savolitinib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Healthy Subjects",PHASE1,COMPLETED,27/12/2019,6/3/2020,6/3/2020,14,ACTUAL,,,['Solid Tumors'],"['Savolitinib', 'Midazolam']","['B988', 'B1992']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)'], ['Gamma-aminobutyric acid A receptor']]","[['c-Met'], ['GABAA receptor']]"
59772,NCT04132050,A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788,A Phase III Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788,PHASE3,COMPLETED,24/12/2019,25/9/2023,21/12/2021,34,ACTUAL,,,['Idiopathic Thrombocytopenic Purpura'],"['fostamatinib disodium', 'Placebo Control']",['B8680'],[[]],[[]],[[]],[[]]
41353,NCT04193904,A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer,A Safety and Preliminary Efficacy Study of the Oral Live Biotherapeutic MRx0518 With Hypofractionated Preoperative Radiation for Resectable Pancreatic Cancer,PHASE1,TERMINATED,20/12/2019,8/5/2023,8/5/2023,13,ACTUAL,,,['Pancreatic Cancer'],"['CJRB 102', 'Hypofractionated Radiation Therapy']",['B3955'],[['Small Molecule']],[['Small Molecule']],[['Toll like receptor 5']],[['TLR5']]
41293,NCT04187352,A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma,"A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1001 in Combination With Fluorouracil and Cisplatin (FP) Compared to Placebo in Combination With FP as First-Line Therapy in Subjects With Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)",PHASE3,COMPLETED,19/12/2019,7/10/2022,7/10/2022,540,ACTUAL,,,['Esophageal Cancer'],"['Sugemalimab', 'Fluorouracil', 'Cisplatin', 'Placebo Control']","['B1529', 'B493', 'B49']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Programmed death-ligand 1'], ['Thymidylate synthase'], ['DNA']]","[['PDL1'], ['TYMS'], ['DNA']]"
41405,NCT04200417,Chemoembolization for Lung Tumors,Phase I Study of Transarterial Chemoembolization of Lung Metastases,PHASE1,COMPLETED,13/12/2019,19/4/2022,19/4/2022,10,ACTUAL,,,"['Thoracic Neoplasm', 'Rare Neoplasm', 'Thoracic Neoplasm', 'Thoracic Neoplasm']","['Ethiodized oil', 'Mitomycin', 'Chemoembolization', 'Tris-acryl Gelatin Microspheres']","['B138', 'B13']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], []]","[[], []]"
39499,NCT03935893,Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers,A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers,PHASE2,RECRUITING,3/12/2019,30/6/2037,30/6/2036,240,ESTIMATED,,,"['Gastric Cancer', 'Colorectal Cancer', 'Pancreatic Cancer', 'Sarcoma', 'Mesothelioma', 'Neuroendocrine Tumors', 'Epithelial Neoplasm', 'Merkel Cell Carcinoma', 'Mismatch Repair Deficiency', 'Microsatellite Instability']","['Aldesleukin', 'Tumor Infiltrating Lymphocyte', 'Fludarabine', 'Cyclophosphamide']","['B136', 'B346', 'B2818']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule']]","[['Interleukin'], ['Small Molecule'], ['Small Molecule']]","[['Interleukin-2 receptor'], ['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA']]","[['IL-2R'], ['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA']]"
40865,NCT04133337,Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC,One-arm Exploratory Study on the Efficacy and Safety of Apatinib Combined With SHR-1210 Injection (PD-1 Antibody) in the Treatment of Removable IB-IIIA Non-small Cell Lung Cancer,PHASE1/PHASE2,UNKNOWN,1/11/2019,30/6/2021,1/6/2020,20,ESTIMATED,,,"['Lung Diseases', 'Neoplasms', 'Respiratory Tract Diseases', 'Thoracic Neoplasm', 'Non-Small Cell Lung Cancer']","['Rivoceranib', 'Camrelizumab']","['B948', 'B1309']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 2'], ['Programmed cell death protein 1']]","[['SRC', 'c-Kit', 'VEGFR2'], ['PD-1']]"
39848,NCT03984448,"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas",Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas,PHASE2/PHASE3,ACTIVE_NOT_RECRUITING,22/10/2019,1/4/2028,1/4/2028,363,ESTIMATED,,,"['Double-Hit Lymphoma', 'Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Double-Hit Lymphoma', 'High Grade B-Cell Lymphoma']","['Biospecimen Collection', 'Bone Marrow Biopsy', 'Computed Tomography', 'Cyclophosphamide', 'doxorubicin hydrochloride', 'Etoposide', 'Lumbar Puncture', 'Positron Emission Tomography', 'Prednisone', 'Rituximab', 'Venetoclax', 'vincristine sulfate']","['B2818', 'B9124', 'B1463', 'B1979', 'B163', 'B927', 'B9307']","[['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Small Molecule'], []]","[['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], []]","[['DNA'], [], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Glucocorticoid receptor'], ['B-lymphocyte antigen CD20'], ['Apoptosis regulator Bcl-2'], []]","[['DNA'], [], ['TOP2'], ['GR'], ['CD20'], ['Bcl-2'], []]"
45887,NCT04865289,Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study,"A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)",PHASE3,COMPLETED,22/10/2019,14/1/2025,2/10/2023,130,ACTUAL,,,['Female Reproductive System Neoplasm'],"['Lenvatinib', 'Pembrolizumab', 'Paclitaxel', 'Carboplatin']","['B261', 'B936', 'B1250', 'B274']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Programmed cell death protein 1'], ['Tubulin beta-1 chain'], ['DNA']]","[['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['PD-1'], ['TUBB1'], ['DNA']]"
59738,NCT04074187,A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP),An Open-label Multicenter Trial to Study the Efficacy and Safety of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura,PHASE2/PHASE3,COMPLETED,21/10/2019,19/5/2021,19/5/2021,21,ACTUAL,,,['Thrombotic Thrombocytopenic Purpura'],"['Caplacizumab', 'Plasmapheresis', 'Methylprednisolone', 'Prednisolone', 'Rituximab']","['B1988', 'B266', 'B163']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['Glucocorticoid receptor'], ['Glucocorticoid receptor'], ['B-lymphocyte antigen CD20']]","[['GR'], ['GR'], ['CD20']]"
39934,NCT03994796,Genetic Testing in Guiding Treatment for Patients With Brain Metastases,Genomically-Guided Treatment Trial in Brain Metastases,PHASE2,RECRUITING,17/10/2019,30/6/2028,31/10/2026,186,ESTIMATED,,,"['CDK Gene Mutation', 'Brain Metastasis', 'Solid Tumors', 'Connective and Soft Tissue Neoplasm', 'PI3K Gene Mutation', 'ROS1 Gene Mutation', 'KRAS G12C Mutation']","['Abemaciclib', 'Paxalisib', 'Entrectinib', 'Adagrasib']","['B980', 'B1112', 'B534', 'B1500']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6'], [], ['Anaplastic lymphoma kinase', 'Nerve growth factor receptor Trk-A', 'Neurotrophic tyrosine kinase receptor type 2', 'Neurotrophic tyrosine kinase receptor type 3', 'Proto-oncogene tyrosine-protein kinase ROS'], ['GTPase KRas G12C']]","[['CDK4', 'CDK6'], ['PI3K family'], ['ALK', 'TRKA', 'TrkB', 'TrkC', 'ROS1'], ['KRAS G12C']]"
59647,NCT03857841,A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD,A Safety Study of Intravenous Infusion of Bone Marrow Mesenchymal Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia,PHASE1,TERMINATED,9/10/2019,20/5/2021,20/5/2021,3,ACTUAL,,,['Bronchopulmonary Dysplasia'],"[""Dulbecco's Phosphate-Buffered Saline""]",[],[],[],[],[]
38485,NCT03792763,"Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients","Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial ""DEFENCE"" (DEnosumab for the REductioN of the Smoldering Myeloma TransformatioN InCidence RatE)",PHASE2,COMPLETED,30/9/2019,14/9/2023,14/9/2023,8,ACTUAL,,,['Multiple Myeloma'],"['Denosumab', 'Placebo Control']",['B235'],[['Antibody']],[['Monoclonal Antibody']],[['Tumor necrosis factor ligand superfamily member 11']],[['RANKL']]
41952,NCT04277221,ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM),"Autologous Dendritic Cell / Tumor Antigen (ADCTA-SSI-G1) for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM): A Multi-center, Open-label, Randomized Phase III Clinical Trial",PHASE3,UNKNOWN,19/9/2019,31/12/2022,31/12/2022,118,ESTIMATED,,,['Glioblastoma'],[],[],[],[],[],[]
40309,NCT04050462,Nivolumab Combined With BMS-986253 in HCC Patients,"A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 in Advanced Hepatocellular Carcinoma (HCC) Patients",PHASE2,ACTIVE_NOT_RECRUITING,12/9/2019,13/12/2025,13/12/2024,23,ACTUAL,,,['Hepatocellular Carcinoma'],"['Nivolumab', 'Cabiralizumab', 'HuMax IL8']","['B714', 'B1307', 'B2718']","[['Antibody'], ['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Programmed cell death protein 1'], ['Colony stimulating factor 1 receptor'], ['Interleukin-8']]","[['PD-1'], ['CSF-1R'], ['IL-8']]"
40101,NCT04021368,RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome,A Phase Ib Study of RVU120 (SEL120) in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome,PHASE1,ACTIVE_NOT_RECRUITING,4/9/2019,30/12/2024,30/12/2024,112,ESTIMATED,,,"['Acute Myeloid Leukemia', 'Myelodysplastic Syndrome']",['RVU 120'],['B3760'],[['Small Molecule']],[['Small Molecule']],"[['Cyclin-dependent kinase 19', 'Cyclin-dependent kinase 8']]","[['CDK19', 'CDK8']]"
40918,NCT04139772,Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.,A Randomized Multicenter Phase III Trial Comparing Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.,PHASE3,UNKNOWN,1/9/2019,1/7/2024,1/12/2023,18,ACTUAL,,,['Castration-Resistant Prostate Carcinoma'],"['Docetaxel', 'Prednisone', 'Abiraterone acetate', 'Enzalutamide']","['B2814', 'B1979', 'B877', 'B25']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['Glucocorticoid receptor'], ['Steroid 17-alpha-hydroxylase'], ['Androgen Receptor']]","[['TUBB1'], ['GR'], ['CYP17A1'], ['AR']]"
40252,NCT04043494,International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma,LBL 2018 - International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma,PHASE3,RECRUITING,23/8/2019,22/11/2027,22/11/2027,683,ESTIMATED,,,['Non-Hodgkin Lymphoma'],"['Cyclophosphamide', 'Cytarabine', 'Dexamethasone', 'Daunorubicin', 'Doxorubicin', 'Ifosfamide', 'Mercaptopurine', 'Methotrexate', 'Pegaspargase', 'Prednisone', 'Prednisolone', 'Tioguanine', 'Vincristine', 'Vindesine']","['B2818', 'B2050', 'B1128', 'B476', 'B1914', 'B8', 'B2978', 'B997', 'B675', 'B1979', 'B266', 'B2887', 'B2083', 'B2787']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Enzyme'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['DNA-directed DNA polymerase'], ['Glucocorticoid receptor'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], [], ['Dihydrofolate reductase'], ['Asparagine'], ['Glucocorticoid receptor'], ['Glucocorticoid receptor'], ['DNA'], ['Tubulin beta-1 chain'], ['Tubulin beta-1 chain']]","[['DNA'], ['DNA-directed DNA polymerase'], ['GR'], ['TOP2'], ['TOP2'], ['DNA'], ['HPRT1'], ['DHFR'], ['ASN'], ['GR'], ['GR'], ['DNA'], ['TUBB1'], ['TUBB1']]"
42968,NCT04439890,A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer,"A Randomized, Double-blind, Multicenter Phase III Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer",PHASE3,UNKNOWN,8/8/2019,31/12/2021,1/6/2021,369,ESTIMATED,,,['Lung Non-Squamous Non-Small Cell Carcinoma'],"['catequentinib hydrochloride', 'Carboplatin', 'pemetrexed disodium', 'Placebo Control']","['B9013', 'B274', 'B8763']","[[], ['Small Molecule'], []]","[[], ['Small Molecule'], []]","[[], ['DNA'], []]","[[], ['DNA'], []]"
60334,NCT05585645,A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With AranespÂ® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD),"A Multicenter, Double-blind, Randomized, Parallel Comparative Study of Efficacy and Safety of Nanogen's Darbepoetin Alfa With AranespÂ® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis",PHASE3,COMPLETED,8/8/2019,23/11/2022,23/11/2022,214,ACTUAL,,,"['Anemia', 'Chronic Kidney Disease Requiring Chronic Dialysis']",['Darbepoetin alfa'],['B156'],[['Other Protein Therapy']],[['Colony-Stimulating Factor']],[['Erythropoietin receptor']],[['EPO receptor']]
39192,NCT03892018,The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol,"An Open-label, Crossover Study of the Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol",PHASE1,TERMINATED,5/8/2019,12/5/2023,12/5/2023,29,ACTUAL,,,['Epithelial Neoplasm'],['Oral Paclitaxel + Encequidar - Hanmi'],['B2557'],[['Small Molecule']],[['Small Molecule']],"[['P-glycoprotein 1', 'Tubulin beta-1 chain']]","[['P-gp', 'TUBB1']]"
39844,NCT03984097,A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM),"An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy",PHASE1,ACTIVE_NOT_RECRUITING,29/7/2019,31/3/2026,31/3/2026,50,ACTUAL,,,['Multiple Myeloma'],"['Mezagitamab', 'Lenalidomide', 'Dexamethasone', 'Bortezomib', 'Pomalidomide']","['B1339', 'B2071', 'B1128', 'B958', 'B1446']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Molecular glue'], ['Small Molecule'], ['Small Molecule'], ['Molecular glue']]","[['Lymphocyte differentiation antigen CD38'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos'], ['Glucocorticoid receptor'], ['Proteasome'], ['Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos']]","[['CD38'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3'], ['GR'], ['Proteasome'], ['CRBN', 'IKZF1', 'IL-6', 'TNF-Î±', 'IKZF3']]"
39793,NCT03977194,Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy,Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel Chemotherapy,PHASE3,ACTIVE_NOT_RECRUITING,23/7/2019,31/12/2026,31/8/2024,500,ESTIMATED,,,['Epithelial Neoplasm'],"['Carboplatin', 'Paclitaxel', 'Atezolizumab']","['B274', 'B1250', 'B1084']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['DNA'], ['Tubulin beta-1 chain'], ['Programmed death-ligand 1']]","[['DNA'], ['TUBB1'], ['PDL1']]"
36239,NCT03492671,Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer,A Phase II Trial of Pre-operative Chemotherapy (With Gemcitabine and Nab- Paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients With Resectable Pancreatic Adenocarcinoma,PHASE2,RECRUITING,17/7/2019,30/9/2026,30/9/2026,30,ESTIMATED,,,"['Pancreatic Cancer', 'Pancreatic Cancer']","['Gemcitabine', 'Nab-paclitaxel', 'Stereotactic Body Radiation Therapy']","['B2079', 'B7744']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain']]","[['DNA', 'RNR'], ['TUBB1']]"
40134,NCT04025593,Biomarker Guided Treatment in DLBCL,"A Randomized, Phase 2 Study of Biomarker Guided Treatment in DLBCL",PHASE2,UNKNOWN,17/7/2019,1/6/2023,1/7/2021,128,ESTIMATED,,,['Diffuse Large B-Cell Lymphoma'],"['Cyclophosphamide', 'Rituximab', 'Doxorubicin', 'Vincristine', 'Prednisone', 'Ibrutinib', 'Lenalidomide', 'Chidamide', 'Decitabine']","['B2818', 'B163', 'B1914', 'B2083', 'B1979', 'B499', 'B2071', 'B9734', 'B113']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Molecular glue'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['B-lymphocyte antigen CD20'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Tubulin beta-1 chain'], ['Glucocorticoid receptor'], ['Tyrosine-protein kinase BTK'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos'], ['Histone deacetylase'], ['DNA', 'DNA (cytosine-5)-methyltransferase 3A', 'DNA (cytosine-5)-methyltransferase 3B']]","[['DNA'], ['CD20'], ['TOP2'], ['TUBB1'], ['GR'], ['BTK'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3'], ['HDAC'], ['DNMT1', 'DNMT3A', 'DNMT3B']]"
39482,NCT03933735,A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma,"A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects With Relapsed or Refractory Multiple Myeloma",PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,24/6/2019,12/5/2026,12/5/2026,220,ACTUAL,,,['Multiple Myeloma'],['Etentamig'],['B11356'],[['Antibody']],[['Bispecific T-Cell Engager']],"[['B-cell maturation protein', 'T cell surface glycoprotein CD3']]","[['BCMA', 'CD3']]"
40789,NCT04121507,ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy,A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma,PHASE2,COMPLETED,24/6/2019,2/2/2023,30/3/2022,60,ACTUAL,,,"['Non-Hodgkin Lymphoma', 'High Grade B-Cell Lymphoma', 'Intestinal T-Cell Lymphoma']","['Emtricitabine', 'Allogeneic Stem Cell Transplantation', 'Bone Marrow Biopsy', 'Calcium trisodium pentetate', 'TC']","['B2078', 'B3914']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[[], []]","[['HIV-1 RT'], []]"
39838,NCT03983759,Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer,Clinical Study of Sequential Sequential Sintilimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer After Chemotherapy Combined With Adoptive Cellular Immunotherapy,PHASE2,UNKNOWN,20/6/2019,31/5/2021,31/5/2021,40,ESTIMATED,,,"['Small Cell Lung Cancer', 'Extensive Stage Lung Small Cell Carcinoma', 'Adoptive Cellular Immunotherapy', 'Leukemia', 'Maintenance']",['Sintilimab'],['B1337'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
40269,NCT04045847,CD147-CART Cells in Patients With Recurrent Malignant Glioma.,"A Clinical Study to Investigate the Safety, Tolerance and Efficacy Evaluation of Single-centre, Open-label of Local Treatment of CD147-CART in Recurrent Glioblastoma.",EARLY_PHASE1,UNKNOWN,30/5/2019,30/5/2022,30/10/2020,31,ESTIMATED,,,"['Glioblastoma', 'CD147 Positive']",['Autologous Anti-CD147 CAR T-cells'],[],[],[],[],[]
38511,NCT03795597,"Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)",Phase I/II Study Utilizing High Dose Busulfan and Melphalan With Escalating Carfilzomib as Conditioning in Autologous Peripheral Blood Stem Cell Transplantation for Patients With Multiple Myeloma,PHASE1/PHASE2,UNKNOWN,22/5/2019,1/11/2023,1/11/2022,36,ESTIMATED,,,['Multiple Myeloma'],"['Carfilzomib', 'Busulfan', 'Melphalan']","['B1471', 'B2060', 'B2073']","[['Engineered Protein Therapy'], ['Small Molecule'], ['Small Molecule']]","[['Synthetic Peptide'], ['Small Molecule'], ['Small Molecule']]","[['Proteasome'], ['DNA'], ['DNA']]","[['Proteasome'], ['DNA'], ['DNA']]"
39462,NCT03930953,"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)","A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).",PHASE1/PHASE2,RECRUITING,20/5/2019,18/4/2027,17/4/2026,438,ESTIMATED,,,['Non-Hodgkin Lymphoma'],"['Golcadomide', 'Rituximab', 'Obinutuzumab', 'Tafasitamab', 'Valemetostat']","['B1752', 'B163', 'B443', 'B1396', 'B1556']","[['Small Molecule'], ['Antibody'], ['Antibody'], ['Antibody'], ['Small Molecule']]","[['Molecular glue'], ['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Cereblon'], ['B-lymphocyte antigen CD20'], ['B-lymphocyte antigen CD20'], ['B-lymphocyte antigen CD19'], ['Enhancer of zeste homolog 1', 'Histone-lysine N-methyltransferase EZH2']]","[['CRBN'], ['CD20'], ['CD20'], ['CD19'], ['EZH1', 'EZH2']]"
39322,NCT03910387,Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer,Weight Loss in Patients With Advanced Stage Pancreatic Cancer: Role of Serotonin and Effects of Telotristat Ethyl,PHASE2,ACTIVE_NOT_RECRUITING,17/4/2019,1/10/2024,26/10/2023,22,ESTIMATED,,,"['Pancreatic Cancer', 'Pancreatic Cancer', 'Pancreatic Cancer', 'Pancreatic Cancer', 'Pancreatic Cancer']","['Gemcitabine', 'Nab-paclitaxel', 'telotristat ethyl']","['B2079', 'B7744', 'B9338']","[['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], []]","[['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain'], []]","[['DNA', 'RNR'], ['TUBB1'], []]"
42455,NCT04356430,Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer,Medical Ethics Committee of Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University,PHASE2,UNKNOWN,1/4/2019,1/12/2023,1/3/2021,75,ESTIMATED,,,['Prostate Cancer'],"['Abiraterone acetate', 'Laparoscopic Radical Prostatectomy with Robotics', 'Prednisone', 'Goserelin']","['B877', 'B1979', 'B121']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Steroid 17-alpha-hydroxylase'], ['Glucocorticoid receptor'], ['Gonadotropin-releasing hormone receptor']]","[['CYP17A1'], ['GR'], ['GnRHR']]"
39423,NCT03924986,Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC),"A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317) Combined With Gemcitabine Plus Cisplatin Versus Placebo Combined With Gemcitabine Plus Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer",PHASE3,COMPLETED,27/3/2019,8/12/2023,26/3/2021,263,ACTUAL,,,['Nasopharyngeal Cancer'],"['Tislelizumab', 'Placebo Control', 'Gemcitabine', 'Cisplatin']","['B1344', 'B2079', 'B49']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['DNA', 'Ribonucleotide reductase'], ['DNA']]","[['PD-1'], ['DNA', 'RNR'], ['DNA']]"
38679,NCT03818061,Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck,"A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC)",PHASE2,ACTIVE_NOT_RECRUITING,26/3/2019,1/3/2024,1/3/2024,33,ACTUAL,,,['Head and Neck Neoplasm'],"['Atezolizumab', 'Bevacizumab']","['B1084', 'B167']","[['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Programmed death-ligand 1'], ['Vascular endothelial growth factor A']]","[['PDL1'], ['VEGF-A']]"
38563,NCT03802058,Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer,Concurrent Nab--paclitaxel/Carboplatin and Thoracic Radiotherapy in Inoperable Stage III Squamous Cell Lung Cancer,PHASE2,TERMINATED,20/3/2019,12/12/2021,12/12/2021,24,ACTUAL,,,"['Non-Small Cell Lung Cancer', 'Epithelial Neoplasm']","['Nab-paclitaxel', 'Carboplatin', 'Thoracic Radiation Therapy']","['B7744', 'B274']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['DNA']]","[['TUBB1'], ['DNA']]"
38269,NCT03764137,Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer,Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer,PHASE1/PHASE2,WITHDRAWN,14/3/2019,31/1/2026,31/1/2025,0,ACTUAL,,,['Colon Carcinoma'],['Panitumumab'],['B194'],[['Antibody']],[['Monoclonal Antibody']],[['Epidermal growth factor receptor erbB1']],[['EGFR']]
59633,NCT03825744,Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia,A Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia,PHASE3,COMPLETED,5/3/2019,3/7/2024,3/7/2024,240,ACTUAL,,,['Severe Aplastic Anemia'],"['eltrombopag olamine', 'Placebo Control', 'Best Practice']",['B9032'],[[]],[[]],[[]],[[]]
38205,NCT03754933,Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer,"Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer",PHASE1/PHASE2,COMPLETED,11/2/2019,31/12/2024,29/12/2023,10,ACTUAL,,,['Head and Neck Neoplasm'],"['Purine nucleoside phosphorylase', 'fludarabine phosphate']","['B3968', 'B8555']","[['Gene Therapy'], []]","[['Gene Transfer Therapy'], []]","[['Purine nucleoside phosphorylase'], []]","[['PNP'], []]"
39723,NCT03967938,Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes,Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes,PHASE2,ACTIVE_NOT_RECRUITING,7/2/2019,31/12/2025,31/12/2024,540,ESTIMATED,,,['Advanced Cancers Harbouring Mutations in HRG'],['Olaparib'],['B1818'],[['Small Molecule']],[['Small Molecule']],"[['PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors)', 'PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)', 'Poly']]","[['PARP1', 'PARP2', 'PARP3']]"
37573,NCT03671811,Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy,Open-Label Randomized Phase II Trial of Megestrol Acetate With or Without Pterostilbene in Patients With Endometrial Cancer Scheduled for Hysterectomy,PHASE2,ACTIVE_NOT_RECRUITING,21/1/2019,10/4/2025,10/4/2025,44,ACTUAL,,,"['Intraepithelial Neoplasia', 'Endometrial Cancer']","['Megestrol acetate', 'Pterostilbene']",['B9385'],[[]],[[]],[[]],[[]]
36199,NCT03486197,Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma,Phase II Trial of Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma,PHASE2,TERMINATED,17/1/2019,1/5/2024,1/11/2023,12,ACTUAL,,,['Urothelial Carcinoma'],"['Laboratory Biomarker Analysis', 'Pembrolizumab', 'Radiation Therapy']",['B936'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
37976,NCT03724968,Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression,A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression,PHASE2,TERMINATED,17/1/2019,28/5/2020,28/5/2020,2,ACTUAL,,,"['Metastatic Melanoma', 'Skin Melanoma', 'Acral Lentiginous Melanoma']","['Nivolumab', 'Relatlimab', 'Ipilimumab']","['B714', 'B1199', 'B480']","[['Antibody'], ['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Programmed cell death protein 1'], ['Lymphocyte activation gene 3 protein'], ['Cytotoxic T-Lymphocyte-Associated Antigen 4']]","[['PD-1'], ['LAG3'], ['CTLA4']]"
38939,NCT03851237,CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy,Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy,PHASE1,RECRUITING,2/1/2019,31/12/2025,31/12/2025,75,ESTIMATED,,,['Pancreatic Cancer'],"['Copper Cu 64-DOTA-ECL1i', 'Calcium trisodium pentetate']",['B3914'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
51966,NCT05728632,Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines,Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines (CONTROL Trial),PHASE3,UNKNOWN,1/1/2019,28/2/2023,28/2/2023,80,ACTUAL,,,"['Breast Cancer', 'Diffuse Large B-Cell Lymphoma', 'Cardiotoxicity', 'Left Ventricular Dysfunction', 'Leukemia']","['Nebivolol', 'Placebo Control']",['B1445'],[['Small Molecule']],[['Small Molecule']],[['Beta-1 adrenergic receptor']],[['Î²1-adrenergic receptor']]
37189,NCT03616886,Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC,A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer,PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,28/12/2018,31/12/2025,31/3/2025,129,ACTUAL,,,['Triple-Negative Breast Cancer'],"['Paclitaxel', 'Carboplatin', 'Durvalumab', 'Oleclumab']","['B1250', 'B274', 'B977', 'B1190']","[['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Tubulin beta-1 chain'], ['DNA'], ['Programmed death-ligand 1'], [""5'-nucleotidase""]]","[['TUBB1'], ['DNA'], ['PDL1'], ['CD73']]"
38692,NCT03819465,A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC,"A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)",PHASE1,ACTIVE_NOT_RECRUITING,27/12/2018,26/3/2026,23/5/2023,175,ACTUAL,,,['Epithelial Neoplasm'],"['Durvalumab', 'Danvatirsen', 'Oleclumab', 'Volrustomig', 'Pemetrexed', 'Carboplatin', 'Gemcitabine', 'Cisplatin', 'Nab-paclitaxel', 'Rilvegostomig']","['B977', 'B1315', 'B1190', 'B1786', 'B814', 'B274', 'B2079', 'B49', 'B7744', 'B1871']","[['Antibody'], ['Antisense Oligonucleotide (ASO)'], ['Antibody'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Monoclonal Antibody'], ['Antisense Oligonucleotide (ASO)'], ['Monoclonal Antibody'], ['Bispecific Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Bispecific Antibody']]","[['Programmed death-ligand 1'], ['Signal transducer and activator of transcription 3'], [""5'-nucleotidase""], ['Cytotoxic T-Lymphocyte-Associated Antigen 4', 'Programmed cell death protein 1'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase'], ['DNA'], ['DNA', 'Ribonucleotide reductase'], ['DNA'], ['Tubulin beta-1 chain'], ['Programmed cell death protein 1', 'T cell immunoglobulin and ITIM domains']]","[['PDL1'], ['STAT3'], ['CD73'], ['CTLA4', 'PD-1'], ['DHFR', 'GART', 'TYMS'], ['DNA'], ['DNA', 'RNR'], ['DNA'], ['TUBB1'], ['PD-1', 'TIGIT']]"
38208,NCT03755141,Efficacy and Safety of Trastuzumab Biosimilar (HerzumaÂ®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer,"Open Label, Multicenter, Prospective Phase II Study to Investigate the Efficacy and Safety of Trastuzumab Biosimilar (HerzumaÂ®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer Who Progressed After 2 or More HER-2 Directed Chemotherapy",PHASE2,UNKNOWN,15/12/2018,30/6/2022,15/12/2021,119,ESTIMATED,,,"['HER2-Positive Breast Cancer', 'Brain Metastasis']",['Trastuzumab'],['B168'],[['Antibody']],[['Monoclonal Antibody']],[['Receptor protein-tyrosine kinase erbB-2']],[['HER2']]
34819,NCT03298945,Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens,Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens,PHASE4,COMPLETED,13/12/2018,30/6/2024,30/12/2023,2239,ACTUAL,,,['Colorectal Cancer'],"['Bowel Preparation', 'Macrogol 3350-Based Iso-Osmotic Laxative']",[],[],[],[],[]
37010,NCT03596281,Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer,An Open-label Phase 1 of Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Platinum Resistant Epithelial Ovarian Cancer,PHASE1,COMPLETED,5/12/2018,11/4/2023,11/3/2021,47,ACTUAL,,,['Ovarian Cancer'],"['Pembrolizumab', 'Bevacizumab', 'Pegylated liposomal doxorubicin']","['B936', 'B167', 'B2819']","[['Antibody'], ['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['Vascular endothelial growth factor A'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)']]","[['PD-1'], ['VEGF-A'], ['DNA', 'TOP2']]"
36889,NCT03579446,Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer,Levorphanol as a Second Line Opioid in Cancer Patients Undergoing Opioid Rotation: An Open Label Study,EARLY_PHASE1,ACTIVE_NOT_RECRUITING,29/11/2018,15/6/2026,15/6/2026,43,ACTUAL,,,"['Hematology', 'Solid Tumors', 'Solid Tumors']","['Hydrocodone Measurement', 'Hydromorphone', 'Levorphanol Measurement', 'Morphine', 'Oxycodone', 'Oxymorphone', 'Questionnaire Administration']","['B1153', 'B2007', 'B1993', 'B2105']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Mu opioid receptor'], ['Kappa opioid receptor', 'Mu opioid receptor'], ['Opioid receptors'], ['Opioid receptors']]","[['Î¼ opioid receptor'], ['Î´ opioid receptor', 'Îº opioid receptor', 'Î¼ opioid receptor'], ['Opioid receptors'], ['Opioid receptors']]"
37504,NCT03663166,Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC),Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC,PHASE1/PHASE2,TERMINATED,20/11/2018,22/10/2021,22/10/2021,19,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Thoracic Radiation Therapy', 'Cisplatin', 'Etoposide', 'Carboplatin', 'Paclitaxel', 'Pemetrexed', 'Ipilimumab', 'Nivolumab']","['B49', 'B1463', 'B274', 'B1250', 'B814', 'B480', 'B714']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], ['Tubulin beta-1 chain'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase'], ['Cytotoxic T-Lymphocyte-Associated Antigen 4'], ['Programmed cell death protein 1']]","[['DNA'], ['TOP2'], ['DNA'], ['TUBB1'], ['DHFR', 'GART', 'TYMS'], ['CTLA4'], ['PD-1']]"
36388,NCT03513484,Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia,"Phase Ib, Open Label, Combination Study of Nintedanib With 5-Azacitidine in Acute Myeloid Leukemia Characterized by HOX Gene Overexpression, That Are Not Candidates of Intensive Chemotherapy",PHASE1,ACTIVE_NOT_RECRUITING,14/11/2018,31/1/2027,1/12/2025,44,ESTIMATED,,,"['Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Fibroblast Growth Factor Basic Form Measurement', 'Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Acute Myeloid Leukemia']","['Azacitidine', 'Laboratory Biomarker Analysis', 'Nintedanib']","['B322', 'B1705']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'Tyrosine-protein kinase receptor FLT3', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['DNMT1'], ['FGFR1', 'FGFR2', 'FGFR3', 'PDGFRÎ±', 'PDGFRÎ²', 'FLT3', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
37514,NCT03664687,Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL),"A Randomised, Multicentre, Pragmatic Trial Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)",PHASE4,ACTIVE_NOT_RECRUITING,31/10/2018,31/8/2025,2/4/2020,211,ACTUAL,,,['Breast Cancer'],['Zoledronic acid'],['B2822'],[['Small Molecule']],[['Small Molecule']],"[['Bone resorption factor', 'FDPS inhibitors(Farnesyl diphosphate synthase inhibitors)']]","[['Bone resorption factor', 'FDPS']]"
37837,NCT03706547,Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM,Clinical Study of Anti-CD19/BCMA Bispecific Chimeric Antigen Receptors (CARs) T Cell Therapy for Relapsed and Refractory Multiple Myeloma,PHASE1,UNKNOWN,30/10/2018,31/12/2021,31/7/2020,20,ESTIMATED,,,"['Multiple Myeloma', 'Multiple Myeloma']","['Anti-CD19/BCMA bispecific CAR-T cell therapy - Hrain Biotechnology', 'Fludarabine', 'Cyclophosphamide']","['B4482', 'B346', 'B2818']","[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)'], ['Small Molecule'], ['Small Molecule']]","[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)'], ['Small Molecule'], ['Small Molecule']]","[['B-cell maturation protein', 'B-lymphocyte antigen CD19'], ['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA']]","[['BCMA', 'CD19'], ['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA']]"
35785,NCT03426904,Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer,Neoadjuvant Chemotherapy for Non-metastatic Locally Advanced Colon Cancer: A Prospective Multicenter Randomized Controlled Trial,PHASE3,ACTIVE_NOT_RECRUITING,24/10/2018,28/12/2030,31/12/2024,708,ESTIMATED,,,['Colon Carcinoma'],[],[],[],[],[],[]
37901,NCT03714490,MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer,MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy (SCPRT) Followed by Consolidation Chemotherapy Versus Long Course Chemoradiation for Unresectable Rectal Cancer,PHASE2,RECRUITING,23/10/2018,30/9/2025,30/9/2024,200,ESTIMATED,,,['Digestive System Neoplasm'],"['Hydrocortisone', 'Capecitabine', 'Chemoradiotherapy', 'Oxaliplatin', 'Surgical Procedure']","['B1133', 'B474', 'B1229']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Glucocorticoid receptor'], ['Thymidylate synthase'], ['DNA']]","[['GR'], ['TYMS'], ['DNA']]"
37394,NCT03646461,Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC,"A Multi-Institutional, Open-Label, Randomized, Phase II Trial Of Ibrutinib In Combination With EGFR Inhibition Or PD-1 Inhibition In Patients With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma",PHASE2,ACTIVE_NOT_RECRUITING,17/10/2018,30/12/2025,11/12/2025,5,ACTUAL,,,"['Head and Neck Neoplasm', 'Head and Neck Squamous Cell Carcinoma']","['Ibrutinib', 'Cetuximab', 'Nivolumab']","['B499', 'B164', 'B714']","[['Small Molecule'], ['Antibody'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Tyrosine-protein kinase BTK'], ['Epidermal growth factor receptor erbB1'], ['Programmed cell death protein 1']]","[['BTK'], ['EGFR'], ['PD-1']]"
37852,NCT03708328,"A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors","An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors",PHASE1,COMPLETED,15/10/2018,9/7/2024,9/7/2024,134,ACTUAL,,,"['Solid Tumors', 'Metastatic Melanoma', 'Non-Small Cell Lung Cancer', 'Small Cell Lung Cancer', 'Esophageal Squamous Cell Carcinoma']",['RG7769'],['B1550'],[['Antibody']],[['Bispecific Antibody']],"[['Hepatitis A virus cellular receptor 2', 'Programmed cell death protein 1']]","[['TIM3', 'PD-1']]"
37690,NCT03689699,Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8),Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer,PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,11/10/2018,31/1/2025,31/5/2024,60,ESTIMATED,,,"['Prostate Cancer', 'Prostate Cancer']","['Nivolumab', 'Degarelix', 'HuMax IL8']","['B714', 'B1231', 'B2718']","[['Antibody'], ['Engineered Protein Therapy'], ['Antibody']]","[['Monoclonal Antibody'], ['Synthetic Peptide'], ['Monoclonal Antibody']]","[['Programmed cell death protein 1'], ['Gonadotropin-releasing hormone receptor'], ['Interleukin-8']]","[['PD-1'], ['GnRHR'], ['IL-8']]"
37911,NCT03715517,Spinal Anesthesia For Enhanced Recovery After Liver Surgery,Spinal Anesthesia for Enhanced Recovery After Liver Surgery,,RECRUITING,4/10/2018,31/1/2026,31/12/2025,128,ESTIMATED,,,"['Hepatectomy', 'Pain, Postoperative', 'Liver Cancer']","['Lidocaine', 'Thoracic Epidural Analgesia', 'Morphine', 'Spinal Block', 'Bupivacaine', 'Hydromorphone']","['B2044', 'B2007', 'B39', 'B1153']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Sodium channel alpha subunit'], ['Kappa opioid receptor', 'Mu opioid receptor'], [], ['Mu opioid receptor']]","[['SCN1A'], ['Î´ opioid receptor', 'Îº opioid receptor', 'Î¼ opioid receptor'], [], ['Î¼ opioid receptor']]"
32670,NCT03011671,Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma,A Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide in Adults With Newly Diagnosed MGMT Promoter-Methylated IDH Wildtype Glioblastoma,PHASE1,RECRUITING,3/10/2018,31/10/2026,1/10/2026,60,ESTIMATED,,,['High-Grade Glioma'],"['Acetazolamide', 'Temozolomide']","['B537', 'B2056']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[[], ['DNA']]","[['CAs'], ['DNA']]"
37841,NCT03707093,Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma,A Study of CD137 Agonist ADG106 Administered Intravenously in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma,PHASE1,COMPLETED,17/9/2018,30/9/2022,24/1/2022,49,ACTUAL,,,['Digestive System Neoplasm'],['ADG 106'],['B2590'],[['Antibody']],[['Monoclonal Antibody']],[['Tumor necrosis factor receptor superfamily member 9']],[['4-1BB']]
33260,NCT03090880,Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE),Long-term Prophylaxis of Venous Thromboembolism With Low-molecular-weight Heparin in Patients With Metastatic Lung Cancer,PHASE3,TERMINATED,14/9/2018,18/8/2021,18/8/2021,59,ACTUAL,,,"['Venous Thromboembolism', 'Thoracic Neoplasm']",['Tinzaparin sodium'],['B134'],[['Small Molecule']],[['Small Molecule']],[['Antithrombin-III']],[['AT III']]
36000,NCT03457142,"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy",Phase II Study of Targeting CD28 in Multiple Myeloma With Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy,PHASE2,TERMINATED,11/9/2018,6/11/2024,21/11/2022,15,ACTUAL,,,"['Multiple Myeloma', 'Multiple Myeloma']","['Abatacept', 'Dexamethasone', 'Ixazomib citrate', 'Laboratory Biomarker Analysis']","['B192', 'B1128', 'B8740']","[['Engineered Protein Therapy'], ['Small Molecule'], ['Small Molecule']]","[['Fusion Protein'], ['Small Molecule'], ['Small Molecule']]","[['Cluster of differentiation 80', 'Cluster of differentiation 86'], ['Glucocorticoid receptor'], ['Proteasome']]","[['CD80', 'CD86'], ['GR'], ['Proteasome']]"
36945,NCT03587038,OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma,Feasibility Pilot Study of OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma,PHASE1,ACTIVE_NOT_RECRUITING,3/9/2018,30/11/2026,23/12/2020,27,ACTUAL,,,['Glioblastoma'],"['disufenton sodium', 'Temozolomide', 'Photon Beam Radiation Therapy']","['B9358', 'B2056']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], ['DNA']]","[[], ['DNA']]"
37516,NCT03664895,"Density Lowering Effect of ""OFS Add on to TMX""(DELFINO Trial)",Density Lowering Effect of Ovarian Function Suppression in Premenopausal Breast Cancer Patients Who Had no Density Change With One Year of Tamoxifen Treatment,PHASE3,RECRUITING,3/9/2018,31/12/2024,2/12/2024,224,ESTIMATED,,,['Breast Cancer'],"['leuprolide acetate', 'goserelin acetate']","['B9379', 'B8328']","[[], []]","[[], []]","[[], []]","[[], []]"
37047,NCT03600467,Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma,"A Single-arm, Open-label, Signal-seeking, Phase IIa Trial of the Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive GBM",PHASE2,TERMINATED,13/8/2018,28/2/2021,28/2/2021,4,ACTUAL,,,"['Solid Tumors', 'Androgen Receptor Gene Overexpression']","['Seviteronel', 'Dexamethasone']","['B961', 'B1128']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Androgen Receptor', 'Steroid 17-alpha-hydroxylase'], ['Glucocorticoid receptor']]","[['AR', 'CYP17A1'], ['GR']]"
36909,NCT03580928,"Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL","A Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia",PHASE2,ACTIVE_NOT_RECRUITING,7/8/2018,31/12/2027,10/4/2024,72,ACTUAL,,,['Chronic Lymphocytic Leukemia'],"['Venetoclax', 'Obinutuzumab', 'Acalabrutinib']","['B927', 'B443', 'B1096']","[['Small Molecule'], ['Antibody'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Apoptosis regulator Bcl-2'], ['B-lymphocyte antigen CD20'], ['Tyrosine-protein kinase BTK']]","[['Bcl-2'], ['CD20'], ['BTK']]"
37190,NCT03617003,Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11),Phase I Study of WST11 Phototherapy for Upper Tract Urothelial Carcinoma,PHASE1,ACTIVE_NOT_RECRUITING,1/8/2018,2/12/2025,2/12/2025,30,ACTUAL,,,['Urothelial Carcinoma'],"['Padeliporfin', 'Endoscopic Procedure']",['B1493'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
34572,NCT03265717,"DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia",A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia,PHASE2,TERMINATED,25/7/2018,30/6/2020,30/6/2020,26,ACTUAL,,,['Chronic Lymphocytic Leukemia'],['HTERT DNA vaccine Invectys'],['B2600'],[['Cancer Vaccine']],[['DNA vaccine']],[['Telomerase reverse transcriptase']],[['TERT']]
37041,NCT03600129,Qudratus Lumborum Block for Postoperative Pain After Endoscopic Prostatectomy.,"Ultrasound-guided Quadratus Lumborum Block for Postoperative Pain Control After Endoscopic Prostatectomy - Double Blinded, Placebo-controlled, Randomised Trial.",,COMPLETED,25/7/2018,21/10/2019,21/10/2019,50,ACTUAL,,,['Prostate Cancer'],"['Quadratus Lumborum Block', 'Ropivacaine', 'Sodium chloride']","['B20', 'B93']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Sodium channel alpha subunit'], []]","[['SCN1A'], []]"
35304,NCT03363867,BEACON - ABC in Recurrent Platinum Resistant HGSOC,"BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian Cancer",PHASE2,ACTIVE_NOT_RECRUITING,10/7/2018,30/6/2025,28/2/2024,30,ACTUAL,,,"['Ovarian Cancer', 'Fallopian Tube Cancer', 'Primary Peritoneal Cancer']","['Atezolizumab', 'Bevacizumab', 'Cobimetinib']","['B1084', 'B167', 'B787']","[['Antibody'], ['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed death-ligand 1'], ['Vascular endothelial growth factor A'], ['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2']]","[['PDL1'], ['VEGF-A'], ['MEK1', 'MEK2']]"
36849,NCT03574402,Phase II Umbrella Study Directed by Next Generation Sequencing,"An Open-label, Multi-center, Phase II Umbrella Study to Assess Efficacy of Targeted Therapy or Immunotherapy Directed by Next Generation Sequencing (NGS) in Chinese Patients With Advanced NSCLC (TRUMP)",PHASE2,UNKNOWN,9/7/2018,30/12/2024,30/12/2022,400,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['Abivertinib Maleate Anhydrous', 'Afatinib', 'Crizotinib', 'Ensartinib', 'Chidamide', 'pyrotinib dimaleate', 'Zorifertinib', 'Pirotinib', 'Nimotuzumab', 'Pemetrexed', 'Cisplatin', 'Sintilimab', 'Gemcitabine', 'Carboplatin']","['B69', 'B1966', 'B1224', 'B9734', 'B8883', 'B2342', 'B3633', 'B662', 'B814', 'B49', 'B1337', 'B2079', 'B274']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2', 'Receptor protein-tyrosine kinase erbB-4'], ['Anaplastic lymphoma kinase', 'c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)', 'Macrophage-stimulating protein receptor', 'Proto-oncogene tyrosine-protein kinase ROS'], ['Anaplastic lymphoma kinase', 'c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)', 'Proto-oncogene tyrosine-protein kinase ROS'], ['Histone deacetylase'], [], [], ['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2', 'Receptor protein-tyrosine kinase erbB-4'], ['Epidermal growth factor receptor erbB1'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase'], ['DNA'], ['Programmed cell death protein 1'], ['DNA', 'Ribonucleotide reductase'], ['DNA']]","[['EGFR L858R', 'EGFR-Ex19del', 'EGFR', 'HER2', 'HER4'], ['ALK', 'c-Met', 'MST1R', 'ROS1'], ['ALK', 'c-Met', 'ROS1'], ['HDAC'], [], ['EGFR L858R', 'EGFR-Ex19del'], ['EGFR', 'HER2', 'HER4'], ['EGFR'], ['DHFR', 'GART', 'TYMS'], ['DNA'], ['PD-1'], ['DNA', 'RNR'], ['DNA']]"
36424,NCT03516591,A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes,"A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes",PHASE1,COMPLETED,22/6/2018,31/7/2020,31/7/2020,14,ACTUAL,,,['Myelodysplastic Syndrome'],['Vixtimotamab'],['B2452'],[['Antibody']],[['Bispecific Antibody']],"[['Myeloid cell surface antigen CD33', 'T cell surface glycoprotein CD3']]","[['CD33', 'CD3']]"
36579,NCT03535727,"A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer","A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer",PHASE1/PHASE2,COMPLETED,21/6/2018,3/10/2022,3/10/2022,48,ACTUAL,,,"['Digestive System Neoplasm', 'Pancreatic Diseases', 'Endocrine Neoplasm', 'Lung Adenocarcinoma', 'Pancreatic Cancer', 'Epithelial Neoplasm', 'Neoplasms', 'Digestive System Neoplasm', 'Digestive System Neoplasm', 'Endocrine Neoplasm']","['Nab-paclitaxel', 'Gemcitabine', 'Capecitabine', 'Cisplatin', 'Irinotecan']","['B7744', 'B2079', 'B474', 'B49', 'B1679']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['DNA', 'Ribonucleotide reductase'], ['Thymidylate synthase'], ['DNA'], ['DNA topoisomerase I']]","[['TUBB1'], ['DNA', 'RNR'], ['TYMS'], ['DNA'], ['TOP1']]"
59481,NCT03483675,Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease,Randomized Feasibility Study of Discontinuation Versus Continuation of Immunosuppressive Therapy (IST) in Patients With Chronic Graft Versus Host Disease (GVHD),PHASE2,COMPLETED,6/6/2018,3/3/2021,14/5/2020,21,ACTUAL,,,['Chronic Graft Versus Host Disease'],['Immunosuppressive Therapy'],[],[],[],[],[]
36529,NCT03529266,Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma.,"Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage After Esophagectomy for Esophageal or Junctional Carcinoma: A Phase II,Single Armï¼ŒProspective Study.",PHASE2,COMPLETED,1/6/2018,22/8/2021,31/3/2019,57,ACTUAL,,,"['Esophageal Cancer', 'Gastroesophageal Junction Cancer', 'Anastomotic Leak']","['Fibrin Sealant', 'Surgical Procedure']",[],[],[],[],[]
35662,NCT03410693,Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma,"A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy",PHASE2/PHASE3,COMPLETED,31/5/2018,27/10/2020,27/10/2020,175,ACTUAL,,,['Epithelial Neoplasm'],"['Rogaratinib', 'Docetaxel', 'Paclitaxel', 'Vinflunine']","['B1143', 'B2814', 'B1250', 'B774']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Fibroblast growth factor receptors'], ['Tubulin beta-1 chain'], ['Tubulin beta-1 chain'], ['Tubulin beta-1 chain']]","[['FGFRs'], ['TUBB1'], ['TUBB1'], ['TUBB1']]"
36562,NCT03533582,Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery,Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT),PHASE3,ACTIVE_NOT_RECRUITING,24/5/2018,31/12/2026,31/12/2026,537,ESTIMATED,,,"['Hepatocellular Carcinoma', 'Liver Cancer', 'Hepatocellular Carcinoma', 'Liver Cancer', 'Liver Cancer']","['Carboplatin', 'Cisplatin', 'Doxorubicin', 'Etoposide', 'Fluorouracil', 'Gemcitabine', 'Irinotecan', 'Laboratory Biomarker Analysis', 'Oxaliplatin', 'Resection', 'Sorafenib', 'vincristine sulfate']","['B274', 'B49', 'B1914', 'B1463', 'B493', 'B2079', 'B1679', 'B1229', 'B270', 'B9307']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['DNA'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Thymidylate synthase'], ['DNA', 'Ribonucleotide reductase'], ['DNA topoisomerase I'], ['DNA'], ['C-Raf kinase', 'Platelet-derived growth factor receptor beta', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], []]","[['DNA'], ['DNA'], ['TOP2'], ['TOP2'], ['TYMS'], ['DNA', 'RNR'], ['TOP1'], ['DNA'], ['CRAF', 'PDGFRÎ²', 'BRAF', 'c-Kit', 'FLT3', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3'], []]"
36122,NCT03473756,Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma,"An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma",PHASE1,COMPLETED,15/5/2018,10/7/2024,16/7/2021,37,ACTUAL,,,['Urothelial Carcinoma'],"['Rogaratinib', 'Atezolizumab']","['B1143', 'B1084']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Fibroblast growth factor receptors'], ['Programmed death-ligand 1']]","[['FGFRs'], ['PDL1']]"
36631,NCT03544125,Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer,A Pilot Study of Olaparib and Durvalumab in Patients With Metastatic Triple Negative Breast Cancer,PHASE1,COMPLETED,3/5/2018,18/11/2020,7/8/2018,3,ACTUAL,,,"['Breast Cancer', 'Breast Cancer', 'HER2-Negative Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Triple-Negative Breast Cancer']","['Durvalumab', 'Olaparib']","['B977', 'B1818']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed death-ligand 1'], ['PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors)', 'PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)', 'Poly']]","[['PDL1'], ['PARP1', 'PARP2', 'PARP3']]"
34421,NCT03245554,Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol,Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol,EARLY_PHASE1,UNKNOWN,1/5/2018,1/9/2020,1/9/2020,80,ESTIMATED,,,['Digestive System Neoplasm'],['Propranolol'],['B872'],[['Small Molecule']],[['Small Molecule']],[['Beta adrenergic receptors']],[['Î²-adrenoceptors']]
41861,NCT04263298,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,"A Randomized, Multi-center, Open-label, Phase III Trial of Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer (FAMILY)",PHASE3,RECRUITING,1/5/2018,1/5/2030,1/5/2025,210,ESTIMATED,,,['Brain Metastasis'],"['Fulvestrant', 'Capecitabine']","['B276', 'B474']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Estrogen receptors'], ['Thymidylate synthase']]","[['ER'], ['TYMS']]"
35138,NCT03341520,Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma,Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/II Using Response Adapted Involved Site Radiotherapy in Combination With Gazyvaro,PHASE2,ACTIVE_NOT_RECRUITING,24/4/2018,31/5/2024,11/11/2021,89,ACTUAL,,,"['Grade 1 Follicular Lymphoma', 'Grade 2 Follicular Lymphoma', 'Grade 1 Follicular Lymphoma', 'Grade 2 Follicular Lymphoma']","['Obinutuzumab', 'Low Dose Radiation Therapy']",['B443'],[['Antibody']],[['Monoclonal Antibody']],[['B-lymphocyte antigen CD20']],[['CD20']]
36047,NCT03464201,Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study,Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study,PHASE2,COMPLETED,13/4/2018,11/11/2020,11/11/2020,16,ACTUAL,,,['Ovarian Cancer'],['Enzalutamide'],['B25'],[['Small Molecule']],[['Small Molecule']],[['Androgen Receptor']],[['AR']]
34371,NCT03239392,A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL,A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma,PHASE1/PHASE2,COMPLETED,1/4/2018,30/6/2020,30/6/2020,50,ACTUAL,,,"['T-Cell Large Granular Lymphocyte Leukemia', 'Primary Cutaneous T-Cell Non-Hodgkin Lymphoma']",['EQ 101'],['B4350'],[['Engineered Protein Therapy']],[['Synthetic Peptide']],"[['Interleukin-15', 'Interleukin-2', 'Interleukin-9']]","[['IL-15', 'IL-2', 'IL-9']]"
36215,NCT03488225,Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia,Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia,PHASE2,TERMINATED,28/3/2018,2/4/2020,2/4/2020,4,ACTUAL,,,"['Acute Lymphoblastic Leukemia', 'Acute Lymphoblastic Leukemia', 'Philadelphia chromosome-negative acute lymphoblastic leukemia']","['Cyclophosphamide', 'Cytarabine', 'Dexamethasone', 'doxorubicin hydrochloride', 'Inotuzumab ozogamicin', 'Laboratory Biomarker Analysis', 'leucovorin calcium', 'Mercaptopurine', 'Methotrexate', 'Ofatumumab', 'Prednisone', 'Rituximab', 'vincristine sulfate']","['B2818', 'B2050', 'B1128', 'B9124', 'B686', 'B8438', 'B2978', 'B997', 'B201', 'B1979', 'B163', 'B9307']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Antibody Drug Conjugate (ADC)'], [], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Antibody'], []]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Antibody Drug Conjugate (ADC)'], [], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Monoclonal Antibody'], []]","[['DNA'], ['DNA-directed DNA polymerase'], ['Glucocorticoid receptor'], [], ['CD22', 'DNA'], [], [], ['Dihydrofolate reductase'], ['B-lymphocyte antigen CD20'], ['Glucocorticoid receptor'], ['B-lymphocyte antigen CD20'], []]","[['DNA'], ['DNA-directed DNA polymerase'], ['GR'], [], ['CD22', 'DNA'], [], ['HPRT1'], ['DHFR'], ['CD20'], ['GR'], ['CD20'], []]"
59488,NCT03492931,"PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)","A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to Less Than 24 Months, With Sickle Cell Disease (HESTIA4)",PHASE1,COMPLETED,28/3/2018,7/5/2019,7/5/2019,21,ACTUAL,,,['Sickle Cell Disease'],['Ticagrelor'],[],[],[],[],[]
31652,NCT02876640,Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer,Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect,PHASE1,TERMINATED,16/3/2018,3/6/2022,3/6/2022,27,ACTUAL,,,"['Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Ductal Carcinoma In Situ', 'Breast Cancer', 'Breast Cancer']","['Biospecimen Collection', 'Retinoid 9cUAB30', 'Therapeutic Conventional Surgery']",[],[],[],[],[]
59459,NCT03418168,A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects,"An Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Peritoneal Dialysis Subjects With Renal Anemia",PHASE3,COMPLETED,22/2/2018,29/7/2019,25/7/2019,51,ACTUAL,,,"['Anemia', 'Renal Insufficiency, Chronic']",['Molidustat'],[],[],[],[],[]
35606,NCT03402230,Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers,Clinical Study of AvmacolÂ® for Detoxification of Tobacco Carcinogens in Heavy Smokers,EARLY_PHASE1,COMPLETED,20/2/2018,24/7/2022,10/1/2020,49,ACTUAL,,,"['Epithelial Neoplasm', 'Epithelial Neoplasm']","['Broccoli Sprout/Broccoli Seed Extract Supplement', 'Laboratory Biomarker Analysis', 'Questionnaire Administration']",[],[],[],[],[]
35644,NCT03407300,A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients,"A Prospective, Randomized Clinical Study of Safety and Efficacy by Using Docetaxel With or Without Traditional Chinese Medicine XH1 in Patients With Stage â…¢B-â…£ Non-small Cell Lung Cancer (NSCLC) Who Failed With First-line Chemotherapy",PHASE2,UNKNOWN,1/2/2018,1/2/2019,1/2/2019,80,ESTIMATED,,,['Non-Small Cell Lung Cancer'],['Docetaxel'],['B2814'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
35553,NCT03395873,"Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy","A Phase I Study of Avelumab in Combination With Decitabine as First Line Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy",PHASE1,TERMINATED,29/1/2018,15/5/2019,15/5/2019,7,ACTUAL,,,['Acute Myeloid Leukemia'],"['Decitabine', 'Avelumab']","['B113', 'B1121']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['DNA', 'DNA (cytosine-5)-methyltransferase 3A', 'DNA (cytosine-5)-methyltransferase 3B'], ['Programmed death-ligand 1']]","[['DNMT1', 'DNMT3A', 'DNMT3B'], ['PDL1']]"
35509,NCT03390062,A Study of Apatinib in Recurrent or Recurrent High-grade Glioma,"An One Arm, Open and Prospective Studyof Apatinib for the Treatment of Recurrent or Recurrent High-grade Glioma",PHASE2,UNKNOWN,4/1/2018,1/8/2020,20/12/2019,30,ESTIMATED,,,['Glioma'],['Rivoceranib'],['B948'],[['Small Molecule']],[['Small Molecule']],"[['SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 2']]","[['SRC', 'c-Kit', 'VEGFR2']]"
33806,NCT03164772,Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC,A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC),PHASE1/PHASE2,COMPLETED,20/12/2017,29/10/2021,29/10/2021,61,ACTUAL,,,"['Epithelial Neoplasm', 'Non-Small Cell Lung Cancer']","['Durvalumab', 'Tremelimumab', 'CV 9202', 'Intradermal Route of Administration']","['B977', 'B692', 'B3361']","[['Antibody'], ['Antibody'], ['Cancer Vaccine']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['mRNA Vaccine']]","[['Programmed death-ligand 1'], ['Cytotoxic T-Lymphocyte-Associated Antigen 4'], ['Trophoblast glycoprotein']]","[['PDL1'], ['CTLA4'], ['MAGEC1', 'MAGEC2', '5T4']]"
35498,NCT03389035,Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT,"Phase 1-2a Trial to Determine the Feasibility and Safety of a Single Dose of Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Adult and Pediatric Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, After Hematopoietic Stem Cell Transplantation",PHASE1/PHASE2,COMPLETED,20/12/2017,30/12/2022,31/3/2021,21,ACTUAL,,,['Acute Lymphoblastic Leukemia'],[],[],[],[],[],[]
34310,NCT03231176,Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer,"A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy",PHASE2,COMPLETED,19/12/2017,13/4/2020,5/7/2019,62,ACTUAL,,,['Biliary Tract Cancer'],"['Varlitinib', 'Capecitabine']","['B566', 'B474']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2', 'Receptor protein-tyrosine kinase erbB-4'], ['Thymidylate synthase']]","[['EGFR', 'HER2', 'HER4'], ['TYMS']]"
34942,NCT03315364,Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy,"A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of LiporaxelÂ® (Oral Paclitaxel) Compared to TaxolÂ® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer",PHASE2/PHASE3,ACTIVE_NOT_RECRUITING,18/12/2017,31/12/2025,19/2/2024,549,ACTUAL,,,['Breast Cancer'],['Paclitaxel'],['B1250'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
35211,NCT03350477,Bioinformation Therapy for Gastric Cancer,Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresctable Gastric Cancer,PHASE2/PHASE3,COMPLETED,30/11/2017,30/11/2018,30/11/2018,120,ACTUAL,,,['Gastric Cancer'],"['Ablation Therapy', 'Qilisheng Immunoregulatory Oral Solution']",[],[],[],[],[]
34818,NCT03298893,Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months,A Phase-I Study of Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months. NiCOL,PHASE1/PHASE2,COMPLETED,27/11/2017,7/3/2022,30/10/2020,21,ACTUAL,,,"['Cervical Cancer', 'Cervical Cancer']","['Nivolumab', 'Cisplatin', 'Radiation Therapy']","['B714', 'B49']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Programmed cell death protein 1'], ['DNA']]","[['PD-1'], ['DNA']]"
35298,NCT03362723,A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors,"A Multi-Center, Open-Label, Clinical Pharmacology Study for Idasanutlin, an MDM2 Antagonist With a Hybrid Randomized/Sequential, Single-Dose, 4-Period, Crossover Design to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Patients With Solid Tumors",PHASE1,COMPLETED,27/11/2017,11/6/2019,11/6/2019,48,ACTUAL,,,['Solid Tumors'],['RG7388'],['B849'],[['Small Molecule']],[['Small Molecule']],[['p53-binding protein Mdm-2']],[['MDM2']]
35223,NCT03352947,Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma,INTERIM: a Randomised Phase II Feasibility Study of INTERmittent Versus Continuous Dosing or Oral Targeted Combination Therapy in Patients With BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma,PHASE2,COMPLETED,3/11/2017,27/11/2020,31/3/2020,79,ACTUAL,,,['Male Reproductive System Neoplasm'],"['Dabrafenib', 'Trametinib']","['B542', 'B575']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['C-Raf kinase', 'Serine/threonine-protein kinase B-raf'], ['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2']]","[['CRAF', 'BRAF'], ['MEK1', 'MEK2']]"
35788,NCT03427242,Apatinib for Advanced Biliary Carcinoma,A Phase II Study of Apatinib Treatment for Advanced Biliary Tract Carcinoma After Failure of the First-line Chemotherapy,PHASE2,UNKNOWN,1/11/2017,31/10/2022,31/10/2021,55,ESTIMATED,,,['Biliary Tract Cancer'],['Rivoceranib'],['B948'],[['Small Molecule']],[['Small Molecule']],"[['SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 2']]","[['SRC', 'c-Kit', 'VEGFR2']]"
29229,NCT02570958,ENB Robotic ICG Guided Surgery: A Novel Technique for Targeting Small Lung Tumors,Robotic ICG Guided Surgery (RIGGS) Using Electromagnetic Navigational Bronchoscopy (ENB): A Novel Technique for Targeting Small Lung Tumors,PHASE1,WITHDRAWN,31/10/2017,31/10/2017,31/10/2017,0,ACTUAL,,,"['Non-Small Cell Lung Cancer', 'Thoracic Surgery']","['Indocyanine green', 'Wedge Excision', 'Lobectomy', 'Segmentectomy']",['B361'],[['Imaging']],[['Imaging Agent']],[[]],[[]]
34262,NCT03222609,A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis,A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE),PHASE2,COMPLETED,31/10/2017,29/1/2025,28/3/2022,191,ACTUAL,,,['Primary Myelofibrosis'],"['Ruxolitinib', 'Navitoclax']","['B481', 'B1453']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tyrosine-protein kinase JAK1', 'Tyrosine-protein kinase JAK2'], ['Apoptosis regulator Bcl-2', 'Apoptosis regulator Bcl-X']]","[['JAK1', 'JAK2'], ['Bcl-2', 'Bcl-XL']]"
33366,NCT03106779,"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs","A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors",PHASE3,COMPLETED,26/10/2017,4/12/2024,25/5/2020,233,ACTUAL,,,['Chronic Myeloid Leukemia'],"['Asciminib', 'Bosutinib']","['B1240', 'B889']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Bcr-Abl tyrosine kinase'], ['Bcr-Abl tyrosine kinase', 'SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)']]","[['BCR-ABL1'], ['BCR-ABL1', 'SRC']]"
30807,NCT02760953,TURBt With Adjuvant Cryoablation to Treat Bladder Cancer,"A Multi Center, Randomized, Parallel Controlled Study of Applying Transurethral Resection of Bladder Tumor With Adjuvant Cryoablation to Treat Bladder Cancer",,UNKNOWN,19/10/2017,31/12/2018,30/10/2018,150,ESTIMATED,,,['Urinary System Neoplasm'],"['Cryosurgery', 'Epirubicin']",['B1236'],[['Small Molecule']],[['Small Molecule']],"[['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)']]","[['DNA', 'TOP2']]"
34325,NCT03233347,"Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma","A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma",PHASE2,ACTIVE_NOT_RECRUITING,13/10/2017,8/7/2025,1/7/2022,82,ESTIMATED,,,"['Hodgkin Lymphoma', 'Hodgkin Lymphoma', 'Hodgkin Lymphoma', 'Hodgkin Lymphoma', 'Hodgkin Lymphoma', 'Hodgkin Lymphoma', 'Classic Hodgkin Lymphoma']","['Brentuximab vedotin', 'Dacarbazine', 'Doxorubicin', 'Laboratory Biomarker Analysis', 'Nivolumab', 'Vinblastine']","['B407', 'B1647', 'B1914', 'B714', 'B355']","[['Antibody Drug Conjugate (ADC)'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Small Molecule']]","[['Antibody Drug Conjugate (ADC)'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule']]","[['CD30 modulators(Tumor necrosis factor receptor superfamily member 8 modulators)'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Programmed cell death protein 1'], ['Tubulin beta-1 chain']]","[['Beta-tubulin ', 'CD30'], ['DNA'], ['TOP2'], ['PD-1'], ['TUBB1']]"
33839,NCT03168100,"2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma","University of Arkansas (UARK# 2017-03): A Single-Arm, Open-label Study of Anti-SLAMF7 mAb Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma (Total Therapy 8)",PHASE2,WITHDRAWN,1/10/2017,24/1/2019,24/1/2019,0,ACTUAL,,,['Multiple Myeloma'],"['Elotuzumab', 'Lenalidomide', 'Dexamethasone', 'Bortezomib']","['B418', 'B2071', 'B1128', 'B958']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Molecular glue'], ['Small Molecule'], ['Small Molecule']]","[['SLAM family member 7'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos'], ['Glucocorticoid receptor'], ['Proteasome']]","[['SLAMF7'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3'], ['GR'], ['Proteasome']]"
34495,NCT03256071,Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT,Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT,PHASE2/PHASE3,UNKNOWN,30/9/2017,30/9/2021,30/9/2020,90,ESTIMATED,,,"['Acute Myeloid Leukemia', 'Allogeneic Hematopoietic Stem Cell Transplantation', 'Conditioning']","['Decitabine', 'Semustine', 'Cytarabine', 'Busulfan', 'Cyclophosphamide']","['B113', 'B264', 'B2050', 'B2060', 'B2818']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA', 'DNA (cytosine-5)-methyltransferase 3A', 'DNA (cytosine-5)-methyltransferase 3B'], ['DNA'], ['DNA-directed DNA polymerase'], ['DNA'], ['DNA']]","[['DNMT1', 'DNMT3A', 'DNMT3B'], ['DNA'], ['DNA-directed DNA polymerase'], ['DNA'], ['DNA']]"
34744,NCT03288493,P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM),"Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)",PHASE1/PHASE2,TERMINATED,20/9/2017,27/4/2022,27/4/2022,105,ACTUAL,,,['Multiple Myeloma'],['Rimiducid'],['B870'],[['Small Molecule']],[['Small Molecule']],[['FK506-binding protein 1A ligand']],[['FKBP12']]
32924,NCT03045653,Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer,Efficacy and Safety of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Endocrine Therapy Resisted Breast Cancer,PHASE2,COMPLETED,1/9/2017,21/2/2019,21/2/2019,30,ACTUAL,,,['Breast Cancer'],['Tamoxifen'],['B2062'],[['Small Molecule']],[['Small Molecule']],[['Estrogen receptors']],[['ER']]
34680,NCT03280264,Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism,An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy,PHASE3,COMPLETED,30/8/2017,9/4/2019,9/4/2019,18,ACTUAL,,,"['Parathyroid Cancer', 'Primary Hyperparathyroidism']",['Evocalcet'],['B1293'],[['Small Molecule']],[['Small Molecule']],[['Calcium sensing receptor']],[['CaSR']]
34044,NCT03194932,Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage,A Phase I and Expansion Cohort Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia,PHASE1,COMPLETED,11/7/2017,22/6/2022,27/10/2020,62,ACTUAL,,,['Acute Myeloid Leukemia'],"['Venetoclax', 'Cytarabine', 'Idarubicin', 'Triple Intrathecal Chemotherapy', 'Azacitidine']","['B927', 'B2050', 'B41', 'B322']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Apoptosis regulator Bcl-2'], ['DNA-directed DNA polymerase'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA']]","[['Bcl-2'], ['DNA-directed DNA polymerase'], ['DNA', 'TOP2'], ['DNMT1']]"
39608,NCT03950141,Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer,Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer Treated With 4 Cycles Chemotherapy Valued as Stable Disease (SD),PHASE2,UNKNOWN,1/7/2017,1/7/2020,1/7/2019,30,ESTIMATED,,,['HER-2 Negatived Gastric Cancer'],"['Rivoceranib', 'Gimeracil/oteracil/tegafur']","['B948', 'B2855']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 2'], ['Thymidylate synthase']]","[['SRC', 'c-Kit', 'VEGFR2'], ['TYMS']]"
32892,NCT03042416,18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety,18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety,PHASE3,COMPLETED,29/6/2017,2/6/2021,5/3/2021,400,ACTUAL,,,"['Congenital Hyperinsulinism', 'Kidney Wilms Tumor', 'Neuroendocrine Tumors', 'Parkinson Disease', 'Central Nervous System Neoplasm']",['Fluorodopa-F-18'],['B6494'],[['Radiopharmaceutical Imaging']],[['Radiopharmaceutical Imaging']],[[]],[[]]
34303,NCT03229200,Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.,Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.,PHASE4,ENROLLING_BY_INVITATION,22/5/2017,10/5/2027,10/5/2027,600,ESTIMATED,,,"['High Grade B-Cell Lymphoma', 'Non-Hodgkin Lymphoma', 'Hematology', 'Graft Versus Host Disease', 'Solid Tumors']",['Ibrutinib'],['B499'],[['Small Molecule']],[['Small Molecule']],[['Tyrosine-protein kinase BTK']],[['BTK']]
33212,NCT03085069,A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC,"An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer",PHASE2,UNKNOWN,3/5/2017,20/8/2023,20/8/2020,146,ACTUAL,,,"['Thoracic Neoplasm', 'Non-Small Cell Lung Cancer', 'Respiratory System Neoplasm', 'Thoracic Neoplasm', 'Respiratory Tract Disease', 'Respiratory System Neoplasm', 'Epithelial Neoplasm']",['Camrelizumab'],['B1309'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
29197,NCT02567422,"Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer","A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)",PHASE1,ACTIVE_NOT_RECRUITING,17/4/2017,23/4/2025,31/12/2023,43,ACTUAL,,,"['Carcinoma of Unknown Primary', 'Head and Neck Squamous Cell Carcinoma', 'Hypopharyngeal Cancer', 'Laryngeal Cancer', 'Lip and Oral Cavity Cancer', 'Oropharyngeal Cancer', 'Head and Neck Squamous Cell Carcinoma', 'Hypopharyngeal Cancer', 'Laryngeal Cancer', 'Lip and Oral Cavity Cancer', 'Oropharyngeal Cancer', 'Head and Neck Squamous Cell Carcinoma']","['Berzosertib', 'Cisplatin', 'Computed Tomography', 'Laboratory Biomarker Analysis', 'Magnetic Resonance Imaging', 'Positron Emission Tomography', 'Radiation Therapy']","['B1162', 'B49']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Serine-protein kinase ATR'], ['DNA']]","[['ATR'], ['DNA']]"
33835,NCT03167853,Study of JS001 in Patients With Advanced Neuroendocrine Tumors,Phase Ib Study of Safety and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Neuroendocrine Tumors Following Failure of First-Line,PHASE1,COMPLETED,6/4/2017,11/5/2019,11/12/2018,40,ACTUAL,,,['Neuroendocrine Tumors'],['Anti-PD1 Monoclonal Antibody'],[],[],[],[],[]
56362,NCT06390839,Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C),MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CDK4 or CDK6 Amplification,PHASE2,ACTIVE_NOT_RECRUITING,22/3/2017,31/12/2025,15/1/2022,43,ACTUAL,,,"['Hematology', 'Solid Tumors', 'Hematology', 'Solid Tumors']","['Biopsy', 'Biospecimen Collection', 'Computed Tomography', 'Magnetic Resonance Imaging', 'Palbociclib']",['B504'],[['Small Molecule']],[['Small Molecule']],"[['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6']]","[['CDK4', 'CDK6']]"
32742,NCT03020030,Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,PHASE3,ACTIVE_NOT_RECRUITING,3/3/2017,30/11/2034,30/11/2026,560,ACTUAL,,,['Acute Lymphoblastic Leukemia'],"['Pegaspargase', 'Crisantaspase', 'Cyclophosphamide', 'Cytarabine', 'Dasatinib', 'Dexamethasone', 'Dexrazoxane', 'Doxorubicin', 'Etoposide', 'Hydrocortisone', 'leucovorin calcium', 'Mercaptopurine', 'Methotrexate', 'Nelarabine', 'Vincristine']","['B675', 'B723', 'B2818', 'B2050', 'B293', 'B1128', 'B392', 'B1914', 'B1463', 'B1133', 'B8438', 'B2978', 'B997', 'B112', 'B2083']","[['Other Protein Therapy'], ['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Enzyme'], ['Enzyme'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Asparagine'], ['Asparagine'], ['DNA'], ['DNA-directed DNA polymerase'], ['Bcr-Abl tyrosine kinase', 'Ephrin type-A receptor 2'], ['Glucocorticoid receptor'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Glucocorticoid receptor'], [], [], ['Dihydrofolate reductase'], ['DNA polymerase alpha subunit'], ['Tubulin beta-1 chain']]","[['ASN'], ['ASN'], ['DNA'], ['DNA-directed DNA polymerase'], ['BCR-ABL1', 'EphA2', 'FYN'], ['GR'], ['TOP2'], ['TOP2'], ['TOP2'], ['GR'], [], ['HPRT1'], ['DHFR'], ['POLA1'], ['TUBB1']]"
32971,NCT03052127,Study in Subjects With Small Primary Choroidal Melanoma,"A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma",PHASE1/PHASE2,COMPLETED,27/2/2017,26/1/2021,26/1/2021,57,ACTUAL,,,"['Uveal Melanoma', 'Eye Neoplasm', 'Uveal Melanoma']","['Belzupacap sarotalocan', 'Laser Activation']",['B1665'],[['Radiopharmaceutical']],[['Radiopharmaceutical']],[[]],[[]]
26368,NCT02216578,Ph II CABOGIST in GIST,"Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib",PHASE2,COMPLETED,2/2/2017,23/2/2021,20/5/2019,51,ACTUAL,,,['Soft Tissue Sarcoma'],['Cabozantinib'],['B591'],[['Small Molecule']],[['Small Molecule']],"[['AXL receptor tyrosine kinase', 'c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['AXL', 'c-Met', 'c-Kit', 'FLT3', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
30965,NCT02782546,Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation,A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation,PHASE2,RECRUITING,30/1/2017,31/7/2026,31/7/2026,60,ESTIMATED,,,['Acute Myeloid Leukemia'],"['Allogeneic Hematopoietic Stem Cell Transplantation', 'Tacrolimus', 'Mycophenolate mofetil', 'Filgrastim', 'Donor-derived Cytokine-induced Memory-like Natural Killer Cells', 'ALT 801', 'Leukapheresis']","['B2846', 'B310', 'B157', 'B2462']","[['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy'], ['Engineered Protein Therapy']]","[['Small Molecule'], ['Small Molecule'], ['Colony-Stimulating Factor'], ['Fusion Protein']]","[[], [""Inosine-5'-monophosphate dehydrogenase""], ['Colony stimulating factor 3 receptor'], []]","[['CaN'], ['IMPDH'], ['CSF-3R'], ['GCGR', 'GLP-1R']]"
32055,NCT02935205,Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer,A Phase I/II Study of Enzalutamide in Combination With Indomethacin in Castration-Resistant Prostate Cancer (CRPC),PHASE1/PHASE2,RECRUITING,17/1/2017,31/12/2024,31/3/2024,38,ESTIMATED,,,"['Prostate Cancer', 'Prostate Cancer', 'Prostate Cancer']","['Enzalutamide', 'Indometacin']","['B25', 'B4114']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Androgen Receptor'], ['Cyclooxygenases']]","[['AR'], ['COX']]"
33631,NCT03141463,Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions,"Immune Modulating Effects and Safety of Vvax001, a Therapeutic Semliki Forest Virus Based Cancer Vaccine, in Patients With a History of (Pre) Malignant Cervical Lesions.",PHASE1,COMPLETED,13/1/2017,28/11/2017,28/11/2017,12,ACTUAL,,,"['Intraepithelial Neoplasia', 'Cervical Cancer']",['Vvax 001'],['B4012'],[[]],[[]],"[['HPV E6', 'Protein E7']]","[['HPV E6', 'E7']]"
33303,NCT03096184,A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers,A Non-randomized Phase II Study of Apatinib Mesylate Tablets Plus Tegafur Gimeracil Oteracil Potassium Capsules in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck,PHASE2,UNKNOWN,23/12/2016,1/5/2019,31/7/2018,38,ESTIMATED,,,['Head and Neck Squamous Cell Carcinoma'],"['rivoceranib mesylate', 'Gimeracil/oteracil/tegafur']","['B8835', 'B2855']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], ['Thymidylate synthase']]","[[], ['TYMS']]"
31688,NCT02881554,Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery,Functional Liver Imaging With Sulfur Colloid SPECT/CT in Primary and Metastatic Liver Cancer Patients Receiving Liver-Directed Treatment: A Pilot Study,,TERMINATED,21/12/2016,9/2/2025,31/7/2024,48,ACTUAL,,,"['Hepatocellular Carcinoma', 'Liver Cancer', 'Liver Cancer', 'Vascular Thrombosis', 'Intrahepatic Cholangiocarcinoma', 'Liver Cancer']","['Computed Tomography', 'Single Photon Emission Computed Tomography', 'technetium tc-99m sulfur colloid']",['B9546'],[[]],[[]],[[]],[[]]
32338,NCT02970539,"Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers","A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers",PHASE1,UNKNOWN,8/12/2016,31/12/2022,27/3/2019,36,ACTUAL,,,"['Gastric Cancer', 'Esophageal Cancer', 'Gastro-esophageal Cancer']","['Oral Paclitaxel + Encequidar - Hanmi', 'Paclitaxel', 'HM 30181A', 'Ramucirumab']","['B2557', 'B1250', 'B3500', 'B449']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['P-glycoprotein 1', 'Tubulin beta-1 chain'], ['Tubulin beta-1 chain'], ['P-glycoprotein 1'], ['Vascular endothelial growth factor receptor 2']]","[['P-gp', 'TUBB1'], ['TUBB1'], ['P-gp'], ['VEGFR2']]"
32269,NCT02962063,"Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer",Phase Ib/II Study of Induction Chemotherapy and Durvalumab (MEDI4736) and Tremelimumab With Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma,PHASE1/PHASE2,RECRUITING,30/11/2016,30/11/2025,30/11/2025,79,ESTIMATED,,,"['Esophageal Cancer', 'Gastroesophageal Junction Cancer']","['Durvalumab', 'Carboplatin', 'Paclitaxel', 'External Beam Radiation Therapy', 'Esophagogastrectomy', 'Tremelimumab']","['B977', 'B274', 'B1250', 'B692']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['Programmed death-ligand 1'], ['DNA'], ['Tubulin beta-1 chain'], ['Cytotoxic T-Lymphocyte-Associated Antigen 4']]","[['PDL1'], ['DNA'], ['TUBB1'], ['CTLA4']]"
32793,NCT03027739,CART-19 Cells For MRD Positive CD19+ ALL,CART-19 Cells For Patients With Minimal Residual Disease (MRD) Positive CD19+ Acute Lymphoblastic Leukemia,PHASE2/PHASE3,UNKNOWN,30/11/2016,31/12/2020,31/12/2019,20,ESTIMATED,,,['Acute Lymphoblastic Leukemia'],['Tisagenlecleucel'],['B971'],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['B-lymphocyte antigen CD19']],[['CD19']]
31156,NCT02810990,Bosutinib in Elderly Chronic Myeloid Leukemia,"Bosutinib Efficacy, Safety, Tolerability (BEST) Study in Elderly Chronic Myeloid Leukemia Patients Failing Front-line Treatment With Other Tyrosine Kinase Inhibitors",PHASE2,COMPLETED,17/11/2016,22/6/2022,30/4/2020,65,ACTUAL,,,['Chronic Myeloid Leukemia'],['Bosutinib'],['B889'],[['Small Molecule']],[['Small Molecule']],"[['Bcr-Abl tyrosine kinase', 'SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)']]","[['BCR-ABL1', 'SRC']]"
31623,NCT02873598,A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer,A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer,PHASE1,COMPLETED,17/11/2016,28/11/2022,7/6/2019,14,ACTUAL,,,['Pancreatic Cancer'],"['FOLFIRINOX', 'Gemcitabine', 'Paclitaxel', 'Stereotactic Body Radiation Therapy']","['B2079', 'B1250']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain']]","[['DNA', 'RNR'], ['TUBB1']]"
31962,NCT02921919,Open-Label Extension and Safety Study of Talazoparib,"A SINGLE-ARM, OPEN-LABEL, MULTICENTER, EXTENDED TREATMENT, SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB",PHASE2,COMPLETED,8/11/2016,20/7/2021,20/7/2021,120,ACTUAL,,,['Cancer'],['Talazoparib'],['B928'],[['Small Molecule']],[['Small Molecule']],"[['PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors)', 'PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)']]","[['PARP1', 'PARP2']]"
59181,NCT02940886,Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA),"A Phase III, Randomised, Open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside/Ferric Derisomaltose (MonoferÂ®/MonoferricÂ®) and Iron Sucrose in Subjects With Iron Deficiency Anemia (FERWON-IDA)",PHASE3,COMPLETED,8/11/2016,28/3/2018,28/3/2018,1512,ACTUAL,,,"['Iron-Deficiency Anemia', 'Iron-Deficiency Anemia']","['Iron Isomaltoside 1000', 'Iron sucrose']",['B104'],[['Small Molecule']],[['Small Molecule']],[[]],[['Phosphates']]
31961,NCT02921893,"Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome","Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome",EARLY_PHASE1,COMPLETED,31/10/2016,13/5/2024,21/4/2022,21,ACTUAL,,,"['Plasmacytoma', 'Plasma Cell Neoplasm']","['Dexamethasone', 'Ixazomib citrate', 'Lenalidomide', 'Questionnaire Administration']","['B1128', 'B8740', 'B2071']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Molecular glue']]","[['Glucocorticoid receptor'], ['Proteasome'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos']]","[['GR'], ['Proteasome'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3']]"
32104,NCT02942173,CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT,A Phase II Prospective Randomized Trial of Donor T-memory Cells (CD45RA Depleted) Infusion for Prevention of Infections After Allogeneic TcRÎ±Î²/CD19-depleted Hematopoietic Stem Cell Transplantation,PHASE2/PHASE3,COMPLETED,31/10/2016,21/8/2020,21/8/2019,150,ACTUAL,,,"['Graft Versus Host Disease', 'Leukemia', 'Hematology', 'Myelodysplastic Syndrome', 'Graft Versus Host Disease', 'Opportunistic Infections']",['CD45RA-depleted Donor T-lymphocytes'],[],[],[],[],[]
32142,NCT02946021,Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema,Assessment of Lymphatic Structure and Function Pre- and Post- Treatment and During Recovery in Head and Neck Cancer Patients Using NIR Fluorescence Lymphatic Imaging,PHASE1/PHASE2,COMPLETED,31/10/2016,28/2/2018,28/2/2018,11,ACTUAL,,,"['Head and Neck Neoplasm', 'Cardiovascular Neoplasm', 'Head and Neck Neoplasm']","['Indocyanine green', 'Near-Infrared Fluorescence Imaging']",['B361'],[['Imaging']],[['Imaging Agent']],[[]],[[]]
37111,NCT03606863,Peripheral Parenteral Nutrition vs Conventional Fluid in Colorectal Resection in ERAS,"A RANDOMIZED, CONTROLLED, CLINICAL TRIAL TO COMPARE PERIPHERAL PARENTERAL NUTRITION (PeriOlimel N4-E) VERSUS CONVENTIONAL FLUID THERAPY IN ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL IN COLORECTAL CANCER SURGERY.",PHASE3,UNKNOWN,31/10/2016,30/4/2019,31/1/2018,200,ESTIMATED,,,"['Colon Carcinoma', 'Parenteral Nutrition', 'Fast-track']",['Total Parenteral Nutrition'],[],[],[],[],[]
31626,NCT02873975,A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency,A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency,PHASE2,COMPLETED,12/10/2016,1/7/2021,30/9/2020,27,ACTUAL,,,['Epithelial Neoplasm'],['Prexasertib'],['B1009'],[['Small Molecule']],[['Small Molecule']],"[['Checkpoint kinase 1', 'Checkpoint kinase 2']]","[['Chk1', 'Chk2']]"
31282,NCT02829840,"Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)","Phase I/II, Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",PHASE1/PHASE2,WITHDRAWN,30/9/2016,,30/9/2021,0,ACTUAL,,,"['Leukemia', 'Acute Myeloid Leukemia', 'Myelodysplastic Syndrome']","['Ponatinib', 'Azacitidine']","['B64', 'B322']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Bcr-Abl tyrosine kinase', 'Protein-tyrosine kinases'], ['DNA']]","[['BCR-ABL1', 'Protein-tyrosine kinases'], ['DNMT1']]"
33101,NCT03070548,A Study of Talazoparib in Patients With Advanced Solid Tumors,A Phase 1 Open-label Study Of 14c-labeled Talazoparib In Patients With Advanced Solid Tumors,PHASE1,COMPLETED,30/9/2016,30/6/2017,30/6/2017,6,ACTUAL,,,['Solid Tumors'],['Talazoparib'],['B928'],[['Small Molecule']],[['Small Molecule']],"[['PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors)', 'PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)']]","[['PARP1', 'PARP2']]"
31828,NCT02903914,Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors,"Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",PHASE1,COMPLETED,14/9/2016,15/8/2022,30/4/2020,260,ACTUAL,,,"['Anal Cancer', 'Solid Tumors', 'Colorectal Cancer', 'Gastric Cancer', 'Head and Neck Neoplasm', 'Thoracic Neoplasm', 'Renal Cell Carcinoma', 'Bladder Cancer', 'Urothelial Carcinoma', 'Mesothelioma']","['Numidargistat', 'Pembrolizumab']","['B1243', 'B936']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Arginase-1'], ['Programmed cell death protein 1']]","[['ARG1'], ['PD-1']]"
31680,NCT02880371,A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,"A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors",PHASE1/PHASE2,TERMINATED,1/9/2016,24/10/2019,17/9/2019,82,ACTUAL,,,['Solid Tumors'],"['ARRY 382', 'Pembrolizumab']","['B2345', 'B936']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Colony stimulating factor 1 receptor'], ['Programmed cell death protein 1']]","[['CSF-1R'], ['PD-1']]"
30863,NCT02768792,High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML,LCCC 1522: Phase 2 Study of High Dose Cytarabine Followed by Pembrolizumab in Relapsed and Refractory Acute Myeloid Leukemia,PHASE2,COMPLETED,22/8/2016,20/6/2024,27/11/2019,38,ACTUAL,,,['Acute Myeloid Leukemia'],['Pembrolizumab'],['B936'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed cell death protein 1']],[['PD-1']]
30478,NCT02721550,A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC,A Perspective Trial of Sodium Glycididazole Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma,PHASE4,TERMINATED,1/8/2016,30/6/2018,30/6/2018,2,ACTUAL,,,['Digestive System Neoplasm'],['Sodium Glycididazole'],[],[],[],[],[]
30273,NCT02693067,A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver,"A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products",PHASE1,UNKNOWN,31/7/2016,30/9/2023,1/9/2021,12,ACTUAL,,,['Neuroendocrine Tumors'],['Rose bengal sodium'],['B2120'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
31717,NCT02886897,A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors,A Phase II Study of Combinations of Dendritic Cells and Cytokine-induced Killer Cell ï¼ˆD-CIK) Immunotherapy And Anti-Programmed Death-1 In Refractory Solid Tumors,PHASE1/PHASE2,UNKNOWN,31/7/2016,31/10/2019,30/9/2019,50,ESTIMATED,,,"['Hepatocellular Carcinoma', 'Renal Cell Carcinoma', 'Bladder Cancer', 'Colorectal Cancer', 'Non-Small Cell Lung Cancer', 'Breast Cancer']","['PD-1 Inhibitor', 'Valproic acid']",['B29'],[['Small Molecule']],[['Small Molecule']],[['Histone deacetylase']],[['HDAC']]
31985,NCT02924753,The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).,The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Acute Lymphoblastic Leukemia.,PHASE1,UNKNOWN,18/7/2016,31/12/2019,31/7/2019,20,ESTIMATED,,,['T-cell acute lymphoblastic leukemia'],"['Cyclophosphamide', 'Fludarabine', 'CART-19 - Henan Cancer Hospital']","['B2818', 'B346', 'B12210']","[['Small Molecule'], ['Small Molecule'], ['Cell Therapy']]","[['Small Molecule'], ['Small Molecule'], ['T-Cell Chimeric Antigen Receptor (CAR) Therapy']]","[['DNA'], ['Ribonucleotide reductase', 'RNA polymerase II'], []]","[['DNA'], ['DNA polymerase III', 'RNR', 'RNA polymerase II'], []]"
30517,NCT02724878,Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,PHASE2,COMPLETED,15/7/2016,31/12/2024,13/11/2019,65,ACTUAL,,,['Clear Cell Renal Cell Carcinoma'],"['Bevacizumab', 'Atezolizumab']","['B167', 'B1084']","[['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Vascular endothelial growth factor A'], ['Programmed death-ligand 1']]","[['VEGF-A'], ['PDL1']]"
30522,NCT02725489,Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers,Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Women's Cancers,PHASE2,COMPLETED,3/6/2016,2/12/2020,30/12/2019,13,ACTUAL,,,"['Breast Cancer', 'Ovarian Cancer', 'Fallopian Tube Cancer', 'Primary Peritoneal Cancer', 'Uterine Cancer', 'Cervical Cancer', 'Endometrial Cancer']",['Durvalumab'],['B977'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed death-ligand 1']],[['PDL1']]
31139,NCT02808442,Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia,"A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia",PHASE1,COMPLETED,3/6/2016,4/11/2020,17/9/2020,13,ACTUAL,,,"['Acute Lymphoblastic Leukemia', 'Acute Lymphoblastic Leukemia']",['Allo 501'],['B4196'],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['Chimeric Antigen Receptor T-Cell Therapy (CAR-T)']],[['B-lymphocyte antigen CD19']],[['CD19']]
30034,NCT02661685,Safety Study of Adoptive Transfer of Autologous IKDC-like Cells,An Immunotherapy for Metastatic Cancer Patients by Adoptive Transfer of Autologous IKDC-like Cells - Phase 1 Clinical Trial,PHASE1,COMPLETED,31/5/2016,31/10/2019,31/10/2019,6,ACTUAL,,,['Neoplasm Metastasis'],['Autologous Interferon-producing Killer Dendritic Cells'],[],[],[],[],[]
30906,NCT02775370,A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck,Phase II Study of Apatinib Mesylate Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck,PHASE2,UNKNOWN,31/5/2016,31/12/2018,31/12/2017,68,ACTUAL,,,['Epithelial Neoplasm'],['rivoceranib mesylate'],['B8835'],[[]],[[]],[[]],[[]]
31000,NCT02787369,ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL,A Phase Ib Study of ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed Chronic Lymphocytic Leukemia,PHASE1,ACTIVE_NOT_RECRUITING,31/5/2016,30/4/2027,30/4/2026,3,ACTUAL,,,['Chronic Lymphocytic Leukemia'],"['Ricolinostat', 'Ibrutinib', 'Idelalisib']","['B835', 'B499', 'B802']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Histone deacetylase 6'], ['Tyrosine-protein kinase BTK'], ['Phosphatidylinositol 3 kinase delta']]","[['HDAC6'], ['BTK'], ['PI3KÎ´']]"
42949,NCT04439123,Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y),MATCH Treatment Subprotocol Y: AZD5363 in Patients With Tumors With AKT Mutations,PHASE2,ACTIVE_NOT_RECRUITING,31/5/2016,19/3/2026,8/11/2019,35,ACTUAL,,,"['Hematology', 'Solid Tumors', 'Hematology', 'Hematology', 'Solid Tumors', 'Multiple Myeloma']",['Capivasertib'],['B822'],[['Small Molecule']],[['Small Molecule']],"[['Serine/threonine-protein kinase AKT', 'Serine/threonine-protein kinase AKT2', 'Serine/threonine-protein kinase AKT3']]","[['AKT1', 'AKT2', 'AKT3']]"
23165,NCT01821833,Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel,"A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome",,COMPLETED,24/5/2016,3/8/2022,16/1/2018,60,ACTUAL,,,"['Breast Cancer', 'Female Reproductive System Neoplasm', 'Connective and Soft Tissue Neoplasm']","['Omega 3 fatty acids', 'Placebo Control', 'Paclitaxel']","['B4385', 'B1250']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], ['Tubulin beta-1 chain']]","[[], ['TUBB1']]"
30946,NCT02780310,Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,"A Phase II Study of Lenvatinib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",PHASE2,ACTIVE_NOT_RECRUITING,19/5/2016,31/5/2025,31/5/2025,33,ACTUAL,,,['Epithelial Neoplasm'],['Lenvatinib'],['B261'],[['Small Molecule']],[['Small Molecule']],"[['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
30269,NCT02692248,Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT,"Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to ASCT",PHASE2,COMPLETED,7/4/2016,19/1/2021,8/11/2018,64,ACTUAL,,,['Diffuse Large B-Cell Lymphoma'],"['Ibrutinib', 'Rituximab', 'Gemcitabine', 'Oxaliplatin', 'Dexamethasone']","['B499', 'B163', 'B2079', 'B1229', 'B1128']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Tyrosine-protein kinase BTK'], ['B-lymphocyte antigen CD20'], ['DNA', 'Ribonucleotide reductase'], ['DNA'], ['Glucocorticoid receptor']]","[['BTK'], ['CD20'], ['DNA', 'RNR'], ['DNA'], ['GR']]"
30294,NCT02697058,Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer,"Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese Patients With Metastatic Pancreatic Cancer, Which Progressed or Recurred After Prior Gemcitabine-Based Therapy",PHASE2,COMPLETED,30/3/2016,28/8/2018,4/5/2017,84,ACTUAL,,,['Pancreatic Cancer'],"['Irinotecan Sucrosofate', 'Fluorouracil', 'Levoleucovorin Calcium']","['B493', 'B9431']","[['Small Molecule'], []]","[['Small Molecule'], []]","[['Thymidylate synthase'], []]","[['TYMS'], []]"
30238,NCT02688712,ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,Phase II Study of TGFÎ² Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma,PHASE2,ACTIVE_NOT_RECRUITING,24/3/2016,31/12/2025,31/12/2025,50,ESTIMATED,,,['Rectal Carcinoma'],"['Galunisertib', 'Capecitabine', 'Fluorouracil', 'Total Mesorectal Excision']","['B833', 'B474', 'B493']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Transforming growth factor beta receptor 1'], ['Thymidylate synthase'], ['Thymidylate synthase']]","[['ALK5'], ['TYMS'], ['TYMS']]"
30394,NCT02712112,A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs,Randomized Phase 2 Study of Intermittent vs Continuous Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors (GISTs),PHASE2,COMPLETED,16/3/2016,15/6/2019,15/6/2019,51,ACTUAL,,,['Connective and Soft Tissue Neoplasm'],['imatinib mesylate'],['B9326'],[[]],[[]],[[]],[[]]
29955,NCT02653105,Women at Risk of Breast Cancer and OLFM4,"Evaluation of the Circulating Concentration of OlfactomÃ©dine 4 (OLFM4) in Women With a BRCA1 or 2 Gene Mutation or at High Risk of Developing Breast Cancer, According to the Imaging",,RECRUITING,8/3/2016,28/2/2026,28/2/2026,300,ESTIMATED,,,['Ovarian Cancer'],['OLFM4 Gene'],[],[],[],[],[]
59060,NCT02680574,Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),"Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)",PHASE3,COMPLETED,29/2/2016,31/7/2020,18/6/2020,1725,ACTUAL,,,"['Anemia', 'Non-Dialysis-Dependent Chronic Kidney Disease']","['Vadadustat', 'Darbepoetin alfa']",['B156'],[['Other Protein Therapy']],[['Colony-Stimulating Factor']],[['Erythropoietin receptor']],[['EPO receptor']]
36773,NCT03564704,Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL,"An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia",PHASE2/PHASE3,UNKNOWN,14/2/2016,30/5/2021,30/5/2021,80,ESTIMATED,,,"['Leukemia', 'Acute Leukemia', 'Non-Hodgkin Lymphoma', 'Acute Lymphoblastic Leukemia', 'T-cell acute lymphoblastic leukemia', 'Acute Lymphoblastic Leukemia', 'T Lymphoblastic Lymphoma', 'Acute Lymphoblastic Leukemia']","['Dexamethasone', 'Vincristine', 'Cyclophosphamide', 'Idarubicin', 'Pegaspargase', 'doxorubicin hydrochloride', 'Methotrexate', 'Mercaptopurine', 'Etoposide', 'Cytarabine', 'Bone Marrow Aspiration', 'Intrathecal Chemotherapy', 'Radiation Therapy', 'Next Generation Sequencing', 'Allogeneic Hematopoietic Stem Cell Transplantation', 'IMWG Flow MRD-negative', 'Fluorescence In Situ Hybridization', 'Flow Cytometry', 'Karyotyping', 'Chidamide', 'Positron Emission Tomography and Computed Tomography Scan']","['B1128', 'B2083', 'B2818', 'B41', 'B675', 'B9124', 'B997', 'B2978', 'B1463', 'B2050', 'B9734']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy'], [], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Enzyme'], [], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Glucocorticoid receptor'], ['Tubulin beta-1 chain'], ['DNA'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['Asparagine'], [], ['Dihydrofolate reductase'], [], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA-directed DNA polymerase'], ['Histone deacetylase']]","[['GR'], ['TUBB1'], ['DNA'], ['DNA', 'TOP2'], ['ASN'], [], ['DHFR'], ['HPRT1'], ['TOP2'], ['DNA-directed DNA polymerase'], ['HDAC']]"
28348,NCT02460367,Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer,A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS),PHASE1,TERMINATED,31/1/2016,13/1/2021,17/7/2017,16,ACTUAL,,,"['Non-Small Cell Lung Cancer', 'Non-Small Cell Lung Cancer', 'Non-Small Cell Lung Cancer']","['Docetaxel', 'Tergenpumatucel-L', 'Indoximod']","['B2814', 'B701', 'B1942']","[['Small Molecule'], ['Cancer Vaccine'], ['Small Molecule']]","[['Small Molecule'], ['Whole Tumor Cell Vaccine'], ['Small Molecule']]","[['Tubulin beta-1 chain'], [], ['Indoleamine 2,3-dioxygenase']]","[['TUBB1'], [], ['IDO1']]"
29671,NCT02621970,"Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma","Randomized Phase 3 Trial of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy Versus Concurrent Chemotherapy Alone in High Risk Nasopharyngeal Carcinoma Patients Treated With Intensity-modulated Radiotherapy",PHASE3,UNKNOWN,31/1/2016,31/1/2024,31/1/2022,534,ESTIMATED,,,['Nasopharyngeal Cancer'],"['Cisplatin', 'Docetaxel', 'Capecitabine', 'Intensity-Modulated Radiation Therapy']","['B49', 'B2814', 'B474']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Tubulin beta-1 chain'], ['Thymidylate synthase']]","[['DNA'], ['TUBB1'], ['TYMS']]"
30107,NCT02671955,"A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer","An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer",PHASE1,TERMINATED,31/1/2016,31/7/2017,31/1/2017,12,ACTUAL,,,['Digestive System Neoplasm'],['Onvatilimab'],['B1381'],[['Antibody']],[['Monoclonal Antibody']],[['V-domain Ig suppressor of T-cell activation']],[['VISTA']]
28857,NCT02523469,"ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer","A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer",PHASE1/PHASE2,COMPLETED,8/1/2016,24/2/2023,24/2/2023,58,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['ALT 801', 'Nivolumab']","['B2462', 'B714']","[['Engineered Protein Therapy'], ['Antibody']]","[['Fusion Protein'], ['Monoclonal Antibody']]","[[], ['Programmed cell death protein 1']]","[['GCGR', 'GLP-1R'], ['PD-1']]"
28338,NCT02459067,ImmuniCellÂ® in Patients With Advanced Cancers,"Adaptive Study of the Safety, Tolerability & Efficacy of Autologous Î³Î´ T Lymphocyte Therapy (ImmuniCellÂ®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial",PHASE2,TERMINATED,31/12/2015,27/11/2018,27/11/2018,8,ACTUAL,,,"['Malignant Melanoma', 'Non-Small Cell Lung Cancer', 'Renal Cell Carcinoma']",['Autologous gamma delta T cell therapy- TC BioPharm'],['B4252'],[['Chimeric Antigen Receptor Gamma Delta (Î³Î´) T-Cell Therapy (CAR-Î³Î´T)']],[['Chimeric Antigen Receptor Gamma Delta (Î³Î´) T-Cell Therapy (CAR-Î³Î´T)']],[[]],[[]]
29800,NCT02634827,Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation,A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation,PHASE2,TERMINATED,30/12/2015,12/6/2018,18/3/2017,1,ACTUAL,,,"['Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Acute Myeloid Leukemia']","['Decitabine', 'Laboratory Biomarker Analysis', 'Midostaurin']","['B113', 'B1973']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA', 'DNA (cytosine-5)-methyltransferase 3A', 'DNA (cytosine-5)-methyltransferase 3B'], ['Platelet-derived growth factor receptor beta', 'Protein kinase C alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Vascular endothelial growth factor receptor 2']]","[['DNMT1', 'DNMT3A', 'DNMT3B'], ['PDGFRÎ²', 'PKCÎ±', 'c-Kit', 'FLT3', 'VEGFR2']]"
29674,NCT02622932,"Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients","A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients",PHASE1,COMPLETED,2/12/2015,31/8/2017,30/12/2016,6,ACTUAL,,,['Solid Tumors'],"['Catequentinib', 'Carbon C 14 Anlotinib Hydrochloride']",['B1436'],[['Small Molecule']],[['Small Molecule']],"[['Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
27678,NCT02384382,A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC),"A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÃVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER",PHASE2,COMPLETED,30/11/2015,3/5/2019,3/5/2019,23,ACTUAL,,,"['Prostate Cancer', 'Castration-Resistant Prostate Carcinoma']",['Enzalutamide'],['B25'],[['Small Molecule']],[['Small Molecule']],[['Androgen Receptor']],[['AR']]
28631,NCT02496741,Metformin And Chloroquine in IDH1/2-mutated Solid Tumors,"Phase Ib Study of Metformin and Chloroquine in IDH1/2-mutated Patients With Glioma, Intrahepatic Cholangiocarcinoma or Chondrosarcoma",PHASE1/PHASE2,COMPLETED,30/11/2015,18/11/2019,18/11/2019,15,ACTUAL,,,"['Glioma', 'Bile Duct Cancer', 'Chondrosarcoma']","['Metformin', 'Chloroquine']","['B298', 'B2032']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Protein kinase AMP-activated non-catalytic subunit beta 1'], []]","[['PRKAB1'], []]"
58973,NCT02549352,Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up,Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up,PHASE3,COMPLETED,30/11/2015,31/8/2017,22/9/2016,391,ACTUAL,,,['Actinic Keratosis'],['Ingenol disoxate'],['B1166'],[['Small Molecule']],[['Small Molecule']],[['Protein kinase C']],[['PKC']]
29571,NCT02608216,[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer,[18F]Fluorothymidine (FLT) PET/CT Imaging in Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 and Weekly Paclitaxel Therapy,PHASE1,ACTIVE_NOT_RECRUITING,30/11/2015,30/11/2025,30/11/2025,20,ESTIMATED,,,"['Breast Neoplasm', 'Brain Metastasis', 'Breast Cancer']","['Fluorothymidine F-18', 'Calcium trisodium pentetate', 'Ribociclib', 'Paclitaxel']","['B3914', 'B1026', 'B1250']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6'], ['Tubulin beta-1 chain']]","[[], ['CDK4', 'CDK6'], ['TUBB1']]"
28683,NCT02501902,Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC,AN OPEN-LABEL PHASE IB STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS ABRAXANE (REGISTERED) (NAB-PACLITAXEL) IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA,PHASE1,COMPLETED,23/11/2015,27/12/2018,10/10/2018,76,ACTUAL,,,['Pancreatic Cancer'],"['Palbociclib', 'Nab-paclitaxel']","['B504', 'B7744']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6'], ['Tubulin beta-1 chain']]","[['CDK4', 'CDK6'], ['TUBB1']]"
28611,NCT02494713,Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,Neoadjuvant Androgen Deprivation Therapy and Chemotherapy Followed by Radical Prostatectomy in Patients With Prostate Cancer,PHASE2,TERMINATED,31/10/2015,14/9/2017,14/9/2017,4,ACTUAL,,,['Prostate Cancer'],"['Degarelix', 'Doxorubicin', 'Ketoconazole', 'Docetaxel', 'Estramustine']","['B1231', 'B1914', 'B349', 'B2814', 'B350']","[['Engineered Protein Therapy'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Synthetic Peptide'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Gonadotropin-releasing hormone receptor'], ['Top II inhibitors (Topoisomerase II inhibitors)'], [], ['Tubulin beta-1 chain'], ['Src homology phosphotyrosyl phosphatase 2']]","[['GnRHR'], ['TOP2'], ['C14DM'], ['TUBB1'], ['SHP2']]"
28794,NCT02514603,A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers,A Phase 1 Study of LY2606368 in Japanese Patients With Advanced Solid Tumors,PHASE1,COMPLETED,31/10/2015,10/4/2017,10/4/2017,12,ACTUAL,,,['Male Reproductive System Neoplasm'],['Prexasertib'],['B1009'],[['Small Molecule']],[['Small Molecule']],"[['Checkpoint kinase 1', 'Checkpoint kinase 2']]","[['Chk1', 'Chk2']]"
29253,NCT02574533,Pilot Study of Vigilâ„¢ + Pembrolizumab for Advanced Melanoma,A Pilot Study of Vigilâ„¢ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma,PHASE1,COMPLETED,31/10/2015,30/9/2017,30/9/2017,2,ACTUAL,,,"['Skin Melanoma', 'Malignant Melanoma', 'Male Reproductive System Neoplasm']","['Armodafinil', 'Pembrolizumab']","['B118', 'B936']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Dopamine receptors', 'Dopamine transporter'], ['Programmed cell death protein 1']]","[['DRDs', 'DAT'], ['PD-1']]"
29906,NCT02648711,"Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors",Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies,PHASE1,TERMINATED,31/10/2015,7/5/2018,17/10/2017,41,ACTUAL,,,['Solid Tumors'],"['Davamotecan Pegadexamer', 'Bevacizumab', 'mFOLFOX6']",['B167'],[['Antibody']],[['Monoclonal Antibody']],[['Vascular endothelial growth factor A']],[['VEGF-A']]
30741,NCT02752204,An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma,Torch: A Phase II Study to Determine the Safety and Efficacy of the Dual mTORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL),PHASE2,COMPLETED,31/10/2015,6/2/2020,7/9/2017,36,ACTUAL,,,['Diffuse Large B-Cell Lymphoma'],"['Vistusertib', 'Rituximab']","['B824', 'B163']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Serine/threonine-protein kinase mTOR'], ['B-lymphocyte antigen CD20']]","[['mTOR'], ['CD20']]"
27067,NCT02308072,Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer,A Phase I Trial of Olaparib in Addition to Cisplatin-based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NHSCC),PHASE1,ACTIVE_NOT_RECRUITING,30/9/2015,28/2/2025,30/6/2020,70,ESTIMATED,,,['Head and Neck Neoplasm'],"['Olaparib', 'Cisplatin', 'Intensity-Modulated Radiation Therapy']","['B1818', 'B49']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors)', 'PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)', 'Poly'], ['DNA']]","[['PARP1', 'PARP2', 'PARP3'], ['DNA']]"
36342,NCT03507088,Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer,Fluorine-18 Fluoroestradiol Positron Emission Tomography-computed Tomography: an in Vivo Biomarker Predicting Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer?,,COMPLETED,1/9/2015,1/7/2018,1/7/2018,36,ACTUAL,,,['Brain Metastasis'],['Contrast Enhanced PET-CT Scan'],[],[],[],[],[]
26000,NCT02166658,A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet),A Phase II Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet),PHASE2,TERMINATED,31/8/2015,18/1/2018,30/4/2017,8,ACTUAL,,,"['Breast Cancer', 'Thoracic Neoplasm', 'Central Nervous System Neoplasm', 'Progressive Brain Metastases']",['Cabazitaxel'],['B185'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
28790,NCT02514382,"Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",A Phase 1b Study of REOLYSINÂ® (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma,PHASE1,COMPLETED,21/8/2015,19/4/2022,19/4/2022,14,ACTUAL,,,"['Multiple Myeloma', 'Multiple Myeloma']","['Bortezomib', 'Dexamethasone', 'Laboratory Biomarker Analysis', 'Pelareorep']","['B958', 'B1128', 'B1022']","[['Small Molecule'], ['Small Molecule'], ['Oncolytic Virus']]","[['Small Molecule'], ['Small Molecule'], ['Oncolytic Virus']]","[['Proteasome'], ['Glucocorticoid receptor'], []]","[['Proteasome'], ['GR'], []]"
58958,NCT02526329,Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant,A Phase 1 Single Center Safety and Feasibility Study of Primary T Regulatory Cell Therapy to Treat Visceral Acute Graft-versus-Host Disease Following Hematopoietic Cell Transplantation,PHASE1,WITHDRAWN,6/8/2015,30/6/2023,30/11/2022,0,ACTUAL,,,['Graft Versus Host Disease'],"['Donor Regulatory T-lymphocytes', 'Laboratory Biomarker Analysis']",[],[],[],[],[]
27565,NCT02367040,Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL),"A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3",PHASE3,COMPLETED,3/8/2015,15/11/2024,31/8/2020,458,ACTUAL,,,['Non-Hodgkin Lymphoma'],"['Copanlisib', 'Placebo Control', 'Rituximab']","['B954', 'B163']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Phosphatidylinositol 3 kinase alpha', 'Phosphatidylinositol 3 kinase delta'], ['B-lymphocyte antigen CD20']]","[['PI3KÎ±', 'PI3KÎ´'], ['CD20']]"
27675,NCT02383966,Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer,"A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck",PHASE3,COMPLETED,31/7/2015,20/12/2021,19/1/2018,243,ACTUAL,,,['Head and Neck Squamous Cell Carcinoma'],"['Cetuximab', 'Cisplatin', 'Carboplatin', 'Fluorouracil']","['B164', 'B49', 'B274', 'B493']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['DNA'], ['DNA'], ['Thymidylate synthase']]","[['EGFR'], ['DNA'], ['DNA'], ['TYMS']]"
28626,NCT02496208,Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors,A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,PHASE1,ACTIVE_NOT_RECRUITING,22/7/2015,30/9/2026,30/9/2026,152,ESTIMATED,,,"['Urinary Tract Carcinoma', 'Clear Cell Renal Cell Carcinoma', 'Urothelial Carcinoma', 'Urinary Tract Squamous Cell Carcinoma', 'Urothelial Carcinoma', 'Urothelial Carcinoma', 'Urothelial Carcinoma', 'Kidney Cancer', 'Genitourinary System Neoplasm', 'Solid Tumors', 'Renal Cell Carcinoma', 'Male Reproductive System Neoplasm', 'Male Reproductive System Neoplasm', 'Ureter Urothelial Carcinoma', 'Urethral Cancer', 'Ureter Urothelial Carcinoma', 'Ureter Urothelial Carcinoma', 'Renal Pelvis Carcinoma', 'Non-Clear Cell Renal Cell Carcinoma', 'Bladder Cancer', 'Male Reproductive System Neoplasm', 'Renal Cell Carcinoma', 'Urothelial Carcinoma', 'Urothelial Carcinoma', 'Ureter Urothelial Carcinoma', 'Urethral Cancer', 'Bladder Cancer', 'Male Reproductive System Neoplasm', 'Renal Cell Carcinoma', 'Urothelial Carcinoma']","['Biopsy', 'Biospecimen Collection', 'cabozantinib s-malate', 'Computed Tomography', 'Echocardiography', 'Ipilimumab', 'Magnetic Resonance Imaging', 'Nivolumab']","['B8690', 'B480', 'B714']","[[], ['Antibody'], ['Antibody']]","[[], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[[], ['Cytotoxic T-Lymphocyte-Associated Antigen 4'], ['Programmed cell death protein 1']]","[[], ['CTLA4'], ['PD-1']]"
27975,NCT02420223,Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients,Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant (HCT) Recipients,PHASE2,COMPLETED,17/7/2015,29/2/2020,31/7/2018,25,ACTUAL,,,['Multiple Myeloma'],['Propranolol'],['B872'],[['Small Molecule']],[['Small Molecule']],[['Beta adrenergic receptors']],[['Î²-adrenoceptors']]
28117,NCT02436408,VISmodegib for ORbital and Periocular Basal Cell Carcinoma,VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB),PHASE4,COMPLETED,15/7/2015,30/9/2020,30/9/2020,35,ACTUAL,,,['Epithelial Neoplasm'],['Vismodegib'],['B1643'],[['Small Molecule']],[['Small Molecule']],[['Smoothened receptor']],[['SMO']]
28638,NCT02497378,A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma,A Phase 1b Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Patients With Relapsed or Refractory Multiple Myeloma (MM),PHASE1,COMPLETED,10/7/2015,6/3/2018,6/3/2018,8,ACTUAL,,,['Multiple Myeloma'],"['Daratumumab', 'Bortezomib', 'Dexamethasone']","['B415', 'B958', 'B1128']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Lymphocyte differentiation antigen CD38'], ['Proteasome'], ['Glucocorticoid receptor']]","[['CD38'], ['Proteasome'], ['GR']]"
21296,NCT01591356,EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors,EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery: A Phase I Clinical Trial,PHASE1,ACTIVE_NOT_RECRUITING,1/7/2015,30/4/2025,30/4/2025,49,ACTUAL,,,['Solid Tumors'],"['EphA2-targeting DOPC-encapsulated siRNA', 'Laboratory Biomarker Analysis']",[],[],[],[],[]
28503,NCT02482311,"Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours","A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours",PHASE1,COMPLETED,1/7/2015,22/8/2019,25/1/2018,92,ACTUAL,,,['Ovarian Cancer'],['Adavosertib'],['B532'],[['Small Molecule']],[['Small Molecule']],[['Serine/threonine-protein kinase WEE1']],[['WEE1']]
28134,NCT02438358,Feasibility Study of Intraoperative Imaging in Breast Cancer,Feasibility of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer,PHASE1/PHASE2,COMPLETED,30/6/2015,31/10/2017,30/9/2017,60,ACTUAL,,,['Breast Cancer'],"['Pegulicianine acetate', 'LUM Imaging Device']",['B1499'],[['Imaging']],[['Imaging Agent']],[['Cathepsin']],[['Cathepsin']]
28574,NCT02489903,"RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)","A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)",PHASE2,COMPLETED,30/6/2015,6/12/2021,6/12/2021,139,ACTUAL,,,"['Neuroendocrine Carcinoma', 'Non-Small Cell Lung Cancer', 'Neuroendocrine Tumors', 'Ovarian Cancer']","['Nibrozetone', 'Cisplatin', 'Etoposide', 'Carboplatin', 'Irinotecan', 'Vinorelbine', 'Pegylated liposomal doxorubicin', 'Gemcitabine', 'Taxanes', 'Paclitaxel', 'Nab-paclitaxel', 'Pemetrexed']","['B2298', 'B49', 'B1463', 'B274', 'B1679', 'B1929', 'B2819', 'B2079', 'B3069', 'B1250', 'B7744', 'B814']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Cluster of differentiation 47', 'NACHT, LRR and PYD domains-containing protein 3'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], ['DNA topoisomerase I'], ['Tubulin beta-1 chain'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain'], ['Tubulin beta-1 chain'], ['Tubulin beta-1 chain'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase']]","[['c-Myc', 'CD47', 'NLRP3'], ['DNA'], ['TOP2'], ['DNA'], ['TOP1'], ['TUBB1'], ['DNA', 'TOP2'], ['DNA', 'RNR'], ['TUBB1'], ['TUBB1'], ['TUBB1'], ['DHFR', 'GART', 'TYMS']]"
26289,NCT02207309,Pazopanib Maintenance Phase II,"A Randomized, Double Blind, Phase II Trial of Pazopanib Versus Placebo as Maintenance Therapy in Patients With Retroperitoneal and Visceral High-risk Soft Tissue Sarcomas Following Prior Neo- and/or Adjuvant Doxorubicin / Ifosfamide Chemotherapy With Regional Hyperthermia",PHASE2,TERMINATED,22/6/2015,29/7/2016,29/7/2016,1,ACTUAL,,,['Sarcoma'],"['Pazopanib', 'Placebo Control']",['B1649'],[['Small Molecule']],[['Small Molecule']],"[['Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['PDGFRÎ±', 'PDGFRÎ²', 'c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
38225,NCT03757754,HPPH Photodynamic Therapy for Patients With Esophageal Cancer,"Evalution of Safety, Tolerability and Pharmacokinetics of of HPPH in Ascending Dose for Cancer Patients in Phase I Clinical Trial",PHASE1,UNKNOWN,3/6/2015,27/5/2019,20/1/2019,30,ESTIMATED,,,['Esophageal Cancer'],"['HPPH', 'Light Dosimetry', 'CLR 1404 I-124']","['B1701', 'B3484']","[['Small Molecule'], ['Imaging']]","[['Small Molecule'], ['Imaging Agent']]","[[], ['Serine/threonine-protein kinase AKT']]","[[], ['AKT1']]"
27758,NCT02394795,"Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC","A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer",PHASE3,COMPLETED,29/5/2015,14/1/2022,14/1/2022,823,ACTUAL,,,['Colorectal Cancer'],"['Oxaliplatin', 'Levoleucovorin Calcium', 'Fluorouracil', 'Panitumumab', 'Bevacizumab']","['B1229', 'B9431', 'B493', 'B194', 'B167']","[['Small Molecule'], [], ['Small Molecule'], ['Antibody'], ['Antibody']]","[['Small Molecule'], [], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['DNA'], [], ['Thymidylate synthase'], ['Epidermal growth factor receptor erbB1'], ['Vascular endothelial growth factor A']]","[['DNA'], [], ['TYMS'], ['EGFR'], ['VEGF-A']]"
27775,NCT02396134,Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant,"A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant",PHASE2,COMPLETED,21/5/2015,19/9/2024,4/3/2018,61,ACTUAL,,,"['Chronic Myeloid Leukemia', 'Acute Lymphoblastic Leukemia', 'AML with maturation', 'Hodgkin Lymphoma', 'Non-Hodgkin Lymphoma', 'Chronic Myeloid Leukemia', 'Cytomegaloviral Infection', 'Hematology', 'HLA-A*0201 Positive Cells Present', 'Myelodysplastic Syndrome', 'Non-Hodgkin Lymphoma', 'Chronic Lymphocytic Leukemia', 'Primary Myelofibrosis', 'Myeloproliferative Neoplasm']","['CMVpp65-A*0201 Peptide Vaccine', 'Placebo Control', 'Laboratory Biomarker Analysis']",[],[],[],[],[]
42975,NCT04440956,An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours,"Positron Emission Tomography (PET) Imaging of Patients With Low & Intermediate Grade Neuroendocrine Tumors Using 64Cu-SARTATE: A Single Centre, Open-Label, Non-Randomized, Phase-0 Microdosing Investigation",EARLY_PHASE1,COMPLETED,21/5/2015,25/2/2016,25/2/2016,10,ACTUAL,,,['Neuroendocrine Tumors'],['64Cu-SARTATE'],['B2812'],[['Radiopharmaceutical Imaging']],[['Radiopharmaceutical Imaging']],[['Somatostatin receptor 2']],[['SSTR2']]
26939,NCT02292550,Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.,A Phase Ib/II Study of the ALK Inhibitor Ceritinib in Combination With the CDK4/6 Inhibitor LEE011 in Patients With ALK-positive Non-Small Cell Lung Cancer,PHASE1,COMPLETED,14/5/2015,26/9/2018,26/9/2018,27,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Ribociclib', 'Ceritinib']","['B1026', 'B850']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Cyclin-dependent kinase 4', 'Cyclin-dependent kinase 6'], ['Anaplastic lymphoma kinase']]","[['CDK4', 'CDK6'], ['ALK']]"
27114,NCT02314169,Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer,A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal,PHASE2,ACTIVE_NOT_RECRUITING,13/5/2015,21/3/2026,15/2/2025,37,ACTUAL,,,"['Anal Cancer', 'Anal Cancer', 'Anal Cancer']","['Biospecimen Collection', 'Computed Tomography', 'Ipilimumab', 'Magnetic Resonance Imaging', 'Nivolumab']","['B480', 'B714']","[['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Cytotoxic T-Lymphocyte-Associated Antigen 4'], ['Programmed cell death protein 1']]","[['CTLA4'], ['PD-1']]"
26928,NCT02291055,A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer,Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer,PHASE1/PHASE2,TERMINATED,30/4/2015,20/11/2020,9/7/2019,75,ACTUAL,,,"['Cervical Cancer', 'Cancer', 'Head and Neck Neoplasm']","['Axalimogene filolisbac', 'Durvalumab']","['B3449', 'B977']","[['Oncolytic Bacteria'], ['Antibody']]","[['Oncolytic Bacteria'], ['Monoclonal Antibody']]","[['Protein E7'], ['Programmed death-ligand 1']]","[['E7'], ['PDL1']]"
27463,NCT02353741,Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC,"Concurrent EGFR-TKIs and Thoracic Radiation Therapy in EGFR Active Mutation for the First Line Treatment of Non-Small Cell Lung Cancer at Stage IV: A Single-arm, Open-label, Single Center, Phase II Trial.",PHASE2,TERMINATED,30/4/2015,1/12/2018,30/6/2018,10,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Erlotinib', 'Thoracic Radiation Therapy']",['B1928'],[['Small Molecule']],[['Small Molecule']],[['Epidermal growth factor receptor erbB1']],"[['EGFR L858R', 'EGFR-Ex19del', 'EGFR']]"
28906,NCT02530411,Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer,A Randomised Double Blind Placebo Controlled Phase II Study of Fulvestrant With or Without the Addition of Vandetanib as Treatment for Patients With Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy,PHASE2,UNKNOWN,30/4/2015,31/12/2020,31/12/2018,160,ESTIMATED,,,['Neoplasms'],"['Fulvestrant', 'Vandetanib']","['B276', 'B854']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Estrogen receptors'], ['Epidermal growth factor receptor erbB1', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 2']]","[['ER'], ['EGFR', 'RET', 'VEGFR2']]"
31568,NCT02866370,Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium,A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium,PHASE2,UNKNOWN,30/4/2015,31/3/2021,31/3/2020,120,ESTIMATED,,,"['Ovarian Clear Cell Adenocarcinoma', 'Endometrial Clear Cell Adenocarcinoma']","['Nintedanib', 'Paclitaxel', 'Carboplatin', 'Pegylated liposomal doxorubicin', 'Topotecan', 'Doxorubicin']","['B1705', 'B1250', 'B274', 'B2819', 'B2067', 'B1914']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'Tyrosine-protein kinase receptor FLT3', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Tubulin beta-1 chain'], ['DNA'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA topoisomerase I'], ['Top II inhibitors (Topoisomerase II inhibitors)']]","[['FGFR1', 'FGFR2', 'FGFR3', 'PDGFRÎ±', 'PDGFRÎ²', 'FLT3', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['TUBB1'], ['DNA'], ['DNA', 'TOP2'], ['TOP1'], ['TOP2']]"
28125,NCT02437227,"A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours","A Phase 1, First in Man, Dual Centre, Open-label Dose Escalation Study With Expansion to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CCT3833 (BAL3833), a panRAF Inhibitor, Given Orally in Patients With Advanced Solid Tumours, Including Metastatic Melanoma",PHASE1,COMPLETED,15/4/2015,31/7/2018,31/12/2017,31,ACTUAL,,,"['Male Reproductive System Neoplasm', 'Cancer']",['BAL 3833'],['B6689'],[['Small Molecule']],[['Small Molecule']],[['RAF serine/threonine protein kinase']],[['Raf kinase']]
27190,NCT02322281,"TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy","TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy",PHASE3,TERMINATED,28/2/2015,29/3/2018,29/3/2018,149,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Rociletinib', 'Pemetrexed', 'Gemcitabine', 'Paclitaxel', 'Docetaxel']","['B1040', 'B814', 'B2079', 'B1250', 'B2814']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['EGFR T790M'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase'], ['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain'], ['Tubulin beta-1 chain']]","[['EGFR T790M'], ['DHFR', 'GART', 'TYMS'], ['DNA', 'RNR'], ['TUBB1'], ['TUBB1']]"
27392,NCT02345408,Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma,An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma,PHASE1,COMPLETED,28/2/2015,6/5/2020,6/5/2020,54,ACTUAL,,,['Pancreatic Cancer'],['CCR2 Antagonist CCX872-B'],[],[],[],[],[]
28812,NCT02517918,Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma,Metronomic Cyclophosphamide and Methotrexate Combined With Zoledronic Acid and Sirolimus in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma. A Phase Ib Study From the French Sarcoma Group,PHASE1,COMPLETED,28/2/2015,16/11/2021,5/9/2016,23,ACTUAL,,,"['Solid Tumors', 'Osteosarcoma']","['Sirolimus', 'Cyclophosphamide', 'Methotrexate', 'Zoledronic acid']","['B1227', 'B2818', 'B997', 'B2822']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Serine/threonine-protein kinase mTOR'], ['DNA'], ['Dihydrofolate reductase'], ['Bone resorption factor', 'FDPS inhibitors(Farnesyl diphosphate synthase inhibitors)']]","[['mTOR'], ['DNA'], ['DHFR'], ['Bone resorption factor', 'FDPS']]"
59017,NCT02616601,"Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis","A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Fluorouracil Cream, 0.5% and CaracÂ® (Fluorouracil) Cream, 0.5% in Subjects With Actinic Keratoses",PHASE3,COMPLETED,27/2/2015,17/9/2015,17/9/2015,422,ACTUAL,,,['Actinic Keratosis'],"['Fluorouracil', 'Vehicle Control']",['B493'],[['Small Molecule']],[['Small Molecule']],[['Thymidylate synthase']],[['TYMS']]
39000,NCT03862170,Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer,Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer: a Phase III Randomized Trial,PHASE3,TERMINATED,10/2/2015,28/2/2023,29/2/2020,158,ACTUAL,,,['Prostate Cancer'],"['Ciprofloxacin', 'Cefazolin']",['B2048'],[['Small Molecule']],[['Small Molecule']],[[]],[['Bacterial DNA gyrase']]
26593,NCT02250846,Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC,Phase II Study of EGFR-TKI in Patients With EGFR Mutation Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis,PHASE2,UNKNOWN,31/1/2015,31/1/2017,31/1/2016,70,ESTIMATED,,,['Lung Non-Squamous Non-Small Cell Carcinoma'],[],[],[],[],[],[]
26801,NCT02276560,Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC,Phase II Multicenter Trial of Neoadjuvant Cisplatin and Nab-paclitaxel for (N2) Defined Stage IIIA Non-Small Cell Lung Cancer (NSCLC),PHASE2,TERMINATED,31/1/2015,30/6/2016,30/6/2016,1,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Cisplatin', 'Nab-paclitaxel', 'Surgical Procedure', 'Pemetrexed', 'Gemcitabine']","['B49', 'B7744', 'B814', 'B2079']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Tubulin beta-1 chain'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase'], ['DNA', 'Ribonucleotide reductase']]","[['DNA'], ['TUBB1'], ['DHFR', 'GART', 'TYMS'], ['DNA', 'RNR']]"
27110,NCT02314052,"Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma","Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Hepatocellular Carcinoma (HCC)",PHASE1/PHASE2,TERMINATED,27/1/2015,11/10/2016,11/10/2016,21,ACTUAL,,,['Hepatocellular Carcinoma'],['DCR MYC'],['B4865'],[['Small Interfering RNA (siRNA)']],[['Small Interfering RNA (siRNA)']],[[]],[['c-Myc']]
26633,NCT02254954,"Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma","A Single-center, Open-label, Phase 1 Study of Macitentan, Radiotherapy and Temozolomide Concurrent Therapy Followed by Maintenance Therapy With Macitentan and Temozolomide in Subjects With Newly Diagnosed Glioblastoma",PHASE1,TERMINATED,8/1/2015,29/9/2016,29/9/2016,30,ACTUAL,,,['Glioblastoma'],"['Macitentan', 'Temozolomide', 'Radiation Therapy']","['B574', 'B2056']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Endothelin receptor type A', 'Endothelin receptor type B'], ['DNA']]","[['ETA', 'ETRB'], ['DNA']]"
27726,NCT02391038,MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C,A Phase 1/2 Trial of MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase 2) Expressing Guanylyl Cyclase C (GCC),PHASE1,TERMINATED,31/12/2014,31/10/2015,31/10/2015,12,ACTUAL,,,"['Advanced Gastrointestinal Carcinoma', 'Gastroesophageal Junction Cancer', 'Gastric Cancer', 'Gastroesophageal Junction Cancer', 'Gastric Cancer', 'Gastroesophageal Junction Cancer', 'Digestive System Neoplasm']",['Indusatumab vedotin'],['B1395'],[['Antibody Drug Conjugate (ADC)']],[['Antibody Drug Conjugate (ADC)']],[['Heat-stable enterotoxin receptor']],"[['Beta-tubulin ', 'GC-C']]"
26985,NCT02298387,A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors,A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors,PHASE1,COMPLETED,22/12/2014,8/9/2017,23/5/2017,71,ACTUAL,,,['Solid Tumors'],['Navicixizumab'],['B1180'],[['Antibody']],[['Bispecific Antibody']],"[['Delta-like protein 4', 'Vascular endothelial growth factor']]","[['DLL4', 'VEGF']]"
27055,NCT02306278,The Effects of Gabapentin Premedication on Neurosurgery,"The Effects of Gabapentin Premedication on Postoperative Pain,Nausea,Vomiting and Sedation in Patients Undergoing Neurosurgery",,COMPLETED,14/12/2014,30/6/2016,31/12/2015,122,ACTUAL,,,['Central Nervous System Neoplasm'],"['Gabapentin', 'B Vitamin']",['B2098'],[[]],[[]],[[]],"[['CACNA2D1', 'CACNA2D2']]"
26882,NCT02285179,Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen,Phase I/Prospective Randomized Phase II Trial Of the Safety and Efficacy of Tamoxifen in Combination With GDC-0032 Compared With Tamoxifen alONe.,PHASE1/PHASE2,COMPLETED,30/11/2014,1/5/2022,1/5/2022,189,ACTUAL,,,['Breast Cancer'],"['Taselisib', 'Tamoxifen']","['B846', 'B2062']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Phosphatidylinositol 3 kinase alpha'], ['Estrogen receptors']]","[['PI3KÎ±'], ['ER']]"
32681,NCT03012945,Epidural Anesthesia-analgesia and Long-term Outcome,Impact of Epidural Anesthesia-analgesia on Long-term Outcome in Elderly Patients After Surgery: 5-year Follow-up of a Multicenter Randomized Controlled Trial,,COMPLETED,1/11/2014,30/9/2019,30/9/2019,1802,ACTUAL,,,"['Elderly', 'Malignant Tumor', 'Surgical Resection', 'Epidural Anesthesia', 'Long-term Outcome']","['Ropivacaine', 'Sufentanil', 'General Anesthesia Procedure', 'Propofol', 'Sevoflurane', 'Morphine']","['B20', 'B1995', 'B1822', 'B100', 'B2007']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Sodium channel alpha subunit'], ['Opioid receptors'], ['Gamma-aminobutyric acid A receptor'], [], ['Kappa opioid receptor', 'Mu opioid receptor']]","[['SCN1A'], ['Opioid receptors'], ['GABAA receptor'], [], ['Î´ opioid receptor', 'Îº opioid receptor', 'Î¼ opioid receptor']]"
26328,NCT02212197,Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer,"A Phase II, Open Label, Active Control, Multi-National, Multi-Centre, Randomized, Parallel Group Study Assessing Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of CAM2032 (Leuprolide Acetate FluidCrystalÂ® Injection Depot Once Monthly) After Repeat Doses of 3.75 mg and 7.5 mg of Leuprolide Acetate vs. EligardÂ® 7.5 mg in Patients With Prostate Cancer",PHASE2,COMPLETED,30/9/2014,31/3/2016,30/11/2015,51,ACTUAL,,,['Prostate Cancer'],['leuprolide acetate'],['B9379'],[[]],[[]],[[]],[[]]
26783,NCT02274337,"Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer","Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent",PHASE1/PHASE2,UNKNOWN,30/9/2014,31/12/2017,30/6/2017,100,ESTIMATED,,,['Non-Small Cell Lung Cancer'],['Abivertinib'],['B1351'],[['Small Molecule']],[['Small Molecule']],[['EGFR T790M']],[['EGFR T790M']]
26376,NCT02217709,Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer,Phase 2 Trial of Phenelzine in Non-metastatic Recurrent Prostate Cancer,PHASE2,COMPLETED,8/9/2014,29/6/2020,29/6/2020,26,ACTUAL,,,"['Prostate Cancer', 'Prostate Cancer', 'Prostate Cancer', 'Prostate Cancer', 'Prostate Cancer', 'Prostate Cancer']","['phenelzine sulfate', 'Laboratory Biomarker Analysis', 'Questionnaire Administration']",['B8274'],[[]],[[]],[[]],[[]]
26470,NCT02231723,A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer,A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma,PHASE1,COMPLETED,31/8/2014,30/6/2020,30/6/2020,139,ACTUAL,,,['Pancreatic Cancer'],"['Napabucasin', 'Nab-paclitaxel', 'Gemcitabine', 'Oxaliplatin', 'Folinic acid', 'Irinotecan', 'Fluorouracil', 'Irinotecan Sucrosofate']","['B1984', 'B7744', 'B2079', 'B1229', 'B226', 'B1679', 'B493']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule']]","[['Signal transducer and activator of transcription 3'], ['Tubulin beta-1 chain'], ['DNA', 'Ribonucleotide reductase'], ['DNA'], [], ['DNA topoisomerase I'], ['Thymidylate synthase']]","[['STAT3'], ['TUBB1'], ['DNA', 'RNR'], ['DNA'], [], ['TOP1'], ['TYMS']]"
27516,NCT02361112,Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer,A Phase I Study of Pyrotinib In Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer,PHASE1,COMPLETED,31/8/2014,31/12/2016,31/8/2016,38,ESTIMATED,,,['Brain Metastasis'],"['Pyrotinib', 'Capecitabine']","['B1071', 'B474']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2', 'Receptor protein-tyrosine kinase erbB-4'], ['Thymidylate synthase']]","[['EGFR', 'HER2', 'HER4'], ['TYMS']]"
24890,NCT02029417,"Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age,PHASE2,TERMINATED,31/7/2014,31/12/2015,30/11/2015,2,ACTUAL,,,"['Acute Myeloid Leukemia', 'Acute Megakaryoblastic Leukemia', 'AML with minimal differentiation', 'Acute Myeloid Leukemia', 'Acute Monocytic Leukemia', 'AML with maturation', 'AML without maturation', 'Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Acute Myeloid Leukemia', 'Acute Myelomonocytic Leukemia', 'Acute Erythroid Leukemia', 'Acute Erythroid Leukemia', 'Acute Myeloid Leukemia', 'Acute Myeloid Leukemia']","['Cytarabine', 'Omacetaxine mepesuccinate', 'Decitabine', 'Laboratory Biomarker Analysis']","['B2050', 'B1561', 'B113']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA-directed DNA polymerase'], [], ['DNA', 'DNA (cytosine-5)-methyltransferase 3A', 'DNA (cytosine-5)-methyltransferase 3B']]","[['DNA-directed DNA polymerase'], ['80s ribosome'], ['DNMT1', 'DNMT3A', 'DNMT3B']]"
25591,NCT02115035,"A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib","A Phase II Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib (VMRB) in Patients With Relapsed or Refractory Multiple Myeloma Who Have Activated BRAF Mutation",PHASE1/PHASE2,WITHDRAWN,31/7/2014,31/7/2017,31/7/2017,0,ACTUAL,,,['Multiple Myeloma'],['Vemurafenib'],['B216'],[['Small Molecule']],[['Small Molecule']],[[]],[['BRAF V600E']]
58765,NCT02128191,No Treatment Versus Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants,"Efficacy and Safety of No Treatment Compared With Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants: a Randomized, Double-blind, Placebo-controlled, Non-inferiority Clinical Trial",PHASE2,COMPLETED,31/7/2014,31/8/2019,31/8/2019,142,ACTUAL,,,['Bronchopulmonary Dysplasia (BPD)'],"['Ibuprofen', 'Sodium chloride']","['B1816', 'B93']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Cyclooxygenase-1', 'Cyclooxygenase-2'], []]","[['COX-1', 'COX-2'], []]"
26185,NCT02194426,"First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients","A Phase I Multi-centre, Open-label, Repeated-dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0250 in Patients With Advanced Solid Tumours",PHASE1/PHASE2,COMPLETED,31/7/2014,20/2/2018,20/2/2018,58,ACTUAL,,,['Neoplasms'],['MP 0250'],['B2530'],[['Engineered Protein Therapy']],[['Fusion Protein']],"[['c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)', 'Vascular endothelial growth factor receptor']]","[['c-Met', 'VEGFR']]"
23665,NCT01880359,AF CRT +/- Nimorazole in HNSCC,"A Blind Randomized Multicenter Study of Accelerated Fractionated Chemo-radiotherapy With or Without the Hypoxic Cell Radiosensitizer Nimorazole (Nimoral), Using a 15-gene Signature for Hypoxia in the Treatment of Squamous Cell Carcinoma of the Head and Neck.",PHASE3,UNKNOWN,25/7/2014,9/1/2023,6/9/2019,640,ESTIMATED,,,['Head and Neck Squamous Cell Carcinoma'],"['Cisplatin', 'Radiation Therapy', 'Placebo Control', 'Nimorazole']","['B49', 'B1448']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], []]","[['DNA'], []]"
58803,NCT02195869,Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease,A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease,PHASE1/PHASE2,COMPLETED,14/7/2014,15/9/2017,15/9/2017,45,ACTUAL,,,['Graft Versus Host Disease'],['Ibrutinib'],['B499'],[['Small Molecule']],[['Small Molecule']],[['Tyrosine-protein kinase BTK']],[['BTK']]
25492,NCT02101684,Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.,Open Label Phase II Clinical Trial of Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.,PHASE2,TERMINATED,30/6/2014,11/1/2017,11/1/2017,10,ACTUAL,,,['Female Reproductive System Neoplasm'],['Orteronel'],['B519'],[['Small Molecule']],[['Small Molecule']],[['Steroid 17-alpha-hydroxylase']],[['CYP17A1']]
25639,NCT02119468,Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma,Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma,PHASE1/PHASE2,COMPLETED,30/6/2014,1/12/2022,18/5/2016,32,ACTUAL,,,"['Multiple Myeloma', 'Multiple Myeloma']","['Ixazomib citrate', 'Dexamethasone', 'Pomalidomide']","['B8740', 'B1128', 'B1446']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Molecular glue']]","[['Proteasome'], ['Glucocorticoid receptor'], ['Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos']]","[['Proteasome'], ['GR'], ['CRBN', 'IKZF1', 'IL-6', 'TNF-Î±', 'IKZF3']]"
26063,NCT02176746,A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer,Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Colorectal,PHASE1/PHASE2,COMPLETED,30/6/2014,31/5/2015,31/5/2015,40,ACTUAL,,,['Digestive System Neoplasm'],['Cancer vaccine'],['B2933'],[[]],[[]],[[]],[[]]
26603,NCT02252146,Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation,"Phase I/II Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Presence of the MyD88 L265P Mutation",PHASE1/PHASE2,COMPLETED,30/6/2014,31/12/2016,31/12/2016,6,ACTUAL,,,['Diffuse Large B-Cell Lymphoma'],['Bazlitoran'],['B1379'],[['Antisense Oligonucleotide (ASO)']],[['Antisense Oligonucleotide (ASO)']],"[['Toll like receptor 7', 'Toll like receptor 8', 'Toll like receptor 9']]","[['TLR7', 'TLR8', 'TLR9']]"
25166,NCT02059239,Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma,A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's) and Phase 2 Expansion Cohort,PHASE1/PHASE2,COMPLETED,4/6/2014,15/6/2020,16/12/2019,34,ACTUAL,,,"['Hodgkin Lymphoma', 'Non-Hodgkin Lymphoma']","['Bendamustine', 'Carmustine', 'Etoposide', 'Melphalan', 'Cytarabine', 'Alemtuzumab', 'Autologous Hematopoietic Stem Cell Transplantation', 'Allogeneic Hematopoietic Stem Cell Transplantation', 'Rituximab']","['B1689', 'B1806', 'B1463', 'B2073', 'B2050', 'B169', 'B163']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['DNA'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], ['DNA-directed DNA polymerase'], ['CAMPATH-1 antigen'], ['B-lymphocyte antigen CD20']]","[['DNA'], ['DNA'], ['TOP2'], ['DNA'], ['DNA-directed DNA polymerase'], ['CD52'], ['CD20']]"
23013,NCT01802814,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group,PHASE3,COMPLETED,31/5/2014,31/7/2023,31/7/2023,700,ACTUAL,,,['Acute Lymphoblastic Leukemia'],['Epratuzumab'],['B666'],[['Antibody']],[['Antibody']],[['CD22']],[['CD22']]
24167,NCT01943188,Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer,Pilot Study of Local Tumor Irradiation With Autologous T-Cell Infusion for Metastatic Renal Cell Carcinoma,PHASE1,TERMINATED,31/5/2014,,31/3/2016,2,ACTUAL,,,"['Clear Cell Renal Cell Carcinoma', 'Renal Cell Carcinoma', 'Renal Cell Carcinoma']","['Stereotactic Body Radiation Therapy', 'Cyclophosphamide', 'Therapeutic Autologous Lymphocytes', 'Laboratory Biomarker Analysis']",['B2818'],[['Small Molecule']],[['Small Molecule']],[['DNA']],[['DNA']]
25241,NCT02069093,"Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer","A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane",PHASE2,COMPLETED,31/5/2014,31/3/2016,31/3/2016,92,ACTUAL,,,['Breast Cancer'],"['Dexamethasone', 'Everolimus', 'Exemestane']","['B1128', 'B511', 'B86']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Glucocorticoid receptor'], ['Mammalian target of Rapamycin', 'mTOR Complex 2'], ['Aromatase']]","[['GR'], ['mTORC1', 'mTORC2'], ['aromatase']]"
58770,NCT02137785,Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities,A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities,PHASE3,COMPLETED,31/5/2014,31/3/2015,31/3/2015,269,ACTUAL,,,['Actinic Keratosis'],"['Aminolevulinic acid', 'aminolevulinic acid hydrochloride', 'Blue Light Photodynamic Therapy Illuminator']","['B1965', 'B9175']","[[], []]","[[], []]","[[], []]","[[], []]"
25561,NCT02111577,Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer,"A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy",PHASE3,COMPLETED,26/5/2014,28/1/2020,28/1/2020,1182,ACTUAL,,,['Castration-Resistant Prostate Carcinoma'],"['Docetaxel', 'Prednisone', 'Stapuldencel-T', 'Placebo Control']","['B2814', 'B1979', 'B2306']","[['Small Molecule'], ['Small Molecule'], ['Cancer Vaccine']]","[['Small Molecule'], ['Small Molecule'], ['Dendritic Cell Vaccine']]","[['Tubulin beta-1 chain'], ['Glucocorticoid receptor'], []]","[['TUBB1'], ['GR'], []]"
24971,NCT02038010,BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx,A Phase I Study of BYL719 and Trastuzumab-MCC-DM1 in HER2-Positive Metastatic Breast Cancer Patients With Progression on Prior Trastuzumab and Taxane-Based Therapy,PHASE1,COMPLETED,21/5/2014,20/5/2017,15/4/2015,17,ACTUAL,,,"['HER2-Positive Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer']","['Alpelisib', 'Trastuzumab emtansine', 'Laboratory Biomarker Analysis']","['B848', 'B460']","[['Small Molecule'], ['Antibody Drug Conjugate (ADC)']]","[['Small Molecule'], ['Antibody Drug Conjugate (ADC)']]","[['Phosphatidylinositol 3 kinase alpha'], ['Receptor protein-tyrosine kinase erbB-2']]","[['PI3KÎ±'], ['Beta-tubulin ', 'HER2']]"
25257,NCT02071537,Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors,A Phase 1 Study of Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors,PHASE1,COMPLETED,13/5/2014,31/12/2018,3/3/2018,24,ACTUAL,,,"['Malignant Neoplasm', 'Solid Tumors']","['Chloroquine', 'Carboplatin', 'Gemcitabine']","['B2032', 'B274', 'B2079']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['DNA'], ['DNA', 'Ribonucleotide reductase']]","[[], ['DNA'], ['DNA', 'RNR']]"
25161,NCT02058381,A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer,A Phase Ib Dose De-escalation Study of the Combination of Tamoxifen Plus Goserelin Acetate With Alpelisib (BYL719) or Buparlisib (BKM120) in Premenopausal Patients With Hormone Receptor-positive/HER2-negative Locally Advanced or Metastatic Breast Cancer,PHASE1,COMPLETED,6/5/2014,19/6/2018,19/6/2018,40,ACTUAL,,,"['Pre-menopausal Breast Cancer', 'PI3K Pathway Inhibition']","['Alpelisib', 'Buparlisib']","['B848', 'B540']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Phosphatidylinositol 3 kinase alpha'], ['Phosphatidylinositol 3 kinase alpha', 'Phosphatidylinositol 3 kinase beta', 'Phosphatidylinositol 3 kinase delta', 'Phosphatidylinositol 3 kinase gamma']]","[['PI3KÎ±'], ['PI3KÎ±', 'PI3KÎ²', 'PI3KÎ´', 'PI3KÎ³']]"
46950,NCT05008237,Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study,Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study,PHASE2,UNKNOWN,2/5/2014,31/5/2023,31/5/2022,42,ACTUAL,,,['Salivary Gland Cancer'],"['Docetaxel', 'Cisplatin']","['B2814', 'B49']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['DNA']]","[['TUBB1'], ['DNA']]"
24561,NCT01991873,Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer,Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer,PHASE2,COMPLETED,30/4/2014,18/2/2023,18/2/2023,387,ACTUAL,,,['Colorectal Cancer'],['Panitumumab'],['B194'],[['Antibody']],[['Monoclonal Antibody']],[['Epidermal growth factor receptor erbB1']],[['EGFR']]
25215,NCT02065869,Safety Study of Gene Modified Donor T-cells Following TCRÎ±Î²+ Depleted Stem Cell Transplant,Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRÎ±Î²+ T Cells in Paediatric Patients Affected by Haematological Disorders,PHASE1/PHASE2,TERMINATED,30/4/2014,7/9/2021,30/6/2020,187,ACTUAL,,,"['Acute Lymphoblastic Leukemia', 'Acute Myeloid Leukemia', 'Non-Hodgkin Lymphoma', 'Myelodysplastic Syndrome', 'Primary Immunodeficiency', 'Anemia, Aplastic', 'Osteopetrosis', 'Hemoglobinopathies', 'Myeloid Neoplasm', 'Fanconi Anemia', 'Diamond-Blackfan Anemia', 'Thalassemia', 'Anemia, Sickle Cell']","['Rivogenlecleucel', 'Rimiducid']","['B1178', 'B870']","[['T-Cell Replacement Therapy'], ['Small Molecule']]","[['T-Cell Replacement Therapy'], ['Small Molecule']]","[[], ['FK506-binding protein 1A ligand']]","[[], ['FKBP12']]"
25867,NCT02146118,A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma,A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR(Epidermal Growth Factor Receptor) Mutant Lung Adenocarcinoma,PHASE2,UNKNOWN,30/4/2014,31/3/2016,30/9/2015,42,ESTIMATED,,,['Non-Small Cell Lung Cancer'],"['Erlotinib', 'Phosphatidylcholine-Bound Silybin']",['B1928'],[['Small Molecule']],[['Small Molecule']],[['Epidermal growth factor receptor erbB1']],"[['EGFR L858R', 'EGFR-Ex19del', 'EGFR']]"
25621,NCT02117167,SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients,Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer,PHASE2,COMPLETED,23/4/2014,31/12/2023,22/12/2018,999,ACTUAL,,,['Epithelial Neoplasm'],"['Vistusertib', 'ABSK 091', 'Capivasertib', 'Sapitinib', 'Selumetinib', 'Vandetanib', 'Pemetrexed', 'Durvalumab', 'Savolitinib', 'Olaparib']","['B824', 'B2283', 'B822', 'B852', 'B360', 'B854', 'B814', 'B977', 'B988', 'B1818']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Serine/threonine-protein kinase mTOR'], ['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3'], ['Serine/threonine-protein kinase AKT', 'Serine/threonine-protein kinase AKT2', 'Serine/threonine-protein kinase AKT3'], ['Epidermal growth factor receptor erbB1', 'HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists)', 'Receptor protein-tyrosine kinase erbB-2'], ['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2'], ['Epidermal growth factor receptor erbB1', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 2'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase'], ['Programmed death-ligand 1'], ['c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)'], ['PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors)', 'PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)', 'Poly']]","[['mTOR'], ['FGFR1', 'FGFR2', 'FGFR3'], ['AKT1', 'AKT2', 'AKT3'], ['EGFR', 'HER3', 'HER2'], ['MEK1', 'MEK2'], ['EGFR', 'RET', 'VEGFR2'], ['DHFR', 'GART', 'TYMS'], ['PDL1'], ['c-Met'], ['PARP1', 'PARP2', 'PARP3']]"
30297,NCT02697552,Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma,A Phase 1 Open-label Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma,PHASE1,COMPLETED,31/3/2014,31/10/2016,31/10/2016,13,ACTUAL,,,['Non-Hodgkin Lymphoma'],['Tucidinostat'],['B1065'],[['Small Molecule']],[['Small Molecule']],[['Histone deacetylase']],[['HDAC']]
25951,NCT02159365,Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,PHASE2,COMPLETED,8/3/2014,11/7/2018,30/6/2016,84,ACTUAL,,,['Multiple Myeloma'],"['Elotuzumab', 'Lenalidomide', 'Dexamethasone']","['B418', 'B2071', 'B1128']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Molecular glue'], ['Small Molecule']]","[['SLAM family member 7'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos'], ['Glucocorticoid receptor']]","[['SLAMF7'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3'], ['GR']]"
23777,NCT01895842,Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),PHASE1,COMPLETED,28/2/2014,2/4/2019,2/4/2019,31,ESTIMATED,,,['Leukemia'],['Ruxolitinib'],['B481'],[['Small Molecule']],[['Small Molecule']],"[['Tyrosine-protein kinase JAK1', 'Tyrosine-protein kinase JAK2']]","[['JAK1', 'JAK2']]"
25001,NCT02041429,Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca,Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer,PHASE1/PHASE2,COMPLETED,28/2/2014,31/1/2021,31/5/2016,20,ACTUAL,,,"['Breast Cancer', 'Brain Metastasis']","['Ruxolitinib', 'Paclitaxel']","['B481', 'B1250']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tyrosine-protein kinase JAK1', 'Tyrosine-protein kinase JAK2'], ['Tubulin beta-1 chain']]","[['JAK1', 'JAK2'], ['TUBB1']]"
25298,NCT02076230,A Phase 1 TH-302 Mass Balance Trial,"A Phase I, Open-Label, Two-Center Trial to Investigate the Mass Balance and Metabolite Profile of TH-302 in Cancer Patients With Locally Advanced or Metastatic Solid Tumors",PHASE1,COMPLETED,28/2/2014,31/3/2016,30/9/2014,10,ACTUAL,,,['Solid Tumors'],"['[14C] TH-302', 'Evofosfamide']","['B11493', 'B864']","[['Radiopharmaceutical Imaging'], ['Small Molecule']]","[['Radiopharmaceutical Imaging'], ['Small Molecule']]","[[], ['DNA']]","[[], ['DNA']]"
25390,NCT02089178,"Comparison of the Effect of Total Intravenous Anesthesia and Inhalation Anesthesia on Cancer Cell Cytotoxicity, Micrometastasis and Recurrence of Tumor in Patients Undergoing Breast Tumor Resection",,,TERMINATED,28/2/2014,30/12/2014,30/12/2014,48,ACTUAL,,,['Breast Cancer'],"['Propofol', 'Remifentanil', 'Sevoflurane', 'General Anesthesia Procedure']","['B1822', 'B2', 'B100']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Gamma-aminobutyric acid A receptor'], ['Mu opioid receptor'], []]","[['GABAA receptor'], ['Î¼ opioid receptor'], []]"
39792,NCT03977103,Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT,Antileukemic Activity of Allogeneic Hematopoietic Stem Cell Transplantation With Fractionated Total Body Irradiation or Total Marrow and Lymph Node Irradiation Followed by Adoptive Immunotherapy With Regulatory and Conventional T Cells,PHASE2,UNKNOWN,28/2/2014,28/2/2023,28/2/2023,80,ESTIMATED,,,"['Acute Myeloid Leukemia', 'Acute Lymphoblastic Leukemia', 'Myeloproliferative Neoplasm', 'Hematology', 'Multiple Myeloma', 'Other Hematologic Malignant Neoplasms']","['Radiation Therapy', 'Carvedilol', 'glucosamine sulfate potassium chloride', 'Allogeneic Hematopoietic Stem Cell Transplantation']","['B2019', 'B9375']","[['Small Molecule'], []]","[['Small Molecule'], []]","[['Adrenergic receptor alpha-1', 'Beta-1 adrenergic receptor', 'Beta-2 adrenergic receptor'], []]","[['adrenergic receptor', 'ADRA1A', 'Î²1-adrenergic receptor', 'Î²2-adrenergic receptor'], []]"
24864,NCT02027090,High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease,High Dose Versus Routine Dose Icotinib in Pretreated Non-small Cell Lung Cancer Patients With Stable Disease: a Phase II Randomized Study,PHASE2,UNKNOWN,31/1/2014,31/12/2016,30/6/2016,64,ESTIMATED,,,['Non-Small Cell Lung Cancer'],['Icotinib'],['B553'],[['Small Molecule']],[['Small Molecule']],[['Epidermal growth factor receptor erbB1']],"[['EGFR L858R', 'EGFR']]"
24897,NCT02029937,High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia,"High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: A Randomized, Multicenter Trial of Accuracy, Yield, and Clinical Impact",PHASE2,UNKNOWN,31/1/2014,31/12/2021,31/12/2021,1300,ESTIMATED,,,"['Eye Neoplasm', 'Intraepithelial Neoplasia']","['Proflavine Hemisulfate', 'High-Resolution Microendoscopy']",[],[],[],[],[]
19645,NCT01397799,Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML),"A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy",PHASE1,COMPLETED,31/12/2013,31/7/2014,31/7/2014,24,ACTUAL,,,['Acute Myeloid Leukemia'],['Tirbanibulin'],['B1943'],[['Small Molecule']],[['Small Molecule']],"[['SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)', 'Tubulin beta-1 chain']]","[['SRC', 'TUBB1']]"
21277,NCT01588951,Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior,Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior,PHASE2/PHASE3,TERMINATED,31/12/2013,30/4/2017,30/4/2017,10,ACTUAL,,,['Acute Myeloid Leukemia'],"['Cytarabine', 'Allogeneic Stem Cell Transplantation']",['B2050'],[['Small Molecule']],[['Small Molecule']],[['DNA-directed DNA polymerase']],[['DNA-directed DNA polymerase']]
21844,NCT01659502,Investigator's Initiated Phase II Study for Pancreatic Cancer Patients,,PHASE2,UNKNOWN,31/12/2013,,31/10/2014,10,ESTIMATED,,,['Pancreatic Cancer'],['TL 118'],['B4686'],[['Small Molecule']],[['Small Molecule']],[[]],[['H2 receptor']]
24037,NCT01928030,Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer,Pilot Phase 1-2 Investigational Study to Assess the Efficacy and Safety of Recombinant Hyaluronidase (rHUPH20) in the Treatment of Secondary Lymphedema Resulting From Local Management of Malignancy,PHASE1/PHASE2,TERMINATED,31/12/2013,30/11/2015,30/11/2015,3,ACTUAL,,,"['Lymphedema', 'Malignant Neoplasm']",['Recombinant Human Hyaluronidase'],[],[],[],[],[]
24522,NCT01987102,"Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.","An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the ModufolinÂ® Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients",PHASE1/PHASE2,COMPLETED,31/12/2013,3/1/2017,3/1/2017,18,ACTUAL,,,['Osteosarcoma'],"['Folinic acid', 'Folitixorin', 'High-Dose Methotrexate Regimen']","['B226', 'B68']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], ['Thymidylate synthase']]","[[], ['TYMS']]"
24648,NCT02001272,EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer,"EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer",PHASE2,COMPLETED,31/12/2013,29/2/2020,29/2/2020,120,ACTUAL,,,['Ovarian Cancer'],"['Paclitaxel', 'Carboplatin']","['B1250', 'B274']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['DNA']]","[['TUBB1'], ['DNA']]"
24386,NCT01969695,An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma,An Extension Study of Venetoclax in Subjects With Advanced Non-Hodgkin's Lymphoma,PHASE1,COMPLETED,20/12/2013,16/12/2019,16/12/2019,11,ACTUAL,,,['Non-Hodgkin Lymphoma'],['Venetoclax'],['B927'],[['Small Molecule']],[['Small Molecule']],[['Apoptosis regulator Bcl-2']],[['Bcl-2']]
24427,NCT01974349,To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers,"A Phase I, Randomized, Open-label, Single-center, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Aged 18 to 45 Years",PHASE1,COMPLETED,30/11/2013,28/2/2014,28/2/2014,39,ACTUAL,,,['Solid Tumors'],['Selumetinib'],['B360'],[['Small Molecule']],[['Small Molecule']],"[['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2']]","[['MEK1', 'MEK2']]"
23069,NCT01809171,Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients,Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients,PHASE2/PHASE3,TERMINATED,31/10/2013,31/8/2015,31/8/2015,15,ACTUAL,,,"['Breast Cancer', 'Musculoskeletal Disease']","['Colecalciferol', 'Placebo Control']",['B2111'],[[]],[[]],[['Vitamin D receptor']],[['VDR']]
23566,NCT01866449,Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme,Prospective Controlled Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme (GBM)- The C-GBM Study -,PHASE2,COMPLETED,31/10/2013,25/8/2017,31/12/2016,24,ACTUAL,,,['Glioblastoma'],['Cabazitaxel'],['B185'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
58667,NCT01976195,High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP,"An Open-label, Randomized Multicenter Investigation of High-dose Dexamethasone Combining Thalidomide Versus High-dose Dexamethasone Mono-therapy for Management of Newly-diagnosed Immune Thrombocytopenia",PHASE2,WITHDRAWN,31/10/2013,,31/12/2014,0,ACTUAL,,,['Primary Immune Thrombocytopenia'],"['Dexamethasone', 'Thalidomide']","['B1128', 'B1641']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Molecular glue']]","[['Glucocorticoid receptor'], ['Alpha-1-acid glycoprotein 1', 'Alpha-1-acid glycoprotein 2', 'Cereblon', 'DNA-binding protein Ikaros', 'Sal-like protein 4', 'Tumor necrosis factor', 'Zinc finger protein Aiolos']]","[['GR'], ['AGP1', 'AGP2', 'CRBN', 'IKZF1', 'SALL4', 'TNF', 'IKZF3']]"
24544,NCT01989845,Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer,"Prospective, Multicenter Study Investigating Efficacy and Safety of Oral Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism in Korean Patients With Cancers",PHASE4,COMPLETED,31/10/2013,31/12/2016,31/12/2016,127,ACTUAL,,,"['Rivaroxaban', 'Cancer-associated Thrombosis', 'Recurrence', 'Genitourinary System Neoplasm']",['Rivaroxaban'],['B535'],[['Small Molecule']],[['Small Molecule']],[['Factor Xa']],[['factor Xa']]
23409,NCT01848132,Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.,Multicenter Randomized Phase II Study of Treatment With R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.,PHASE2,COMPLETED,3/10/2013,31/8/2018,31/1/2018,121,ACTUAL,,,['Diffuse Large B-Cell Lymphoma'],"['Bortezomib', 'Rituximab', 'Cyclophosphamide', 'Doxorubicin', 'Prednisone', 'Vincristine']","['B958', 'B163', 'B2818', 'B1914', 'B1979', 'B2083']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Proteasome'], ['B-lymphocyte antigen CD20'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Glucocorticoid receptor'], ['Tubulin beta-1 chain']]","[['Proteasome'], ['CD20'], ['DNA'], ['TOP2'], ['GR'], ['TUBB1']]"
23553,NCT01864772,"Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC","Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment",PHASE2,COMPLETED,30/9/2013,26/5/2020,30/4/2020,85,ACTUAL,,,['Head and Neck Squamous Cell Carcinoma'],"['Carboplatin', 'Fluorouracil', 'Cetuximab']","['B274', 'B493', 'B164']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['DNA'], ['Thymidylate synthase'], ['Epidermal growth factor receptor erbB1']]","[['DNA'], ['TYMS'], ['EGFR']]"
23153,NCT01820325,Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer,"A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology",PHASE1,TERMINATED,9/9/2013,18/6/2014,18/6/2014,6,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Buparlisib', 'Carboplatin', 'Paclitaxel']","['B540', 'B274', 'B1250']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Phosphatidylinositol 3 kinase alpha', 'Phosphatidylinositol 3 kinase beta', 'Phosphatidylinositol 3 kinase delta', 'Phosphatidylinositol 3 kinase gamma'], ['DNA'], ['Tubulin beta-1 chain']]","[['PI3KÎ±', 'PI3KÎ²', 'PI3KÎ´', 'PI3KÎ³'], ['DNA'], ['TUBB1']]"
25355,NCT02083692,Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling,Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling.,EARLY_PHASE1,COMPLETED,5/9/2013,6/4/2017,9/5/2016,50,ACTUAL,,,['Head and Neck Squamous Cell Carcinoma'],['Metformin'],['B298'],[['Small Molecule']],[['Small Molecule']],[['Protein kinase AMP-activated non-catalytic subunit beta 1']],[['PRKAB1']]
23128,NCT01816594,NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer,"NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer",PHASE2,COMPLETED,3/9/2013,18/2/2015,18/2/2015,50,ACTUAL,,,['HER2-Positive Breast Cancer'],"['Buparlisib', 'Trastuzumab', 'Paclitaxel', 'Placebo']","['B540', 'B168', 'B1250']","[['Small Molecule'], ['Antibody'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Phosphatidylinositol 3 kinase alpha', 'Phosphatidylinositol 3 kinase beta', 'Phosphatidylinositol 3 kinase delta', 'Phosphatidylinositol 3 kinase gamma'], ['Receptor protein-tyrosine kinase erbB-2'], ['Tubulin beta-1 chain']]","[['PI3KÎ±', 'PI3KÎ²', 'PI3KÎ´', 'PI3KÎ³'], ['HER2'], ['TUBB1']]"
24078,NCT01932580,"Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma","Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma",PHASE2,COMPLETED,31/8/2013,30/6/2015,30/6/2015,10,ACTUAL,,,"['Gastric Cancer', 'Esophageal Cancer']","['Fluorouracil', 'Oxaliplatin', 'Docetaxel']","['B493', 'B1229', 'B2814']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Thymidylate synthase'], ['DNA'], ['Tubulin beta-1 chain']]","[['TYMS'], ['DNA'], ['TUBB1']]"
22954,NCT01795430,"Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma","A Pilot Study of Whole-body MRI-guided Intensity Modulated Radiation Therapy Combined With Systemic Chemotherapy Followed by High-Dose Chemotherapy With Busulfan, Melphalan and Topotecan and Stem Cell Rescue in Patients With Poor Risk Ewing's Sarcoma",,WITHDRAWN,31/7/2013,,31/3/2018,0,ACTUAL,,,"['Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)', 'Ewing Sarcoma', 'Soft Tissue Sarcoma', 'Peripheral Primitive Neuroectodermal Tumor', 'Central Nervous System Embryonal Tumor', 'Connective and Soft Tissue Neoplasm', 'Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor']","['Etoposide', 'Ifosfamide', 'Intensity-Modulated Radiation Therapy', 'topotecan hydrochloride', 'Busulfan', 'Melphalan', 'Autologous Hematopoietic Stem Cell Transplantation', 'Peripheral Blood Stem Cell Transplantation', 'Autologous Bone Marrow Transplantation']","['B1463', 'B8', 'B9293', 'B2060', 'B2073']","[['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule']]","[['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], [], ['DNA'], ['DNA']]","[['TOP2'], ['DNA'], [], ['DNA'], ['DNA']]"
23421,NCT01849380,Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer,Neoadjuvant Epirubicin-cyclophosphamide-S-1 (ECS) Versus Epirubicin-cyclophosphamide-5-FU (ECF) in Local Advanced Breast Cancer,PHASE4,UNKNOWN,30/6/2013,30/6/2018,31/10/2013,240,ESTIMATED,,,"['Breast Neoplasm', 'Gastric Cancer']","['Gimeracil/oteracil/tegafur', 'Fluorouracil']","['B2855', 'B493']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Thymidylate synthase'], ['Thymidylate synthase']]","[['TYMS'], ['TYMS']]"
20354,NCT01481233,Oral Colchicine in Men With Castrate Resistant Prostate Cancer,Phase II Trial of Oral Colchicine in Men With Castrate-Resistant Prostate Cancer Who Have Failed Taxotere-Based Chemotherapy,PHASE2,WITHDRAWN,31/5/2013,31/8/2013,31/8/2013,0,ACTUAL,,,['Prostate Cancer'],['Colchicine'],['B19'],[[]],[[]],[['Tubulin beta-1 chain']],[['TUBB1']]
23418,NCT01849250,Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors,"A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease",PHASE2,COMPLETED,31/5/2013,22/4/2020,11/1/2016,65,ACTUAL,,,"['Breast Neoplasm', 'Breast Ductal Carcinoma In Situ', 'Breast Cancer', 'Breast Cancer', 'Breast Paget Disease', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer', 'Breast Cancer']","['Docosahexaenoic acid', 'Placebo Control']",['B5914'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
23576,NCT01867866,Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone,"A Phase 1, Open-Label, Randomized, Parallel Group Study Evaluating the Pharmacokinetics of FTD as a Component of TAS-102 Compared With FTD Alone",PHASE1,COMPLETED,31/5/2013,30/6/2016,31/10/2013,44,ACTUAL,,,['Solid Tumors'],"['Tipiracil/trifluridine', 'Trifluridine']","['B2936', 'B43']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Thymidine phosphorylase', 'Thymidylate synthase'], ['DNA-directed DNA polymerase']]","[['TYMP', 'TYMS'], ['DNA-directed DNA polymerase']]"
23395,NCT01846416,A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR],"A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer",PHASE2,COMPLETED,30/5/2013,18/12/2017,7/1/2015,138,ACTUAL,,,['Non-Small Cell Lung Cancer'],['Atezolizumab'],['B1084'],[['Antibody']],[['Monoclonal Antibody']],[['Programmed death-ligand 1']],[['PDL1']]
44318,NCT04635852,Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients,"EffentoraÂ® for Dyspnoea - Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients: A Multicenter, Open Label, Randomized, Morphine-controlled, Crossover, Phase II-TRIAL",PHASE2,COMPLETED,31/3/2013,31/12/2014,30/11/2014,10,ACTUAL,,,"['Cancer', 'Respiratory System Neoplasm']","['Fentanyl', 'Morphine']","['B1961', 'B2007']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Opioid receptors'], ['Kappa opioid receptor', 'Mu opioid receptor']]","[['Opioid receptors'], ['Î´ opioid receptor', 'Îº opioid receptor', 'Î¼ opioid receptor']]"
21592,NCT01630564,Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies,Phase I Study of Ex Vivo Expanded Donor Cord Blood T-Lymphocyte Infusion in Post-Transplant Relapsed Patients,PHASE1,TERMINATED,11/3/2013,30/5/2018,30/5/2018,2,ACTUAL,,,['Hematology'],"['Aldesleukin', 'Umbilical Cord Blood Stem Cell', 'Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion', 'Umbilical Cord Blood-Derived Lymphocyte Therapy']",['B136'],[['Other Protein Therapy']],[['Interleukin']],[['Interleukin-2 receptor']],[['IL-2R']]
23035,NCT01805037,Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas,A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas,PHASE1/PHASE2,TERMINATED,5/3/2013,31/12/2018,18/9/2017,20,ACTUAL,,,"['Diffuse Large B-Cell Lymphoma', 'T-Cell Non-Hodgkin Lymphoma', 'Anaplastic Large Cell Lymphoma', 'Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type', 'Burkitt Lymphoma', 'Contiguous Stage II Adult Diffuse Large Cell Lymphoma', 'Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma', 'Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Non-Hodgkin Lymphoma', 'Grade 1 Follicular Lymphoma', 'Grade 2 Follicular Lymphoma', 'Grade 3 Follicular Lymphoma', 'Mantle Cell Lymphoma', 'Marginal Zone Lymphoma', 'Small Lymphocytic Lymphoma', 'Primary Cutaneous B-Cell Non-Hodgkin Lymphoma', 'Epstein-Barr Virus Infection', 'Extranodal Marginal Zone Lymphoma', 'T-Cell Non-Hodgkin Lymphoma', 'Non-Hodgkin Lymphoma', 'Nodal Marginal Zone Lymphoma', 'Burkitt Lymphoma', 'Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma', 'Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma', 'Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Non-Hodgkin Lymphoma', 'Grade 1 Follicular Lymphoma', 'Grade 2 Follicular Lymphoma', 'Grade 3 Follicular Lymphoma', 'Mantle Cell Lymphoma', 'Marginal Zone Lymphoma', 'Small Lymphocytic Lymphoma', 'Hematology', 'T-Cell Non-Hodgkin Lymphoma', 'Post-Transplant Lymphoproliferative Disorder', 'Hairy Cell Leukemia', 'Burkitt Lymphoma', 'Recurrent Adult Diffuse Mixed Cell Lymphoma', 'Recurrent Adult Diffuse Small Cleaved Cell Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Hodgkin Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Non-Hodgkin Lymphoma', 'Adult T-Cell Leukemia/Lymphoma', 'Primary Cutaneous T-Cell Non-Hodgkin Lymphoma', 'Grade 1 Follicular Lymphoma', 'Grade 3 Follicular Lymphoma', 'Mantle Cell Lymphoma', 'Marginal Zone Lymphoma', 'Mycosis Fungoides and Sezary Syndrome', 'Small Lymphocytic Lymphoma', 'Hairy Cell Leukemia', 'Digestive System Neoplasm', 'Splenic Marginal Zone Lymphoma', 'Burkitt Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Stage I Adult Diffuse Mixed Cell Lymphoma', 'Stage I Adult Diffuse Small Cleaved Cell Lymphoma', 'Hodgkin Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Non-Hodgkin Lymphoma', 'Adult T-Cell Leukemia/Lymphoma', 'Primary Cutaneous T-Cell Non-Hodgkin Lymphoma', 'Grade 1 Follicular Lymphoma', 'Grade 2 Follicular Lymphoma', 'Grade 3 Follicular Lymphoma', 'Mantle Cell Lymphoma', 'Marginal Zone Lymphoma', 'Small Lymphocytic Lymphoma', 'Mycosis Fungoides and Sezary Syndrome', 'Mycosis Fungoides and Sezary Syndrome', 'Hodgkin Lymphoma', 'Adult T-Cell Leukemia/Lymphoma', 'Primary Cutaneous T-Cell Non-Hodgkin Lymphoma', 'Mycosis Fungoides and Sezary Syndrome', 'Grade 2 Follicular Lymphoma', 'Mycosis Fungoides and Sezary Syndrome', 'Burkitt Lymphoma', 'Stage III Adult Diffuse Large Cell Lymphoma', 'Stage III Adult Diffuse Mixed Cell Lymphoma', 'Stage III Adult Diffuse Small Cleaved Cell Lymphoma', 'Hodgkin Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Non-Hodgkin Lymphoma', 'Adult T-Cell Leukemia/Lymphoma', 'Primary Cutaneous T-Cell Non-Hodgkin Lymphoma', 'Grade 1 Follicular Lymphoma', 'Grade 2 Follicular Lymphoma', 'Grade 3 Follicular Lymphoma', 'Mantle Cell Lymphoma', 'Marginal Zone Lymphoma', 'Small Lymphocytic Lymphoma', 'Mycosis Fungoides and Sezary Syndrome', 'Mycosis Fungoides and Sezary Syndrome', 'Burkitt Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Stage IV Adult Diffuse Mixed Cell Lymphoma', 'Stage IV Adult Diffuse Small Cleaved Cell Lymphoma', 'Hodgkin Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Non-Hodgkin Lymphoma', 'Adult T-Cell Leukemia/Lymphoma', 'T-Cell Non-Hodgkin Lymphoma', 'Grade 1 Follicular Lymphoma', 'Grade 2 Follicular Lymphoma', 'Grade 3 Follicular Lymphoma', 'Mantle Cell Lymphoma', 'Marginal Zone Lymphoma', 'Small Lymphocytic Lymphoma', 'Mycosis Fungoides and Sezary Syndrome', 'Mycosis Fungoides and Sezary Syndrome', 'T-Cell Large Granular Lymphocyte Leukemia', 'Testicular Cancer', 'Hairy Cell Leukemia', 'Waldenstrom Macroglobulinemia']","['Brentuximab vedotin', 'Rituximab', 'Laboratory Biomarker Analysis']","['B407', 'B163']","[['Antibody Drug Conjugate (ADC)'], ['Antibody']]","[['Antibody Drug Conjugate (ADC)'], ['Monoclonal Antibody']]","[['CD30 modulators(Tumor necrosis factor receptor superfamily member 8 modulators)'], ['B-lymphocyte antigen CD20']]","[['Beta-tubulin ', 'CD30'], ['CD20']]"
23049,NCT01806675,18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy,Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of Î±vÎ²3 Integrins Expression as a Biomarker of Angiogenesis,PHASE1/PHASE2,COMPLETED,4/3/2013,30/4/2019,7/12/2016,25,ACTUAL,,,"['Nasopharyngeal Cancer', 'Recurrent Lymphoepithelioma of the Oropharynx', 'Carcinoma of Unknown Primary', 'Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity', 'Lip and Oral Cavity Cancer', 'Nasopharyngeal Cancer', 'Non-Small Cell Lung Cancer', 'Oropharyngeal Cancer', 'Pancreatic Cancer', 'Head and Neck Squamous Cell Carcinoma', 'Rectal Carcinoma', 'Renal Cell Carcinoma', 'Salivary Gland Cancer', 'Breast Cancer', 'Non-Small Cell Lung Cancer', 'Breast Cancer', 'Non-Small Cell Lung Cancer', 'Breast Cancer', 'Breast Cancer', 'Non-Small Cell Lung Cancer', 'Pancreatic Cancer', 'Renal Cell Carcinoma', 'Colon Carcinoma', 'Rectal Carcinoma', 'Salivary Gland Cancer', 'Colon Carcinoma', 'Salivary Gland Cancer', 'Salivary Gland Cancer', 'Lip and Oral Cavity Cancer', 'Solid Tumors', 'Glioblastoma', 'Glioblastoma', 'Gliosarcoma', 'Male Breast Cancer', 'Head and Neck Squamous Cell Carcinoma', 'Lip and Oral Cavity Cancer', 'Central Nervous System Neoplasm', 'Skin Basal Cell Carcinoma', 'Colon Carcinoma', 'Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity', 'Hypopharyngeal Cancer', 'Epithelial Neoplasm', 'Laryngeal Cancer', 'Lip and Oral Cavity Cancer']","['Positron Emission Tomography and Computed Tomography Scan', '2-Fluoropropionyl-labeled Pegylated Dimeric RGD Peptide']",[],[],[],[],[]
22862,NCT01783522,Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib,A Placebo Controlled Study to Estimate the Effect Size of Glutamine as a Supplement to Prevent Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma Patients,PHASE2,TERMINATED,28/2/2013,30/11/2013,30/11/2013,9,ACTUAL,,,"['Chemotherapeutic Agent Toxicity', 'Multiple Myeloma', 'Peripheral Neuropathy']","['Glutamine', 'Placebo Control']",['B2094'],[[]],[[]],[[]],[[]]
22919,NCT01790737,"First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02","A Prospective Phase II Study to Assess Immunophenotypic Remission After 3-drug Induction Followed by Randomized Stem Cell Mobilization, Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma",PHASE2,COMPLETED,31/1/2013,26/2/2019,10/10/2018,80,ACTUAL,,,['Multiple Myeloma'],"['Cyclophosphamide', 'Filgrastim']","['B2818', 'B157']","[['Small Molecule'], ['Other Protein Therapy']]","[['Small Molecule'], ['Colony-Stimulating Factor']]","[['DNA'], ['Colony stimulating factor 3 receptor']]","[['DNA'], ['CSF-3R']]"
23514,NCT01859819,Treatment for Advanced B-Cell Lymphoma,"Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma",PHASE2,COMPLETED,31/1/2013,30/6/2021,30/6/2020,45,ACTUAL,,,"['Diffuse Large B-Cell Lymphoma', 'Burkitt Lymphoma', 'High Grade B-Cell Lymphoma']","['Rituximab', 'Cytarabine']","['B163', 'B2050']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['B-lymphocyte antigen CD20'], ['DNA-directed DNA polymerase']]","[['CD20'], ['DNA-directed DNA polymerase']]"
22521,NCT01738451,A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors,"A Two-Part Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors: An Open-label, Dose-escalating Safety Lead-in Study Followed by a Single-sequence, Placebo-controlled, Single-blind Study",PHASE1,COMPLETED,22/1/2013,28/11/2014,28/11/2014,50,ACTUAL,,,['Cancer'],"['Dabrafenib', 'Placebo Control']",['B542'],[['Small Molecule']],[['Small Molecule']],"[['C-Raf kinase', 'Serine/threonine-protein kinase B-raf']]","[['CRAF', 'BRAF']]"
22534,NCT01740271,A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients,Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy,PHASE2,RECRUITING,31/12/2012,30/6/2025,30/6/2015,48,ESTIMATED,,,['Breast Neoplasm'],['Epirubicin'],['B1236'],[['Small Molecule']],[['Small Molecule']],"[['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)']]","[['DNA', 'TOP2']]"
22692,NCT01759810,Proteome-based Personalized Immunotherapy of Glioblastoma,Proteome-based Personalized Immunotherapy of Malignant Brain Tumors,PHASE2/PHASE3,UNKNOWN,31/12/2012,31/12/2020,31/12/2018,60,ESTIMATED,,,['Glioblastoma'],"['Dendritic Cell Vaccine', 'Therapeutic Allogeneic Hematopoietic Stem Cells', 'Cytotoxic T lymphocytes', 'Therapeutic Autologous Hematopoietic Stem Cells']",['B3554'],[[]],[[]],[[]],[[]]
22448,NCT01729338,Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma,Phase II Subcutaneous VELCADE and Oral Cyclophosphamide-based Induction + Sequential VELCADE and Revlimid Maintenance for Newly Diagnosed Multiple Myeloma in Non-transplant Candidates: An Entirely Non-intravenous Regimen,PHASE2,TERMINATED,19/12/2012,31/12/2016,31/12/2015,17,ACTUAL,,,['Multiple Myeloma'],"['Bortezomib', 'Cyclophosphamide', 'Lenalidomide']","['B958', 'B2818', 'B2071']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Molecular glue']]","[['Proteasome'], ['DNA'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos']]","[['Proteasome'], ['DNA'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3']]"
22719,NCT01763606,Enoxaparin Versus Aspirin in Patients With Cancer and Stroke,A Pilot Trial of Enoxaparin Versus Aspirin in Patients With Cancer and Stroke,,COMPLETED,18/12/2012,3/4/2019,3/4/2019,20,ACTUAL,,,['Cancer Patients First-ever Acute Ischemic Stroke'],"['enoxaparin', 'Aspirin']","['B8353', 'B856']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], ['Cyclooxygenases']]","[[], ['COX']]"
21838,NCT01659021,Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia,"A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia",PHASE3,TERMINATED,4/12/2012,15/8/2018,15/8/2018,261,ACTUAL,,,['Chronic Lymphocytic Leukemia'],"['Idelalisib', 'Ofatumumab']","['B802', 'B201']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Phosphatidylinositol 3 kinase delta'], ['B-lymphocyte antigen CD20']]","[['PI3KÎ´'], ['CD20']]"
22732,NCT01764880,SST0001 (Roneparstat) in Advanced Multiple Myeloma,Phase I Dose Finding Study Assessing Safety and Tolerability of SST0001 in Advanced Multiple Myeloma.,PHASE1,COMPLETED,30/11/2012,30/11/2016,30/11/2016,19,ACTUAL,,,['Multiple Myeloma'],['Roneparstat'],['B2799'],[['Small Molecule']],[['Small Molecule']],[[]],[['HPSE']]
30512,NCT02724267,Targeted Internal Radiation Therapy in Advanced HCC Patients.,A Randomized Controlled Prospective Study of Targeted Internal Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma.,,COMPLETED,30/11/2012,31/12/2015,30/6/2015,200,ACTUAL,,,"['Internal Radiation', 'Hepatocellular Carcinoma']",['Iodine I131 Derlotuximab biotin'],['B1012'],[['Radiopharmaceutical Imaging']],[['Radiopharmaceutical Imaging']],[[]],[[]]
58492,NCT01680965,Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease,Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease,PHASE1/PHASE2,COMPLETED,14/11/2012,30/8/2020,31/8/2020,44,ACTUAL,,,['Chronic Graft Versus Host Disease'],['Ofatumumab'],['B201'],[['Antibody']],[['Monoclonal Antibody']],[['B-lymphocyte antigen CD20']],[['CD20']]
21244,NCT01585350,A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients,"A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients, With Evaluation of the Injection Site Microenvironment",PHASE1,COMPLETED,31/10/2012,31/10/2014,31/7/2014,53,ACTUAL,,,['Male Reproductive System Neoplasm'],"['MELITAC 12.1 Peptide Vaccine', ""Incomplete Freund's adjuvant"", 'Poly ICLC']","['B1603', 'B3068']","[['Vaccine Adjuvant'], ['Small Molecule']]","[['Vaccine Adjuvant'], ['Small Molecule']]","[[], ['Toll like receptor 3']]","[[], ['TLR3']]"
21960,NCT01671774,Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer,"Multicenter, Open-label, Exploratory Phase I Pilot Study to Investigate Safety, Pharmacodynamics, and Pharmacokinetics of Immunological Effects and Activity of Combining Multiple Doses of IMAB362 With Immunomodulation (Zoledronic Acid, Interleukin-2) in Patients With Advanced Adenocarcinoma of the Stomach, the Lower Esophagus, or the Gastroesophageal Junction",PHASE1,COMPLETED,16/10/2012,13/10/2014,13/10/2014,29,ACTUAL,,,"['Gastric Cancer', 'Gastroesophageal Junction Cancer', 'Esophageal Cancer']","['Zolbetuximab', 'Zoledronic acid', 'Interleukin-2']","['B755', 'B2822', 'B2881']","[['Antibody'], ['Small Molecule'], []]","[['Monoclonal Antibody'], ['Small Molecule'], []]","[['Claudin 18.2'], ['Bone resorption factor', 'FDPS inhibitors(Farnesyl diphosphate synthase inhibitors)'], []]","[['CLDN18.2'], ['Bone resorption factor', 'FDPS'], []]"
21613,NCT01633060,"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi","A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment",PHASE3,TERMINATED,3/10/2012,21/9/2017,23/5/2016,432,ACTUAL,,,['Brain Metastasis'],"['Fulvestrant', 'Buparlisib', 'Placebo']","['B276', 'B540']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Estrogen receptors'], ['Phosphatidylinositol 3 kinase alpha', 'Phosphatidylinositol 3 kinase beta', 'Phosphatidylinositol 3 kinase delta', 'Phosphatidylinositol 3 kinase gamma']]","[['ER'], ['PI3KÎ±', 'PI3KÎ²', 'PI3KÎ´', 'PI3KÎ³']]"
21502,NCT01617226,Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS,Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy,PHASE2,COMPLETED,30/9/2012,31/12/2020,31/3/2016,260,ACTUAL,,,['Acute Myeloid Leukemia'],"['Azacitidine', 'Vorinostat']","['B322', 'B2107']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Histone deacetylase']]","[['DNMT1'], ['HDAC']]"
22593,NCT01746992,CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma,"An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma",PHASE4,UNKNOWN,30/9/2012,31/12/2018,30/9/2018,200,ESTIMATED,,,"['Anaplastic Large Cell Lymphoma', 'Peripheral T-Cell Lymphoma, Not Otherwise Specified', 'Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type', 'Enteropathy-Associated T-Cell Lymphoma', 'T-Cell Non-Hodgkin Lymphoma', 'Primary Cutaneous T-Cell Non-Hodgkin Lymphoma']","['Cyclophosphamide', 'Vincristine', 'Doxorubicin', 'Prednisone', 'Ifosfamide', 'Pirarubicin', 'Etoposide phosphate', 'Methotrexate']","['B2818', 'B2083', 'B1914', 'B1979', 'B8', 'B829', 'B98', 'B997']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Tubulin beta-1 chain'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Glucocorticoid receptor'], ['DNA'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Dihydrofolate reductase']]","[['DNA'], ['TUBB1'], ['TOP2'], ['GR'], ['DNA'], ['DNA', 'TOP2'], ['TOP2'], ['DHFR']]"
22442,NCT01728623,A Study of E7080 in Subjects With Advanced Thyroid Cancer,A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer,PHASE2,COMPLETED,3/9/2012,1/10/2015,9/7/2015,51,ACTUAL,,,['Thyroid Cancer'],['Lenvatinib'],['B261'],[['Small Molecule']],[['Small Molecule']],"[['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
21885,NCT01663415,"A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-NaÃ¯ve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","A Phase 2, Multicenter, Single-arm Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-NaÃ¯ve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer",PHASE2,WITHDRAWN,31/8/2012,31/10/2014,31/10/2014,0,ACTUAL,,,['Castration-Resistant Prostate Carcinoma'],['Enzalutamide'],['B25'],[['Small Molecule']],[['Small Molecule']],[['Androgen Receptor']],[['AR']]
21625,NCT01634880,Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies,Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies,PHASE2,WITHDRAWN,31/7/2012,31/3/2013,31/3/2013,0,ACTUAL,,,['Head and Neck Neoplasm'],"['Panitumumab', 'Adjuvant Radiotherapy']",['B194'],[['Antibody']],[['Monoclonal Antibody']],[['Epidermal growth factor receptor erbB1']],[['EGFR']]
22639,NCT01752257,EF5 in Melanoma Patients,Pilot Study to Characterize the HRHV Axis in the Microenvironment of Melanoma in Patients Undergoing Isolated Limb Infusion or Hypothermic Isolated Limb Perfusion With Melphalan,PHASE1,COMPLETED,31/7/2012,31/8/2014,31/8/2014,15,ACTUAL,,,['Male Reproductive System Neoplasm'],[],[],[],[],[],[]
58639,NCT01929980,Bortezomib to Treat Significant Complication of HSCT,Use of Bortezomib to Treat Refractory Autoimmune Cytopenia(s) in Allogeneic Stem Cell Transplantation,PHASE2,COMPLETED,31/7/2012,31/5/2014,31/5/2014,4,ACTUAL,,,"['Allogeneic Stem Cell Transplantation', 'Refractory Autoimmune Cytopenia(s)']",['Bortezomib'],['B958'],[['Small Molecule']],[['Small Molecule']],[['Proteasome']],[['Proteasome']]
21456,NCT01611766,Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?,"Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial",PHASE3,UNKNOWN,19/7/2012,31/12/2022,31/12/2019,356,ESTIMATED,,,"['Ovarian Cancer', 'Fallopian Tube Cancer', 'Primary Peritoneal Cancer']",['Cytoreductive Surgery'],[],[],[],[],[]
21408,NCT01607580,Efficacy Study of Low-dose Glucocorticoid Prophylaxis for Acute Graft-versus-host Disease(GVHD),"Risk Stratification-directed Low-dose Glucocorticoid Prophylaxis for Acute GVHD After Unmanipulated Haploidentical Blood and Marrow Transplantation--a Randomized, Controlled, Clinical Trial",,COMPLETED,30/6/2012,28/2/2014,30/11/2013,145,ACTUAL,,,['Leukemia'],['Methylprednisolone'],['B1988'],[['Small Molecule']],[['Small Molecule']],[['Glucocorticoid receptor']],[['GR']]
22145,NCT01693445,"S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer","Dose Finding Study of S-1, Oxaliplatin, and Irinotecan Combination Chemotherapy for Patients With Inoperable Advanced or Metastatic Gastrointestinal Cancers",PHASE1,COMPLETED,30/6/2012,31/8/2014,28/2/2014,22,ACTUAL,,,['Digestive System Neoplasm'],"['Oxaliplatin', 'Irinotecan', 'Gimeracil/oteracil/tegafur']","['B1229', 'B1679', 'B2855']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['DNA topoisomerase I'], ['Thymidylate synthase']]","[['DNA'], ['TOP1'], ['TYMS']]"
58421,NCT01531387,Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE),Sparing Conversion to Abnormal TCD Elevation (SCATE) - a Phase III Clinical Trial to Compare Standard Care (Observation) With Alternative Therapy (Hydroxyurea) for Reducing the Risk of Converting to an Abnormal TCD Velocity in Children With Sickle Cell Anemia and Conditional Pre-treatment TCD Velocities.,PHASE3,TERMINATED,31/5/2012,31/1/2014,31/1/2014,38,ACTUAL,,,['Sickle Cell Disease'],['Hydroxycarbamide'],['B3055'],[['Small Molecule']],[['Small Molecule']],[['Ribonucleotide reductase']],[['RNR']]
58445,NCT01583816,"Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions","Prospective, Randomized, Partly Blinded, in Part Placebo-controlled, Multicenter, Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions",PHASE2,COMPLETED,31/5/2012,30/6/2014,30/11/2013,218,ACTUAL,,,['Actinic Keratosis'],"['Resiquimod', 'Placebo Control']",['B1115'],[['Small Molecule']],[['Small Molecule']],"[['Toll like receptor 7', 'Toll like receptor 8']]","[['TLR7', 'TLR8']]"
21336,NCT01596647,Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors,"A Phase I, Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effect of TKI258 on the Pharmacokinetics of Caffeine, Diclofenac, Omeprazole and Midazolam Administered as a Four-drug Cocktail in Patients With Advanced Solid Tumors, Excluding Breast Cancer",PHASE1,COMPLETED,31/5/2012,31/7/2014,31/7/2014,39,ACTUAL,,,['Solid Tumors'],"['Caffeine', 'Diclofenac', 'Omeprazole', 'Midazolam', 'dovitinib lactate']","['B44', 'B286', 'B328', 'B1992', 'B9088']","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[[], ['Cyclooxygenases'], [], ['Gamma-aminobutyric acid A receptor'], []]","[[], ['COX'], ['Proton pump'], ['GABAA receptor'], []]"
21131,NCT01570868,Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP),Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase,PHASE2,TERMINATED,30/4/2012,31/5/2016,31/5/2016,51,ACTUAL,,,['Leukemia'],['Ponatinib'],['B64'],[['Small Molecule']],[['Small Molecule']],"[['Bcr-Abl tyrosine kinase', 'Protein-tyrosine kinases']]","[['BCR-ABL1', 'Protein-tyrosine kinases']]"
21802,NCT01655719,Pioglitazone in Thyroid Cancers,Phase 2 Study of Pioglitazone in Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene,PHASE2,COMPLETED,30/4/2012,31/3/2017,31/3/2017,1,ACTUAL,,,['Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene'],['Pioglitazone'],['B1960'],[['Small Molecule']],[['Small Molecule']],[['Peroxisome proliferator-activated receptor Î³']],[['PPARÎ³']]
21142,NCT01572662,Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning,Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation,PHASE2,COMPLETED,11/4/2012,11/8/2022,11/8/2022,201,ACTUAL,,,"['Leukemia', 'Acute Myeloid Leukemia', 'Acute Lymphoblastic Leukemia', 'Chronic Myeloid Leukemia', 'Chronic Lymphocytic Leukemia', 'Myeloproliferative Neoplasm', 'Non-Hodgkin Lymphoma', 'Hodgkin Lymphoma', 'Multiple Myeloma', 'Myelodysplastic Syndrome']","['fludarabine phosphate', 'Busulfan', 'Hematopoietic Cell Transplantation', 'Tacrolimus', 'Methotrexate', 'Filgrastim']","['B8555', 'B2060', 'B2846', 'B997', 'B157']","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy']]","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Colony-Stimulating Factor']]","[[], ['DNA'], [], ['Dihydrofolate reductase'], ['Colony stimulating factor 3 receptor']]","[[], ['DNA'], ['CaN'], ['DHFR'], ['CSF-3R']]"
19113,NCT01334502,"Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL),PHASE1,COMPLETED,31/3/2012,31/8/2017,28/2/2015,26,ACTUAL,,,['Hematology'],"['Rituximab', 'Cyclophosphamide', 'doxorubicin hydrochloride', 'Everolimus', 'Prednisone', 'vincristine sulfate']","['B163', 'B2818', 'B9124', 'B511', 'B1979', 'B9307']","[['Antibody'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], []]","[['Monoclonal Antibody'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], []]","[['B-lymphocyte antigen CD20'], ['DNA'], [], ['Mammalian target of Rapamycin', 'mTOR Complex 2'], ['Glucocorticoid receptor'], []]","[['CD20'], ['DNA'], [], ['mTORC1', 'mTORC2'], ['GR'], []]"
20677,NCT01516996,Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer,Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx,PHASE2,UNKNOWN,31/3/2012,31/3/2018,30/9/2013,80,ESTIMATED,,,"['Oropharyngeal Cancer', 'Hypopharyngeal Cancer']","['Docetaxel', 'Cisplatin', 'Intensity-Modulated Radiation Therapy', 'Nimotuzumab']","['B2814', 'B49', 'B662']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['Tubulin beta-1 chain'], ['DNA'], ['Epidermal growth factor receptor erbB1']]","[['TUBB1'], ['DNA'], ['EGFR']]"
21009,NCT01554254,Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation,Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation,PHASE2,WITHDRAWN,31/3/2012,,31/12/2013,0,ACTUAL,,,"['Cord Blood Transplant', 'Hematology', 'Inherited Metabolic Disease']",['Angiotensin-1-7'],['B4147'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
23713,NCT01886066,Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer,Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer: A Prospective Trial,,COMPLETED,31/3/2012,30/9/2021,21/6/2019,156,ACTUAL,,,"['Endometrial Cancer', 'Sentinel Lymph Node', 'Indocyanine Green']",['Indocyanine green'],['B361'],[['Imaging']],[['Imaging Agent']],[[]],[[]]
23641,NCT01876043,"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial","Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial",PHASE2,TERMINATED,29/2/2012,30/4/2015,30/4/2015,24,ACTUAL,,,['Dedifferentiated Liposarcoma'],['Plitidepsin'],['B1472'],[['Small Molecule']],[['Small Molecule']],[['Elongation factor 1-alpha 1']],[['EEF1A1']]
20780,NCT01527136,Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery,A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of CBLB502 in Patients With Advanced Cancers,PHASE1,COMPLETED,31/1/2012,31/10/2014,31/10/2014,25,ACTUAL,,,['Solid Tumors'],"['Entolimod', 'Laboratory Biomarker Analysis']",['B702'],[[]],[[]],[['Toll like receptor 5']],[['TLR5']]
20917,NCT01542437,"Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer","Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2",PHASE2,COMPLETED,31/1/2012,30/6/2017,30/6/2014,66,ACTUAL,,,"['Non-Small Cell Lung Cancer', 'Lung Adenocarcinoma', 'HER-2']",['Afatinib'],['B69'],[['Small Molecule']],[['Small Molecule']],"[['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2', 'Receptor protein-tyrosine kinase erbB-4']]","[['EGFR L858R', 'EGFR-Ex19del', 'EGFR', 'HER2', 'HER4']]"
21524,NCT01620736,Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load,Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load,PHASE2,WITHDRAWN,31/1/2012,31/12/2014,31/12/2013,0,ACTUAL,,,['Adult T-Cell Leukemia/Lymphoma'],['Raltegravir'],['B859'],[['Small Molecule']],[['Small Molecule']],[['Gag-Pol polyprotein']],"[['HIV-1 integrase', 'Gag-pol']]"
35310,NCT03364439,R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients,"Prospective, Multicentre Phase II Study With R-CHOP- 14 or R-CHOP-21 & Consolidation PET-Oriented Radiotherapy (RT) in Diffuse Large B Cell Lymphoma (DLBCL) Patients With Low Risk Profile According to Age-adjusted IPI (0 With Bulky or 1)",PHASE2,COMPLETED,31/1/2012,18/3/2021,30/4/2018,109,ACTUAL,,,['Diffuse Large B-Cell Lymphoma'],['Radiation Therapy'],[],[],[],[],[]
19884,NCT01428492,Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma,"A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma",PHASE1,COMPLETED,31/12/2011,31/10/2015,31/10/2015,90,ACTUAL,,,['Multiple Myeloma'],"['Afuresertib', 'Bortezomib', 'Dexamethasone']","['B807', 'B958', 'B1128']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Proteasome'], ['Glucocorticoid receptor']]","[['AKT'], ['Proteasome'], ['GR']]"
20249,NCT01469572,"Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases","Phase IB/II Study of Pasireotide, Everolimus and Selective Internal Radioembolization Therapy (SIRT) for Unresectable Neuroendocrine Hepatic Metastases",PHASE1,COMPLETED,31/12/2011,31/10/2018,31/10/2018,13,ACTUAL,,,['Neuroendocrine Tumors'],"['Pasireotide', 'Transarterial Radioembolization', 'Everolimus']","['B2794', 'B511']","[['Engineered Protein Therapy'], ['Small Molecule']]","[['Synthetic Peptide'], ['Small Molecule']]","[['Somatostatin receptor 2'], ['Mammalian target of Rapamycin', 'mTOR Complex 2']]","[['SSTR2', 'SSTR1', 'SSTR3', 'SSTR5'], ['mTORC1', 'mTORC2']]"
20351,NCT01481129,Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,A Phase 2 Study of MK-2206 in Patients With Relapsed or Refractory Diffuse Large-B Cell Lymphoma,PHASE2,COMPLETED,31/12/2011,30/6/2014,30/6/2013,22,ACTUAL,,,['Diffuse Large B-Cell Lymphoma'],"['MK 2206', 'Laboratory Biomarker Analysis']",['B2113'],[['Small Molecule']],[['Small Molecule']],[[]],[['AKT']]
20625,NCT01510756,Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL),A Phase II Translational Study of Sorafenib for the Treatment of Chronic Lymphocytic Leukemia Patients,PHASE2,TERMINATED,31/12/2011,31/12/2014,31/5/2014,4,ACTUAL,,,['Chronic Lymphocytic Leukemia'],['Sorafenib'],['B270'],[['Small Molecule']],[['Small Molecule']],"[['C-Raf kinase', 'Platelet-derived growth factor receptor beta', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['CRAF', 'PDGFRÎ²', 'BRAF', 'c-Kit', 'FLT3', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
20233,NCT01468389,Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction,A Randomized Multicenter Phase III Study:Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone vs.Taxanes or Platinum Combined With Capecitabine in Advanced Adenocarcinoma of the Stomach or Esophagogastric Junction.,PHASE3,UNKNOWN,30/11/2011,30/6/2013,31/1/2013,300,ESTIMATED,,,['Gastric Cancer'],['Capecitabine'],['B474'],[['Small Molecule']],[['Small Molecule']],[['Thymidylate synthase']],[['TYMS']]
19158,NCT01339442,BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer,"A Phase 1 Trial of BKM 120, a Novel Oral Selective Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer",PHASE1,COMPLETED,14/11/2011,28/12/2016,21/12/2016,31,ACTUAL,,,"['Hormone Receptor-Positive Breast Cancer', 'Breast Cancer', 'Breast Cancer']","['Buparlisib', 'Fulvestrant', 'Biopsy']","['B540', 'B276']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Phosphatidylinositol 3 kinase alpha', 'Phosphatidylinositol 3 kinase beta', 'Phosphatidylinositol 3 kinase delta', 'Phosphatidylinositol 3 kinase gamma'], ['Estrogen receptors']]","[['PI3KÎ±', 'PI3KÎ²', 'PI3KÎ´', 'PI3KÎ³'], ['ER']]"
33443,NCT03117335,Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer,"Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study",PHASE3,COMPLETED,10/11/2011,17/1/2017,14/11/2016,560,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Placebo', 'Vinorelbine', 'Cisplatin', 'Recombinant Human Endostatin']","['B1929', 'B49']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['DNA']]","[['TUBB1'], ['DNA']]"
20168,NCT01460979,"Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma","Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma",PHASE2,COMPLETED,31/10/2011,30/11/2015,30/6/2015,47,ACTUAL,,,"['Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm']",['Temsirolimus'],['B114'],[['Small Molecule']],[['Small Molecule']],[['Serine/threonine-protein kinase mTOR']],[['mTOR']]
19906,NCT01431664,AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia,A Cancer Research UK Phase I/IIa Trial of AT9283 (A Selective Inhibitor of Aurora Kinases) Given Over 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents Aged 6 Months to 18 Years With Relapsed and Refractory Acute Leukemia,PHASE1,COMPLETED,30/9/2011,31/7/2014,31/7/2014,7,ACTUAL,,,['Leukemia'],"['AT9283', 'Laboratory Biomarker Analysis']",['B2665'],[['Small Molecule']],[['Small Molecule']],"[['Bcr-Abl tyrosine kinase', 'Serine/threonine-protein kinase Aurora-A', 'Serine/threonine-protein kinase Aurora-B', 'Tyrosine-protein kinase JAK2', 'Tyrosine-protein kinase receptor FLT3']]","[['BCR-ABL1', 'Aurora A', 'Aurora B', 'JAK2', 'FLT3']]"
19615,NCT01394120,Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer,Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer,PHASE2,UNKNOWN,31/8/2011,31/12/2013,31/12/2012,60,ESTIMATED,,,['Pancreatic Cancer'],"['FOLFIRINOX', 'FOLFOX', 'FOLFIRI', 'Capecitabine', 'Gemcitabine', 'Erlotinib', 'GEM-CAP', 'Erlotinib/Gemcitabine']","['B474', 'B2079', 'B1928']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Thymidylate synthase'], ['DNA', 'Ribonucleotide reductase'], ['Epidermal growth factor receptor erbB1']]","[['TYMS'], ['DNA', 'RNR'], ['EGFR L858R', 'EGFR-Ex19del', 'EGFR']]"
19889,NCT01429051,A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain,"A Dose Titrated Clinical Trial With a Placebo-controlled, Double-blind, Randomised, Cross-over Phase to Demonstrate the Efficacy of 400 Î¼g Intranasal Fentanyl (INFS) Dose Strength, and to Evaluate 12 Weeks Safety and Nasal Tolerability of All Dose Strengths Between 50 Î¼g and 400 Î¼g, in Cancer Patients With Breakthrough Pain.",PHASE3,COMPLETED,31/8/2011,31/1/2013,31/1/2013,46,ACTUAL,,,"['Break Through Pain', 'Cancer']","['Fentanyl', 'Placebo Control']",['B1961'],[['Small Molecule']],[['Small Molecule']],[['Opioid receptors']],[['Opioid receptors']]
25021,NCT02043756,Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection,Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Solid Tumor,PHASE1,COMPLETED,31/8/2011,31/8/2013,30/6/2013,20,ACTUAL,,,['Neoplasms'],"['Liposomal Mitoxantrone Hydrochloride', 'Mitoxantrone']",['B1952'],[['Small Molecule']],[['Small Molecule']],"[['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)']]","[['DNA', 'TOP2']]"
14017,NCT00816959,Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma,"Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma",PHASE3,UNKNOWN,31/7/2011,30/4/2014,30/4/2014,1200,ESTIMATED,,,['Hodgkin Lymphoma'],"['Hyaluronidase/rituximab', 'ABVD']",['B4253'],[['Antibody']],[['Monoclonal Antibody']],"[['B-lymphocyte antigen CD20', 'Hyaluronic acid']]","[['CD20', 'Hyaluronic acid']]"
18119,NCT01232296,A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment,"An Open-label, Randomized, Multi-center, Phase II Study to Compare the Safety and Efficacy of TKI258 Versus Sorafenib as First-line Treatment in Adult Patients With Advanced Hepatocellular Carcinoma",PHASE2,COMPLETED,31/7/2011,30/4/2014,30/4/2014,162,ACTUAL,,,['Hepatocellular Carcinoma'],"['Dovitinib', 'Sorafenib']","['B1819', 'B270']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Colony stimulating factor 1 receptor', 'Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 3', 'Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Vascular endothelial growth factor receptor'], ['C-Raf kinase', 'Platelet-derived growth factor receptor beta', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['CSF-1R', 'FGFR1', 'FGFR3', 'PDGFRÎ²', 'c-Kit', 'FLT3', 'VEGFR'], ['CRAF', 'PDGFRÎ²', 'BRAF', 'c-Kit', 'FLT3', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
19530,NCT01384253,Safety Study of Â²Â¹Â²Pb-TCMC-Trastuzumab Radio Immunotherapy,Phase I Trial of Intraperitoneal Â²Â¹Â²Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy,PHASE1,COMPLETED,31/7/2011,31/7/2016,31/10/2015,18,ACTUAL,,,"['Breast Neoplasm', 'Peritoneal and Retroperitoneal Neoplasm', 'Female Reproductive System Neoplasm', 'Pancreatic Cancer', 'Digestive System Neoplasm']","['212 Pb TCMC trastuzumab', 'Trastuzumab']","['B5230', 'B168']","[['Antibody Radiopharmaceutical'], ['Antibody']]","[['Antibody Radiopharmaceutical'], ['Monoclonal Antibody']]","[['Receptor protein-tyrosine kinase erbB-2'], ['Receptor protein-tyrosine kinase erbB-2']]","[['HER2'], ['HER2']]"
19358,NCT01362374,"Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors","A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of Ipatasertib (GDC-0068) in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",PHASE1,COMPLETED,11/7/2011,16/10/2020,16/10/2020,122,ACTUAL,,,['Neoplasms'],"['Fluorouracil', 'Docetaxel', 'Enzalutamide', 'RG7440', 'Folinic acid', 'Oxaliplatin', 'Paclitaxel']","['B493', 'B2814', 'B25', 'B795', 'B226', 'B1229', 'B1250']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule']]","[['Thymidylate synthase'], ['Tubulin beta-1 chain'], ['Androgen Receptor'], [], [], ['DNA'], ['Tubulin beta-1 chain']]","[['TYMS'], ['TUBB1'], ['AR'], ['AKT'], [], ['DNA'], ['TUBB1']]"
19893,NCT01430013,Trial of Endostar Combined With CHOPT for T Cell Lymphoma,Phase II Trial of Endostar Combined With CHOPT for T Cell Lymphoma,PHASE2,UNKNOWN,30/6/2011,31/12/2015,30/11/2015,30,ESTIMATED,,,['T-Cell Non-Hodgkin Lymphoma'],"[' Endostar', 'Cyclophosphamide', 'Pirarubicin', 'Vincristine', 'Teniposide', 'Prednisone']","['B7015', 'B2818', 'B829', 'B2083', 'B1473', 'B1979']","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Vascular endothelial growth factor receptor'], ['DNA'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['Tubulin beta-1 chain'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Glucocorticoid receptor']]","[['VEGFR'], ['DNA'], ['DNA', 'TOP2'], ['TUBB1'], ['TOP2'], ['GR']]"
19052,NCT01328496,Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen,Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen,PHASE2,COMPLETED,15/6/2011,31/10/2016,31/10/2016,14,ACTUAL,,,"['Hematology', 'Epithelial Neoplasm', 'Hematology']","['Fludarabine', 'Cyclophosphamide', 'Cyclosporin', 'Mycophenolate mofetil', 'Filgrastim', 'Total-Body Irradiation', 'Umbilical Cord Blood Transplantation']","['B346', 'B2818', 'B2845', 'B310', 'B157']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Colony-Stimulating Factor']]","[['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA'], [], [""Inosine-5'-monophosphate dehydrogenase""], ['Colony stimulating factor 3 receptor']]","[['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA'], ['CaN'], ['IMPDH'], ['CSF-3R']]"
19519,NCT01382706,Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder,Single Arm Phase II Study of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder as Second Line Treatment,PHASE2,TERMINATED,13/6/2011,15/12/2017,15/7/2013,15,ACTUAL,,,"['Bladder Cancer', 'Bladder Cancer', 'Bladder Cancer', 'Urothelial Carcinoma']","['Docetaxel', 'lapatinib ditosylate', 'Immunohistochemistry Staining Method', 'Fluorescence In Situ Hybridization', 'Laboratory Biomarker Analysis']","['B2814', 'B9143']","[['Small Molecule'], []]","[['Small Molecule'], []]","[['Tubulin beta-1 chain'], []]","[['TUBB1'], []]"
21664,NCT01639625,Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application,"Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External Endocavitary Brachytherapy + Concurrent Hemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation",PHASE2,COMPLETED,31/5/2011,31/1/2016,30/9/2015,18,ACTUAL,,,"['Cervical Cancer', 'Cervical Cancer']",['CIGB 300'],['B5098'],[['Engineered Protein Therapy']],[['Synthetic Peptide']],[['Casein kinase II']],[['CK2']]
16612,NCT01074177,Understanding Mechanisms of Acquired Resistance to BIBW2992,Understanding Mechanisms of Acquired Resistance to BIBW2992,,COMPLETED,28/2/2011,31/3/2017,31/3/2017,24,ACTUAL,,,"['Non-Small Cell Lung Cancer', 'Lung Adenocarcinoma']",['Afatinib'],['B69'],[['Small Molecule']],[['Small Molecule']],"[['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2', 'Receptor protein-tyrosine kinase erbB-4']]","[['EGFR L858R', 'EGFR-Ex19del', 'EGFR', 'HER2', 'HER4']]"
17690,NCT01191697,"CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer","Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",PHASE2,ACTIVE_NOT_RECRUITING,28/2/2011,31/7/2025,31/12/2021,37,ACTUAL,,,"['Esophageal Cancer', 'Gastric Cancer']","['Bevacizumab', 'Trastuzumab', 'Oxaliplatin', 'Capecitabine']","['B167', 'B168', 'B1229', 'B474']","[['Antibody'], ['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Vascular endothelial growth factor A'], ['Receptor protein-tyrosine kinase erbB-2'], ['DNA'], ['Thymidylate synthase']]","[['VEGF-A'], ['HER2'], ['DNA'], ['TYMS']]"
18974,NCT01320020,"A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients","A Phase I, Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients",PHASE1,TERMINATED,28/2/2011,31/3/2013,31/3/2013,16,ACTUAL,,,['Epithelial Neoplasm'],['Catumaxomab'],['B681'],[['Antibody']],[['Bispecific Antibody']],"[['Epithelial cell adhesion molecule', 'T cell surface glycoprotein CD3']]","[['EpCAM', 'CD3']]"
19730,NCT01409499,Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC),A Prospective Multicenter Non-randomized Controlled Study of Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma,PHASE4,COMPLETED,31/1/2011,31/1/2018,30/6/2017,180,ACTUAL,,,"['Hepatectomy', 'Hepatocellular Carcinoma', 'Sorafenib']","['Sorafenib', 'Hepatectomy', 'Transarterial Chemoembolization']",['B270'],[['Small Molecule']],[['Small Molecule']],"[['C-Raf kinase', 'Platelet-derived growth factor receptor beta', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['CRAF', 'PDGFRÎ²', 'BRAF', 'c-Kit', 'FLT3', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
21044,NCT01558947,Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer,"Peri-operative Chemotherapy With ECX (Epirubicin + Cisplatin + Capecitabine) or XP (Capecitabine + Cisplatin) in the Treatment of Advanced Gastric Cancer: a Randomized, Multicenter, Parallel Control",PHASE2,UNKNOWN,31/1/2011,30/6/2013,31/12/2012,2,ESTIMATED,,,['Gastric Cancer'],"['Epirubicin', 'Capecitabine', 'Cisplatin']","['B1236', 'B474', 'B49']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['Thymidylate synthase'], ['DNA']]","[['DNA', 'TOP2'], ['TYMS'], ['DNA']]"
17353,NCT01156142,Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy,A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy,PHASE3,COMPLETED,31/12/2010,2/3/2015,31/5/2012,155,ACTUAL,,,"['Head and Neck Neoplasm', 'Mucositis', 'Oral Complications of Radiation Therapy', 'Connective and Soft Tissue Neoplasm']","['Doxepin Hydrochloride', 'Placebo Control']",[],[],[],[],[]
18313,NCT01251172,RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma,Phase II Study of RO4929097 to Eradicate Residual Disease in Patients With Multiple Myeloma Post Single Autologous Stem Cell Transplant,PHASE2,WITHDRAWN,31/12/2010,,31/7/2012,0,ACTUAL,,,"['Multiple Myeloma', 'Multiple Myeloma', 'Multiple Myeloma', 'Multiple Myeloma']","['Autologous Hematopoietic Stem Cell Transplantation', 'RG 4733', 'Stem Cell Mobilization Therapy', 'In Vitro-Treated Peripheral Blood Stem Cell Transplantation', 'Laboratory Biomarker Analysis', 'Melphalan']","['B2428', 'B2073']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Gamma-secretase'], ['DNA']]","[['Î³-secretase'], ['DNA']]"
18405,NCT01260506,Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme,,PHASE1/PHASE2,COMPLETED,31/12/2010,20/12/2018,23/7/2015,75,ESTIMATED,,,['Glioblastoma'],"['Ofranergene obadenovec', 'Bevacizumab']","['B1099', 'B167']","[['Gene Therapy'], ['Antibody']]","[['Gene Transfer Therapy'], ['Monoclonal Antibody']]","[['Apoptosis-mediating surface antigen FAS', 'Tumor necrosis factor receptor superfamily member 1A'], ['Vascular endothelial growth factor A']]","[['FasR', 'TNFR1'], ['VEGF-A']]"
18875,NCT01308645,Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC),"Phaseâ…¡, Open Label, Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma",PHASE2,UNKNOWN,31/12/2010,31/3/2012,31/12/2011,30,ESTIMATED,,,['Hepatocellular Carcinoma'],['Epinephrine'],['B2001'],[['Small Molecule']],[['Small Molecule']],[['Beta-1 adrenergic receptor']],[['Î²1-adrenergic receptor']]
48097,NCT05167370,High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors,High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors,PHASE2,TERMINATED,13/12/2010,24/4/2012,29/4/2011,2,ACTUAL,,,"['Solid Tumors', 'Central Nervous System Neoplasm']","['Amifostine', 'Melphalan', 'Thiotepa']","['B3', 'B2073', 'B1998']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Alkaline phosphatase, tissue-nonspecific isozyme'], ['DNA'], ['DNA']]","[['TNSALP'], ['DNA'], ['DNA']]"
18190,NCT01238770,Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer,"A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer",PHASE1/PHASE2,COMPLETED,30/11/2010,31/10/2015,31/10/2014,10,ACTUAL,,,['Ovarian Cancer'],"['Pazopanib', 'Cyclophosphamide']","['B1649', 'B2818']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['DNA']]","[['PDGFRÎ±', 'PDGFRÎ²', 'c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['DNA']]"
18232,NCT01242449,Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer,A Phase II Investigation of Oral Vinorelbine in Combination With Trastuzumab for 1st and 2nd Line Treatment of Women With Metastatic HER2 Positive Breast Cancer,PHASE2,COMPLETED,30/11/2010,31/10/2014,31/10/2012,10,ACTUAL,,,['Breast Cancer'],"['Trastuzumab', 'Vinorelbine']","['B168', 'B1929']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Receptor protein-tyrosine kinase erbB-2'], ['Tubulin beta-1 chain']]","[['HER2'], ['TUBB1']]"
18038,NCT01222754,Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas,A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas,PHASE1,COMPLETED,23/11/2010,17/4/2019,17/4/2019,29,ACTUAL,,,"['Diffuse Intrinsic Pontine Glioma', 'Anaplastic Astrocytoma', 'High-Grade Glioma']","['Lenalidomide', 'Radiation Therapy', 'Theophylline']","['B2071', 'B506']","[['Small Molecule'], ['Small Molecule']]","[['Molecular glue'], ['Small Molecule']]","[['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos'], ['Adenosine A2b receptor']]","[['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3'], ['A1R', 'PDE', 'A2bR']]"
17971,NCT01217437,Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors,"Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial",PHASE2,COMPLETED,22/11/2010,30/6/2021,31/12/2017,108,ACTUAL,,,"['Central Nervous System Neoplasm', 'Pineoblastoma', 'Medulloblastoma', 'Peripheral Primitive Neuroectodermal Tumor', 'Medulloblastoma', 'Peripheral Primitive Neuroectodermal Tumor']","['Bevacizumab', 'irinotecan hydrochloride', 'Temozolomide']","['B167', 'B9055', 'B2056']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Vascular endothelial growth factor A'], [], ['DNA']]","[['VEGF-A'], [], ['DNA']]"
17735,NCT01195376,A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors,"A Phase I Study of BEZ235, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors",PHASE1,COMPLETED,31/10/2010,31/7/2013,31/7/2013,35,ACTUAL,,,['Solid Tumors'],['Dactolisib'],['B500'],[['Small Molecule']],[['Small Molecule']],[['Serine/threonine-protein kinase mTOR']],"[['PI3K family', 'mTOR']]"
18213,NCT01240577,"An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas","An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas",PHASE1,COMPLETED,26/10/2010,30/7/2012,30/7/2012,10,ACTUAL,,,"['Neoplasms', 'Hematology']",['Ropidoxuridine'],['B562'],[['Small Molecule']],[['Small Molecule']],[['Thymidine kinase']],[['thymidine kinase']]
17758,NCT01197625,Vaccine Therapy in Curative Resected Prostate Cancer Patients,"Trial of Vaccine Therapy in Curative Resected Prostate Cancer Patients Using Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin",PHASE1/PHASE2,ACTIVE_NOT_RECRUITING,30/9/2010,30/9/2025,30/9/2024,30,ESTIMATED,,,['Prostate Cancer'],[],['B2909'],[[]],[[]],[[]],[[]]
18068,NCT01226407,Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile,"Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer",PHASE1,UNKNOWN,30/9/2010,28/2/2013,28/2/2013,36,ESTIMATED,,,['Solid Tumors'],['Ivaltinostat'],['B2421'],[['Small Molecule']],[['Small Molecule']],[['Histone deacetylase']],[['HDAC']]
18529,NCT01271920,Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab,"A Phase Ib/II, Multi-center, Open-label Study to Evaluate the Efficacy of AUY922 in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer, That Has Progressed After or During at Least One Trastuzumab-containing Regimen",PHASE1/PHASE2,COMPLETED,30/9/2010,31/10/2013,31/10/2013,45,ACTUAL,,,['HER2-Positive Breast Cancer'],"['Luminespib', 'Trastuzumab']","['B858', 'B168']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Heat shock protein HSP90'], ['Receptor protein-tyrosine kinase erbB-2']]","[['HSP90'], ['HER2']]"
19419,NCT01370876,Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer,A Phase II Trial Evaluating Efficacy and Safety of OpatinÂ® (Oxaliplatin)/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer,PHASE2,TERMINATED,30/9/2010,31/5/2012,31/8/2011,46,ESTIMATED,,,"['Head and Neck Neoplasm', 'Head and Neck Neoplasm']","['Oxaliplatin', 'Fluorouracil']","['B1229', 'B493']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Thymidylate synthase']]","[['DNA'], ['TYMS']]"
26426,NCT02225652,"A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.","A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.",PHASE2,COMPLETED,30/9/2010,31/7/2014,30/9/2013,11,ACTUAL,,,['Breast Cancer'],"['Fluorouracil', 'Epirubicin', 'Cyclophosphamide', 'Filgrastim', 'Paclitaxel']","['B493', 'B1236', 'B2818', 'B157', 'B1250']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Colony-Stimulating Factor'], ['Small Molecule']]","[['Thymidylate synthase'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], ['Colony stimulating factor 3 receptor'], ['Tubulin beta-1 chain']]","[['TYMS'], ['DNA', 'TOP2'], ['DNA'], ['CSF-3R'], ['TUBB1']]"
59120,NCT02817555,Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients,"A Randomized, Controlled Trial of Costs Associated With Anemia Therapy in Hemodialysis Patients Treated With Intravenous Darbepoetin Alfa Versus Epoetin Alfa",PHASE4,COMPLETED,30/9/2010,31/5/2013,31/5/2013,50,ACTUAL,,,"['Anemia', 'Chronic Kidney Disease']","['Epoetin alfa', 'Sodium Ferric Gluconate Complex', 'Darbepoetin alfa']","['B155', 'B156']","[['Other Protein Therapy'], ['Other Protein Therapy']]","[['Colony-Stimulating Factor'], ['Colony-Stimulating Factor']]","[['Erythropoietin receptor'], ['Erythropoietin receptor']]","[['EPO receptor'], ['EPO receptor']]"
18513,NCT01270724,"Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)","A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors",PHASE2,COMPLETED,31/8/2010,9/12/2019,23/10/2019,10,ACTUAL,,,['Central Nervous System Neoplasm'],"['Gemcitabine', 'Paclitaxel', 'Oxaliplatin', 'corticotropin-releasing hormone']","['B2079', 'B1250', 'B1229', 'B8703']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain'], ['DNA'], []]","[['DNA', 'RNR'], ['TUBB1'], ['DNA'], []]"
22356,NCT01718379,Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.,A Phase II Study Evaluating the Efficacy/Safety of Lenalidomide With or Without Epoetin Beta in Transfusion-dependent ESA-resistant Patients With IPSS Low- and Intermediate-1 Risk Myelodysplastic Syndromes Without Chromosome 5 Abnormality.,PHASE2,COMPLETED,31/7/2010,30/6/2016,30/11/2012,132,ACTUAL,,,['Myelodysplastic Syndrome'],"['Lenalidomide', 'Epoetin beta']","['B2071', 'B731']","[['Small Molecule'], ['Other Protein Therapy']]","[['Molecular glue'], ['Colony-Stimulating Factor']]","[['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos'], ['Erythropoietin receptor']]","[['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3'], ['EPO receptor']]"
14148,NCT00829413,SonoVueÂ®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization,"Characterization Of Focal Liver Lesions With SonovueÂ®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Unenhanced Ultrasound Imaging Using Histology Or Combined Imaging/Clinical Data As Truth Standard",PHASE3,COMPLETED,30/6/2010,31/7/2013,31/7/2013,353,ACTUAL,,,['Liver Cancer'],['Sulfur hexafluoride'],['B483'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
16770,NCT01091454,Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer,Phase II Trial of Brostallicin and Cisplatin in Patients With Metastatic Triple Negative Breast Cancer,PHASE2,COMPLETED,30/6/2010,1/11/2014,30/6/2012,48,ACTUAL,,,['Triple-Negative Breast Cancer'],"['Brostallicin', 'Cisplatin']","['B78', 'B49']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], ['DNA']]","[['DNA'], ['DNA']]"
17204,NCT01138163,Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer",PHASE2,COMPLETED,30/6/2010,31/5/2013,31/10/2012,121,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Docetaxel', 'Bavituximab', 'Placebo Control']","['B2814', 'B404']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Tubulin beta-1 chain'], ['Phosphatidylserine']]","[['TUBB1'], ['Phosphatidylserine']]"
58205,NCT01146574,"A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.","A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).",PHASE2,COMPLETED,30/6/2010,7/3/2016,7/3/2016,50,ACTUAL,,,['Anemia'],"['Sotatercept', 'Placebo Control']",['B455'],[['Engineered Protein Therapy']],[['Fusion Protein']],"[['activin A receptor type 2A', 'Growth/differentiation factor 8']]","[[' ACVR1B', 'GDF11', 'ACVR2A', 'MSTN']]"
17377,NCT01159028,"Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS","A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1001 (L-Grb-2 Antisense Oligonucleotide) in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, or Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome",PHASE1,COMPLETED,30/6/2010,30/3/2017,30/3/2017,60,ESTIMATED,,,"['Acute Myeloid Leukemia', 'Acute Lymphoblastic Leukemia', 'Myelodysplastic Syndrome', 'Myeloid Neoplasm']","['Prexigebersen', 'Low-dose Cytarabine Regimen']",['B1177'],[['DNA Oligonucleotide Therapy']],[['DNA Oligonucleotide Therapy']],[['Growth factor receptor-bound protein 2']],[['GRB2']]
17871,NCT01208194,Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma,"Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma With Disease Control After Initial First-line Therapy",PHASE2,COMPLETED,30/6/2010,31/3/2013,31/12/2012,59,ACTUAL,,,['Colorectal Cancer'],"['Lefitolimod', 'Placebo Control']",['B1322'],[['Gene Therapy']],[['Oligonucleotide Therapy']],[['Toll like receptor 9']],[['TLR9']]
19004,NCT01323933,First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors,"A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB0024 in Adult Patients With Advanced Solid Tumors",PHASE1,COMPLETED,30/6/2010,31/3/2012,31/3/2012,32,ACTUAL,,,['Neoplasms'],['Simtuzumab'],['B767'],[['Antibody']],[['Monoclonal Antibody']],[['Lysyl oxidase homolog 2']],[['LOXL2']]
19405,NCT01369121,Tolerability Study of XereceptÂ® in Pediatric Patients,"A Phase I/II Open Label Individual Dose Titration Trial of the Human Corticotropin- Releasing Factor (hCRF), Corticorelin Acetate Injection (XereceptÂ®), to Determine the Tolerability of XereceptÂ® in a Pediatric Population",PHASE1/PHASE2,TERMINATED,30/6/2010,31/3/2013,31/10/2012,15,ACTUAL,,,"['Brain Edema', 'Central Nervous System Neoplasm']",['Corticorelin'],['B648'],[['Other Protein Therapy']],[['Hormone']],[[]],[[]]
16800,NCT01094860,Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies,A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies,PHASE1,COMPLETED,8/6/2010,9/8/2018,9/8/2018,29,ACTUAL,,,['Leukemia'],['Nelarabine'],['B112'],[['Small Molecule']],[['Small Molecule']],[['DNA polymerase alpha subunit']],[['POLA1']]
17882,NCT01209208,Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis,"Double-blind, Double-dummy, Randomised, Placebo-controlled, Multi-centre Phase III Study on the Efficacy and Tolerability of a 8-week Treatment With Budesonide vs. Mesalazine vs. Placebo in Patients With Lymphocytic Colitis",PHASE3,COMPLETED,31/5/2010,30/6/2017,30/6/2017,57,ACTUAL,,,['Lymphocytic Colitis'],"['Budesonide', 'Mesalazine', 'Placebo Control']","['B283', 'B5657']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Glucocorticoid receptor'], []]","[['GR'], ['PP2A']]"
16945,NCT01110785,Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer,"Safety and Efficacy of the Addition of Simvastatin to Panitumumab in K-ras Mutant Advanced or Metastatic Colorectal Cancer Patients. A Single-Arm, Multicenter, Phase II Study Using a Simon Two Stage Design.",PHASE2,UNKNOWN,30/4/2010,,30/4/2012,46,ESTIMATED,,,['Colorectal Cancer'],"['Panitumumab', 'Simvastatin', 'Laboratory Biomarker Analysis']","['B194', 'B17']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['HMG-CoA reductase']]","[['EGFR'], ['HMG-CoA reductase']]"
16641,NCT01077453,Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer,Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer,PHASE1,COMPLETED,31/3/2010,,30/6/2014,112,ACTUAL,,,"['Healthy, no Evidence of Disease', 'Breast Cancer']","['Letrozole', 'Laboratory Biomarker Analysis']",['B302'],[['Small Molecule']],[['Small Molecule']],"[['Aromatase', 'Estrogen receptors']]","[['aromatase', 'ER']]"
17020,NCT01118975,GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers,GCC 0845: Pilot and Phase II- Vorinostat and Lapatinib in Patients With Advanced Solid Tumor Malignancies and Women With Recurrent Local-Regional or Metastatic Breast Cancer to Evaluate Response and Biomarkers of EMT and Breast Cancer Stem Cells,PHASE1/PHASE2,TERMINATED,31/3/2010,31/10/2012,31/10/2012,12,ACTUAL,,,"['Breast Cancer', 'Neoplasm Metastasis']","['Vorinostat', 'Lapatinib']","['B2107', 'B1930']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Histone deacetylase'], ['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2']]","[['HDAC'], ['EGFR', 'HER2']]"
16329,NCT01042522,"Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors","A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary",PHASE2,UNKNOWN,8/2/2010,2/11/2022,12/6/2020,63,ACTUAL,,,"['Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm', 'Ovarian Sex Cord-Stromal Tumor', 'Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm']","['bleomycin sulfate', 'Carboplatin', 'Cisplatin', 'Etoposide phosphate', 'Laboratory Biomarker Analysis', 'Paclitaxel']","['B8952', 'B274', 'B49', 'B98', 'B1250']","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['DNA'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Tubulin beta-1 chain']]","[[], ['DNA'], ['DNA'], ['TOP2'], ['TUBB1']]"
17956,NCT01216436,Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma,Phase 1 Study of Local Modulation of Immune Receptor Function to Enhance Immune Responses to Dendritic Cell Vaccination in Subjects With Metastatic Melanoma,PHASE1,TERMINATED,31/1/2010,31/10/2013,31/10/2013,2,ACTUAL,,,['Metastatic Melanoma'],['Autologous OFA-iLRP RNA-Transfected Dendritic Cell Vaccine'],[],[],[],[],[]
18269,NCT01246427,Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer,Placebo-controlled Evaluation of the Homeopathic Drug BRN01 for the Treatment of Hot Flashes in Women With Non Metastatic Breast Cancer Treated by Adjuvant Hormonal Therapy,PHASE3,COMPLETED,31/1/2010,30/11/2014,31/5/2014,138,ACTUAL,,,['Breast Cancer'],"['Homeopathy Therapy', 'Placebo Control']",[],[],[],[],[]
16180,NCT01024920,Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.,"A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer",PHASE2,COMPLETED,16/12/2009,19/6/2020,8/11/2011,99,ACTUAL,,,['Non-Clear Cell Renal Cell Carcinoma'],"['Nintedanib', 'Sunitinib']","['B1705', 'B1915']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'Tyrosine-protein kinase receptor FLT3', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Platelet-derived growth factor receptor beta', 'RTK inhibitors(Receptor protein-tyrosine kinase inhibitors)', 'Vascular endothelial growth factor receptor']]","[['FGFR1', 'FGFR2', 'FGFR3', 'PDGFRÎ±', 'PDGFRÎ²', 'FLT3', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['PDGFRÎ²', 'RTK', 'VEGFR']]"
16479,NCT01059552,Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC),Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC),PHASE1,COMPLETED,16/12/2009,21/10/2019,22/7/2015,18,ACTUAL,,,['Non-Small Cell Lung Cancer'],['Vorinostat'],['B2107'],[['Small Molecule']],[['Small Molecule']],[['Histone deacetylase']],[['HDAC']]
17607,NCT01183494,A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients,A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients,PHASE1,COMPLETED,12/12/2009,2/6/2017,2/6/2017,17,ACTUAL,,,['Colorectal Cancer'],"['Bevacizumab', 'Irinotecan', 'Fluorouracil/folinic-acid']","['B167', 'B1679', 'B4749']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Vascular endothelial growth factor A'], ['DNA topoisomerase I'], ['Thymidylate synthase']]","[['VEGF-A'], ['TOP1'], ['TYMS']]"
16056,NCT01013740,Lapatinib in Combination With Vinorelbine,"A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination With Vinorelbine or Capecitabine in Women With ErbB2 Overexpressing Metastatic Breast Cancer",PHASE2,COMPLETED,25/11/2009,1/3/2016,21/8/2012,112,ACTUAL,,,['Cancer'],"['Vinorelbine', 'Lapatinib', 'Capecitabine']","['B1929', 'B1930', 'B474']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2'], ['Thymidylate synthase']]","[['TUBB1'], ['EGFR', 'HER2'], ['TYMS']]"
16125,NCT01019382,A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer,Phase II Trial of the Effect of Gemcitabine With Intravenous Omega-3 Fish Oil Infusion in Patients With Unresectable Pancreatic Adenocarcinoma,PHASE2,COMPLETED,31/10/2009,30/6/2014,30/6/2014,50,ACTUAL,,,['Pancreatic Cancer'],"['Gemcitabine', 'Fish oil']","['B2079', 'B1120']","[['Small Molecule'], []]","[['Small Molecule'], []]","[['DNA', 'Ribonucleotide reductase'], []]","[['DNA', 'RNR'], []]"
13722,NCT00788697,SonoVueÂ®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization,"Characterization of Focal Liver Lesions With SONOVUEÂ®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Un-enhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard",PHASE3,COMPLETED,30/9/2009,31/7/2013,31/7/2013,349,ACTUAL,,,['Liver Cancer'],"['Sulfur hexafluoride', 'Contrast-Enhanced Ultrasound', 'Unenhanced ultrasound']",['B483'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
15731,NCT00982436,Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer,A Pilot Study to Evaluate Response to Neoadjuvant Chemotherapy With Cisplatin and Docetaxel Followed by Chemoradiation Therapy With Carboplatin in Stage IV Non-metastatic Head and Neck Cancer,PHASE1/PHASE2,UNKNOWN,30/9/2009,31/12/2012,30/9/2012,37,ESTIMATED,,,['Head and Neck Neoplasm'],"['Docetaxel', 'Cisplatin', 'Radiation Therapy', 'Carboplatin']","['B2814', 'B49', 'B274']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['DNA'], ['DNA']]","[['TUBB1'], ['DNA'], ['DNA']]"
17397,NCT01160484,"Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma","A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma",PHASE2,COMPLETED,30/9/2009,30/9/2012,31/12/2011,40,ACTUAL,,,['Multiple Myeloma'],"['Dexamethasone', 'Bortezomib', 'Pegylated Liposomal Doxorubicin Hydrochloride', 'Lenalidomide']","['B1128', 'B958', 'B2071']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Molecular glue']]","[['Glucocorticoid receptor'], ['Proteasome'], ['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos']]","[['GR'], ['Proteasome'], ['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3']]"
15416,NCT00952289,COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",PHASE3,COMPLETED,31/8/2009,31/10/2015,30/11/2010,309,ACTUAL,,,['Myeloproliferative Neoplasm'],"['Ruxolitinib', 'Placebo Control']",['B481'],[['Small Molecule']],[['Small Molecule']],"[['Tyrosine-protein kinase JAK1', 'Tyrosine-protein kinase JAK2']]","[['JAK1', 'JAK2']]"
58044,NCT00838513,Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS),"An Open-label, Multi-center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (AHUS)",PHASE2,COMPLETED,31/7/2009,31/12/2013,31/10/2010,15,ACTUAL,,,['Atypical Hemolytic Uremic Syndrome'],['Eculizumab'],['B195'],[['Antibody']],[['Monoclonal Antibody']],[[]],[['C5']]
15158,NCT00927589,A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer,"A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer",PHASE1,COMPLETED,31/7/2009,28/2/2013,28/2/2013,59,ACTUAL,,,['Epithelial Neoplasm'],"['Carboplatin', 'Docetaxel', 'Trastuzumab']","['B274', 'B2814', 'B168']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['DNA'], ['Tubulin beta-1 chain'], ['Receptor protein-tyrosine kinase erbB-2']]","[['DNA'], ['TUBB1'], ['HER2']]"
15217,NCT00933374,Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma,"A Single Arm, Multi-center Phase II Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma After Failure of Prior Platin-based Chemotherapy",PHASE2,TERMINATED,31/7/2009,30/9/2013,31/1/2013,28,ACTUAL,,,['Bladder Cancer'],"['Paclitaxel', 'Everolimus']","['B1250', 'B511']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['Mammalian target of Rapamycin', 'mTOR Complex 2']]","[['TUBB1'], ['mTORC1', 'mTORC2']]"
15517,NCT00961896,"A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients","A Double-blind, Randomized, Vehicle-controlled Proof of Concept (PoC) Study to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Topical Administrations of LDE225 (a Specific Smoothened Inhibitor) on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients Followed by an Open Label, Randomized Expansion Group to Test Two Different Strengths of an Improved LDE225 Formulation for Extended Treatment Durations",PHASE2,COMPLETED,31/7/2009,,31/8/2010,18,ACTUAL,,,['Skin Basal Cell Carcinoma'],"['Drug Vehicle', 'Sonidegib']",['B593'],[['Small Molecule']],[['Small Molecule']],[['Smoothened receptor']],[['SMO']]
15520,NCT00962507,Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,"A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma",PHASE1,COMPLETED,31/7/2009,31/1/2013,31/1/2013,11,ACTUAL,,,"['Hematology', 'Plasma Cell Neoplasm']","['Everolimus', 'Panobinostat', 'Laboratory Biomarker Analysis']","['B511', 'B1683']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Mammalian target of Rapamycin', 'mTOR Complex 2'], ['Hypoxia-inducible factor 1 alpha', 'Vascular endothelial growth factor']]","[['mTORC1', 'mTORC2'], ['HDACs', 'HIF-1Î±', 'VEGF']]"
48928,NCT05278728,Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer,Phase IIa Study of Nimotuzumab Plus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer With Wild Type K-ras,PHASE1/PHASE2,COMPLETED,31/7/2009,31/12/2013,31/8/2013,31,ACTUAL,,,['Colorectal Cancer'],"['Nimotuzumab', 'Irinotecan']","['B662', 'B1679']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['DNA topoisomerase I']]","[['EGFR'], ['TOP1']]"
15059,NCT00918723,"Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)",PHASE1/PHASE2,COMPLETED,30/6/2009,31/10/2016,31/10/2016,40,ACTUAL,,,"['Small Lymphocytic Lymphoma', 'Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma', 'Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma', 'Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma', 'Chronic Lymphocytic Leukemia', 'Chronic Lymphocytic Leukemia']","['fludarabine phosphate', 'Cyclophosphamide', 'Rituximab', 'Vorinostat']","['B8555', 'B2818', 'B163', 'B2107']","[[], ['Small Molecule'], ['Antibody'], ['Small Molecule']]","[[], ['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule']]","[[], ['DNA'], ['B-lymphocyte antigen CD20'], ['Histone deacetylase']]","[[], ['DNA'], ['CD20'], ['HDAC']]"
15296,NCT00940784,Clopidogrel and Aspirin for the Treatment of Polycythemia Vera,"MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera",PHASE2,WITHDRAWN,30/6/2009,31/1/2011,31/1/2011,0,ACTUAL,,,['Polycythemia Vera'],"['Clopidogrel', 'Aspirin', 'Hydroxycarbamide', 'Placebo Control']","['B473', 'B856', 'B3055']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Cyclooxygenases'], ['Ribonucleotide reductase']]","[['P2Y12 receptor'], ['COX'], ['RNR']]"
20793,NCT01528501,Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008),"An Open-label, Uncontrolled Phase II Trial of HDAC-Inhibitor LBH589 in Patients With Chemo-refractory Metastatic Gastric Cancer Overexpressing Histone Deacetylases (HDACs) - CLBH589BDE03T",PHASE2,TERMINATED,30/6/2009,,28/2/2013,28,ESTIMATED,,,['Gastric Cancer'],['Panobinostat'],['B1683'],[['Small Molecule']],[['Small Molecule']],"[['Hypoxia-inducible factor 1 alpha', 'Vascular endothelial growth factor']]","[['HDACs', 'HIF-1Î±', 'VEGF']]"
13911,NCT00807170,Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases,A Phase I Study of ZD6474 (Vandetanib) Concurrent With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Patients With Non-small Cell Lung Cancer (NSCLC),PHASE1,TERMINATED,31/5/2009,31/8/2010,31/8/2010,5,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Vandetanib', 'Whole-Brain Radiotherapy']",['B854'],[['Small Molecule']],[['Small Molecule']],"[['Epidermal growth factor receptor erbB1', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 2']]","[['EGFR', 'RET', 'VEGFR2']]"
14992,NCT00911326,Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma,"A Ph 3, Prospective, Open-Label, Multicenter Study of LymphoseekÂ®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma",PHASE3,TERMINATED,31/5/2009,31/8/2013,31/8/2013,101,ACTUAL,,,['Head and Neck Squamous Cell Carcinoma'],['Tc 99m tilmanocept'],['B2197'],[['Imaging']],[['Imaging Agent']],[['Macrophage mannose receptor 1']],[['CD206']]
20068,NCT01449344,Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL,"Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma",PHASE3,UNKNOWN,9/5/2009,31/12/2018,31/12/2018,128,ACTUAL,,,['Mantle Cell Lymphoma'],"['Rituximab', 'Cytarabine', 'Dexamethasone', 'Bortezomib']","['B163', 'B2050', 'B1128', 'B958']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['B-lymphocyte antigen CD20'], ['DNA-directed DNA polymerase'], ['Glucocorticoid receptor'], ['Proteasome']]","[['CD20'], ['DNA-directed DNA polymerase'], ['GR'], ['Proteasome']]"
14181,NCT00833040,"A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain","A Multicenter, Randomized, Placebo-Controlled, Crossover Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 Compared to Placebo in the Treatment of Cancer Breakthrough Pain",PHASE2,COMPLETED,30/4/2009,31/3/2010,31/3/2010,34,ACTUAL,,,"['Cancer', 'Connective and Soft Tissue Neoplasm']","['Sufentanil', 'Placebo Control']",['B1995'],[['Small Molecule']],[['Small Molecule']],[['Opioid receptors']],[['Opioid receptors']]
14538,NCT00868478,The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL),Phase I-II Trial of the Anti CD74 Monoclonal Antibody-Milatuzumab as a Single Agent in Refractory Chronic Lymphocytic Leukemia,PHASE1/PHASE2,UNKNOWN,30/4/2009,30/4/2012,30/4/2011,15,ESTIMATED,,,['Chronic Lymphocytic Leukemia'],['Milatuzumab'],['B437'],[['Antibody']],[['Monoclonal Antibody']],[['HLA-DR antigens-associated invariant chain']],[['CD74']]
22450,NCT01729663,"Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients","Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients",PHASE2/PHASE3,UNKNOWN,30/4/2009,,31/12/2018,108,ESTIMATED,,,['Skin Melanoma'],"['Allogeneic Irradiated Melanoma Cell Vaccine CSF470', 'BCG vaccine', 'Molgramostim', 'Interferon-alpha-2']","['B722', 'B734', 'B5612']","[['Live biotherapeutics'], ['Other Protein Therapy'], []]","[['Live biotherapeutics'], ['Colony-Stimulating Factor'], []]","[[], ['Granulocyte-macrophage colony-stimulating factor receptor'], ['Interferon alpha/beta receptor']]","[[], ['CSF-2R'], ['IFNAR']]"
14415,NCT00858429,Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases,Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver,PHASE1,COMPLETED,1/4/2009,8/7/2014,19/3/2014,18,ACTUAL,,,"['Liver Cancer', 'Anal Cancer']","['Capecitabine', 'Yttrium Y 90 Glass Microspheres']",['B474'],[['Small Molecule']],[['Small Molecule']],[['Thymidylate synthase']],[['TYMS']]
13101,NCT00723398,Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention,Combination of Low Dose Antiestrogens With Omega-3 Fatty Acids for Prevention of Hormone-independent Breast Cancer,,COMPLETED,31/3/2009,30/4/2015,30/4/2015,266,ACTUAL,,,['Breast Cancer'],"['Omega-3-acid ethyl esters', 'Raloxifene']","['B101', 'B2055']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[[], ['Estrogen receptor beta', 'Estrogen receptors']]","[['Lipid', 'Triglyceride'], ['ERÎ²', 'ER']]"
14499,NCT00866177,MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma,Phase II Trial of Hyd-sulfate AZD6244 [NSC 748727] in Patients With BRAF or NRAS Mutated Melanomas,PHASE2,COMPLETED,31/3/2009,30/9/2013,30/9/2013,167,ACTUAL,,,"['Skin Melanoma', 'Skin Melanoma', 'Skin Melanoma']","['Laboratory Biomarker Analysis', 'Selumetinib']",['B360'],[['Small Molecule']],[['Small Molecule']],"[['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2']]","[['MEK1', 'MEK2']]"
14519,NCT00867061,"Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)","A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 5-day Continuous Intravenous Dosing Of ON 01910.Na Administered Every 2 Weeks in Patients With Intermediate-1, Intermediate-2, or High Risk Myelodysplastic Syndrome (MDS)",PHASE1/PHASE2,WITHDRAWN,31/3/2009,30/9/2010,30/6/2010,0,ACTUAL,,,['Myelodysplastic Syndrome'],['Rigosertib Sodium'],[],[],[],[],[]
15197,NCT00931450,Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer,"Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer.",PHASE1/PHASE2,UNKNOWN,31/3/2009,,31/10/2011,70,ESTIMATED,,,['Breast Cancer'],"['Exemestane', 'sunitinib malate', 'Placebo Control']","['B86', 'B9127']","[['Small Molecule'], []]","[['Small Molecule'], []]","[['Aromatase'], []]","[['aromatase'], []]"
22806,NCT01775423,A Study of BBI608 in Adult Patients With Advanced Malignancies,A Phase I Clinical Study of BBI608 in Adult Patients With Advanced Malignancies,PHASE1,COMPLETED,31/3/2009,6/8/2015,6/8/2015,87,ACTUAL,,,['Solid Tumors'],['Napabucasin'],['B1984'],[['Small Molecule']],[['Small Molecule']],[['Signal transducer and activator of transcription 3']],[['STAT3']]
14068,NCT00821886,Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer,Phase II Study of Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer,PHASE2,COMPLETED,28/2/2009,31/10/2014,31/7/2011,60,ACTUAL,,,['Breast Cancer'],"['Ixabepilone', 'Trastuzumab', 'Carboplatin']","['B186', 'B168', 'B274']","[['Small Molecule'], ['Antibody'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['Receptor protein-tyrosine kinase erbB-2'], ['DNA']]","[['TUBB1'], ['HER2'], ['DNA']]"
14179,NCT00832819,E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC),E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC),PHASE1,COMPLETED,28/2/2009,31/10/2011,31/7/2011,28,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Lenvatinib', 'Paclitaxel', 'Carboplatin']","['B261', 'B1250', 'B274']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Fibroblast growth factor receptor 1', 'Fibroblast growth factor receptor 2', 'Fibroblast growth factor receptor 3', 'Fibroblast growth factor receptor 4', 'Platelet-derived growth factor receptor alpha', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Tubulin beta-1 chain'], ['DNA']]","[['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'PDGFRÎ±', 'c-Kit', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['TUBB1'], ['DNA']]"
14297,NCT00846508,Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis,Phase III Randomized Trial of Comparing CCRT vs. RT Alone for Cervical Cancer Patients Primarily Treated by Radiotherapy and With Clinically Defined Good-prognosis,PHASE3,UNKNOWN,28/2/2009,31/1/2013,31/1/2012,208,ESTIMATED,,,['Cervical Cancer'],['Cisplatin'],['B49'],[['Small Molecule']],[['Small Molecule']],[['DNA']],[['DNA']]
18079,NCT01227408,"Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer","Phase II Clinical Trial of Neoadjuvant Weekly Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer",PHASE2,WITHDRAWN,28/2/2009,28/2/2011,28/2/2010,0,ACTUAL,,,['Breast Cancer'],"['Doxorubicin', 'Paclitaxel poliglumex', 'Capecitabine', 'Cyclophosphamide', 'Methotrexate']","['B1914', 'B689', 'B474', 'B2818', 'B997']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Top II inhibitors (Topoisomerase II inhibitors)'], ['Tubulin beta-1 chain'], ['Thymidylate synthase'], ['DNA'], ['Dihydrofolate reductase']]","[['TOP2'], ['TUBB1'], ['TYMS'], ['DNA'], ['DHFR']]"
15105,NCT00923247,"A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)","A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)",PHASE1/PHASE2,TERMINATED,19/2/2009,9/12/2016,1/4/2016,22,ACTUAL,,,['Thyroid Gland Medullary Carcinoma'],"['Bortezomib', 'Vandetanib']","['B958', 'B854']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Proteasome'], ['Epidermal growth factor receptor erbB1', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 2']]","[['Proteasome'], ['EGFR', 'RET', 'VEGFR2']]"
14250,NCT00841555,Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma,A Phase I Trial of Hypofraction Radiotherapy + Temozolomide in the Treatment of Patients With Glioblastoma Multiforme and Anaplastic Astrocytoma of the Brain,PHASE1,COMPLETED,13/2/2009,25/11/2014,13/2/2013,9,ACTUAL,,,['Anaplastic Astrocytoma'],"['Temozolomide', 'Radiation Therapy', 'Hypofractionated Radiation Therapy', 'Intensity-Modulated Radiation Therapy']",['B2056'],[['Small Molecule']],[['Small Molecule']],[['DNA']],[['DNA']]
14347,NCT00850785,Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer,A Pilot Study of Autologous Tumor DRibble Vaccine With Docetaxel in Stage IIIB and IV Non-Small Cell Lung Cancer,PHASE1,COMPLETED,31/1/2009,31/5/2012,31/5/2012,6,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Docetaxel', 'Granulocyte macrophage colony stimulating factor', 'DPV 001']","['B2814', 'B2912', 'B4310']","[['Small Molecule'], [], ['Cancer Vaccine']]","[['Small Molecule'], [], ['Dendritic Cell Vaccine']]","[['Tubulin beta-1 chain'], ['Granulocyte-macrophage colony-stimulating factor receptor'], ['Toll-like receptor']]","[['TUBB1'], ['CSF-2R'], ['TLR']]"
58030,NCT00807872,Radioimmunoimaging of AL Amyloidosis,Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4,PHASE1,COMPLETED,31/12/2008,31/7/2013,31/3/2012,40,ACTUAL,,,['Primary Amyloidosis'],['124I-labeled monoclonal antibody Mu 11-1F4'],['B11441'],[['Antibody']],[['Monoclonal Antibody']],[[]],[[]]
14140,NCT00828841,Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC,A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC),PHASE2,COMPLETED,31/12/2008,31/8/2012,31/7/2012,601,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Cetuximab', 'Paclitaxel', 'Carboplatin', 'Gemcitabine', 'Cisplatin']","['B164', 'B1250', 'B274', 'B2079', 'B49']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['Tubulin beta-1 chain'], ['DNA'], ['DNA', 'Ribonucleotide reductase'], ['DNA']]","[['EGFR'], ['TUBB1'], ['DNA'], ['DNA', 'RNR'], ['DNA']]"
14175,NCT00832520,Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight,INST 0816: Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight,PHASE2,TERMINATED,30/11/2008,30/6/2011,31/7/2010,13,ACTUAL,,,['Digestive System Neoplasm'],['Mirtazapine'],['B1991'],[['Small Molecule']],[['Small Molecule']],[['Adrenergic receptors alpha-2']],[['ADRA2']]
14941,NCT00906750,A Study of a Live Intranasal Influenza Vaccine in Children With Cancer,"A Pilot Study of Flumist, a Live Attenuated Intranasal Influenza Vaccine, and Inactivated Influenza Vaccine in Children With Cancer",PHASE1,COMPLETED,31/10/2008,31/7/2011,31/7/2011,56,ACTUAL,,,['Cancer'],"['Trivalent Live-Attenuated Influenza Vaccine', 'Influenza vaccine']",['B4643'],[[]],[[]],[[]],[[]]
13170,NCT00729833,"Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors","Phase 1, Open Label, Sequential Cohort, Dose Escalation Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors",PHASE1,TERMINATED,30/9/2008,30/4/2013,31/8/2011,45,ACTUAL,,,"['Digestive System Neoplasm', 'Solid Tumors']","['Figitumumab', 'Sunitinib']","['B424', 'B1915']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Insulin-like growth factor I receptor'], ['Platelet-derived growth factor receptor beta', 'RTK inhibitors(Receptor protein-tyrosine kinase inhibitors)', 'Vascular endothelial growth factor receptor']]","[['IGF-1R'], ['PDGFRÎ²', 'RTK', 'VEGFR']]"
58057,NCT00860600,Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients,The Clinical Trial of PG2 in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP),PHASE2,COMPLETED,30/9/2008,31/8/2011,31/8/2011,14,ACTUAL,,,['Essential Thrombocythemia'],['PG 2'],['B4176'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
14708,NCT00882973,Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer,,PHASE1,COMPLETED,30/9/2008,30/11/2010,31/8/2009,18,ACTUAL,,,['Pancreatic Cancer'],['Paclitaxel'],['B1250'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
17766,NCT01198392,Trial of S-1 Plus Cisplatin in Gastric Cancer,A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer,PHASE3,UNKNOWN,30/9/2008,31/12/2011,31/12/2011,270,ESTIMATED,,,['Gastric Cancer'],"['Gimeracil/oteracil/tegafur', 'Cisplatin', 'Fluorouracil']","['B2855', 'B49', 'B493']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Thymidylate synthase'], ['DNA'], ['Thymidylate synthase']]","[['TYMS'], ['DNA'], ['TYMS']]"
13367,NCT00750841,Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours,"A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINâ„¢), in Patients With Advanced Solid Tumours",PHASE1,ACTIVE_NOT_RECRUITING,9/9/2008,31/12/2025,30/7/2009,64,ACTUAL,,,['Solid Tumors'],"['Cediranib', 'Rifampicin']","['B1693', 'B3413']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], []]","[['VEGFR1', 'VEGFR2', 'VEGFR3'], ['RNAP']]"
13213,NCT00733850,Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer,"A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine (G+K) Versus Gemcitabine in Patients With Advanced Pancreatic Cancer",PHASE2,COMPLETED,31/8/2008,30/6/2014,30/6/2014,85,ACTUAL,,,['Pancreatic Cancer'],"['Kanglaite', 'Gemcitabine']","['B4083', 'B2079']","[['Herbal/Traditional Chinese Medicine'], ['Small Molecule']]","[['Herbal/Traditional Chinese Medicine'], ['Small Molecule']]","[['Apoptosis-mediating surface antigen FAS', 'Apoptosis regulator Bcl-2'], ['DNA', 'Ribonucleotide reductase']]","[['FasR', 'Bcl-2'], ['DNA', 'RNR']]"
13472,NCT00764517,"Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma","Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma",PHASE2,COMPLETED,31/8/2008,31/3/2017,31/1/2015,57,ACTUAL,,,"['B-Cell Non-Hodgkin Lymphoma', 'Chronic Lymphocytic Leukemia', 'Non-Hodgkin Lymphoma', 'B-Cell Non-Hodgkin Lymphoma']","['Cladribine', 'Laboratory Biomarker Analysis', 'Rituximab', 'Vorinostat']","['B365', 'B163', 'B2107']","[['Small Molecule'], ['Antibody'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Ribonucleotide reductase'], ['B-lymphocyte antigen CD20'], ['Histone deacetylase']]","[['RNR'], ['CD20'], ['HDAC']]"
13700,NCT00786812,"Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase","An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",PHASE4,COMPLETED,31/8/2008,31/1/2012,31/1/2012,89,ACTUAL,,,['Chronic Myeloid Leukemia'],['Nilotinib'],['B861'],[['Small Molecule']],[['Small Molecule']],"[['Bcr-Abl tyrosine kinase', 'Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor']]","[['BCR-ABL1', 'PDGFRÎ²', 'c-Kit']]"
12505,NCT00669565,Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer,A Phase II Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Locally Advanced or Metastatic Breast Cancer,PHASE2,COMPLETED,31/7/2008,31/8/2010,31/7/2010,46,ACTUAL,,,['Breast Cancer'],"['Bavituximab', 'Carboplatin', 'Paclitaxel']","['B404', 'B274', 'B1250']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Phosphatidylserine'], ['DNA'], ['Tubulin beta-1 chain']]","[['Phosphatidylserine'], ['DNA'], ['TUBB1']]"
13263,NCT00738764,A Trial of PDL192 in Subjects With Advanced Solid Tumors,"A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors",PHASE1,COMPLETED,31/7/2008,31/10/2011,31/10/2011,30,ACTUAL,,,['Cancer'],['Enavatuzumab'],['B419'],[['Antibody']],[['Monoclonal Antibody']],[['TNF superfamily receptor 12A']],[['TWEAKR']]
14937,NCT00906360,"Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck","A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUXÂ®), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-risk/Recurrent Poor Prognosis Head and Neck Cancer",PHASE1,TERMINATED,31/7/2008,,30/9/2012,36,ACTUAL,,,"['Head and Neck Squamous Cell Carcinoma', 'Carcinoma of Unknown Primary', 'Salivary Gland Cancer', 'Hypopharyngeal Cancer', 'Laryngeal Cancer', 'Lip and Oral Cavity Cancer', 'Epithelial Neoplasm', 'Oropharyngeal Cancer', 'Head and Neck Squamous Cell Carcinoma', 'Laryngeal Cancer', 'Lip and Oral Cavity Cancer', 'Salivary Gland Cancer', 'Salivary Gland Cancer', 'Hypopharyngeal Cancer', 'Laryngeal Cancer', 'Lip and Oral Cavity Cancer', 'Nasopharyngeal Cancer', 'Oropharyngeal Cancer', 'Head and Neck Squamous Cell Carcinoma', 'Laryngeal Cancer', 'Lip and Oral Cavity Cancer', 'Salivary Gland Cancer', 'Hypopharyngeal Cancer', 'Laryngeal Cancer', 'Lip and Oral Cavity Cancer', 'Head and Neck Squamous Cell Carcinoma', 'Oropharyngeal Cancer', 'Head and Neck Squamous Cell Carcinoma', 'Laryngeal Cancer', 'Lip and Oral Cavity Cancer', 'Lip and Oral Cavity Cancer', 'Epithelial Neoplasm']","['sunitinib malate', '3-Dimensional Conformal Radiation Therapy', 'Cetuximab']","['B9127', 'B164']","[[], ['Antibody']]","[[], ['Monoclonal Antibody']]","[[], ['Epidermal growth factor receptor erbB1']]","[[], ['EGFR']]"
13084,NCT00722293,"A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors","A Phase I, Open-label, Study of the Safety, Pharmacokinetics, and Pharmacodynamics Dose Escalation of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors",PHASE1,COMPLETED,8/7/2008,25/2/2014,11/6/2012,111,ACTUAL,,,['Breast Neoplasm'],"['Doxorubicin', 'Pazopanib', 'Epirubicin']","['B1914', 'B1649', 'B1236']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Top II inhibitors (Topoisomerase II inhibitors)'], ['Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)']]","[['TOP2'], ['PDGFRÎ±', 'PDGFRÎ²', 'c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['DNA', 'TOP2']]"
57938,NCT00642967,A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis,"A Single Arm, Open Label, French Multi-centre Study to Assess the Maintenance of Hemoglobin Levels With Once Monthly Subcutaneous Administration of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Patients With Chronic Kidney Disease Not on Dialysis",PHASE3,COMPLETED,30/6/2008,31/8/2010,31/8/2010,127,ACTUAL,,,['Anemia'],['Methoxy Polyethylene Glycol-Epoetin beta'],[],[],[],[],[]
12687,NCT00684996,Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer,A Phase I and a Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) With or Without MEDI-522 (NSC-719850),PHASE1/PHASE2,TERMINATED,30/6/2008,31/10/2010,31/10/2010,5,ACTUAL,,,"['Renal Cell Carcinoma', 'Renal Cell Carcinoma', 'Renal Cell Carcinoma', 'Renal Cell Carcinoma']","['Etaracizumab', 'Bevacizumab']","['B1826', 'B167']","[['Antibody'], ['Antibody']]","[['Monoclonal Antibody'], ['Monoclonal Antibody']]","[['Integrin alpha-V/beta-3'], ['Vascular endothelial growth factor A']]","[['Î±vÎ²3'], ['VEGF-A']]"
12748,NCT00691054,Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy,Phase II Trial of AbraxaneÂ® in the Treatment of Patients With Pancreatic Cancer Who Have Failed First-Line Treatment With Gemcitabine-Based Therapy,PHASE2,COMPLETED,30/6/2008,31/12/2012,31/12/2012,20,ACTUAL,,,['Pancreatic Cancer'],['Nab-paclitaxel'],['B7744'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
12816,NCT00698009,Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma,Study to Infuse Haploidentical Natural Killer Cells in Patients With Relapsed or Refractory Neuroblastoma,PHASE2,TERMINATED,30/6/2008,30/6/2012,30/6/2012,1,ACTUAL,,,['Kidney Wilms Tumor'],"['Fludarabine', 'Cyclophosphamide', 'Natural killer cell therapy', 'Mesna', 'Interleukin-2']","['B346', 'B2818', 'B3147', 'B2825', 'B2881']","[['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], []]","[['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA'], [], [], []]","[['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA'], [], [], []]"
12858,NCT00702494,Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours,"An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.",PHASE1,COMPLETED,30/6/2008,30/9/2009,30/9/2009,21,ESTIMATED,,,['Solid Tumors'],['THR 317'],['B2229'],[['Antibody']],[['Monoclonal Antibody']],[['Phosphatidylinositol glycan synthesis F']],[['PIGF']]
13002,NCT00715793,Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma,Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma,PHASE1/PHASE2,COMPLETED,30/6/2008,31/8/2015,31/5/2015,39,ACTUAL,,,['Malignant Melanoma'],"['Decitabine', 'Temozolomide', 'Biopsy']","['B113', 'B2056']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA', 'DNA (cytosine-5)-methyltransferase 3A', 'DNA (cytosine-5)-methyltransferase 3B'], ['DNA']]","[['DNMT1', 'DNMT3A', 'DNMT3B'], ['DNA']]"
23991,NCT01922492,Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.,Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug in Partially Pancreatectomized Patients Due to Benign Pancreatic Neoplasm.,,UNKNOWN,31/5/2008,31/12/2017,31/12/2017,28,ACTUAL,,,['Digestive System Neoplasm'],"['Autologous Islet Cell Transplantation', 'Metformin', 'Vildagliptin']","['B298', 'B297']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Protein kinase AMP-activated non-catalytic subunit beta 1'], ['Dipeptidyl peptidase IV']]","[['PRKAB1'], ['DPP-4']]"
12456,NCT00666081,Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies,"A Phase I Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Potential Anti-cancer Activity of the AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies",PHASE1,WITHDRAWN,30/4/2008,31/12/2009,31/12/2009,0,ACTUAL,,,['Cancer'],['GSK 690693'],['B2664'],[['Small Molecule']],[['Small Molecule']],[[]],[['AKT']]
12609,NCT00677144,Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer,A Randomized Phase II Study of Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Advanced or Recurrent Colorectal Cancer,PHASE2,COMPLETED,30/4/2008,30/4/2012,30/4/2012,88,ACTUAL,,,['Digestive System Neoplasm'],"['Oxaliplatin', 'Gimeracil/oteracil/tegafur', 'Capecitabine']","['B1229', 'B2855', 'B474']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Thymidylate synthase'], ['Thymidylate synthase']]","[['DNA'], ['TYMS'], ['TYMS']]"
12063,NCT00629057,A Safety Trial of MVA-BNÂ®-PRO in Men With Androgen-Insensitive Prostate Cancer,"An Open-Label, Phase I Dose Escalation Trial of MVA-BNÂ®-PRO in Men With Androgen-Insensitive Prostate Cancer",PHASE1,COMPLETED,31/3/2008,30/9/2011,31/12/2010,24,ACTUAL,,,['Androgen-insensitive Prostate Cancer'],['MVA-BN-PRO'],['B6315'],[[]],[[]],[[]],[[]]
12145,NCT00634894,"Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","A Phase II, Double-Blinded, Randomized Evaluation of Femara (Letrozole) Versus Placebo for Adjuvant Treatment After Completion of First-Line Chemotherapy for Patients With Optimally Debulked and Chemoresponsive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",PHASE2,WITHDRAWN,31/3/2008,30/9/2008,30/9/2008,0,ACTUAL,,,"['Ovarian Cancer', 'Fallopian Tube Cancer', 'Peritoneal and Retroperitoneal Neoplasm']","['Letrozole', 'Placebo Control']",['B302'],[['Small Molecule']],[['Small Molecule']],"[['Aromatase', 'Estrogen receptors']]","[['aromatase', 'ER']]"
20011,NCT01442909,Pemetrexed Followed by Docetaxel or in Reverse Sequence,Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy,PHASE4,COMPLETED,31/3/2008,30/9/2009,30/9/2009,44,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Docetaxel', 'Pemetrexed']","['B2814', 'B814']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase']]","[['TUBB1'], ['DHFR', 'GART', 'TYMS']]"
11909,NCT00615589,Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen,Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen,PHASE2,TERMINATED,29/2/2008,31/1/2013,31/12/2012,22,ACTUAL,,,"['Multiple Myeloma', 'Plasma Cell Leukemia']","['Fludarabine', 'Busulfan', 'Hematopoietic Cell Transplantation']","['B346', 'B2060']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA']]","[['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA']]"
12011,NCT00624182,Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer,"Phase 1 Study of Gemcitabine With Vaccine Therapy Targeting Tumor Antigen, URLC10, For The Patients With Unresectable or Recurrent Bile Duct Cancer",PHASE1,SUSPENDED,29/2/2008,31/12/2016,30/4/2016,9,ESTIMATED,,,['Bile Duct Cancer'],"['URLC10 peptide vaccine', 'Gemcitabine']","['B3327', 'B2079']","[['Subunit Vaccine'], ['Small Molecule']]","[['Subunit Vaccine'], ['Small Molecule']]","[[], ['DNA', 'Ribonucleotide reductase']]","[[], ['DNA', 'RNR']]"
11729,NCT00602030,Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC,"A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease",PHASE1/PHASE2,COMPLETED,8/1/2008,1/2/2012,4/2/2010,141,ACTUAL,,,"['Non-Small Cell Lung Cancer', 'Non-Small Cell Lung Cancer']","['Entinostat', 'Erlotinib']","['B882', 'B1928']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[[], ['Epidermal growth factor receptor erbB1']]","[['HDACs'], ['EGFR L858R', 'EGFR-Ex19del', 'EGFR']]"
58005,NCT00761085,Methadone in Pediatric and Adult Sickle Cell Patients,Methadone in Pediatric and Adult Sickle Cell Patients,,COMPLETED,1/1/2008,7/11/2010,7/11/2010,47,ACTUAL,,,['Sickle Cell Disease'],"['Morphine', 'Methadone']","['B2007', 'B1990']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Kappa opioid receptor', 'Mu opioid receptor'], ['Glutamate [NMDA] receptor', 'Mu opioid receptor']]","[['Î´ opioid receptor', 'Îº opioid receptor', 'Î¼ opioid receptor'], ['NMDA receptor', 'Î¼ opioid receptor']]"
8399,NCT00357760,Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer,A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma,PHASE2,COMPLETED,31/12/2007,31/10/2015,31/10/2015,94,ACTUAL,,,['Renal Cell Carcinoma'],['Aflibercept'],['B401'],[['Small Molecule']],[['Small Molecule']],"[['Placental Growth Factor', 'Vascular endothelial growth factor A']]","[['PGF', 'VEGF-A']]"
11403,NCT00573755,"Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer",Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer,PHASE2,TERMINATED,31/12/2007,30/4/2013,30/4/2013,4,ACTUAL,,,['Breast Cancer'],"['Anastrozole', 'Exemestane', 'Letrozole', 'sorafenib tosylate', 'Placebo Control']","['B289', 'B86', 'B302', 'B8463']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Aromatase'], ['Aromatase'], ['Aromatase', 'Estrogen receptors'], []]","[['aromatase'], ['aromatase'], ['aromatase', 'ER'], []]"
11550,NCT00585845,Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment,"A Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment",PHASE1,TERMINATED,31/12/2007,28/2/2009,28/2/2009,17,ACTUAL,,,"['Malignant Epithelial Mesothelioma', 'Pancreatic Cancer', 'Non-Small Cell Lung Cancer', 'Adenocarcinoma of the Ovaries']",['CRS 207'],['B3496'],[['Oncolytic Bacteria']],[['Oncolytic Bacteria']],[['MSLN inhibitors(Mesothelin inhibitors)']],[['MSLN']]
11892,NCT00613743,Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and/or Radiotherapy Induced Mucositis,Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and/or Radiotherapy Induced Mucositis,,COMPLETED,31/12/2007,31/12/2008,31/1/2008,30,ESTIMATED,,,"['Cancer', 'Mucositis']","['Morphine', 'Quinine Hydrochloride']",['B2007'],[['Small Molecule']],[['Small Molecule']],"[['Kappa opioid receptor', 'Mu opioid receptor']]","[['Î´ opioid receptor', 'Îº opioid receptor', 'Î¼ opioid receptor']]"
9927,NCT00467051,Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",PHASE2,COMPLETED,5/11/2007,30/6/2018,1/3/2012,20,ACTUAL,,,"['Ovarian Germ Cell Tumor', 'Testicular Germ Cell Cancer', 'Ovarian Cancer', 'Ovarian Germ Cell Tumor', 'Ovarian Germ Cell Tumor', 'Germ Cell Tumor', 'Testicular Germ Cell Cancer', 'Ovarian Germ Cell Tumor', 'Testicular Non-Seminomatous Germ Cell Tumor', 'Testicular Non-Seminomatous Germ Cell Tumor', 'Testicular Germ Cell Cancer', 'Testicular Germ Cell Cancer', 'Testicular Non-Seminomatous Germ Cell Tumor', 'Testicular Non-Seminomatous Germ Cell Tumor', 'Germ Cell Tumor', 'Germ Cell Tumor']","['Carboplatin', 'Filgrastim', 'Ifosfamide', 'Laboratory Biomarker Analysis', 'Paclitaxel']","['B274', 'B157', 'B8', 'B1250']","[['Small Molecule'], ['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Colony-Stimulating Factor'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Colony stimulating factor 3 receptor'], ['DNA'], ['Tubulin beta-1 chain']]","[['DNA'], ['CSF-3R'], ['DNA'], ['TUBB1']]"
9427,NCT00431704,"VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer","Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer, a Phase 2 Study",PHASE2,UNKNOWN,31/10/2007,31/12/2023,31/12/2023,39,ESTIMATED,,,['Brain Metastasis'],"['Vinorelbine', 'Carboplatin', 'Trastuzumab']","['B1929', 'B274', 'B168']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['Tubulin beta-1 chain'], ['DNA'], ['Receptor protein-tyrosine kinase erbB-2']]","[['TUBB1'], ['DNA'], ['HER2']]"
9984,NCT00471445,Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients,Assessment of Topical Treatment Response With Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy (ATTRACT-CPN),PHASE3,COMPLETED,31/10/2007,30/11/2013,30/9/2013,462,ACTUAL,,,"['Neurotoxicity', 'Connective and Soft Tissue Neoplasm', 'Peripheral Neuropathy', 'Solid Tumors']","['Ketamine', 'Amitriptyline', 'Placebo Control']","['B2027', 'B1978']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Glutamate [NMDA] receptor'], ['Norepinephrine transporter', 'Serotonin transporter']]","[['NMDA receptor'], ['NET', 'SERT']]"
10385,NCT00502307,"A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma","A Phase 2, Placebo-Controlled, Randomized, Discontinuation Trial of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma",PHASE2,COMPLETED,31/10/2007,31/8/2010,31/8/2010,272,ACTUAL,,,['Non-Clear Cell Renal Cell Carcinoma'],"['Tivozanib', 'Placebo Control']",['B260'],[['Small Molecule']],[['Small Molecule']],"[['Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['PDGFRÎ²', 'c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
11196,NCT00557609,Phase 2 Study in Patients With MiT Tumors,A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors,PHASE2,COMPLETED,31/10/2007,28/2/2011,31/12/2010,47,ACTUAL,,,"['Renal Cell Carcinoma', 'Alveolar Soft Part Sarcoma', 'Clear Cell Sarcoma']",['Tivantinib'],['B577'],[['Small Molecule']],[['Small Molecule']],[['c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)']],[['c-Met']]
10781,NCT00526799,Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer,A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111,PHASE1/PHASE2,TERMINATED,30/9/2007,31/8/2010,31/1/2010,30,ACTUAL,,,['Ovarian Cancer'],"['Sorafenib', 'Topotecan']","['B270', 'B2067']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['C-Raf kinase', 'Platelet-derived growth factor receptor beta', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['DNA topoisomerase I']]","[['CRAF', 'PDGFRÎ²', 'BRAF', 'c-Kit', 'FLT3', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['TOP1']]"
10792,NCT00527930,Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer,Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer (MBC) Previously Treated With or Resistant to an Anthracycline and Taxane,PHASE2,COMPLETED,30/9/2007,31/10/2013,31/10/2013,87,ACTUAL,,,['Breast Neoplasm'],"['Gimeracil/oteracil/tegafur', 'Oxaliplatin']","['B2855', 'B1229']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Thymidylate synthase'], ['DNA']]","[['TYMS'], ['DNA']]"
10835,NCT00531401,Study of Salirasib to Treat Non-Small Cell Lung Cancer,Salirasib for Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study,PHASE2,COMPLETED,30/9/2007,30/11/2009,30/11/2009,71,ESTIMATED,,,['Non-Small Cell Lung Cancer'],['Salirasib'],['B823'],[['Small Molecule']],[['Small Molecule']],[['GTPase Ras']],[['Ras']]
15431,NCT00954135,Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients,"Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients",PHASE2,UNKNOWN,30/9/2007,31/12/2010,30/6/2010,190,ESTIMATED,,,['Breast Cancer'],"['Letrozole', 'Cyclophosphamide', 'Sorafenib']","['B302', 'B2818', 'B270']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Aromatase', 'Estrogen receptors'], ['DNA'], ['C-Raf kinase', 'Platelet-derived growth factor receptor beta', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['aromatase', 'ER'], ['DNA'], ['CRAF', 'PDGFRÎ²', 'BRAF', 'c-Kit', 'FLT3', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
9627,NCT00446069,A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients,"A Double-blind, Randomized, 2-way Cross-over, Phase II, Efficacy Trial in Cancer Patients to Assess the Overall Efficacy, Patient Preference, Morphine Related Side Effect Profile and Safety of the EgaletÂ® Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST ContinusÂ® 15-120 mg Twice Daily After 2 Weeks of Treatment",PHASE2,COMPLETED,31/8/2007,31/8/2008,30/6/2008,36,ACTUAL,,,"['Connective and Soft Tissue Neoplasm', 'Cancer']",['morphine sulfate'],['B9224'],[[]],[[]],[[]],[[]]
9980,NCT00471276,Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer,A Phase II Study Of Sunitinib Malate Single Agent For The Treatment Of Women With Advanced Breast Cancer,PHASE2,COMPLETED,31/8/2007,30/6/2010,30/6/2010,83,ACTUAL,,,['Breast Neoplasm'],['Sunitinib'],['B1915'],[['Small Molecule']],[['Small Molecule']],"[['Platelet-derived growth factor receptor beta', 'RTK inhibitors(Receptor protein-tyrosine kinase inhibitors)', 'Vascular endothelial growth factor receptor']]","[['PDGFRÎ²', 'RTK', 'VEGFR']]"
14327,NCT00849186,Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer,A Pilot Study of Neoadjuvant SUNITINIB MALATE (Sunitinib) in Patients With Renal Cell Carcinoma Undergoing Nephrectomy,,COMPLETED,31/8/2007,30/4/2010,31/7/2009,20,ACTUAL,,,['Kidney Cancer'],"['sunitinib malate', 'Neoadjuvant Therapy', 'Therapeutic Conventional Surgery']",['B9127'],[[]],[[]],[[]],[[]]
18490,NCT01268163,The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer,"A Phase 1, Double-blinded, Randomised, Multi-centre, Three-period, Three-treatment, Crossover Study to Compare the Intravenous Pharmacokinetic and Safety Characteristics of European TaxotereÂ® and American TaxotereÂ® With Hospira Docetaxel Injection Administered at a Therapeutic Dose in Cancer Patients.",PHASE1,COMPLETED,31/8/2007,31/12/2008,31/12/2008,32,ACTUAL,,,['Cancer'],['Docetaxel'],['B2814'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
22269,NCT01706627,Melatonin In Reduction of Chemotherapy-Induced Toxicity (MIRCIT) Trial,"Melatonin In Cancer Patients Receiving Chemotherapy: A Randomized, Double Blind, Placebo, Controlled Trial",PHASE2/PHASE3,COMPLETED,31/8/2007,30/6/2012,31/12/2011,175,ACTUAL,,,['Advanced Stage Cancer'],['Melatonin'],['B1469'],[['Small Molecule']],[['Small Molecule']],[[]],[['Melatonin receptor']]
11303,NCT00565656,"A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts","A Phase II Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to IPSS) With Excess of Marrow Blasts",PHASE2,TERMINATED,31/7/2007,31/7/2010,31/7/2009,40,ESTIMATED,,,['Myelodysplastic Syndrome'],['Bevacizumab'],['B167'],[['Antibody']],[['Monoclonal Antibody']],[['Vascular endothelial growth factor A']],[['VEGF-A']]
8568,NCT00372905,Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma,A Phase I/II Trial of Combined Weekly Bortezomib (VELCADEÂ®) and Y-90-Ibritumomab Tiuxetan (Zevalin) in Patients With Relapsed or Refractory Follicular Lymphoma and Transformed Non-Hodgkin's Lymphoma,PHASE1/PHASE2,TERMINATED,24/7/2007,8/7/2013,22/6/2010,18,ACTUAL,,,['Hematology'],"['Rituximab', 'Bortezomib', 'Indium In-111 Ibritumomab Tiuxetan', 'Yttrium Y-90 Ibritumomab Tiuxetan', 'Ibritumomab tiuxetan']","['B163', 'B958', 'B175']","[['Antibody'], ['Small Molecule'], ['Antibody Drug Conjugate (ADC)']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Antibody Drug Conjugate (ADC)']]","[['B-lymphocyte antigen CD20'], ['Proteasome'], ['B-lymphocyte antigen CD20']]","[['CD20'], ['Proteasome'], ['CD20']]"
9385,NCT00429182,Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer,Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients,PHASE2,COMPLETED,30/6/2007,29/2/2012,29/2/2012,32,ACTUAL,,,"['Breast Cancer', 'Breast Cancer', 'Breast Cancer']","['Carboplatin', 'Cyclophosphamide', 'Thiotepa', 'Hematopoietic Cell Transplantation']","['B274', 'B2818', 'B1998']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['DNA'], ['DNA']]","[['DNA'], ['DNA'], ['DNA']]"
9951,NCT00469859,"Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia",A Pilot Study of Lestaurtinib (CEP-701) in Combination With Chemotherapy in Young Patients With Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia,PHASE1/PHASE2,COMPLETED,30/6/2007,31/3/2010,31/3/2010,14,ACTUAL,,,['Leukemia'],"['Cytarabine', 'Idarubicin', 'Lestaurtinib']","['B2050', 'B41', 'B1968']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA-directed DNA polymerase'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['Tyrosine-protein kinase receptor FLT3']]","[['DNA-directed DNA polymerase'], ['DNA', 'TOP2'], ['FLT3']]"
10018,NCT00474669,A Phase I Study of Intraperitoneal Hyperthermic Docetaxel,A Phase I Study of Intraperitoneal Hyperthermic Docetaxel at the Time of Second Look Surgery Following Front-Line Normothermic Intraperitoneal and Intravenous Cisplatin/Paclitaxel for Patients With Stage II and III Ovarian Carcinoma,PHASE1,COMPLETED,30/6/2007,31/12/2009,31/12/2009,30,ESTIMATED,,,['Ovarian Cancer'],['Docetaxel'],['B2814'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
15140,NCT00925314,A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma,"A Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects With Stage III Melanoma",PHASE2,UNKNOWN,30/6/2007,31/7/2014,31/7/2011,20,ESTIMATED,,,"['Uveal Melanoma', 'Uveal Melanoma']",['Transgenic Lymphocyte Immunization Vaccine'],[],[],[],[],[]
10323,NCT00498407,A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer,A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer,PHASE2,COMPLETED,31/5/2007,31/12/2008,31/12/2008,16,ACTUAL,,,"['Colorectal Cancer', 'Colorectal Cancer']",['Elacytarabine'],['B589'],[['Small Molecule']],[['Small Molecule']],[['DNA']],[['DNA']]
12319,NCT00653848,Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy,Randomized Adjuvant Phase III Trial of Six Cycles of Docetaxel+Hormonal Treatment Versus Hormonal Treatment in Patients With Intermediate or High-risk Prostate Cancer Treated With Radical Radiotherapy,PHASE3,UNKNOWN,31/5/2007,30/8/2023,30/8/2023,378,ACTUAL,,,['Prostate Cancer'],['Docetaxel'],['B2814'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
9919,NCT00466843,Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome,Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS),PHASE2,UNKNOWN,30/4/2007,28/2/2010,28/2/2010,54,ESTIMATED,,,['Myelodysplastic Syndrome'],"['Antithymocyte globulin', 'Prednisone']","['B2844', 'B1979']","[['Other Protein Therapy'], ['Small Molecule']]","[['Immunoglobulin'], ['Small Molecule']]","[[], ['Glucocorticoid receptor']]","[[], ['GR']]"
11338,NCT00568815,Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL),Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL,PHASE2,COMPLETED,30/4/2007,31/12/2010,31/12/2010,31,ACTUAL,,,['Hematology'],"['Rituximab', 'Etoposide', 'Cytarabine', 'Cisplatin', 'Methionine']","['B163', 'B1463', 'B2050', 'B49', 'B1244']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['B-lymphocyte antigen CD20'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA-directed DNA polymerase'], ['DNA'], []]","[['CD20'], ['TOP2'], ['DNA-directed DNA polymerase'], ['DNA'], []]"
11679,NCT00598091,A Phase I/Expansion Study of Dasatinib,A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer,PHASE1,TERMINATED,30/4/2007,31/5/2012,30/6/2010,30,ACTUAL,,,"['Solid Tumors', 'Pancreatic Cancer']","['Gemcitabine', 'Dasatinib']","['B2079', 'B293']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA', 'Ribonucleotide reductase'], ['Bcr-Abl tyrosine kinase', 'Ephrin type-A receptor 2']]","[['DNA', 'RNR'], ['BCR-ABL1', 'EphA2', 'FYN']]"
11968,NCT00620295,Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors,Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227),PHASE1,COMPLETED,31/3/2007,31/10/2009,28/2/2009,17,ACTUAL,,,"['Breast Cancer', 'Colorectal Cancer', 'Head and Neck Neoplasm', 'Kidney Cancer', 'Thoracic Neoplasm', 'Ovarian Cancer', 'Pancreatic Cancer', 'Prostate Cancer', 'Sarcoma']","['Bortezomib', 'Gemcitabine', 'gemcitabine hydrochloride']","['B958', 'B2079', 'B9303']","[['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], []]","[['Proteasome'], ['DNA', 'Ribonucleotide reductase'], []]","[['Proteasome'], ['DNA', 'RNR'], []]"
13097,NCT00723216,Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery,"Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days for Prevention of Venous Thromboembolism in Patients With Curative Abdominal Cancer Surgery. Physical Prophylaxis Only Arm [Intermittent Pneumatic Compression (IPC)] Will be Used as an Indicator of Event Rates.",PHASE3,COMPLETED,31/3/2007,31/12/2007,31/12/2007,151,ACTUAL,,,['Abdominal Neoplasms'],"['enoxaparin', 'Physical prophylaxis']",['B8353'],[[]],[[]],[[]],[[]]
9440,NCT00432562,A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.,A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion (ANX-530) in Patients With Advanced Cancer.,PHASE1,COMPLETED,28/2/2007,31/12/2007,30/11/2007,31,ACTUAL,,,"['Breast Cancer', 'Non-Small Cell Lung Cancer', 'Non-Hodgkin Lymphoma']",['vinorelbine tartrate'],['B9142'],[[]],[[]],[[]],[[]]
9602,NCT00444535,Lapatinib and Bevacizumab for Metastatic Breast Cancer,"A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer",PHASE2,COMPLETED,27/2/2007,19/6/2020,22/7/2008,52,ACTUAL,,,['Breast Neoplasm'],"['Lapatinib', 'Bevacizumab']","['B1930', 'B167']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2'], ['Vascular endothelial growth factor A']]","[['EGFR', 'HER2'], ['VEGF-A']]"
4507,NCT00085098,Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor,Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma,PHASE3,COMPLETED,31/1/2007,31/5/2009,31/5/2009,24,ACTUAL,,,"['Central Nervous System Neoplasm', 'Central Nervous System Neoplasm']","['Filgrastim', 'Carboplatin', 'Cisplatin', 'Cyclophosphamide', 'Etoposide', 'Radiation Therapy']","['B157', 'B274', 'B49', 'B2818', 'B1463']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Colony-Stimulating Factor'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Colony stimulating factor 3 receptor'], ['DNA'], ['DNA'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)']]","[['CSF-3R'], ['DNA'], ['DNA'], ['DNA'], ['TOP2']]"
9044,NCT00406302,Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC),"Multicenter Phase II Study Evaluating Docetaxel, CDDP, and Cetuximab as Induction Regimen Prior to Surgery in Chemo-naive Patients With NSCLC Stage IB, II and IIIA",PHASE2,COMPLETED,31/1/2007,30/6/2011,30/6/2011,41,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Docetaxel', 'Oxaliplatin', 'Cetuximab', 'Surgical Procedure']","['B2814', 'B1229', 'B164']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['Tubulin beta-1 chain'], ['DNA'], ['Epidermal growth factor receptor erbB1']]","[['TUBB1'], ['DNA'], ['EGFR']]"
57782,NCT00434330,Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis,"A Phase 2, Open-Label, Multi-Center, Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin",PHASE2,COMPLETED,31/12/2006,30/4/2008,30/4/2008,91,ACTUAL,,,"['Anemia', 'Chronic Kidney Disease', 'Chronic Renal Failure']","['Peginesatide', 'Epoetin alfa', 'Epoetin beta']","['B625', 'B155', 'B731']","[['Engineered Protein Therapy'], ['Other Protein Therapy'], ['Other Protein Therapy']]","[['Synthetic Peptide'], ['Colony-Stimulating Factor'], ['Colony-Stimulating Factor']]","[['Erythropoietin receptor'], ['Erythropoietin receptor'], ['Erythropoietin receptor']]","[['EPO receptor'], ['EPO receptor'], ['EPO receptor']]"
57783,NCT00434473,IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome,IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients With Sickle Cell Disease and Vaso-occlusive Crisis),PHASE2,COMPLETED,31/12/2006,31/12/2009,31/8/2009,30,ACTUAL,,,"['Sickle Cell Disease', 'Vaso-occlusive Crisis', 'Acute Chest Syndrome']",[],[],[],[],[],[]
13214,NCT00733889,A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma,"Phase II, Multicentre, Uncontrolled Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Chemotherapy (Docetaxel, Cisplatin, 5-fluorouracil) as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy (Cisplatin) Plus Cetuximab in Patients With a Locoregional Esophageal Carcinoma",PHASE2,COMPLETED,31/12/2006,30/11/2012,30/11/2012,50,ACTUAL,,,['Esophageal Cancer'],"['Cetuximab', 'Docetaxel', 'Cisplatin', 'Fluorouracil', 'Radiation Therapy']","['B164', 'B2814', 'B49', 'B493']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['Tubulin beta-1 chain'], ['DNA'], ['Thymidylate synthase']]","[['EGFR'], ['TUBB1'], ['DNA'], ['TYMS']]"
8703,NCT00382733,Oral Topotecan to Treat Recurrent or Persistent Solid Tumors,"Oral Topotecan, Utilization for a Metronomic Dosing Schedule to Treat Recurrent or Persistent Solid Tumors",PHASE1/PHASE2,COMPLETED,30/11/2006,31/3/2011,31/3/2011,26,ACTUAL,,,['Tumors'],['Topotecan'],['B2067'],[['Small Molecule']],[['Small Molecule']],[['DNA topoisomerase I']],[['TOP1']]
8927,NCT00398281,Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer,Detection of Prostate Cancer With Contrast-Enhanced Ultrasound After Treatment With Dutasteride,PHASE3,COMPLETED,30/11/2006,30/9/2012,31/7/2010,450,ESTIMATED,,,['Prostate Cancer'],"['Dutasteride', 'Placebo Control']",['B108'],[['Small Molecule']],[['Small Molecule']],[['Steroid 5 alpha reductase']],[['5Î±-reductase']]
11119,NCT00551512,Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors,Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors,PHASE1,COMPLETED,30/11/2006,31/5/2009,31/5/2009,48,ACTUAL,,,"['Cancer', 'Solid Tumors']","['CBP 501', 'Cisplatin']","['B2420', 'B49']","[['Engineered Protein Therapy'], ['Small Molecule']]","[['Synthetic Peptide'], ['Small Molecule']]","[['Calmodulin'], ['DNA']]","[['CaM'], ['DNA']]"
12032,NCT00625937,Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer,A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer,PHASE2,UNKNOWN,30/11/2006,,30/11/2010,46,ESTIMATED,,,['Head and Neck Neoplasm'],"['Cisplatin', 'Docetaxel', 'Gimeracil/oteracil/tegafur', 'Radiation Therapy']","['B49', 'B2814', 'B2855']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Tubulin beta-1 chain'], ['Thymidylate synthase']]","[['DNA'], ['TUBB1'], ['TYMS']]"
9117,NCT00411138,Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer,Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy With Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3,PHASE3,ACTIVE_NOT_RECRUITING,23/11/2006,31/12/2024,29/11/2018,670,ESTIMATED,,,['Endometrial Cancer'],"['Radiation Therapy', 'Cisplatin', 'Carboplatin', 'Paclitaxel']","['B49', 'B274', 'B1250']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['DNA'], ['Tubulin beta-1 chain']]","[['DNA'], ['DNA'], ['TUBB1']]"
8575,NCT00373373,Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML,"A Double-blind, Placebo-controlled, Randomized, Multi-center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML",PHASE2,COMPLETED,30/9/2006,31/7/2009,31/7/2009,200,ESTIMATED,,,['Acute Myeloid Leukemia'],"['Sorafenib', 'Placebo Control']",['B270'],[['Small Molecule']],[['Small Molecule']],"[['C-Raf kinase', 'Platelet-derived growth factor receptor beta', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['CRAF', 'PDGFRÎ²', 'BRAF', 'c-Kit', 'FLT3', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
9228,NCT00418093,"Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma","A Phase II Evaluation of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma",PHASE2,TERMINATED,30/9/2006,31/10/2011,31/1/2011,19,ACTUAL,,,"['Ovarian Cancer', 'Fallopian Tube Cancer', 'Primary Peritoneal Cancer']","['Gemcitabine', 'Oxaliplatin', 'Bevacizumab']","['B2079', 'B1229', 'B167']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['DNA', 'Ribonucleotide reductase'], ['DNA'], ['Vascular endothelial growth factor A']]","[['DNA', 'RNR'], ['DNA'], ['VEGF-A']]"
8517,NCT00368121,EMMA-1 (Erbitux for Multiple Myeloma),Phase II Study of Cetuximab for the Refractory or Relapsed Multiple Myeloma EMMA-1(Erbitux for Multiple Myeloma),PHASE2,TERMINATED,31/8/2006,30/6/2012,30/6/2012,13,ACTUAL,,,['Multiple Myeloma'],"['Cetuximab', 'Dexamethasone']","['B164', 'B1128']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['Glucocorticoid receptor']]","[['EGFR'], ['GR']]"
9880,NCT00463073,"Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas","A Phase II Trial With Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide",PHASE2,COMPLETED,31/8/2006,31/12/2008,31/12/2008,32,ACTUAL,,,['High-Grade Glioma'],"['Cetuximab', 'Bevacizumab', 'Irinotecan']","['B164', 'B167', 'B1679']","[['Antibody'], ['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['Vascular endothelial growth factor A'], ['DNA topoisomerase I']]","[['EGFR'], ['VEGF-A'], ['TOP1']]"
13308,NCT00743067,A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors,A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors,PHASE1,COMPLETED,9/8/2006,9/11/2009,2/5/2009,37,ACTUAL,,,['Solid Tumors'],['Foretinib'],['B220'],[['Small Molecule']],[['Small Molecule']],"[['c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)', 'Hepatocyte growth factor', 'Vascular endothelial growth factor receptor 2']]","[['c-Met', 'HGF', 'VEGFR2']]"
8235,NCT00345163,A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN),"A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse",PHASE2,COMPLETED,31/7/2006,30/9/2007,30/9/2007,167,ACTUAL,,,['Glioblastoma'],"['Bevacizumab', 'Irinotecan']","['B167', 'B1679']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Vascular endothelial growth factor A'], ['DNA topoisomerase I']]","[['VEGF-A'], ['TOP1']]"
8690,NCT00381875,"Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV",A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede the Development of Antiretroviral Resistance,PHASE1,COMPLETED,31/7/2006,28/2/2011,28/2/2011,40,ESTIMATED,,,['Nonneoplastic Condition'],"['E1M184V peptide vaccine - National Institutes of Health Clinical Center ', ""Incomplete Freund's adjuvant"", 'Sargramostim', 'Immunoenzyme Procedure']","['B11683', 'B1603', 'B181']","[['Subunit Vaccine'], ['Vaccine Adjuvant'], ['Other Protein Therapy']]","[['Subunit Vaccine'], ['Vaccine Adjuvant'], ['Colony-Stimulating Factor']]","[[], [], ['Granulocyte-macrophage colony-stimulating factor receptor']]","[[], [], ['CSF-2R']]"
8084,NCT00330915,A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.,A Feasibility Study of Pemetrexed Single Agent and Folic Acid Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer,PHASE2,COMPLETED,30/6/2006,30/6/2008,30/6/2008,37,ACTUAL,,,['Digestive System Neoplasm'],['Pemetrexed'],['B814'],[['Small Molecule']],[['Small Molecule']],"[['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase']]","[['DHFR', 'GART', 'TYMS']]"
8161,NCT00336856,Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy,"A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer",PHASE2,COMPLETED,30/6/2006,30/6/2011,30/6/2011,35,ACTUAL,,,"['Colon Carcinoma', 'Rectal Carcinoma']","['Cetuximab', 'Irinotecan']","['B164', 'B1679']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['DNA topoisomerase I']]","[['EGFR'], ['TOP1']]"
8200,NCT00339131,"ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid","Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid",PHASE1,COMPLETED,30/6/2006,31/1/2007,,24,ESTIMATED,,,"['Adrenal Gland Pheochromocytoma', 'Paraganglioma', 'Neuroendocrine Tumors']",['Cold Contaminant-free Iobenguane I-131'],[],[],[],[],[]
8756,NCT00387205,Study To Assess Long Term Safety Of Pazopanib,"An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients",PHASE1,COMPLETED,20/6/2006,8/3/2018,13/2/2013,188,ACTUAL,,,['Non-Clear Cell Renal Cell Carcinoma'],"['Pazopanib', 'Lapatinib']","['B1649', 'B1930']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Platelet-derived growth factor receptor alpha', 'Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], ['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2']]","[['PDGFRÎ±', 'PDGFRÎ²', 'c-Kit', 'VEGFR1', 'VEGFR2', 'VEGFR3'], ['EGFR', 'HER2']]"
7761,NCT00307723,"Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer","A Tolerability and Efficacy Study of the Angiogenesis Inhibitor Bevacizumab in Combination With 5-Fluorouracil, Oxaliplatin, and External Beam Radiation Therapy Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer",PHASE1/PHASE2,TERMINATED,31/5/2006,31/7/2009,31/8/2007,52,ACTUAL,,,"['Pancreatic Cancer', 'Pancreatic Cancer']","['Bevacizumab', 'Fluorouracil', 'Oxaliplatin', 'Gemcitabine', 'External Beam Radiation Therapy']","['B167', 'B493', 'B1229', 'B2079']","[['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Vascular endothelial growth factor A'], ['Thymidylate synthase'], ['DNA'], ['DNA', 'Ribonucleotide reductase']]","[['VEGF-A'], ['TYMS'], ['DNA'], ['DNA', 'RNR']]"
7884,NCT00316875,Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer,"A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of Lapatinib in Combination With Liposomal Doxorubicin in Patients With Metastatic Breast Cancer",PHASE1,COMPLETED,31/5/2006,31/8/2011,31/8/2011,23,ACTUAL,,,['Breast Cancer'],"['lapatinib ditosylate', 'Pegylated liposomal doxorubicin']","['B9143', 'B2819']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)']]","[[], ['DNA', 'TOP2']]"
8322,NCT00352755,A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis,A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis,PHASE2,TERMINATED,31/5/2006,30/4/2009,30/4/2009,18,ACTUAL,,,['Peritoneal and Retroperitoneal Neoplasm'],"['Peritonectomy', 'Fluorouracil', 'FOLFOX']",['B493'],[['Small Molecule']],[['Small Molecule']],[['Thymidylate synthase']],[['TYMS']]
7912,NCT00319748,"Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers","Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers",PHASE2,COMPLETED,30/4/2006,31/12/2008,31/12/2007,15,ACTUAL,,,"['Breast Cancer', 'Ovarian Cancer', 'Endometrial Cancer', 'Cervical Cancer']",['852A'],['B2755'],[['Small Molecule']],[['Small Molecule']],[['Toll like receptor 7']],[['TLR7']]
9753,NCT00454324,Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer,Phase II Clinical Trial of Carboplatin and Abraxane in Patients With Extensive Stage Small Cell Lung Cancer,PHASE2,TERMINATED,30/4/2006,31/12/2014,31/7/2010,30,ACTUAL,,,['Small Cell Lung Cancer'],"['Carboplatin', 'Nab-paclitaxel']","['B274', 'B7744']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Tubulin beta-1 chain']]","[['DNA'], ['TUBB1']]"
10484,NCT00508807,RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies,Clinical Study Protocol RTA 402-C-0501: A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDO-Me) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies,PHASE1,COMPLETED,30/4/2006,31/12/2009,31/12/2009,21,ACTUAL,,,"['Leukemia', 'Solid Tumors']",['Bardoxolone methyl'],['B470'],[['Small Molecule']],[['Small Molecule']],"[['Nuclear factor erythroid 2-related factor 2', 'Nuclear factor NF-kappa-B complex']]","[['Nrf2', 'NF-ÎºB']]"
16727,NCT01087424,Mini-CHOP and Rituximab in Patients Aged Over 80 Years,Phase II Study of Mini-CHOP Plus Rituximab in Non Previously Treated Patients Aged Over 80 Years With CD 20+ Diffuse Large B-Cell Lymphoma,PHASE2,COMPLETED,30/4/2006,30/6/2010,30/6/2010,150,ACTUAL,,,['Diffuse Large B-Cell Lymphoma'],"['Prednisone', 'Rituximab', 'Doxorubicin', 'Cyclophosphamide', 'Vincristine']","['B1979', 'B163', 'B1914', 'B2818', 'B2083']","[['Small Molecule'], ['Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Glucocorticoid receptor'], ['B-lymphocyte antigen CD20'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], ['Tubulin beta-1 chain']]","[['GR'], ['CD20'], ['TOP2'], ['DNA'], ['TUBB1']]"
7934,NCT00321100,"Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab","Phase II Study of the Combination of Cetuximab, Capecitabine, and Oxaliplatin With Out Without Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer",PHASE2,TERMINATED,12/4/2006,18/12/2013,30/4/2009,23,ACTUAL,,,['Digestive System Neoplasm'],"['Bevacizumab', 'Cetuximab', 'Oxaliplatin', 'Capecitabine']","['B167', 'B164', 'B1229', 'B474']","[['Antibody'], ['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Vascular endothelial growth factor A'], ['Epidermal growth factor receptor erbB1'], ['DNA'], ['Thymidylate synthase']]","[['VEGF-A'], ['EGFR'], ['DNA'], ['TYMS']]"
7915,NCT00319839,Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab,A Phase II Study of Albumin Bound-Paclitaxel (AbraxaneTM) for Treatment of Recurrent or Metastatic Head and Neck Cancer With the Addition of Cetuximab (Erbitux) (IMC-225) on Disease Progression,PHASE2,TERMINATED,31/3/2006,30/6/2010,31/5/2009,10,ACTUAL,,,['Head and Neck Neoplasm'],"['Nab-paclitaxel', 'Cetuximab']","['B7744', 'B164']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Tubulin beta-1 chain'], ['Epidermal growth factor receptor erbB1']]","[['TUBB1'], ['EGFR']]"
9247,NCT00420485,Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors,"A Phase I Open-label, Multi-center Dose-escalation Study to Determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors",PHASE1,COMPLETED,31/3/2006,30/11/2010,30/11/2010,120,ACTUAL,,,['Solid Tumors'],['Gimatecan'],['B46'],[['Small Molecule']],[['Small Molecule']],[['DNA topoisomerase I']],[['TOP1']]
9632,NCT00446290,"Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer","A Phase I Study of Docetaxel, Capecitabine and Oxaliplatin (DXO) in Patients With Advanced Stomach Cancer",PHASE1,COMPLETED,31/3/2006,31/10/2007,31/10/2007,22,ACTUAL,,,['Gastric Cancer'],"['Docetaxel', 'Capecitabine', 'Oxaliplatin']","['B2814', 'B474', 'B1229']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['Thymidylate synthase'], ['DNA']]","[['TUBB1'], ['TYMS'], ['DNA']]"
9805,NCT00458796,Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone,Cost-Effective Use of Bisphosphonates in Metastatic Bone Disease - A Comparison of Bone Marker Directed Zoledronic Acid Therapy to a Standard Schedule,,TERMINATED,31/3/2006,,,1500,ESTIMATED,,,"['Breast Cancer', 'Hypercalcemia of Malignancy', 'Anal Cancer', 'Musculoskeletal Complications', 'Connective and Soft Tissue Neoplasm']","['Zoledronic acid', 'Quality-of-Life Assessment']",['B2822'],[['Small Molecule']],[['Small Molecule']],"[['Bone resorption factor', 'FDPS inhibitors(Farnesyl diphosphate synthase inhibitors)']]","[['Bone resorption factor', 'FDPS']]"
9049,NCT00406978,"Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients","A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients",PHASE1/PHASE2,COMPLETED,28/2/2006,30/4/2014,30/9/2010,24,ACTUAL,,,['Multiple Myeloma'],"['Prednisone', 'Melphalan', 'Thalidomide', 'Defibrotide']","['B1979', 'B2073', 'B1641', 'B665']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Gene Therapy']]","[['Small Molecule'], ['Small Molecule'], ['Molecular glue'], ['Gene Therapy']]","[['Glucocorticoid receptor'], ['DNA'], ['Alpha-1-acid glycoprotein 1', 'Alpha-1-acid glycoprotein 2', 'Cereblon', 'DNA-binding protein Ikaros', 'Sal-like protein 4', 'Tumor necrosis factor', 'Zinc finger protein Aiolos'], ['Plasminogen activator inhibitor 1', 'plasminogen activator, tissue type', 'Von willebrand factor']]","[['GR'], ['DNA'], ['AGP1', 'AGP2', 'CRBN', 'IKZF1', 'SALL4', 'TNF', 'IKZF3'], ['PAI-1', 'tPA', 'vWF']]"
57674,NCT00303082,Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity,Clinical Trial for the Prevention of Premature Birth and Neonatal Related Morbidity,PHASE3,TERMINATED,31/1/2006,31/8/2009,31/1/2009,645,ACTUAL,,,"['Bacterial Vaginosis', 'Premature Birth', 'Sepsis', 'Periventricular Leukomalacia', 'Bronchopulmonary Dysplasia']","['Lactobacillus rhamnosus', 'Lactobacillus reuteri Probiotic Tablet']",[],[],[],[],[]
7703,NCT00303953,PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma,Phase II Study of PXD101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphomas,PHASE2,COMPLETED,31/1/2006,31/8/2010,31/1/2010,22,ACTUAL,,,"['Burkitt Lymphoma', 'Diffuse Large B-Cell Lymphoma']",['Belinostat'],['B1217'],[['Small Molecule']],[['Small Molecule']],[['Histone deacetylase']],[['HDAC']]
8818,NCT00389922,Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors,Phase I Study of Two Different Schedules of Lapatinib (GW572016) in Combination With Vinorelbine in Advanced Solid Tumors,PHASE1,COMPLETED,31/12/2005,31/12/2011,30/4/2009,22,ACTUAL,,,['Solid Tumors'],"['lapatinib ditosylate', 'vinorelbine tartrate', 'Comparative Genomic Hybridization', 'Cytogenetic Analysis', 'Gene Expression Analysis', 'Genetic Variation Analysis', 'Polymerase Chain Reaction', 'Polymorphism Analysis', 'Reverse Transcriptase-Polymerase Chain Reaction', 'Immunohistochemistry Staining Method', 'Laboratory Biomarker Analysis']","['B9143', 'B9142']","[[], []]","[[], []]","[[], []]","[[], []]"
11004,NCT00543231,A Phase I Study of G3139 Subcutaneous in Solid Tumors,A Pharmacokinetic and Safety Assessment of G3139 Administered by Subcutaneous Injection to Patients With Solid Tumors,PHASE1,COMPLETED,31/12/2005,31/12/2006,,8,ESTIMATED,,,['Tumors'],"['oblimersen sodium', 'BP1002']","['B8705', 'B3970']","[[], ['DNA Oligonucleotide Therapy']]","[[], ['DNA Oligonucleotide Therapy']]","[[], ['Apoptosis regulator Bcl-2']]","[[], ['Bcl-2']]"
14447,NCT00861419,"To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.","An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors",PHASE1,COMPLETED,31/12/2005,,,88,ESTIMATED,,,['Solid Tumors'],"['Sorafenib', 'motesanib diphosphate', 'Trebananib', 'Sunitinib', 'Bevacizumab']","['B270', 'B9155', 'B678', 'B1915', 'B167']","[['Small Molecule'], [], ['Engineered Protein Therapy'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], [], ['Fusion Protein'], ['Small Molecule'], ['Monoclonal Antibody']]","[['C-Raf kinase', 'Platelet-derived growth factor receptor beta', 'Serine/threonine-protein kinase B-raf', 'Stem cell growth factor receptor', 'Tyrosine-protein kinase receptor FLT3', 'Tyrosine-protein kinase receptor RET', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3'], [], ['Angiopoietin-1', 'Angiopoietin-2', 'TEK receptor tyrosine kinase'], ['Platelet-derived growth factor receptor beta', 'RTK inhibitors(Receptor protein-tyrosine kinase inhibitors)', 'Vascular endothelial growth factor receptor'], ['Vascular endothelial growth factor A']]","[['CRAF', 'PDGFRÎ²', 'BRAF', 'c-Kit', 'FLT3', 'RET', 'VEGFR1', 'VEGFR2', 'VEGFR3'], [], ['Ang1', 'Ang2', 'Tie-2'], ['PDGFRÎ²', 'RTK', 'VEGFR'], ['VEGF-A']]"
6006,NCT00174369,MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer,Phase 2 Study Of The MEK Inhibitor PD-0325901 In Patients With Advanced Non-Small Cell Lung Cancer,PHASE2,TERMINATED,30/11/2005,30/6/2007,30/6/2007,34,ACTUAL,,,['Non-Small Cell Lung Cancer'],['Mirdametinib'],['B1709'],[['Small Molecule']],[['Small Molecule']],"[['Dual specificity mitogen-activated protein kinase kinase 1', 'Dual specificity mitogen-activated protein kinase kinase 2']]","[['MEK1', 'MEK2']]"
6782,NCT00237575,Randomized Phase III Trial of LeukineÂ® vs NeupogenÂ® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer,A Randomized Phase III Trial of LeukineÂ® vs NeupogenÂ® in Patients Receiving Cisplatin and Gemcitabine for Regionally Advanced or Metastatic Urothelial Cancer,PHASE3,TERMINATED,30/11/2005,31/3/2006,31/3/2006,100,,,,['Bladder Cancer'],"['Gemcitabine', 'Cisplatin', 'Sargramostim', 'Filgrastim']","['B2079', 'B49', 'B181', 'B157']","[['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy'], ['Other Protein Therapy']]","[['Small Molecule'], ['Small Molecule'], ['Colony-Stimulating Factor'], ['Colony-Stimulating Factor']]","[['DNA', 'Ribonucleotide reductase'], ['DNA'], ['Granulocyte-macrophage colony-stimulating factor receptor'], ['Colony stimulating factor 3 receptor']]","[['DNA', 'RNR'], ['DNA'], ['CSF-2R'], ['CSF-3R']]"
16468,NCT01058538,A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours,A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours,PHASE1/PHASE2,COMPLETED,30/11/2005,30/11/2009,30/4/2008,33,ACTUAL,,,['Solid Tumors'],"['Bifikafusp alfa', 'Interleukin-2']","['B2472', 'B2881']","[['Cytokine Fusion Protein (Immunocytokine)'], []]","[['Cytokine Fusion Protein (Immunocytokine)'], []]","[['Human fibronectin extra domain B', 'Interleukin-2 receptor'], []]","[['EDB-FN', 'IL-2R'], []]"
35297,NCT03362684,PETACC-8 miR-31-3p and miR-31-5p Ancillary Study,"Ancillary Study of miR-31-3p and miR-31-5p Expression Levels in Patients Enrolled in the PETACC-8 Study, and of the Predictive Role of miR-31-3p Expression Level on Clinical Outcomes of Patients Treated With Cetuximab",PHASE3,COMPLETED,30/11/2005,30/6/2016,30/11/2009,1808,ACTUAL,,,['Colorectal Cancer'],"['Cetuximab', 'FOLFOX']",['B164'],[['Antibody']],[['Monoclonal Antibody']],[['Epidermal growth factor receptor erbB1']],[['EGFR']]
6818,NCT00240682,Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR,Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR.,PHASE2,COMPLETED,31/10/2005,30/6/2009,30/4/2009,37,ACTUAL,,,"['Skin Neoplasm', 'Epithelial Neoplasm']",['Cetuximab'],['B164'],[['Antibody']],[['Monoclonal Antibody']],[['Epidermal growth factor receptor erbB1']],[['EGFR']]
7797,NCT00310050,"Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer",A Phase I Dose-Escalating Study of Induction Gemcitabine/Pemetrexed Followed by Pemetrexed and Concurrent Upper Abdominal Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer,PHASE1,TERMINATED,31/10/2005,31/5/2008,31/5/2008,4,ACTUAL,,,['Pancreatic Cancer'],"['pemetrexed disodium', 'Pemetrexed', 'Radiation Therapy']","['B8763', 'B814']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], ['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase']]","[[], ['DHFR', 'GART', 'TYMS']]"
24758,NCT02013817,CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy,CHAIROS - Effect of Early Brief Intensification by Chemoimmunotherapy With FCR Followed by FR and Rituximab Maintenance on Clinical Response in Chemo-naÃ¯ve Patients With B-CLL,PHASE2,COMPLETED,11/10/2005,24/9/2012,24/9/2012,43,ACTUAL,,,['Chronic Lymphocytic Leukemia'],"['Rituximab', 'Fludarabine', 'Cyclophosphamide']","['B163', 'B346', 'B2818']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['B-lymphocyte antigen CD20'], ['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA']]","[['CD20'], ['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA']]"
5411,NCT00121225,Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma,A Phase II Study of Vorinostat in Patients With Advanced Melanoma,PHASE2,COMPLETED,30/9/2005,30/6/2013,31/3/2009,32,ACTUAL,,,"['Uveal Melanoma', 'Eye Neoplasm', 'Uveal Melanoma', 'Uveal Melanoma', 'Eye Neoplasm', 'Skin Melanoma', 'Skin Melanoma']",['Vorinostat'],['B2107'],[['Small Molecule']],[['Small Molecule']],[['Histone deacetylase']],[['HDAC']]
57627,NCT00247507,The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients,,PHASE4,UNKNOWN,30/9/2005,31/12/2005,,,,,,"['Anemia', 'Atherosclerosis', 'End-Stage Renal Disease', 'Oxidative Stress', 'Pro-Inflammation']",['Acetylcysteine'],['B1964'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
6911,NCT00248404,NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS),A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase,PHASE1/PHASE2,COMPLETED,30/9/2005,12/12/2007,12/12/2007,155,ESTIMATED,,,['Tumors'],['NB 1011'],['B4046'],[['Small Molecule']],[['Small Molecule']],[['Thymidylate synthase']],[['TYMS']]
6930,NCT00250419,V930 First in Man (FIM) Study (V930-002)(COMPLETED),A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients With Cancers Expressing HER-2 and/or CEA,PHASE1,COMPLETED,30/9/2005,30/9/2008,30/9/2008,26,ACTUAL,,,['Cancers Expressing HER-2 and/or CEA'],['V930'],['B3711'],[['Cancer Vaccine']],[['DNA vaccine']],"[['Carcinoembryonic antigen', 'Receptor protein-tyrosine kinase erbB-2']]","[['CEA', 'HER2']]"
7486,NCT00288925,Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment,"Phase Ib/IIa, to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects With Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment",PHASE1/PHASE2,COMPLETED,30/9/2005,,31/12/2007,30,,,,['Pancreatic Cancer'],['Z-360'],['B2540'],[['Small Molecule']],[['Small Molecule']],[['Cholecystokinin B receptor']],[['CCKBR']]
8617,NCT00376740,Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole,"Phase 3 Study of the Effect of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving the Aromatase Inhibitor, Letrozole, in the Adjuvant Setting",PHASE3,COMPLETED,30/9/2005,,30/11/2010,90,ACTUAL,,,['Breast Cancer'],['Zoledronic acid'],['B2822'],[['Small Molecule']],[['Small Molecule']],"[['Bone resorption factor', 'FDPS inhibitors(Farnesyl diphosphate synthase inhibitors)']]","[['Bone resorption factor', 'FDPS']]"
10850,NCT00532285,Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer,Phase II Study of Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer,PHASE2,TERMINATED,30/9/2005,31/8/2009,30/4/2006,44,ACTUAL,,,['Breast Cancer'],"['Paclitaxel', 'Gemcitabine']","['B1250', 'B2079']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['DNA', 'Ribonucleotide reductase']]","[['TUBB1'], ['DNA', 'RNR']]"
5534,NCT00129571,Study of XL820 in Adults With Solid Tumors,A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors,PHASE1,COMPLETED,31/8/2005,,,,,,,['Cancer'],['XL 820'],['B2334'],[['Small Molecule']],[['Small Molecule']],"[['Platelet-derived growth factor receptor beta', 'Stem cell growth factor receptor', 'Vascular endothelial growth factor receptor 2']]","[['PDGFRÎ²', 'c-Kit', 'VEGFR2']]"
6473,NCT00207077,Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors,A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies,PHASE1,COMPLETED,31/8/2005,31/5/2007,31/5/2007,33,ESTIMATED,,,['Neoplasms'],"['Cetuximab', 'Erlotinib']","['B164', 'B1928']","[['Antibody'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['Epidermal growth factor receptor erbB1']]","[['EGFR'], ['EGFR L858R', 'EGFR-Ex19del', 'EGFR']]"
8431,NCT00361088,A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma,A Dose Escalation of Zarnestra (R115777) Combined With VelcadeÂ® (PS-341) in Patients With Relapsed Multiple Myeloma,PHASE1/PHASE2,TERMINATED,31/8/2005,30/6/2007,30/6/2007,42,ACTUAL,,,['Multiple Myeloma'],"['Bortezomib', 'Tipifarnib']","['B958', 'B890']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Proteasome'], ['Protein farnesyltransferase']]","[['Proteasome'], ['Ftase']]"
26103,NCT02182050,Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer,"A Double-blind, Randomised Phase II Study to Determine Efficacy and Safety of Oral Treatment With BIBF 1120 ES 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Advanced Non-small-cell Lung Cancer",PHASE2,COMPLETED,31/8/2005,,31/1/2007,73,ACTUAL,,,['Non-Small Cell Lung Cancer'],['INV-1120'],['B3769'],[['Small Molecule']],[['Small Molecule']],[['Prostanoid EP4 receptor']],[['EP4']]
4974,NCT00100945,Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer,A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent,PHASE2,COMPLETED,31/7/2005,31/10/2009,31/8/2007,70,ACTUAL,,,['Esophageal Cancer'],['Gefitinib'],['B2097'],[['Small Molecule']],[['Small Molecule']],[['Epidermal growth factor receptor erbB1']],[['EGFR']]
5463,NCT00125749,Vaccination of Patients With Stage IV Melanoma With Dendritic Cells,Vaccination of Patients With Stage IV Melanoma With Dendritic Cells Generated Ex Vivo From Monocytes and Loaded With Heat Treated Killed Allogeneic Melanoma Cells,PHASE1/PHASE2,COMPLETED,31/7/2005,30/6/2007,30/6/2007,30,ACTUAL,,,"['Male Reproductive System Neoplasm', 'Neoplasm Metastasis']",['ACT 2001'],['B4572'],[[]],[[]],[[]],[[]]
5653,NCT00138177,"Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors","A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX) in Patients With Colorectal Cancer and Other Solid Tumors",PHASE1,COMPLETED,31/7/2005,,31/8/2011,54,ACTUAL,,,"['Solid Tumors', 'Colon Carcinoma', 'Rectal Carcinoma', 'Colon Carcinoma', 'Rectal Carcinoma', 'Colon Carcinoma', 'Rectal Carcinoma']","['Oxaliplatin', 'leucovorin calcium', 'Vorinostat', 'Fluorouracil']","['B1229', 'B8438', 'B2107', 'B493']","[['Small Molecule'], [], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], [], ['Small Molecule'], ['Small Molecule']]","[['DNA'], [], ['Histone deacetylase'], ['Thymidylate synthase']]","[['DNA'], [], ['HDAC'], ['TYMS']]"
6036,NCT00176748,Treatment for Patients With Metastatic Thyroid Cancer,Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131I Treatment,PHASE2,COMPLETED,31/7/2005,30/6/2009,31/8/2006,3,ACTUAL,,,['Thyroid Cancer'],['Axitinib'],['B262'],[['Small Molecule']],[['Small Molecule']],"[['Protein-tyrosine kinases', 'Vascular endothelial growth factor receptor 1', 'Vascular endothelial growth factor receptor 2', 'Vascular endothelial growth factor receptor 3']]","[['Protein-tyrosine kinases', 'VEGFR1', 'VEGFR2', 'VEGFR3']]"
6341,NCT00196820,Mono Efficacy of Capecitabine (MoniCa),"A Multicenter Phase II Study to Determine the Efficacy of Capecitabine as First Line Monochemotherapy in Patients With HER2 Negative, Medium-risk, Metastatic Breast Cancer",PHASE2,COMPLETED,31/7/2005,31/12/2008,,200,ESTIMATED,,,['Breast Cancer'],['Capecitabine'],['B474'],[['Small Molecule']],[['Small Molecule']],[['Thymidylate synthase']],[['TYMS']]
7238,NCT00271804,Study of Velcade and Thalidomide in Patients With Myelodysplasia,Phase I Dose Escalation Trial of Bortezomib in Combination With Thalidomide in Patients With Myelodysplasia,PHASE1,TERMINATED,30/6/2005,30/4/2007,,28,,,,['Myelodysplastic Syndrome'],['Bortezomib'],['B958'],[['Small Molecule']],[['Small Molecule']],[['Proteasome']],[['Proteasome']]
8937,NCT00398554,Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma,Pilot Study for Therapy Optimising for Hodgkin's Lymphoma in Childhood and Adolescence; Optimising Therapy for Boys With Hodgkin's Lymphoma in Intermediate and Advanced Stages. Safety and Efficacy Study for Drug Combination VECOPA,PHASE2,COMPLETED,30/6/2005,31/3/2013,31/10/2012,16,ACTUAL,,,['Hematology'],"['Cyclophosphamide', 'doxorubicin hydrochloride', 'Etoposide', 'Prednisone', 'vinblastine sulfate', 'vincristine sulfate', 'Radiation Therapy']","['B2818', 'B9124', 'B1463', 'B1979', 'B8563', 'B9307']","[['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], [], []]","[['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], [], []]","[['DNA'], [], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Glucocorticoid receptor'], [], []]","[['DNA'], [], ['TOP2'], ['GR'], [], []]"
11042,NCT00544986,"A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer","A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer",PHASE4,COMPLETED,30/6/2005,30/11/2007,30/11/2007,,,,,['Breast Cancer'],['Anastrozole'],['B289'],[['Small Molecule']],[['Small Molecule']],[['Aromatase']],[['aromatase']]
6606,NCT00217711,"Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","Oxaliplatin, Irinotecan, and Capecitabine as a Combination Regimen for First-Line Treatment of Advanced or Metastatic Colorectal Cancer",PHASE1/PHASE2,COMPLETED,31/5/2005,31/10/2011,31/8/2007,23,ACTUAL,,,['Colorectal Cancer'],"['Capecitabine', 'irinotecan hydrochloride', 'Oxaliplatin']","['B474', 'B9055', 'B1229']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Thymidylate synthase'], [], ['DNA']]","[['TYMS'], [], ['DNA']]"
7595,NCT00295971,"Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease","Stem Cell Enriched, T Cell Depleted Haplocompatible Peripheral Blood Transplantation for Children With Myelodysplastic Disease, Leukemia, Marrow Failure Syndromes, or Severe Immunodeficiency Diseases",PHASE1,COMPLETED,30/4/2005,31/12/2011,31/12/2011,21,ACTUAL,,,"['Congenital Amegakaryocytic Thrombocytopenia', 'Leukemia', 'Myelodysplastic Syndrome', 'Severe Congenital Neutropenia']","['Antithymocyte globulin', 'Therapeutic Allogeneic Lymphocytes', 'fludarabine phosphate', 'Thiotepa', 'Allogeneic Bone Marrow Transplantation', 'Allogeneic Hematopoietic Stem Cell Transplantation', 'In Vitro-Treated Peripheral Blood Stem Cell Transplantation', 'Total-Body Irradiation']","['B2844', 'B8555', 'B1998']","[['Other Protein Therapy'], [], ['Small Molecule']]","[['Immunoglobulin'], [], ['Small Molecule']]","[[], [], ['DNA']]","[[], [], ['DNA']]"
4426,NCT00083083,Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer,Positron Emission Tomography Pre- and Post-treatment Assessment For Locally Advanced Non-Small Cell Lung Carcinoma,PHASE2,UNKNOWN,31/3/2005,,30/6/2006,250,ESTIMATED,,,['Thoracic Neoplasm'],"['Carboplatin', 'Cisplatin', 'Docetaxel', 'Etoposide', 'Paclitaxel', 'vinblastine sulfate', 'vinorelbine tartrate', 'Gene Expression Analysis', 'Positron Emission Tomography', 'Fludeoxyglucose F-18', 'Radiation Therapy']","['B274', 'B49', 'B2814', 'B1463', 'B1250', 'B8563', 'B9142', 'B2838']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], [], ['Radiopharmaceutical Imaging']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], [], ['Radiopharmaceutical Imaging']]","[['DNA'], ['DNA'], ['Tubulin beta-1 chain'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['Tubulin beta-1 chain'], [], [], []]","[['DNA'], ['DNA'], ['TUBB1'], ['TOP2'], ['TUBB1'], [], [], []]"
4995,NCT00101270,Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas,"A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas",PHASE1,COMPLETED,31/3/2005,,30/9/2007,24,ACTUAL,,,"['Burkitt Lymphoma', 'Germ Cell Tumor', 'Diffuse Large B-Cell Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Glioma', 'Glioma', 'Glioma', 'Ependymoma', 'Diffuse Large B-Cell Lymphoma', 'Recurrent Childhood Large Cell Lymphoma', 'Liver Cancer', 'Non-Hodgkin Lymphoma', 'Germ Cell Tumor', 'Medulloblastoma', 'Rhabdomyosarcoma', 'B-Cell Non-Hodgkin Lymphoma', 'Soft Tissue Sarcoma', 'Central Nervous System Embryonal Tumor', 'Glioma', 'Colon Carcinoma', 'Connective and Soft Tissue Neoplasm', 'Skin Melanoma', 'Nasopharyngeal Cancer', 'Recurrent Neuroblastoma', 'Osteosarcoma', 'Kidney Wilms Tumor', 'Hodgkin Lymphoma', 'Solid Tumors']","['irinotecan hydrochloride', 'Oxaliplatin']","['B9055', 'B1229']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[[], ['DNA']]","[[], ['DNA']]"
5110,NCT00106262,"Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer","A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer",PHASE2,TERMINATED,31/3/2005,31/3/2007,,38,,,,['Cervical Cancer'],"['Bortezomib', 'Irinotecan']","['B958', 'B1679']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Proteasome'], ['DNA topoisomerase I']]","[['Proteasome'], ['TOP1']]"
57519,NCT00121602,Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease,"Randomized, Double-Blind, Equivalence Study of the Efficacy of Darbepoetin Alfa Manufactured by Serum Free Bioreactor Technology and Darbepoetin Alfa Manufactured by Roller-Bottle Technology for the Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis",PHASE3,COMPLETED,31/3/2005,31/10/2006,31/10/2005,446,ACTUAL,,,"['Anemia', 'Kidney Disease']",['Darbepoetin alfa'],['B156'],[['Other Protein Therapy']],[['Colony-Stimulating Factor']],[['Erythropoietin receptor']],[['EPO receptor']]
6245,NCT00191854,"Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line","Randomized Phase II Study of Biweekly Gemcitabine-Paclitaxel, Biweekly Gemcitabine-Carboplatin and Biweekly Gemcitabine-Cisplatin as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure",PHASE2,COMPLETED,31/3/2005,30/11/2009,31/8/2008,147,ACTUAL,,,['Breast Cancer'],"['Gemcitabine', 'Paclitaxel', 'Carboplatin', 'Cisplatin']","['B2079', 'B1250', 'B274', 'B49']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA', 'Ribonucleotide reductase'], ['Tubulin beta-1 chain'], ['DNA'], ['DNA']]","[['DNA', 'RNR'], ['TUBB1'], ['DNA'], ['DNA']]"
57494,NCT00102791,A Stratified Sickle Event Randomized Trial (ASSERT),"A Phase III Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 With or Without HU Therapy in Patients With Sickle Cell Disease Who Have Had =>2 Acute Sickle-Related Painful Crises Within the Preceding 12 Months",PHASE3,TERMINATED,28/2/2005,30/6/2007,,297,ACTUAL,,,['Sickle Cell Disease'],['Senicapoc'],[],[],[],[],[]
5695,NCT00142415,Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer,Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 (177^Lu-DOTA-cG250) in Patients With Advanced Renal Cancer,PHASE1/PHASE2,COMPLETED,28/2/2005,31/1/2011,31/1/2011,26,ACTUAL,,,['Renal Cell Carcinoma'],"['Girentuximab', 'Lutetium Lu 177-DOTA']",['B428'],[['Antibody']],[['Monoclonal Antibody']],[['Carbonic anhydrase IX']],[['CAIX']]
13907,NCT00806923,A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC),"A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naÃ¯ve Patients With Advanced or Recurrent Non-squamous NSCLC",PHASE3,COMPLETED,28/2/2005,28/2/2011,28/2/2011,1044,ACTUAL,,,['Lung Non-Squamous Non-Small Cell Carcinoma'],"['Cisplatin', 'Gemcitabine', 'Placebo Control', 'Bevacizumab']","['B49', 'B2079', 'B167']","[['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['DNA'], ['DNA', 'Ribonucleotide reductase'], ['Vascular endothelial growth factor A']]","[['DNA'], ['DNA', 'RNR'], ['VEGF-A']]"
5755,NCT00147901,"Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)",Multicenter Phase II Trial of Fludarabine and Cyclophosphamide in Combination With Alemtuzumab (FC-Cam) for Patients With Relapsed Chronic Lymphocytic Leukemia - CLL-2L Protocol of the German CLL-Study Group (GCLLSG),PHASE2,COMPLETED,31/1/2005,30/11/2011,30/11/2008,61,ACTUAL,,,['Chronic Lymphocytic Leukemia'],"['Alemtuzumab', 'Cyclophosphamide', 'Fludarabine']","['B169', 'B2818', 'B346']","[['Antibody'], ['Small Molecule'], ['Small Molecule']]","[['Monoclonal Antibody'], ['Small Molecule'], ['Small Molecule']]","[['CAMPATH-1 antigen'], ['DNA'], ['Ribonucleotide reductase', 'RNA polymerase II']]","[['CD52'], ['DNA'], ['DNA polymerase III', 'RNR', 'RNA polymerase II']]"
9789,NCT00457743,A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST),A Phase I/II Study of Sunitinib Malate (SU011248) In The Treatment of Patients With Malignant Gastrointestinal Stromal Tumor (GIST) Previously Treated by Imatinib Mesylate.,PHASE1/PHASE2,COMPLETED,31/1/2005,31/8/2008,31/8/2008,36,ACTUAL,,,['Gastrointestinal Stromal Tumor'],['sunitinib malate'],['B9127'],[[]],[[]],[[]],[[]]
14606,NCT00874978,The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality,The Efficacy and Safety of Lenalidomide (RevlimidÂ®) Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome Associated With Del (5q) Cytogenetic Abnormality,PHASE2,COMPLETED,31/1/2005,31/5/2016,31/5/2016,36,ESTIMATED,,,['Myelodysplastic Syndrome'],['Lenalidomide'],['B2071'],[['Small Molecule']],[['Molecular glue']],"[['casein kinase 1 alpha 1', 'Cereblon', 'DNA-binding protein Ikaros', 'Interleukin-2', 'Interleukin-6', 'Tumor necrosis factor Î±', 'Zinc finger protein Aiolos']]","[['IFNÎ³', 'CK1Î±', 'CRBN', 'IKZF1', 'IL-2', 'IL-6', 'TNF-Î±', 'IKZF3']]"
6578,NCT00216437,Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma,"A Phase I Dose Escalation Study to Assess the Maximum Tolerated Dose and Feasibility of Combining Oral Capecitabine (Xeloda) and Conformal Radiotherapy (CRT) for Patients With Unresectable Hepatocellular Carcinoma, Multiple Hepatic Metastases or Cholangiocarcinoma",PHASE1,TERMINATED,31/12/2004,31/3/2007,,30,ESTIMATED,,,['Liver Cancer'],['Capecitabine'],['B474'],[['Small Molecule']],[['Small Molecule']],[['Thymidylate synthase']],[['TYMS']]
3197,NCT00041262,Combination Chemotherapy in Treating Patients With Esophageal Cancer,A Prospective Randomized Trial Comparing Standard Chemotherapy Followed By Resection Versus Infusional Chemotherapy In Patients With Resectable Adenocarcinoma Of The Oesophagus,PHASE3,UNKNOWN,30/11/2004,,,1300,ESTIMATED,,,['Esophageal Cancer'],"['Cisplatin', 'epirubicin hydrochloride', 'Fluorouracil', 'Conventional Surgery', 'Neoadjuvant Therapy']","['B49', 'B8960', 'B493']","[['Small Molecule'], [], ['Small Molecule']]","[['Small Molecule'], [], ['Small Molecule']]","[['DNA'], [], ['Thymidylate synthase']]","[['DNA'], [], ['TYMS']]"
4852,NCT00096135,Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes,Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1â‰¥ 18 Months),,COMPLETED,30/11/2004,,30/9/2013,168,ACTUAL,,,['Leukemia'],"['Filgrastim', 'Cyclophosphamide', 'Cytarabine', 'daunorubicin hydrochloride', 'Dexamethasone', 'Etoposide', 'leucovorin calcium', 'Mercaptopurine', 'Methotrexate', 'Pegaspargase', 'Hydrocortisone', 'vincristine sulfate', 'High-Dose Methotrexate Regimen', 'Cranial Irradiation']","['B157', 'B2818', 'B2050', 'B8625', 'B1128', 'B1463', 'B8438', 'B2978', 'B997', 'B675', 'B1133', 'B9307']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy'], ['Small Molecule'], []]","[['Colony-Stimulating Factor'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Enzyme'], ['Small Molecule'], []]","[['Colony stimulating factor 3 receptor'], ['DNA'], ['DNA-directed DNA polymerase'], [], ['Glucocorticoid receptor'], ['Top II inhibitors (Topoisomerase II inhibitors)'], [], [], ['Dihydrofolate reductase'], ['Asparagine'], ['Glucocorticoid receptor'], []]","[['CSF-3R'], ['DNA'], ['DNA-directed DNA polymerase'], [], ['GR'], ['TOP2'], [], ['HPRT1'], ['DHFR'], ['ASN'], ['GR'], []]"
5841,NCT00155259,"Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer",Docetaxel by 1 Hour Infusion Followed by 24 Hour Infusion of Cisplatin Plus Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer,PHASE2,COMPLETED,31/10/2004,31/12/2006,,47,ACTUAL,,,['Breast Cancer'],"['Docetaxel', 'Cisplatin', 'Capecitabine']","['B2814', 'B49', 'B474']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['DNA'], ['Thymidylate synthase']]","[['TUBB1'], ['DNA'], ['TYMS']]"
4632,NCT00088556,"Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer","Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer",PHASE1/PHASE2,COMPLETED,31/8/2004,31/5/2009,31/5/2009,100,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['canfosfamide hydrochloride', 'Carboplatin', 'Paclitaxel']","['B8736', 'B274', 'B1250']","[[], ['Small Molecule'], ['Small Molecule']]","[[], ['Small Molecule'], ['Small Molecule']]","[[], ['DNA'], ['Tubulin beta-1 chain']]","[[], ['DNA'], ['TUBB1']]"
4782,NCT00093730,BMS-599626 in Treating Patients With Metastatic Solid Tumors,Phase I Study Of BMS-599626 In Patients With Advanced Solid Malignancies That Express Her2,PHASE1,COMPLETED,31/8/2004,,30/4/2006,9,ACTUAL,,,['Solid Tumors'],['BMS 599626'],['B2151'],[['Small Molecule']],[['Small Molecule']],"[['Epidermal growth factor receptor erbB1', 'Receptor protein-tyrosine kinase erbB-2']]","[['EGFR', 'HER2']]"
6029,NCT00176501,Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer,Immunotherapy for Patients With Renal Cell Carcinoma,PHASE2,TERMINATED,31/8/2004,31/8/2008,31/8/2008,3,ACTUAL,,,['Kidney Cancer'],['Therapeutic Allogeneic Lymphocytes'],[],[],[],[],[]
57471,NCT00076102,Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas,"Phase II Trial of Pirfenidone in Children, Adolescents, and Young Adults With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas",PHASE2,COMPLETED,21/7/2004,1/4/2010,1/4/2010,36,ACTUAL,,,"['Neurofibromatosis', 'Neurofibroma']",['Pirfenidone'],['B246'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
6693,NCT00227682,"Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma","A Phase II Study of Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid",PHASE2,TERMINATED,30/6/2004,28/2/2006,28/2/2006,2,ACTUAL,,,['Plasma Cell Neoplasm'],"['Ascorbic acid', 'Arsenic trioxide', 'Dexamethasone', 'Thalidomide']","['B530', 'B2774', 'B1128', 'B1641']","[[], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[[], ['Small Molecule'], ['Small Molecule'], ['Molecular glue']]","[[], ['Retinoic acid receptor alpha'], ['Glucocorticoid receptor'], ['Alpha-1-acid glycoprotein 1', 'Alpha-1-acid glycoprotein 2', 'Cereblon', 'DNA-binding protein Ikaros', 'Sal-like protein 4', 'Tumor necrosis factor', 'Zinc finger protein Aiolos']]","[[], ['RARÎ±'], ['GR'], ['AGP1', 'AGP2', 'CRBN', 'IKZF1', 'SALL4', 'TNF', 'IKZF3']]"
4529,NCT00085462,Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma,Treatment of Patients With Metastatic Melanoma by Lymphodepleting Conditioning Followed by Infusion of TCR-Gene Engineered Lymphocytes and Subsequent Fowlpox gp100 Vaccination,PHASE1,COMPLETED,31/5/2004,30/9/2008,31/5/2007,61,ESTIMATED,,,['Skin Melanoma'],"['Aldesleukin', 'Filgrastim', 'gp100-Fowlpox Vaccine', 'Therapeutic Autologous Lymphocytes', 'Therapeutic Tumor Infiltrating Lymphocytes', 'Cyclophosphamide', 'fludarabine phosphate']","['B136', 'B157', 'B2818', 'B8555']","[['Other Protein Therapy'], ['Other Protein Therapy'], ['Small Molecule'], []]","[['Interleukin'], ['Colony-Stimulating Factor'], ['Small Molecule'], []]","[['Interleukin-2 receptor'], ['Colony stimulating factor 3 receptor'], ['DNA'], []]","[['IL-2R'], ['CSF-3R'], ['DNA'], []]"
6879,NCT00245089,"Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma",Phase II Trial of VAC2.2/VA Therapy for Low-Risk B Group Patients With Rhabdomyosarcoma,PHASE2,UNKNOWN,31/5/2004,,30/4/2011,41,ESTIMATED,,,['Sarcoma'],"['Dactinomycin', 'Cyclophosphamide', 'vincristine sulfate']","['B341', 'B2818', 'B9307']","[['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], []]","[['DNA'], ['DNA'], []]","[['DNA'], ['DNA'], []]"
28355,NCT02461121,HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk,Compare the Safety and Effective of HLA-mismatched Microtransplantation With HLA-matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-risk,PHASE3,COMPLETED,31/5/2004,31/5/2013,31/5/2013,156,ACTUAL,,,['Acute Myeloid Leukemia'],"['HLA mismatched stem cell', 'HLA matched stem cell', 'Cyclosporin', 'Mycophenolate mofetil', 'Cytarabine', 'Fludarabine', 'Antithymocyte globulin', 'Cyclophosphamide']","['B2845', 'B310', 'B2050', 'B346', 'B2844', 'B2818']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Immunoglobulin'], ['Small Molecule']]","[[], [""Inosine-5'-monophosphate dehydrogenase""], ['DNA-directed DNA polymerase'], ['Ribonucleotide reductase', 'RNA polymerase II'], [], ['DNA']]","[['CaN'], ['IMPDH'], ['DNA-directed DNA polymerase'], ['DNA polymerase III', 'RNR', 'RNA polymerase II'], [], ['DNA']]"
5869,NCT00159445,Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer,Phase II Study of Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer,PHASE2,COMPLETED,31/3/2004,30/11/2007,31/3/2007,53,ESTIMATED,,,"['Colorectal Cancer', 'Colon Carcinoma']","['Gemcitabine', 'Capecitabine']","['B2079', 'B474']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA', 'Ribonucleotide reductase'], ['Thymidylate synthase']]","[['DNA', 'RNR'], ['TYMS']]"
4362,NCT00080990,"Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors","An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Oxaliplatin and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors",PHASE1,COMPLETED,29/2/2004,,30/4/2009,46,ACTUAL,,,['Solid Tumors'],"['Alvocidib', 'Fluorouracil', 'Oxaliplatin', 'leucovorin calcium']","['B1252', 'B493', 'B1229', 'B8438']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Cyclin-dependent kinase 9'], ['Thymidylate synthase'], ['DNA'], []]","[['CDK9'], ['TYMS'], ['DNA'], []]"
4100,NCT00072670,A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer,Phase 2 Study of Yondelis in Men With Advanced Prostate Carcinoma,PHASE2,COMPLETED,31/1/2004,30/11/2008,30/9/2008,59,ACTUAL,,,['Prostate Cancer'],['Trabectedin'],['B2772'],[['Small Molecule']],[['Small Molecule']],[['DNA']],[['DNA']]
4220,NCT00077025,Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer,"Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidexâ„¢)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSAâ„¢) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer",PHASE2,COMPLETED,31/1/2004,31/5/2013,31/5/2013,174,ESTIMATED,,,['Breast Cancer'],"['Gefitinib', 'Anastrozole']","['B2097', 'B289']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['Aromatase']]","[['EGFR'], ['aromatase']]"
4252,NCT00077493,BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma,Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas,PHASE1,SUSPENDED,31/1/2004,31/10/2008,31/10/2008,95,ESTIMATED,,,"['Leukemia', 'Hematology']","['CAT 3888', 'Moxetumomab pasudotox', 'Monoclonal antibodies']","['B4105', 'B439', 'B2833']","[['Antibody'], ['Antibody Drug Conjugate (ADC)'], []]","[['Antibody'], ['Antibody Drug Conjugate (ADC)'], []]","[['CD22'], ['CD22'], []]","[['CD22'], ['EEF2', 'CD22'], []]"
6231,NCT00191477,Instillation of Gemcitabine in Patients With Superficial Bladder Cancer,"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder",PHASE3,TERMINATED,31/1/2004,30/6/2008,31/3/2008,355,ACTUAL,,,['Urinary System Neoplasm'],"['Gemcitabine', 'Transurethral Resection of Bladder Tumor', 'Placebo Control']",['B2079'],[['Small Molecule']],[['Small Molecule']],"[['DNA', 'Ribonucleotide reductase']]","[['DNA', 'RNR']]"
57772,NCT00426101,Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004,HLH-2004 Treatment Protocol,PHASE3,COMPLETED,31/1/2004,31/12/2017,31/12/2011,368,ACTUAL,,,['Hemophagocytic Lymphohistiocytosis'],"['Dexamethasone', 'Etoposide', 'Cyclosporin', 'Methotrexate', 'Prednisolone', 'Intrathecal Chemotherapy', 'Hematopoietic Cell Transplantation']","['B1128', 'B1463', 'B2845', 'B997', 'B266']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Glucocorticoid receptor'], ['Top II inhibitors (Topoisomerase II inhibitors)'], [], ['Dihydrofolate reductase'], ['Glucocorticoid receptor']]","[['GR'], ['TOP2'], ['CaN'], ['DHFR'], ['GR']]"
28609,NCT02494596,"A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors","A Phase Ib, Open-Label, Multicenter Study of the Safety and Pharmacokinetics of the Combination of RhuMab 2C4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors",PHASE1,COMPLETED,31/1/2004,30/9/2005,30/9/2005,19,ACTUAL,,,['Solid Tumors'],"['Capecitabine', 'Pertuzumab-biosimilar-Biocad']","['B474', 'B6906']","[['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Monoclonal Antibody']]","[['Thymidylate synthase'], ['Receptor protein-tyrosine kinase erbB-2']]","[['TYMS'], ['HER2']]"
6675,NCT00226798,Immunochemotherapy for Metastatic Renal Cell Carcinoma,"Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study",PHASE2,UNKNOWN,31/12/2003,30/9/2005,,45,,,,['Epithelial Neoplasm'],['Capecitabine'],['B474'],[['Small Molecule']],[['Small Molecule']],[['Thymidylate synthase']],[['TYMS']]
18516,NCT01270906,Safety of CHIR-258 (TKI258) in Advanced Solid Tumors,"A Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodyniamics of CHIR-258 in Subjects With Advanced Solid Tumor Malignancies",PHASE1,TERMINATED,31/12/2003,,31/10/2006,35,ACTUAL,,,"['Neoplasms', 'Cancer', 'Tumors']",['dovitinib lactate'],['B9088'],[[]],[[]],[[]],[[]]
5829,NCT00154349,Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia,Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia,PHASE2,COMPLETED,31/10/2003,28/2/2007,28/2/2007,8,ACTUAL,,,['Philadelphia Chromosome Positive Acute Lymphocytic Leukemia'],['imatinib mesylate'],['B9326'],[[]],[[]],[[]],[[]]
11943,NCT00617968,GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer,"A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Consisting of Either a Docetaxel - Letrozole Combination or Letrozole Alone in Women Over 60 Years of Age Suffering From Grade I or II Operable Hormone Receptor-positive Breast Tumor.",PHASE2,COMPLETED,31/10/2003,30/6/2005,,5,ACTUAL,,,['Breast Neoplasm'],['Docetaxel'],['B2814'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
3998,NCT00069160,"Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer","A Clinical Trial of the P-Glycoprotein Antagonist, Tariquidar (XR9576), in Combination With Docetaxel in Patients With Lung, Ovarian, Renal and Cervical Cancer: Analysis of the Interaction Between Tariquidar and Docetaxel",PHASE2,COMPLETED,30/9/2003,31/12/2009,31/12/2009,48,ACTUAL,,,"['Thoracic Neoplasm', 'Female Reproductive System Neoplasm', 'Female Reproductive System Neoplasm', 'Urinary System Neoplasm']","['Docetaxel', 'Tariquidar', 'Technetium Tc-99m Sestamibi']","['B2814', 'B1002']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['P-glycoprotein 1']]","[['TUBB1'], ['P-gp']]"
4569,NCT00086931,"Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum",A Phase I/II Study of Weekly Intravenous Oxaliplatin in Combination With Oral Daily Capecitabine and Radiation Therapy in the Neoadjuvant Treatment of Rectal Cancer,PHASE1/PHASE2,COMPLETED,30/9/2003,31/5/2010,31/5/2007,37,ACTUAL,,,['Colorectal Cancer'],"['Capecitabine', 'Oxaliplatin', 'Conventional Surgery', 'Chemotherapy', 'Radiation Therapy']","['B474', 'B1229']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Thymidylate synthase'], ['DNA']]","[['TYMS'], ['DNA']]"
10429,NCT00504660,"6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients","Combination of 6-Thioguanine, Capecitabine, Celecoxib and Temozolomide or CCNU for Recurrent Anaplastic Glioma and Glioblastoma Multiforme",PHASE2,COMPLETED,30/9/2003,31/8/2010,31/8/2010,75,ACTUAL,,,"['WHO Grade 3 Glioma', 'Glioblastoma', 'Central Nervous System Neoplasm']","['Capecitabine', 'Celecoxib', 'Temozolomide', 'Lomustine', 'Tioguanine']","['B474', 'B72', 'B2056', 'B1807', 'B2887']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Thymidylate synthase'], ['Cyclooxygenase-2'], ['DNA'], ['DNA'], ['DNA']]","[['TYMS'], ['COX-2'], ['DNA'], ['DNA'], ['DNA']]"
10199,NCT00489983,Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy,A Multicenter Phase 2 Randomized Trial of Single-Agent ALIMTA or ALIMTA With Sequentially Administered GEMZAR as First-Line Chemotherapy in Elderly Patients or Patients Who Are Not Eligible for Platinum-Based Chemotherapy With Advanced NSCLC,PHASE2,COMPLETED,31/7/2003,31/3/2005,,91,ACTUAL,,,['Non-Small Cell Lung Cancer'],"['Pemetrexed', 'Gemcitabine']","['B814', 'B2079']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Dihydrofolate reductase', 'GAR transformylase', 'Thymidylate synthase'], ['DNA', 'Ribonucleotide reductase']]","[['DHFR', 'GART', 'TYMS'], ['DNA', 'RNR']]"
3817,NCT00061958,Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction,A Phase II Study of Arsenic Trioxide (NSC 706363) in Patients With Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction,PHASE2,TERMINATED,30/6/2003,,30/4/2005,50,ACTUAL,,,"['Esophageal Cancer', 'Esophageal Cancer', 'Esophageal Cancer']",['Arsenic trioxide'],['B2774'],[['Small Molecule']],[['Small Molecule']],[['Retinoic acid receptor alpha']],[['RARÎ±']]
3890,NCT00064311,Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation,"A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation",PHASE1/PHASE2,COMPLETED,30/6/2003,30/9/2004,,,,,,"['Breast Cancer', 'Myeloproliferative Neoplasm', 'Gestational Trophoblastic Neoplasia', 'Infectious Disorder', 'Leukemia', 'Hematology', 'Plasma Cell Neoplasm', 'Myelodysplastic Syndrome', 'Myeloid Neoplasm', 'Kidney Wilms Tumor', 'Ovarian Cancer', 'Male Reproductive System Neoplasm']",['Ravuconazole'],[],[],[],[],[]
7910,NCT00319618,Combination Weekly Taxotereâ„¢ With Iressaâ„¢ /Placebo in Metastatic Breast Cancer,A Randomised Phase II Study: Treatment With Daily p.o. Iressaâ„¢ (ZD1839) or Placebo in Combination With Weekly IV Infusion of Docetaxel in Patients With Metastatic Breast Cancer,PHASE2,COMPLETED,30/6/2003,30/6/2006,,66,,,,['Brain Metastasis'],"['Gefitinib', 'Docetaxel']","['B2097', 'B2814']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Epidermal growth factor receptor erbB1'], ['Tubulin beta-1 chain']]","[['EGFR'], ['TUBB1']]"
5950,NCT00168727,ZevalinÂ® Followed by RituxanÂ® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma,ZevalinÂ® (Ibritumomab Tiuxetan) Followed by RituxanÂ® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma,PHASE4,COMPLETED,1/6/2003,31/10/2005,,12,,,,"['Non-Hodgkin Lymphoma', 'Lymphoma, Low-Grade']",['Ibritumomab tiuxetan'],['B175'],[['Antibody Drug Conjugate (ADC)']],[['Antibody Drug Conjugate (ADC)']],[['B-lymphocyte antigen CD20']],[['CD20']]
3789,NCT00060645,"Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)","A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily x 5 Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies",PHASE1,COMPLETED,31/5/2003,28/2/2009,31/5/2006,33,ACTUAL,,,"['Tumors', 'Hematology', 'Multiple Myeloma']",['Ridaforolimus'],['B564'],[['Small Molecule']],[['Small Molecule']],"[['Mammalian target of Rapamycin', 'mTOR Complex 2']]","[['mTORC1', 'mTORC2']]"
5472,NCT00126269,Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary,A Randomized Phase III Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary and a Predicted Favorable Prognosis,PHASE3,UNKNOWN,31/5/2003,,,192,,,,['Epithelial Neoplasm'],"['Cisplatin', 'Gemcitabine']","['B49', 'B2079']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], ['DNA', 'Ribonucleotide reductase']]","[['DNA'], ['DNA', 'RNR']]"
10187,NCT00488709,"Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia",PHASE4,COMPLETED,31/5/2003,30/4/2007,,47,ACTUAL,,,['Acute Myeloid Leukemia'],"['Topotecan', 'Fludarabine', 'Cytarabine']","['B2067', 'B346', 'B2050']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA topoisomerase I'], ['Ribonucleotide reductase', 'RNA polymerase II'], ['DNA-directed DNA polymerase']]","[['TOP1'], ['DNA polymerase III', 'RNR', 'RNA polymerase II'], ['DNA-directed DNA polymerase']]"
16703,NCT01085058,"Predictive Value of the ""Cytocapacity Test"" Patients With Lymphoproliferative Diseases and High-dose Therapy","Predictive Value of the ""Cytocapacity Test"" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy",PHASE2/PHASE3,COMPLETED,31/5/2003,31/12/2004,31/12/2004,169,ACTUAL,,,"['Hodgkin Lymphoma', 'Non-Hodgkin Lymphoma', 'Multiple Myeloma']",['Lenograstim'],['B733'],[['Other Protein Therapy']],[['Colony-Stimulating Factor']],[['Colony stimulating factor 3 receptor']],[['CSF-3R']]
6296,NCT00193479,"Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma","A Phase II Trial of Brief Duration Combination Chemotherapy and Rituximab With Prophylactic Pegfilgrastim, Followed by Maintenance Rituximab, in Elderly/Poor Performance Status Patients With Large B-Cell Non-Hodgkin's Lymphoma",PHASE2,COMPLETED,30/4/2003,28/2/2010,31/7/2008,51,ACTUAL,,,['Non-Hodgkin Lymphoma'],"['Cyclophosphamide', 'Mitoxantrone', 'Vincristine', 'Prednisone', 'Rituximab']","['B2818', 'B1952', 'B2083', 'B1979', 'B163']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Antibody']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody']]","[['DNA'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['Tubulin beta-1 chain'], ['Glucocorticoid receptor'], ['B-lymphocyte antigen CD20']]","[['DNA'], ['DNA', 'TOP2'], ['TUBB1'], ['GR'], ['CD20']]"
9425,NCT00431561,Phase IIb Clinical Trial With TGF-Î²2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma,"Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week",PHASE2,COMPLETED,30/4/2003,31/3/2009,31/3/2009,141,ACTUAL,,,"['Glioblastoma', 'Anaplastic Astrocytoma']","['Trabedersen', 'Temozolomide', 'Procarbazine', 'Lomustine', 'Vincristine', 'Drug Delivery System', 'Intratumoral Route of Administration']","['B659', 'B2056', 'B267', 'B1807', 'B2083']","[['Antisense Oligonucleotide (ASO)'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Antisense Oligonucleotide (ASO)'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['TGF-Beta 2 mRNA'], ['DNA'], ['DNA'], ['DNA'], ['Tubulin beta-1 chain']]","[['TGF-B2 mRNA'], ['DNA'], ['DNA'], ['DNA'], ['TUBB1']]"
3787,NCT00060567,Dose-Finding Study of E7070 in Combination With Irinotecan,Phase I Dose-Finding Study of E7070 in Combination With Irinotecan,PHASE1,COMPLETED,31/3/2003,31/3/2013,31/3/2013,88,ACTUAL,,,['Cancer'],"['Indisulam', 'Irinotecan']","['B2038', 'B1679']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DDB1 and CUL4 associated factor 15', 'RNA binding motif protein 39'], ['DNA topoisomerase I']]","[['DCAF15', 'RBM39'], ['TOP1']]"
4060,NCT00071955,Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma,"A Phase II Study to Evaluate Safety and Efficacy of Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH and GM-CSF Following the Anti-CD20 Antibody, Rituximab, in Previously Treated Patients With Follicular Non-Hodgkin's Lymphoma",PHASE2,COMPLETED,31/3/2003,31/1/2009,,,,,,['Hematology'],"['Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine', 'Sargramostim']",['B181'],[['Other Protein Therapy']],[['Colony-Stimulating Factor']],[['Granulocyte-macrophage colony-stimulating factor receptor']],[['CSF-2R']]
3771,NCT00060242,Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer,Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid,PHASE2,COMPLETED,28/2/2003,31/1/2008,28/2/2007,26,ACTUAL,,,['Head and Neck Neoplasm'],['fosbretabulin disodium'],['B8420'],[[]],[[]],[[]],[[]]
5431,NCT00122499,A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer,A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer,PHASE3,COMPLETED,28/2/2003,28/2/2005,,,,,,"['Prostate Cancer', 'Erectile Dysfunction']",['Tadalafil'],['B2040'],[['Small Molecule']],[['Small Molecule']],[['Phosphodiesterase 5A']],[['PDE5A']]
3792,NCT00060710,CP-461 in the Treatment of Patients With Advanced Melanoma,Phase II Study of CP-461 in the Treatment of Patients With Advanced Melanoma,PHASE2,TERMINATED,31/1/2003,31/12/2004,,35,,,,['Malignant Melanoma'],['Proapoptotic Sulindac Analog CP-461'],[],[],[],[],[]
8117,NCT00334295,Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.,"An Open, Non-randomised Multicentre Phase II Study to Assess the Efficacy and Tolerability of a 250 mg Monthly Dose of i.m. Applied Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.",PHASE2,COMPLETED,31/12/2002,31/1/2011,31/1/2011,35,ACTUAL,,,['Endometrial Cancer'],['Fulvestrant'],['B276'],[['Small Molecule']],[['Small Molecule']],[['Estrogen receptors']],[['ER']]
3709,NCT00058006,Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer,Pilot Randomized Trial Of Adjuvant Celecoxib In Patients With Early Stage Head And Neck And Non-Small Cell Lung Cancers,PHASE2,COMPLETED,30/9/2002,31/12/2006,31/12/2006,,,,,"['Head and Neck Neoplasm', 'Thoracic Neoplasm']","['Celecoxib', 'Adjuvant Therapy']",['B72'],[['Small Molecule']],[['Small Molecule']],[['Cyclooxygenase-2']],[['COX-2']]
3371,NCT00047242,UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors,"The Pharmacokinetic and Safety Profile of UCN-01 in Combination With Irinotecan in Solid Tumors (Primarily Lung, Ovarian and GI Cancers)",PHASE1,COMPLETED,31/8/2002,,28/2/2006,30,ESTIMATED,,,['Solid Tumors'],"['UCN 01', 'irinotecan hydrochloride']","['B2137', 'B9055']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['3-phosphoinositide-dependent protein kinase 1', 'Checkpoint kinase 1', 'Protein kinase C'], []]","[['PDK1', 'Chk1', 'PKC'], []]"
5775,NCT00149019,Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.,Innovative Approaches for Targeted Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.,PHASE2,WITHDRAWN,31/5/2002,30/9/2005,,12,ESTIMATED,,,['Epithelial Neoplasm'],['T-cell Engaging Bispecific Antibody'],[],[],[],[],[]
9661,NCT00448643,Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery,A Phase I Study Using Abdominal Radiotherapy as a Cisplatin Chemosensitizer for Optimally Debulked Stage III/IV Carcinoma of the Endometrium,PHASE1,COMPLETED,31/5/2002,31/3/2011,31/3/2011,12,ACTUAL,,,['Endometrial Cancer'],"['Carboplatin', 'Paclitaxel', 'Cisplatin', 'Whole-Abdominal Irradiation', 'High-Dose-Rate Vaginal Brachytherapy']","['B274', 'B1250', 'B49']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Tubulin beta-1 chain'], ['DNA']]","[['DNA'], ['TUBB1'], ['DNA']]"
3274,NCT00044525,Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients,An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY59-8862 in Patients With Taxane-Resistant Metastatic Breast Cancer,PHASE2,COMPLETED,30/4/2002,29/2/2004,29/2/2004,82,ACTUAL,,,"['Breast Neoplasm', 'Breast Cancer']",['Ortataxel'],['B1114'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
7022,NCT00256230,Disulfiram in Patients With Metastatic Melanoma,"Evaluation of Disulfiram in Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy, Phase I/II",PHASE1/PHASE2,COMPLETED,31/1/2002,31/8/2007,31/8/2007,7,ACTUAL,,,['Skin Melanoma'],['Disulfiram'],['B2106'],[['Small Molecule']],[['Small Molecule']],[['Aldehyde dehydrogenase']],[['ALDH2']]
2643,NCT00023933,Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer,Phase I Trial of 131I-HuCC49^CH2 for Colon Cancer,PHASE1,COMPLETED,31/10/2001,,31/7/2005,15,ACTUAL,,,"['Colon Carcinoma', 'Rectal Carcinoma', 'Colon Carcinoma', 'Rectal Carcinoma', 'Colon Carcinoma', 'Rectal Carcinoma']",['Iodine I 131 Monoclonal Antibody CC49-deltaCH2'],[],[],[],[],[]
57702,NCT00328549,A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV),A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN,PHASE2,COMPLETED,31/10/2001,31/12/2002,,105,ACTUAL,,,"['Hepatitis C', 'Anemia']","['Pegylated Interferon Alfa', 'Ribavirin']",['B372'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
2668,NCT00024310,"Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors",A Phase I Trial of Lometrexol Sodium and Paclitaxel Adminsitered Intravenously Every 21 Days in Conjunction With Oral Folic Acid in Patients With Solid Tumors,PHASE1,UNKNOWN,30/9/2001,,,,,,,"['Solid Tumors', 'Drug/Agent Toxicity by Tissue/Organ']","['Folic acid', 'Lometrexol', 'Paclitaxel']","['B366', 'B999', 'B1250']","[[], ['Small Molecule'], ['Small Molecule']]","[[], ['Small Molecule'], ['Small Molecule']]","[['Folate receptor'], ['Enzymes'], ['Tubulin beta-1 chain']]","[['Folate receptor'], ['Enzymes'], ['TUBB1']]"
2852,NCT00030069,Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes,Calcitriol and Dexamethasone for Myelodysplastic Syndromes,PHASE2,COMPLETED,30/9/2001,31/5/2009,30/9/2007,32,ACTUAL,,,['Myelodysplastic Syndrome'],"['Calcitriol', 'Dexamethasone']","['B2070', 'B1128']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Vitamin D receptor'], ['Glucocorticoid receptor']]","[['VDR'], ['GR']]"
3473,NCT00050843,A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes,,PHASE3,COMPLETED,31/8/2001,29/2/2004,,220,,,,['Myelodysplastic Syndrome'],['Thalidomide'],['B1641'],[['Small Molecule']],[['Molecular glue']],"[['Alpha-1-acid glycoprotein 1', 'Alpha-1-acid glycoprotein 2', 'Cereblon', 'DNA-binding protein Ikaros', 'Sal-like protein 4', 'Tumor necrosis factor', 'Zinc finger protein Aiolos']]","[['AGP1', 'AGP2', 'CRBN', 'IKZF1', 'SALL4', 'TNF', 'IKZF3']]"
3211,NCT00041808,Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver,"A Phase I/II Single Dose Trial to Determine The Safety, Tolerance, Pharmacokinetic Profile, and Preliminary Activity of Intrahepatic Delivery (Via Hepatic Artery Catheterization) of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers ( MTC-DOX) in Patients With Metastatic Cancer to the Liver .",PHASE1/PHASE2,COMPLETED,31/7/2001,30/4/2003,,20,,,,"['Metastases, Neoplasm', 'Digestive System Neoplasm', 'Digestive System Neoplasm', 'Digestive System Neoplasm', 'Pancreatic Cancer', 'Breast Neoplasm', 'Male Reproductive System Neoplasm', 'Sarcoma', 'Digestive System Neoplasm', 'Thoracic Neoplasm', 'Liver Cancer', 'Bile Duct Cancer']","['MTC DOX', 'Chemotherapy']",['B6298'],[['Small Molecule']],[['Small Molecule']],[[]],[[]]
9016,NCT00403624,Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer,Clinical Study to Evaluate a Protocol of Oxaliplatin -UFT- Radiotherapy for the Neoadjuvant Treatment Rectal Cancer,PHASE1/PHASE2,COMPLETED,31/7/2001,30/11/2005,30/11/2005,38,,,,['Digestive System Neoplasm'],['Oxaliplatin'],['B1229'],[['Small Molecule']],[['Small Molecule']],[['DNA']],[['DNA']]
11561,NCT00586898,Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle,Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle,PHASE2,COMPLETED,31/7/2001,31/3/2009,31/3/2009,36,ACTUAL,,,"['Male Reproductive System Neoplasm', 'Cancer', 'Hormonal Cycling']","['Leuprorelin', 'Goserelin', 'Ketoconazole', 'Bicalutamide', 'Testosterone', 'Estradiol']","['B2805', 'B121', 'B349', 'B1219', 'B1129', 'B273']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], []]","[['Hormone'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], []]","[['Gonadotropin-releasing hormone receptor'], ['Gonadotropin-releasing hormone receptor'], [], ['Androgen Receptor'], ['Androgen Receptor'], ['Estrogen receptors']]","[['GnRHR'], ['GnRHR'], ['C14DM'], ['AR'], ['AR'], ['ER']]"
3103,NCT00038649,"Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C",Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Higher-Dose Gleevec (STI571),PHASE2,TERMINATED,30/6/2001,30/11/2013,30/11/2013,117,ACTUAL,,,['Chronic Leukemia'],['imatinib mesylate'],['B9326'],[[]],[[]],[[]],[[]]
2283,NCT00014118,Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer,A Phase II Trial OF Chemoradiation For Organ Preservation In Resectable Stage III or IV Squamous Cell Carcinomas Of The Larynx Or Oropharynx,PHASE2,COMPLETED,6/6/2001,31/5/2009,31/3/2007,,,,,['Head and Neck Neoplasm'],"['Carboplatin', 'Paclitaxel', 'Conventional Surgery', 'Radiation Therapy']","['B274', 'B1250']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Tubulin beta-1 chain']]","[['DNA'], ['TUBB1']]"
2788,NCT00027742,Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma,A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma,PHASE2,COMPLETED,31/5/2001,30/6/2005,30/6/2005,,,,,"['Uveal Melanoma', 'Skin Melanoma']","['Peginterferon alfa-2a', 'Temozolomide']","['B151', 'B2056']","[['Other Protein Therapy'], ['Small Molecule']]","[['Interferon'], ['Small Molecule']]","[['Interferon alpha/beta receptor'], ['DNA']]","[['IFNAR'], ['DNA']]"
6522,NCT00211198,Study of ONTAKÂ® to Treat Cutaneous T-Cell Lymphoma (CTCL),"Open Label Study of ONTAKÂ® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status",PHASE4,COMPLETED,31/5/2001,31/1/2006,31/1/2005,60,,,,['Adult T-Cell Leukemia/Lymphoma'],['Denileukin diftitox'],['B150'],[['Toxin Fusion Protein (Immunotoxin)']],[['Toxin Fusion Protein (Immunotoxin)']],[['Interleukin-2 receptor alpha chain']],[['IL2RA']]
2322,NCT00014690,"ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","A Phase II, Open, Randomized Multicenter Trial to Assess the Efficacy and Tolerability of Intravenous ZD9331 Given as Monotherapy (at Two Doses) or in Combination With Topotecan, in Patients With Ovarian Cancer Refractory or Recurrent After Failing Platinum and Paclitaxel in Combination",PHASE2,COMPLETED,31/3/2001,29/2/2004,,,,,,"['Fallopian Tube Cancer', 'Ovarian Cancer', 'Primary Peritoneal Cancer']","['Clevidipine', 'topotecan hydrochloride']","['B240', 'B9293']","[['Small Molecule'], []]","[['Small Molecule'], []]","[['Voltage-gated L-type calcium channel'], []]","[['L-type calcium channel'], []]"
2582,NCT00022334,Vaccine Therapy in Treating Patients With Liver Cancer,A Phase I/II Trial Testing Immunization With Dendritic Cells Pulsed With Four AFP Peptides in Patients With Hepatocellular Carcinoma,PHASE1/PHASE2,COMPLETED,31/1/2001,31/10/2008,31/12/2004,33,ACTUAL,,,['Liver Cancer'],['Alpha-Fetoprotein'],[],[],[],[],[]
11100,NCT00550784,"Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",Phase I Trial of Tandem Chemotherapy Cycles as Consolidation Therapy for High-Risk Epithelial Ovarian and Primary Peritoneal Cancer Utilizing Intraperitoneal Paclitaxel/IV Cyclophosphamide Followed by IV Topotecan/Intraperitoneal Cisplatin/IV Melphalan Using Hematopoietic Stem Cell Support,PHASE1,COMPLETED,31/1/2001,31/10/2014,31/10/2014,8,ACTUAL,,,"['Fallopian Tube Cancer', 'Ovarian Cancer', 'Peritoneal and Retroperitoneal Neoplasm']","['Filgrastim', 'Cisplatin', 'Cyclophosphamide', 'Melphalan', 'Paclitaxel', 'topotecan hydrochloride', 'TdT-Mediated dUTP Nick End Labeling Assay', 'Gene Expression Analysis', 'Immunohistochemistry Staining Method', 'Peripheral Blood Stem Cell Transplantation']","['B157', 'B49', 'B2818', 'B2073', 'B1250', 'B9293']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Colony-Stimulating Factor'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Colony stimulating factor 3 receptor'], ['DNA'], ['DNA'], ['DNA'], ['Tubulin beta-1 chain'], []]","[['CSF-3R'], ['DNA'], ['DNA'], ['DNA'], ['TUBB1'], []]"
2039,NCT00006257,SU5416 and Paclitaxel in Treating Patients With Advanced Cancer,Phase I Trial of SU5416 in Combination With Weekly Paclitaxel in Patients With Advanced Malignancies,PHASE1,COMPLETED,30/11/2000,,,,,,,['Solid Tumors'],"['Paclitaxel', 'Semaxanib']","['B1250', 'B880']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['Vascular endothelial growth factor receptor 2']]","[['TUBB1'], ['VEGFR2']]"
2129,NCT00006484,Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer,PHASE3,COMPLETED,30/11/2000,30/4/2006,,,,,,['Thoracic Neoplasm'],"['Carboplatin', 'Paclitaxel', 'Tirapazamine']","['B274', 'B1250', 'B1714']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Tubulin beta-1 chain'], ['Top II inhibitors (Topoisomerase II inhibitors)']]","[['DNA'], ['TUBB1'], ['TOP2']]"
1476,NCT00004208,Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome,Antithymocyte Globulin (ATG) and Cyclosporine (CSA) to Treat Patients With Myelodysplastic Syndrome (MDS). A Randomized Trial Comparing ATG + CSA With Best Supportive Care,PHASE3,COMPLETED,31/8/2000,31/10/2011,31/10/2006,86,ACTUAL,,,['Myelodysplastic Syndrome'],"['Antithymocyte Globulin Equine/Cyclosporine Regimen', 'Cyclosporin']",['B2845'],[['Small Molecule']],[['Small Molecule']],[[]],[['CaN']]
2193,NCT00008294,Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer,A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer,PHASE1,COMPLETED,31/8/2000,,31/5/2006,,,,,"['Colorectal Cancer', 'Anal Cancer']","['FOLFOX', 'Dexamethasone', 'Floxuridine', 'Fluorouracil', 'leucovorin calcium', 'Oxaliplatin']","['B1128', 'B2088', 'B493', 'B8438', 'B1229']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule']]","[['Glucocorticoid receptor'], ['Thymidylate synthase'], ['Thymidylate synthase'], [], ['DNA']]","[['GR'], ['TYMS'], ['TYMS'], [], ['DNA']]"
1977,NCT00006107,Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer,Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT),PHASE1,COMPLETED,14/7/2000,3/7/2004,17/7/2003,31,ACTUAL,,,['Head and Neck Neoplasm'],"['Docetaxel', 'Surgical Procedure', 'Radiation Therapy']",['B2814'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
1790,NCT00005841,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,A Phase I Trial of a Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 With ProGP for Patients With Resected Stages III and IV Melanoma,PHASE1,TERMINATED,30/6/2000,31/10/2002,31/12/2000,15,ACTUAL,,,"['Uveal Melanoma', 'Skin Melanoma']","['MART-1 Antigen', 'gp100 Antigen', ""Incomplete Freund's adjuvant"", 'Progenipoietin', 'Tyrosinase Peptide']",['B1603'],[['Vaccine Adjuvant']],[['Vaccine Adjuvant']],[[]],[[]]
1991,NCT00006122,Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia,Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study,PHASE2,COMPLETED,30/6/2000,,31/1/2002,106,ACTUAL,,,['Leukemia'],"['Cytarabine', 'Etoposide', 'Gemtuzumab ozogamicin', 'Idarubicin', 'mitoxantrone hydrochloride']","['B2050', 'B1463', 'B145', 'B41', 'B9162']","[['Small Molecule'], ['Small Molecule'], ['Antibody Drug Conjugate (ADC)'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], ['Antibody Drug Conjugate (ADC)'], ['Small Molecule'], []]","[['DNA-directed DNA polymerase'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA', 'Myeloid cell surface antigen CD33'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], []]","[['DNA-directed DNA polymerase'], ['TOP2'], ['DNA', 'CD33'], ['DNA', 'TOP2'], []]"
1989,NCT00006120,Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer,Phase II Randomized Study of Two Different Schedules of Docetaxel or Paclitaxel for Metastatic Breast Cancer,PHASE2,UNKNOWN,31/5/2000,,,,,,,['Breast Cancer'],"['Docetaxel', 'Paclitaxel']","['B2814', 'B1250']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Tubulin beta-1 chain'], ['Tubulin beta-1 chain']]","[['TUBB1'], ['TUBB1']]"
2323,NCT00015821,Thalidomide in Treating Patients With Myelofibrosis,A Pilot Study of Thalidomide as an Inhibitor of Angiogenesis in the Treatment of Myelofibrosis With Myeloid Metaplasia (MMM),PHASE2,COMPLETED,31/5/2000,,31/12/2007,43,ESTIMATED,,,['Primary Myelofibrosis'],"['Thalidomide', 'Laboratory Biomarker Analysis']",['B1641'],[['Small Molecule']],[['Molecular glue']],"[['Alpha-1-acid glycoprotein 1', 'Alpha-1-acid glycoprotein 2', 'Cereblon', 'DNA-binding protein Ikaros', 'Sal-like protein 4', 'Tumor necrosis factor', 'Zinc finger protein Aiolos']]","[['AGP1', 'AGP2', 'CRBN', 'IKZF1', 'SALL4', 'TNF', 'IKZF3']]"
1806,NCT00005858,"LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer","Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Anti-Lewis Y Immunotoxin Admistered by Continuous Infusion",PHASE1,COMPLETED,30/4/2000,31/12/2003,31/12/2003,25,ACTUAL,,,"['Bladder Cancer', 'Breast Cancer', 'Colorectal Cancer', 'Thoracic Neoplasm', 'Ovarian Cancer', 'Pancreatic Cancer']",['LMB 9'],['B6230'],[['Antibody']],[['Antibody Fragment Drug Conjugate']],[['Lewis-Y antigen']],[['Lewis-Y antigen']]
17051,NCT01122121,"Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer","Comparative Efficacy and Safety of Combined Radiotherapy and Adjuvant Hormone Therapy (Leuprorelin SR 11.25 mg) and Hormone Therapy Alone (Leuprorelin SR 11.25 mg) in Locally Advanced Prostate Cancer (T3-T4 or pT3 on Biopsy, N0, M0)",PHASE3,COMPLETED,31/3/2000,30/6/2009,31/12/2008,273,ACTUAL,,,['Prostate Cancer'],"['leuprolide acetate', 'Radiation Therapy', 'Flutamide']","['B9379', 'B2052']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], ['Androgen Receptor']]","[[], ['AR']]"
21886,NCT01663714,Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.,"Phase II Multicenter Study of Cyclophosphamide, Vincristine, and Prednisone (CVP) Followed by Iodine-131 Anti-B1 Antibody for Patients With Untreated Low-grade Non-Hodgkin's Lymphoma (NHL).",PHASE2,COMPLETED,29/2/2000,29/2/2012,29/2/2012,30,ACTUAL,,,['Non-Hodgkin Lymphoma'],"['Cyclophosphamides', 'Vincristine', 'Prednisone', 'Tositumomab', 'Iodine I 131 tositumomab']","['B3286', 'B2083', 'B1979', 'B173', 'B7755']","[[], ['Small Molecule'], ['Small Molecule'], ['Antibody'], []]","[[], ['Small Molecule'], ['Small Molecule'], ['Monoclonal Antibody'], []]","[['DNA'], ['Tubulin beta-1 chain'], ['Glucocorticoid receptor'], ['B-lymphocyte antigen CD20'], ['B-lymphocyte antigen CD20']]","[['DNA'], ['TUBB1'], ['GR'], ['CD20'], ['CD20']]"
2615,NCT00022932,Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP,Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-Line CHOP,PHASE2,UNKNOWN,31/1/2000,,,,,,,['Non-Hodgkin Lymphoma'],['Iodine I 131 tositumomab'],['B7755'],[[]],[[]],[['B-lymphocyte antigen CD20']],[['CD20']]
18061,NCT01225874,Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL,"ALinC 17, Classification Â©), B-precursor Induction Treatment (I)",,COMPLETED,31/12/1999,,31/3/2006,3762,ACTUAL,,,['Leukemia'],"['Calaspargase pegol', 'Cytarabine', 'daunorubicin hydrochloride', 'Dexamethasone', 'Methotrexate', 'Pegaspargase', 'Prednisone', 'vincristine sulfate']","['B711', 'B2050', 'B8625', 'B1128', 'B997', 'B675', 'B1979', 'B9307']","[['Other Protein Therapy'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Other Protein Therapy'], ['Small Molecule'], []]","[['Enzyme'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Enzyme'], ['Small Molecule'], []]","[['Asparagine'], ['DNA-directed DNA polymerase'], [], ['Glucocorticoid receptor'], ['Dihydrofolate reductase'], ['Asparagine'], ['Glucocorticoid receptor'], []]","[['ASN'], ['DNA-directed DNA polymerase'], [], ['GR'], ['DHFR'], ['ASN'], ['GR'], []]"
1443,NCT00004172,"Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer",Peripheral Stem Cell Transplantation Protocol for Patients With Previously Treated Advanced Breast Cancer - A Phase II Pilot Study,PHASE2,COMPLETED,31/10/1999,31/10/2003,31/10/2003,,,,,['Breast Cancer'],"['Filgrastim', 'Carboplatin', 'Cyclophosphamide', 'Ifosfamide', 'Thiotepa', 'Peripheral Blood Stem Cell Transplantation', 'Radiation Therapy']","['B157', 'B274', 'B2818', 'B8', 'B1998']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Colony-Stimulating Factor'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Colony stimulating factor 3 receptor'], ['DNA'], ['DNA'], ['DNA'], ['DNA']]","[['CSF-3R'], ['DNA'], ['DNA'], ['DNA'], ['DNA']]"
1444,NCT00004173,Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer,A Phase I Study of Oxaliplatin in Combination With Paclitaxel,PHASE1,UNKNOWN,31/10/1999,,,,,,,['Solid Tumors'],"['Oxaliplatin', 'Paclitaxel']","['B1229', 'B1250']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Tubulin beta-1 chain']]","[['DNA'], ['TUBB1']]"
1178,NCT00003810,Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas,A Phase II Study of Gemcitabine and Docetaxel in Pancreatic Adenocarcinoma,PHASE2,COMPLETED,11/8/1999,,31/5/2002,,,,,['Pancreatic Cancer'],"['Docetaxel', 'gemcitabine hydrochloride']","['B2814', 'B9303']","[['Small Molecule'], []]","[['Small Molecule'], []]","[['Tubulin beta-1 chain'], []]","[['TUBB1'], []]"
11286,NCT00563862,Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0),Prospective Randomized Study on Therapeutic Gain Achieved By Chemoradiation And/Or Accelerated Radiation For T3-4N0-1M0 Nasopharyngeal Carcinoma,,TERMINATED,31/7/1999,30/6/2007,,465,ACTUAL,,,"['Head and Neck Neoplasm', 'Epithelial Neoplasm']","['Conventional Radiotherapy', 'Accelerated Radiation Therapy', 'Cisplatin', 'Fluorouracil']","['B49', 'B493']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Thymidylate synthase']]","[['DNA'], ['TYMS']]"
1432,NCT00004158,Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,A Phase I/II Study of Targeted Radiotherapy Using Holmium-166-DOTMP With Melphalan and Peripheral Blood Stem Cell Transplantation for Treatment of Multiple Myeloma,PHASE1/PHASE2,COMPLETED,30/6/1999,31/1/2006,,,,,,['Plasma Cell Neoplasm'],"['Melphalan', 'Peripheral Blood Stem Cell Transplantation', 'Ho 166 DOTMP']",['B2073'],[['Small Molecule']],[['Small Molecule']],[['DNA']],[['DNA']]
1046,NCT00003645,Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence,A Phase III Randomized Prospective Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence,PHASE3,TERMINATED,14/6/1999,20/3/2017,20/3/2017,64,ACTUAL,,,['Prostate Cancer'],"['Flutamide', 'leuprolide acetate']","['B2052', 'B9379']","[['Small Molecule'], []]","[['Small Molecule'], []]","[['Androgen Receptor'], []]","[['AR'], []]"
1158,NCT00003779,Biological Therapy in Treating Patients With Bladder Cancer,A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ,PHASE3,COMPLETED,30/11/1998,30/6/2010,30/6/2001,40,ACTUAL,,,['Bladder Cancer'],['BCG vaccine'],['B722'],[['Live biotherapeutics']],[['Live biotherapeutics']],[[]],[[]]
1061,NCT00003664,Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically,"Combination Chemobiotherapy With Gemcitabine, 5-Fluorouracil, Interleukin-2 and Alpha Interferon in Patients With Metastatic or Unresectable Renal Cell Cancer. A Phase II Study",PHASE2,UNKNOWN,31/10/1998,,,30,ESTIMATED,,,['Kidney Cancer'],"['Aldesleukin', 'Interferon alpha-2b', 'Fluorouracil', 'gemcitabine hydrochloride']","['B136', 'B2811', 'B493', 'B9303']","[['Other Protein Therapy'], ['Other Protein Therapy'], ['Small Molecule'], []]","[['Interleukin'], ['Interferon'], ['Small Molecule'], []]","[['Interleukin-2 receptor'], ['Interferon alpha/beta receptor'], ['Thymidylate synthase'], []]","[['IL-2R'], ['IFNAR'], ['TYMS'], []]"
1076,NCT00003682,Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer,Treatment of Metastatic Prostate Cancer That is Hormone-Independent: Evaluation of the Role of Chemotherapy on the Quality of Life of Patients. Phase II Study,PHASE3,TERMINATED,31/10/1998,31/3/2001,31/3/2001,160,ESTIMATED,,,['Prostate Cancer'],"['doxorubicin hydrochloride', 'Methylprednisolone']","['B9124', 'B1988']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], ['Glucocorticoid receptor']]","[[], ['GR']]"
1470,NCT00004202,"Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer",A Phase II Study of Induction Chemotherapy With Paclitaxel and Carboplatin Followed by Radiation Therapy With RSR13 for Locally Advanced Inoperable Non-Small Cell Lung Cancer,PHASE2,COMPLETED,31/10/1998,31/1/2003,31/1/2003,,,,,['Thoracic Neoplasm'],"['Carboplatin', 'Chemotherapy', 'Efaproxiral', 'Paclitaxel', 'Radiation Therapy']","['B274', 'B502', 'B1250']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['Sickle haemoglobin'], ['Tubulin beta-1 chain']]","[['DNA'], ['Sickle haemoglobin'], ['TUBB1']]"
884,NCT00003447,Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,Vinorelbine Versus Gemcitabine Versus Gemcitabine and Vinorelbine in Elderly Patients With Stage IIIB-IV Non-Small Cell Lung Cancer,PHASE3,UNKNOWN,31/7/1998,,,630,ESTIMATED,,,['Thoracic Neoplasm'],"['gemcitabine hydrochloride', 'vinorelbine tartrate']","['B9303', 'B9142']","[[], []]","[[], []]","[[], []]","[[], []]"
898,NCT00003463,Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas,Phase I Treatment of Adults With Recurrent Supratentorial High Grade Glioma With Gliadel Wafers Plus Irinotecan (CPT-11),PHASE1,COMPLETED,31/7/1998,31/7/2002,31/7/2002,,,,,['Central Nervous System Embryonal Tumor'],"['Carmustine', 'irinotecan hydrochloride', 'Polifeprosan 20', 'Surgical Procedure']","['B1806', 'B9055']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['DNA'], []]","[['DNA'], []]"
1079,NCT00003687,Treatment for Chronic Pain in Patients With Advanced Cancer,A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients,PHASE3,COMPLETED,11/6/1998,10/2/2009,26/9/2001,87,ACTUAL,,,"['Myeloproliferative Neoplasm', 'Leukemia', 'Hematology', 'Plasma Cell Neoplasm', 'Myelodysplastic Syndrome', 'Connective and Soft Tissue Neoplasm', 'Intraepithelial Neoplasia', 'Small Intestinal Cancer', 'Solid Tumors']","['dextromethorphan hydrobromide', 'morphine sulfate']","['B9091', 'B9224']","[[], []]","[[], []]","[[], []]","[[], []]"
730,NCT00003239,Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia,"Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT)",PHASE2,COMPLETED,31/3/1998,31/10/2001,31/10/2001,90,ACTUAL,,,['Leukemia'],"['Interferon alpha-2b', 'Cytarabine', 'Omacetaxine mepesuccinate']","['B2811', 'B2050', 'B1561']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule']]","[['Interferon'], ['Small Molecule'], ['Small Molecule']]","[['Interferon alpha/beta receptor'], ['DNA-directed DNA polymerase'], []]","[['IFNAR'], ['DNA-directed DNA polymerase'], ['80s ribosome']]"
707,NCT00003210,Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease,A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease,PHASE2,COMPLETED,28/2/1998,30/11/2003,30/11/2003,105,ACTUAL,,,"['Extranodal Marginal Zone Lymphoma', 'Nodal Marginal Zone Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Recurrent Adult Diffuse Mixed Cell Lymphoma', 'Recurrent Adult Diffuse Small Cleaved Cell Lymphoma', 'Hodgkin Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'Primary Cutaneous T-Cell Non-Hodgkin Lymphoma', 'Grade 1 Follicular Lymphoma', 'Grade 2 Follicular Lymphoma', 'Grade 3 Follicular Lymphoma', 'Mantle Cell Lymphoma', 'Marginal Zone Lymphoma', 'Mycosis Fungoides and Sezary Syndrome', 'Small Lymphocytic Lymphoma', 'Splenic Marginal Zone Lymphoma', 'Waldenstrom Macroglobulinemia']","['Edodekin alfa', 'Laboratory Biomarker Analysis']",['B730'],[['Other Protein Therapy']],[['Interleukin']],[['Cytokines']],[['Cytokines']]
693,NCT00003193,Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer,Phase I/II Study of Escalating Doses of Taxol Used Concurrently With Ethyol and Accelerated Hyperfractionated Radiotherapy in the Treatment of Stage III and IV Carcinoma of the Head and Neck,PHASE1/PHASE2,COMPLETED,31/1/1998,30/9/2005,30/9/2005,37,ESTIMATED,,,"['Head and Neck Neoplasm', 'Oral Complications']","['Amifostine', 'Paclitaxel', 'Conventional Surgery', 'Radiation Therapy']","['B3', 'B1250']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['Alkaline phosphatase, tissue-nonspecific isozyme'], ['Tubulin beta-1 chain']]","[['TNSALP'], ['TUBB1']]"
811,NCT00003357,Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease,Vaccination of High Risk Breast Cancer Patients Lacking Identifiable Disease With GM2-KLH Conjugate Plus the Immunological Adjuvant QS21,PHASE1,COMPLETED,31/1/1998,30/11/2001,30/11/2001,9,ESTIMATED,,,['Breast Cancer'],"['GM2-KLH Vaccine', 'QS 21']",['B3233'],[['Engineered Protein Therapy']],[['Synthetic Peptide']],[[]],[[]]
640,NCT00003128,"Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus","A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus",PHASE3,COMPLETED,30/11/1997,,28/2/2007,166,ESTIMATED,,,['Sarcoma'],"['Filgrastim', 'Ifosfamide', 'Paclitaxel']","['B157', 'B8', 'B1250']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule']]","[['Colony-Stimulating Factor'], ['Small Molecule'], ['Small Molecule']]","[['Colony stimulating factor 3 receptor'], ['DNA'], ['Tubulin beta-1 chain']]","[['CSF-3R'], ['DNA'], ['TUBB1']]"
1436,NCT00004162,Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma,Phase I Trial of Liposomal Doxorubicin (Doxil) Based Combination Chemotherapy Regimen in AIDS-Associated Non-Hodgkin's Lymphoma,PHASE1,COMPLETED,30/6/1997,31/1/2001,31/1/2001,48,ESTIMATED,,,['Hematology'],"['Sargramostim', 'Methotrexate', 'Pegylated liposomal doxorubicin', 'vincristine sulfate']","['B181', 'B997', 'B2819', 'B9307']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], []]","[['Colony-Stimulating Factor'], ['Small Molecule'], ['Small Molecule'], []]","[['Granulocyte-macrophage colony-stimulating factor receptor'], ['Dihydrofolate reductase'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], []]","[['CSF-2R'], ['DHFR'], ['DNA', 'TOP2'], []]"
57378,NCT00001626,Comparing Therapies for the Treatment of Severe Aplastic Anemia,A Randomized Trial of Antithymocyte Globulin and Cyclosporine Versus Cyclophosphamide and Cyclosporine in the Treatment of Severe Aplastic Anemia,PHASE2,COMPLETED,2/6/1997,3/3/2008,20/2/2001,33,ACTUAL,,,['Severe Aplastic Anemia (SAA)'],"['Antithymocyte globulin', 'Cyclophosphamide', 'Cyclosporin']","['B2844', 'B2818', 'B2845']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule']]","[['Immunoglobulin'], ['Small Molecule'], ['Small Molecule']]","[[], ['DNA'], []]","[[], ['DNA'], ['CaN']]"
748,NCT00003261,Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma,Treatment of HIV-Related Primary Central Nervous System Lymphoma (HIV-PCNSL): A Phase II Trial With Neoadjuvant Chemotherapy (High-Dose Methotrexate (MTX) Plus High-Dose Zidovudine) and Radiotherapy,PHASE2,UNKNOWN,31/5/1997,,,14,ESTIMATED,,,['Hematology'],"['Methotrexate', 'Zidovudine', 'Neoadjuvant Therapy', 'Radiation Therapy']","['B997', 'B263']","[['Small Molecule'], []]","[['Small Molecule'], []]","[['Dihydrofolate reductase'], ['Reverse transcriptase']]","[['DHFR'], ['RT']]"
2440,NCT00019214,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma,Phase I/II Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From The Melanoma Associated Antigens MART-1 and gp 100,PHASE1/PHASE2,COMPLETED,30/4/1997,31/7/2006,,,,,,['Skin Melanoma'],"['MART-1 Antigen', 'Aldesleukin', 'gp100 Antigen']",['B136'],[['Other Protein Therapy']],[['Interleukin']],[['Interleukin-2 receptor']],[['IL-2R']]
5835,NCT00154726,Paclitaxel-HDFL for Locally Advanced and Recurrent/Metastatic Gastric Cancers,A Phase II Study of Weekly Paclitaxel(Taxol)and 24-Hour Infusion High-Dose 5-Fluorouracil and Leucovorin(HDFL)in the Treatment Locally Advanced and Recurrent/Metastatic Gastric Cancers,PHASE2,COMPLETED,30/4/1997,31/8/2005,,40,,,,['Gastric Cancer'],['Paclitaxel'],['B1250'],[['Small Molecule']],[['Small Molecule']],[['Tubulin beta-1 chain']],[['TUBB1']]
537,NCT00002990,Surgery and BCG in Treating Patients With Bladder Cancer,"Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder",PHASE3,COMPLETED,31/3/1997,,30/4/2005,1288,ESTIMATED,,,['Bladder Cancer'],['BCG vaccine'],['B722'],[['Live biotherapeutics']],[['Live biotherapeutics']],[[]],[[]]
923,NCT00003495,Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer,Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Squamos Cell Carcinoma of the Lung,PHASE2,TERMINATED,27/3/1996,4/11/2003,4/11/2003,7,ACTUAL,,,['Thoracic Neoplasm'],"['Antineoplaston-A10', 'Antineoplaston-AS2-1']","['B3226', 'B3227']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[['GTPase Ras', 'Tumor protein p53'], ['GTPase Ras', 'Tumor protein p53']]","[['Ras', 'p53'], ['Ras', 'p53']]"
66,NCT00001449,A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients,A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients,PHASE1,COMPLETED,30/9/1995,30/4/2000,,60,,,,['Neoplasms'],"['Gemcitabine', 'Floxuridine', 'Folinic acid']","['B2079', 'B2088', 'B226']","[['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], []]","[['DNA', 'Ribonucleotide reductase'], ['Thymidylate synthase'], []]","[['DNA', 'RNR'], ['TYMS'], []]"
442,NCT00002865,"High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia","HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR RELAPSED OR REFRACTORY ALL: A PHASE II STUDY OF A MULTIDRUG REGIMEN",PHASE2,COMPLETED,30/4/1995,31/8/2001,30/6/2000,25,ACTUAL,,,['Leukemia'],"['Filgrastim', 'Cyclophosphamide', 'Cytarabine', 'Dexamethasone', 'doxorubicin hydrochloride', 'Etoposide', 'Ifosfamide', 'leucovorin calcium', 'Mesna', 'Methotrexate', 'Hydrocortisone', 'vincristine sulfate', 'Low-LET Cobalt-60 Gamma Ray Therapy', 'Low-LET Photon Therapy']","['B157', 'B2818', 'B2050', 'B1128', 'B9124', 'B1463', 'B8', 'B8438', 'B2825', 'B997', 'B1133', 'B9307']","[['Other Protein Therapy'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Colony-Stimulating Factor'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Colony stimulating factor 3 receptor'], ['DNA'], ['DNA-directed DNA polymerase'], ['Glucocorticoid receptor'], [], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], [], [], ['Dihydrofolate reductase'], ['Glucocorticoid receptor'], []]","[['CSF-3R'], ['DNA'], ['DNA-directed DNA polymerase'], ['GR'], [], ['TOP2'], ['DNA'], [], [], ['DHFR'], ['GR'], []]"
14549,NCT00869284,Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas,Phase II Study Treatment of High Risk Non-Hodgkin's Lymphomas,PHASE2,COMPLETED,31/10/1994,28/2/2009,31/7/1999,45,ACTUAL,,,['Hematology'],"['Cyclophosphamide', 'Epirubicin', 'Vindesine', 'Prednisone', 'Mitoxantrone', 'Cytarabine', 'Total-Body Irradiation', 'Carmustine', 'Etoposide', 'Peripheral Blood Stem Cell']","['B2818', 'B1236', 'B2787', 'B1979', 'B1952', 'B2050', 'B1806', 'B1463']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule']]","[['DNA'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['Tubulin beta-1 chain'], ['Glucocorticoid receptor'], ['DNA', 'Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA-directed DNA polymerase'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)']]","[['DNA'], ['DNA', 'TOP2'], ['TUBB1'], ['GR'], ['DNA', 'TOP2'], ['DNA-directed DNA polymerase'], ['DNA'], ['TOP2']]"
214,NCT00002551,SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed,"Postoperative Evaluation of 5-FU by Bolus Injection vs. 5-FU by Prolonged Venous Infusion Prior to and Following Combined Prolonged Venous Infusion Plus Pelvic XRT vs. Bolus 5-FU Plus Leucovorin Plus Levamisole Prior to and Following Combined Pelvic XRT Plus Bolus 5-FU Plus Leucovorin in Patients With Rectal Cancer, Phase III",PHASE3,COMPLETED,31/3/1994,31/10/2008,31/8/2006,1917,ACTUAL,,,['Colorectal Cancer'],"['Fluorouracil', 'leucovorin calcium', 'levamisole hydrochloride', 'Radiation Therapy']","['B493', 'B8438', 'B8510']","[['Small Molecule'], [], []]","[['Small Molecule'], [], []]","[['Thymidylate synthase'], [], []]","[['TYMS'], [], []]"
57375,NCT00001398,Stem Cell Factor Medication for Aplastic Anemia,A Phase I/II Trial of Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) in Patients Diagnosed With Acquired Aplastic Anemia,PHASE1,COMPLETED,31/10/1993,30/6/2002,,40,,,,"['Aplastic Anemia', 'Hairy Cell Leukemia']",['Ancestim'],[],[],[],[],[]
816,NCT00003364,Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer,A Randomised Study of Timing of Thoracic Irradiation in Small Cell Lung Cancer (Study 8),PHASE3,COMPLETED,31/1/1993,31/8/2006,,398,ESTIMATED,,,['Thoracic Neoplasm'],"['Cisplatin', 'Cyclophosphamide', 'doxorubicin hydrochloride', 'Etoposide', 'vincristine sulfate', 'Radiation Therapy']","['B49', 'B2818', 'B9124', 'B1463', 'B9307']","[['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], [], ['Small Molecule'], []]","[['DNA'], ['DNA'], [], ['Top II inhibitors (Topoisomerase II inhibitors)'], []]","[['DNA'], ['DNA'], [], ['TOP2'], []]"
429,NCT00002844,Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia,Bone Marrow Transplantation for Chronic Lymphocytic Leukemia,PHASE2,COMPLETED,5/3/1991,5/6/2002,5/6/2002,49,ACTUAL,,,['Leukemia'],"['Cyclophosphamide', 'Allogeneic Bone Marrow Transplantation', 'Autologous Bone Marrow Transplantation', 'Total-Body Irradiation', 'Bone Marrow Transplantation']",['B2818'],[['Small Molecule']],[['Small Molecule']],[['DNA']],[['DNA']]
143,NCT00002456,Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation,Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease,PHASE3,COMPLETED,31/5/1986,30/4/2002,,,,,,"['Graft Versus Host Disease', 'Leukemia', 'Hematology']","['Cyclosporin', 'Methotrexate', 'Allogeneic Bone Marrow Transplantation']","['B2845', 'B997']","[['Small Molecule'], ['Small Molecule']]","[['Small Molecule'], ['Small Molecule']]","[[], ['Dihydrofolate reductase']]","[['CaN'], ['DHFR']]"
3,NCT00000660,Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma,Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma,PHASE1,COMPLETED,,31/7/1992,,24,,,,"['Kaposi sarcoma', 'HIV Infection']",['Etoposide'],['B1463'],[['Small Molecule']],[['Small Molecule']],[['Top II inhibitors (Topoisomerase II inhibitors)']],[['TOP2']]
113,NCT00002003,Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas,Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas,PHASE2,COMPLETED,,,,,,,,"['Non-Hodgkin Lymphoma', 'HIV Infection']","['mitoxantrone hydrochloride', 'Etoposide']","['B9162', 'B1463']","[[], ['Small Molecule']]","[[], ['Small Molecule']]","[[], ['Top II inhibitors (Topoisomerase II inhibitors)']]","[[], ['TOP2']]"
3208,NCT00041691,Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery,"A Phase I, Single Dose Escalating Study to Investigate the Tolerability, Pharmacokinetics and Dosimetry of 90 Y-Humanized MN-14 IgG in Colorectal Cancer Patients With Limited Residual Disease After Primary or Salvage Surgery",PHASE1,TERMINATED,,,,30,,,,['Digestive System Neoplasm'],['Labetuzumab Y-90'],['B3435'],[['Antibody Radiopharmaceutical']],[['Antibody Radiopharmaceutical']],[['Carcinoembryonic antigen']],[['CEA']]
8501,NCT00365755,Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma,Comparison of High Dose Rapid Schedule With Conventional Schedule Chemotherapy for Stage 4 Neuroblastoma Over the Age of One Year,PHASE3,COMPLETED,,31/3/2008,,,,,,['Kidney Wilms Tumor'],"['Carboplatin', 'Cisplatin', 'Cyclophosphamide', 'Etoposide', 'Melphalan', 'vincristine sulfate', 'Autologous Bone Marrow Transplantation', 'Conventional Surgery']","['B274', 'B49', 'B2818', 'B1463', 'B2073', 'B9307']","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], ['Small Molecule'], []]","[['DNA'], ['DNA'], ['DNA'], ['Top II inhibitors (Topoisomerase II inhibitors)'], ['DNA'], []]","[['DNA'], ['DNA'], ['DNA'], ['TOP2'], ['DNA'], []]"
19737,NCT01410708,TORI 104 Pre-Surgical Dasatinib,A Pre-Surgical Study to Evaluate Molecular Changes That Occur in Human Breast Cancer Tissue After Short Term Exposure to Dasatinib and To Correlate These Alterations With Pharmacokinetics Parameters,PHASE2,WITHDRAWN,,,,0,ACTUAL,,,['Breast Cancer'],['Dasatinib'],['B293'],[['Small Molecule']],[['Small Molecule']],"[['Bcr-Abl tyrosine kinase', 'Ephrin type-A receptor 2']]","[['BCR-ABL1', 'EphA2', 'FYN']]"